{"c2d64f7e6452161fdf14a03c0513594d47c79be7": [["a b s t r a c tNew findings of widespread neglected diseases among the poor living in wealthy group of 20 (G20) economies and the concept of ''blue marble health\" offer innovative mechanisms for financing urgently new vaccines, especially for vector-borne neglected tropical diseases (NTDs).", [["neglected tropical diseases", "DISEASE", 256, 283], ["NTDs", "DISEASE", 285, 289], ["widespread neglected diseases", "PROBLEM", 31, 60], ["innovative mechanisms", "TREATMENT", 169, 190], ["financing urgently new vaccines", "TREATMENT", 195, 226], ["tropical diseases", "PROBLEM", 266, 283], ["widespread", "OBSERVATION_MODIFIER", 31, 41], ["neglected", "OBSERVATION", 42, 51]]], ["All rights reserved.Introduction: Tropical and infectious disease ''Whack-a-MoleThe ''decade of global health\" that was launched with the 2000 Millennium Development Goals (MDGs) ignited a series of overseas development assistance (ODA) initiatives for poverty-related diseases in Sub-Saharan African and other resource-poor nations [1] .", [["poverty-related diseases", "PROBLEM", 253, 277], ["infectious", "OBSERVATION", 47, 57]]], ["Recent assessments through the Global Burden of Disease Study now show that ODA largely worked, especially through major health initiatives to address HIV/AIDS, tuberculosis, malaria, and NTDs (e.g., PEPFAR, The Global Fund, and the USAID NTD Program) and the vaccine-preventable killer diseases of childhood (e.g., GAVI), with significant reductions in the prevalence and incidence of these conditions [2] [3] [4] [5] .", [["HIV/AIDS", "DISEASE", 151, 159], ["tuberculosis", "DISEASE", 161, 173], ["malaria", "DISEASE", 175, 182], ["NTDs", "DISEASE", 188, 192], ["killer diseases", "DISEASE", 280, 295], ["ODA", "SIMPLE_CHEMICAL", 76, 79], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 403, 418], ["HIV", "SPECIES", 151, 154], ["HIV", "SPECIES", 151, 154], ["Recent assessments", "TEST", 0, 18], ["Disease Study", "TEST", 48, 61], ["HIV/AIDS", "PROBLEM", 151, 159], ["tuberculosis", "PROBLEM", 161, 173], ["malaria", "PROBLEM", 175, 182], ["NTDs", "PROBLEM", 188, 192], ["the vaccine", "TREATMENT", 256, 267], ["preventable killer diseases", "PROBLEM", 268, 295], ["Disease", "OBSERVATION", 48, 55], ["tuberculosis", "OBSERVATION", 161, 173], ["malaria", "OBSERVATION", 175, 182], ["killer diseases", "OBSERVATION", 280, 295]]], ["For several of these diseases it is now even possible to consider elimination or even eradication strategies [6] .Introduction: Tropical and infectious disease ''Whack-a-MoleCounteracting some of these successes has been the recent and dramatic emergence of new infections, such as zoonotic diseases from bats (e.g., Ebola and Nipah virus infections and coronavirus [CoV] infections), rats (e.g., Lassa fever), birds and domestic animals (e.g., influenza strains with pandemic potential and Rift Valley fever); and key vector-borne NTDs transmitted by arthropods (e.g., leishmaniasis, Chagas disease, dengue fever, chikungunya, and Zika virus infection) and snails (e.g., schistosomiasis and food-borne trematodiases) [7] .", [["Tropical and infectious disease", "DISEASE", 128, 159], ["infections", "DISEASE", 262, 272], ["zoonotic diseases", "DISEASE", 282, 299], ["Ebola and Nipah virus infections", "DISEASE", 317, 349], ["coronavirus [CoV] infections", "DISEASE", 354, 382], ["Lassa fever", "DISEASE", 397, 408], ["influenza", "DISEASE", 445, 454], ["pandemic", "DISEASE", 468, 476], ["Rift Valley fever", "DISEASE", 491, 508], ["NTDs transmitted by arthropods", "DISEASE", 532, 562], ["leishmaniasis", "DISEASE", 570, 583], ["Chagas disease", "DISEASE", 585, 599], ["dengue fever", "DISEASE", 601, 613], ["chikungunya", "DISEASE", 615, 626], ["Zika virus infection", "DISEASE", 632, 652], ["schistosomiasis", "DISEASE", 672, 687], ["food-borne trematodiases", "DISEASE", 692, 716], ["Ebola", "ORGANISM", 317, 322], ["Nipah virus infections", "ORGANISM", 327, 349], ["coronavirus [CoV", "ORGANISM", 354, 370], ["rats", "ORGANISM", 385, 389], ["Lassa fever", "ORGANISM", 397, 408], ["Rift Valley fever", "ORGANISM", 491, 508], ["Zika virus", "ORGANISM", 632, 642], ["Ebola", "SPECIES", 317, 322], ["Nipah virus", "SPECIES", 327, 338], ["coronavirus [CoV", "SPECIES", 354, 370], ["rats", "SPECIES", 385, 389], ["Lassa fever", "SPECIES", 397, 408], ["dengue fever", "SPECIES", 601, 613], ["Zika virus", "SPECIES", 632, 642], ["Nipah virus", "SPECIES", 327, 338], ["CoV", "SPECIES", 367, 370], ["Rift Valley fever)", "SPECIES", 491, 509], ["Zika virus", "SPECIES", 632, 642], ["these diseases", "PROBLEM", 15, 29], ["new infections", "PROBLEM", 258, 272], ["zoonotic diseases", "PROBLEM", 282, 299], ["Ebola", "PROBLEM", 317, 322], ["Nipah virus infections", "PROBLEM", 327, 349], ["coronavirus", "PROBLEM", 354, 365], ["CoV] infections", "PROBLEM", 367, 382], ["Lassa fever", "PROBLEM", 397, 408], ["domestic animals", "PROBLEM", 421, 437], ["influenza strains", "PROBLEM", 445, 462], ["pandemic potential", "PROBLEM", 468, 486], ["Rift Valley fever", "PROBLEM", 491, 508], ["borne NTDs", "PROBLEM", 526, 536], ["leishmaniasis", "PROBLEM", 570, 583], ["Chagas disease", "PROBLEM", 585, 599], ["dengue fever", "PROBLEM", 601, 613], ["chikungunya", "PROBLEM", 615, 626], ["Zika virus infection", "PROBLEM", 632, 652], ["snails", "PROBLEM", 658, 664], ["schistosomiasis", "PROBLEM", 672, 687], ["diseases", "OBSERVATION", 21, 29], ["infectious", "OBSERVATION", 141, 151], ["dramatic", "OBSERVATION_MODIFIER", 236, 244], ["new", "OBSERVATION_MODIFIER", 258, 261], ["infections", "OBSERVATION", 262, 272], ["leishmaniasis", "OBSERVATION", 570, 583], ["Chagas disease", "OBSERVATION", 585, 599]]], ["Shown in Table 1 is the global health impact of some of these 21st century emerging and neglected diseases.", [["neglected diseases", "PROBLEM", 88, 106]]], ["They include large epidemics of Ebola virus infection, SARS and MERS CoV, and H1N1 influenza, which since 2009 have killed almost 300,000 people [8] [9] [10] [11] , and the 17 NTDs responsible for almost 150,000 deaths but also 25 million disability adjusted life years due to the chronic and disabling features of most of the NTDs [1] [2] [3] [4] .Introduction: Tropical and infectious disease ''Whack-a-MoleUnder this scenario, we are watching unfold a global version of ''whack-a-mole\", referring to a type of futile arcade game.", [["Ebola virus infection", "DISEASE", 32, 53], ["SARS", "DISEASE", 55, 59], ["influenza", "DISEASE", 83, 92], ["NTDs", "DISEASE", 176, 180], ["deaths", "DISEASE", 212, 218], ["NTDs", "DISEASE", 327, 331], ["Ebola virus", "ORGANISM", 32, 43], ["MERS CoV", "ORGANISM", 64, 72], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 332, 347], ["Ebola virus", "SPECIES", 32, 43], ["H1N1 influenza", "SPECIES", 78, 92], ["people", "SPECIES", 138, 144], ["Ebola virus", "SPECIES", 32, 43], ["MERS CoV", "SPECIES", 64, 72], ["Ebola virus infection", "PROBLEM", 32, 53], ["SARS", "PROBLEM", 55, 59], ["MERS CoV", "PROBLEM", 64, 72], ["H1N1 influenza", "PROBLEM", 78, 92], ["the chronic and disabling features", "PROBLEM", 277, 311], ["large", "OBSERVATION_MODIFIER", 13, 18], ["epidemics", "OBSERVATION", 19, 28], ["Ebola virus infection", "OBSERVATION", 32, 53], ["chronic", "OBSERVATION_MODIFIER", 281, 288]]], ["Thus, since 2000 we have experienced large reductions of some high disease burden infections through effective programs of ODA, only to see the emergence of a new group of diseases, mostly zoonotic infections with pandemic potential and vector-borne NTDs (Fig 1) .Introduction: Tropical and infectious disease ''Whack-a-MoleThe rise since 2009 of serious zoonotic pandemic threats and vector-borne NTDs has become a critical global public health issue.", [["infections", "DISEASE", 82, 92], ["zoonotic infections", "DISEASE", 189, 208], ["pandemic", "DISEASE", 214, 222], ["NTDs", "DISEASE", 250, 254], ["pandemic", "DISEASE", 364, 372], ["vector-borne NTDs", "DISEASE", 385, 402], ["ODA", "SIMPLE_CHEMICAL", 123, 126], ["some high disease burden infections", "PROBLEM", 57, 92], ["diseases", "PROBLEM", 172, 180], ["mostly zoonotic infections", "PROBLEM", 182, 208], ["vector-borne NTDs", "PROBLEM", 385, 402], ["large", "OBSERVATION_MODIFIER", 37, 42], ["reductions", "OBSERVATION_MODIFIER", 43, 53], ["some", "OBSERVATION_MODIFIER", 57, 61], ["high disease", "OBSERVATION", 62, 74], ["burden", "OBSERVATION_MODIFIER", 75, 81], ["infections", "OBSERVATION", 82, 92], ["zoonotic", "OBSERVATION_MODIFIER", 189, 197], ["infections", "OBSERVATION", 198, 208], ["infectious", "OBSERVATION", 291, 301], ["rise", "OBSERVATION_MODIFIER", 328, 332]]], ["It has also becoming apparent that these infections are adversely affecting economic development, together with a new stark reality that they may threaten global security.The new drivers: anthropocene forces and blue marble healthThe uptick of major zoonotic pandemic infections and vectorborne NTDs is not by coincidence.", [["infections", "DISEASE", 41, 51], ["zoonotic pandemic infections", "DISEASE", 250, 278], ["NTDs", "DISEASE", 295, 299], ["these infections", "PROBLEM", 35, 51], ["major zoonotic pandemic infections", "PROBLEM", 244, 278], ["vectorborne NTDs", "PROBLEM", 283, 299], ["infections", "OBSERVATION", 41, 51], ["new", "OBSERVATION_MODIFIER", 175, 178], ["major", "OBSERVATION_MODIFIER", 244, 249], ["zoonotic", "OBSERVATION_MODIFIER", 250, 258], ["pandemic", "OBSERVATION_MODIFIER", 259, 267], ["infections", "OBSERVATION", 268, 278]]], ["Major drivers include both critical environmental and social forces.", [["social forces", "OBSERVATION", 54, 67]]], ["Among the former they include climate change and deforestation, while the latter include urbanization and human migrations, which in some cases is linked to refugee populations fleeing conflict zones of the Middle East and East Africa [12] .", [["human", "ORGANISM", 106, 111], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["deforestation", "TREATMENT", 49, 62], ["Middle", "ANATOMY_MODIFIER", 207, 213]]], ["Such forces might partly explain for example the recent occurrence of widespread Ebola in West Africa, cutaneous leishmaniasis in the Middle East, visceral leishmaniasis in East Africa, and chikungunya and Zika virus infections in the Americas [7, 12] , while in Southern Europe vector-borne NTDs such as dengue, chikungunya, West Nile virus infections and even schistosomiasis have emerged [12, 13] .", [["Ebola", "DISEASE", 81, 86], ["cutaneous leishmaniasis", "DISEASE", 103, 126], ["visceral leishmaniasis", "DISEASE", 147, 169], ["chikungunya", "DISEASE", 190, 201], ["Zika virus infections", "DISEASE", 206, 227], ["NTDs", "DISEASE", 292, 296], ["dengue", "DISEASE", 305, 311], ["chikungunya", "DISEASE", 313, 324], ["West Nile virus infections", "DISEASE", 326, 352], ["schistosomiasis", "DISEASE", 362, 377], ["Ebola", "ORGANISM", 81, 86], ["Zika virus", "ORGANISM", 206, 216], ["West Nile virus", "ORGANISM", 326, 341], ["West Nile virus", "SPECIES", 326, 341], ["Zika virus", "SPECIES", 206, 216], ["West Nile virus", "SPECIES", 326, 341], ["cutaneous leishmaniasis", "PROBLEM", 103, 126], ["visceral leishmaniasis", "PROBLEM", 147, 169], ["chikungunya", "PROBLEM", 190, 201], ["Zika virus infections", "PROBLEM", 206, 227], ["borne NTDs", "PROBLEM", 286, 296], ["dengue", "PROBLEM", 305, 311], ["chikungunya", "PROBLEM", 313, 324], ["West Nile virus infections", "PROBLEM", 326, 352], ["even schistosomiasis", "PROBLEM", 357, 377], ["widespread", "OBSERVATION_MODIFIER", 70, 80], ["Ebola", "OBSERVATION", 81, 86], ["cutaneous", "ANATOMY", 103, 112], ["leishmaniasis", "OBSERVATION", 113, 126], ["Middle", "ANATOMY_MODIFIER", 134, 140], ["visceral", "ANATOMY", 147, 155], ["leishmaniasis", "OBSERVATION", 156, 169], ["chikungunya", "OBSERVATION", 190, 201]]], ["Many of these external forces were recently ascribed to the 'Anthropocene', referring to the origins first geological epoch associated with human-driven activity [12] .", [["human", "ORGANISM", 140, 145], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["external forces", "OBSERVATION", 14, 29]]], ["It was recently noted that (almost paradoxically and with a few notable exceptions) the majority of the poverty-related neglected diseases, including the NTDs, are today mostly prevalent among the poor living in group of 20 (G20) wealthy economies, together with Nigeria whose economy exceeds the bottom three or four G20 countries [1] .", [["poverty", "DISEASE", 104, 111], ["NTDs", "DISEASE", 154, 158], ["neglected diseases", "PROBLEM", 120, 138], ["the NTDs", "PROBLEM", 150, 158], ["neglected", "OBSERVATION_MODIFIER", 120, 129], ["diseases", "OBSERVATION", 130, 138]]], ["Based on data from both the WHO or the Global Burden of Disease Study 2013, the G20 nations and Nigeria account for more than onehalf of the disability adjusted life years from the NTDs and most of the cases of diseases such as Chagas disease, dengue, helminth infections, leishmaniasis, leprosy, and even tuberculosis, among others [14] .", [["NTDs", "DISEASE", 181, 185], ["Chagas disease", "DISEASE", 228, 242], ["dengue", "DISEASE", 244, 250], ["helminth infections", "DISEASE", 252, 271], ["leishmaniasis", "DISEASE", 273, 286], ["leprosy", "DISEASE", 288, 295], ["tuberculosis", "DISEASE", 306, 318], ["Disease Study", "TEST", 56, 69], ["the NTDs", "PROBLEM", 177, 185], ["diseases", "PROBLEM", 211, 219], ["Chagas disease", "PROBLEM", 228, 242], ["dengue", "PROBLEM", 244, 250], ["helminth infections", "PROBLEM", 252, 271], ["leishmaniasis", "PROBLEM", 273, 286], ["leprosy", "PROBLEM", 288, 295], ["tuberculosis", "PROBLEM", 306, 318], ["Disease", "OBSERVATION", 56, 63], ["Chagas disease", "OBSERVATION", 228, 242], ["leishmaniasis", "OBSERVATION", 273, 286], ["tuberculosis", "OBSERVATION", 306, 318]]], ["Certainly the poor living in large middle-income countries such as Brazil, China, India, and Indonesia account for much of this NTD burden, but in addition there are pockets of intense poverty in the Southern United States, Europe, Saudi Arabia, and Australia fostering neglected disease burdens in selected areas [1] .", [["this NTD burden", "PROBLEM", 123, 138], ["neglected disease burdens", "PROBLEM", 270, 295], ["poor", "OBSERVATION_MODIFIER", 14, 18], ["large", "OBSERVATION_MODIFIER", 29, 34], ["middle", "OBSERVATION_MODIFIER", 35, 41], ["pockets", "OBSERVATION_MODIFIER", 166, 173], ["intense", "OBSERVATION_MODIFIER", 177, 184], ["poverty", "OBSERVATION_MODIFIER", 185, 192]]], ["Thus, with the exception of Ebola virus infection and a few other NTDs including African sleeping sickness, the poor living in G20 countries represent the next wave in neglected diseases highlighted above [1, 7] .The need for vaccinesWe urgently need new vaccines for many of the diseases in Table 1 and highlighted above.", [["Ebola virus infection", "DISEASE", 28, 49], ["NTDs", "DISEASE", 66, 70], ["sleeping sickness", "DISEASE", 89, 106], ["Ebola virus", "ORGANISM", 28, 39], ["Ebola virus", "SPECIES", 28, 39], ["Ebola virus", "SPECIES", 28, 39], ["Ebola virus infection", "PROBLEM", 28, 49], ["a few other NTDs", "PROBLEM", 54, 70], ["African sleeping sickness", "PROBLEM", 81, 106], ["neglected diseases", "PROBLEM", 168, 186], ["vaccines", "TREATMENT", 226, 234], ["new vaccines", "TREATMENT", 251, 263], ["the diseases", "PROBLEM", 276, 288], ["Ebola virus", "OBSERVATION", 28, 39], ["diseases", "OBSERVATION", 280, 288]]], ["They include new vaccines for CoVs, Ebola and Nipah virus infections, Lassa fever, Rift Valley fever, and pandemic and zoonotic influenza viruses.", [["Ebola", "DISEASE", 36, 41], ["Nipah virus infections", "DISEASE", 46, 68], ["Lassa fever", "DISEASE", 70, 81], ["Rift Valley fever", "DISEASE", 83, 100], ["pandemic", "DISEASE", 106, 114], ["zoonotic influenza viruses", "DISEASE", 119, 145], ["CoVs", "GENE_OR_GENE_PRODUCT", 30, 34], ["Ebola", "ORGANISM", 36, 41], ["Nipah virus", "ORGANISM", 46, 57], ["Lassa fever", "ORGANISM", 70, 81], ["Rift Valley fever", "ORGANISM", 83, 100], ["Ebola", "SPECIES", 36, 41], ["Nipah virus", "SPECIES", 46, 57], ["Lassa fever", "SPECIES", 70, 81], ["Rift Valley fever", "SPECIES", 83, 100], ["CoVs", "SPECIES", 30, 34], ["Nipah virus", "SPECIES", 46, 57], ["Rift Valley fever", "SPECIES", 83, 100], ["new vaccines", "TREATMENT", 13, 25], ["CoVs", "PROBLEM", 30, 34], ["Ebola", "PROBLEM", 36, 41], ["Nipah virus infections", "PROBLEM", 46, 68], ["Lassa fever", "PROBLEM", 70, 81], ["Rift Valley fever", "PROBLEM", 83, 100], ["pandemic", "PROBLEM", 106, 114], ["zoonotic influenza viruses", "PROBLEM", 119, 145], ["zoonotic", "OBSERVATION_MODIFIER", 119, 127], ["influenza viruses", "OBSERVATION", 128, 145]]], ["But also critically needed are vaccines for the vector-borne NTDs, including both major forms of leishmaniasis, Chagas disease, arbovirus infections, and snailborne trematode infections, especially schistosomiasis [6, 7] .", [["NTDs", "DISEASE", 61, 65], ["leishmaniasis", "DISEASE", 97, 110], ["Chagas disease", "DISEASE", 112, 126], ["arbovirus infections", "DISEASE", 128, 148], ["trematode infections", "DISEASE", 165, 185], ["schistosomiasis", "DISEASE", 198, 213], ["vaccines", "TREATMENT", 31, 39], ["borne NTDs", "PROBLEM", 55, 65], ["leishmaniasis", "PROBLEM", 97, 110], ["Chagas disease", "PROBLEM", 112, 126], ["arbovirus infections", "PROBLEM", 128, 148], ["snailborne trematode infections", "PROBLEM", 154, 185], ["schistosomiasis", "PROBLEM", 198, 213], ["leishmaniasis", "OBSERVATION", 97, 110], ["Chagas disease", "OBSERVATION", 112, 126], ["arbovirus infections", "OBSERVATION", 128, 148], ["trematode", "OBSERVATION_MODIFIER", 165, 174], ["infections", "OBSERVATION", 175, 185]]], ["While there is a lot of promising science and technology being pursued at the preclinical level for developing such these vaccines, it is increasingly evident that our business model for bridging several ''valleys of death\" in product development, including the ones between discovery and phase 1 and then between phase 2 and phase 3, respectively, is broken.", [["death", "DISEASE", 217, 222], ["these vaccines", "TREATMENT", 116, 130], ["death", "PROBLEM", 217, 222]]], ["As a result we have almost no pipeline for the new 21st century pandemic and neglected disease threats.The need for vaccinesA good example of our broken business model can be illustrated for Ebola virus infection, for which the basic scientific discoveries for developing new Ebola vaccines had been published by 2003, but then the technology languished for a decade [15] .", [["Ebola virus infection", "DISEASE", 191, 212], ["Ebola", "DISEASE", 276, 281], ["Ebola virus", "ORGANISM", 191, 202], ["Ebola", "ORGANISM", 276, 281], ["Ebola virus", "SPECIES", 191, 202], ["Ebola virus", "SPECIES", 191, 202], ["Ebola", "SPECIES", 276, 281], ["neglected disease threats", "PROBLEM", 77, 102], ["vaccines", "TREATMENT", 116, 124], ["Ebola virus infection", "PROBLEM", 191, 212], ["new Ebola vaccines", "TREATMENT", 272, 290], ["new", "OBSERVATION_MODIFIER", 272, 275], ["Ebola", "OBSERVATION", 276, 281]]], ["Ultimately true vaccine product development ensued only after the US Government put up more than $100 million to incentivize multinational pharmaceutical companies to translate those efforts into vaccines for clinical testing [15] .", [["multinational pharmaceutical companies", "TREATMENT", 125, 163], ["clinical testing", "TEST", 209, 225]]], ["By the time the vaccine clinical testing began in West Africa, Ebola had mostly disappeared but only after 11,000 people lost their lives [15] .", [["Ebola", "DISEASE", 63, 68], ["Ebola", "ORGANISM", 63, 68], ["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120], ["the vaccine clinical testing", "TEST", 12, 40]]], ["A similar situation occurred for MERS CoV in which hundreds died in outbreaks on the Arabian Peninsula and South Korea due to the absence of a safe and effective vaccine.Financing new vaccines: blue marble health as an alternative to new global fundsPartly in response to the inability to have in hand Ebola and CoV vaccines, in 2015 Plotkin, Mahmoud, and Farrar proposed establishing a global vaccine development fund to pay for the expensive elements of downstream development including phase 3 pivotal clinical trials and industrial scale manufacture [16] .", [["Ebola", "DISEASE", 302, 307], ["hand Ebola", "ORGANISM", 297, 307], ["CoV", "ORGANISM", 312, 315], ["MERS CoV", "SPECIES", 33, 41], ["A similar situation", "PROBLEM", 0, 19], ["a safe and effective vaccine", "TREATMENT", 141, 169], ["hand Ebola", "TREATMENT", 297, 307], ["CoV vaccines", "TREATMENT", 312, 324], ["a global vaccine", "TREATMENT", 385, 401], ["industrial scale manufacture", "TREATMENT", 525, 553]]], ["The emphasis of such a fund would be to support emerging pandemic threats as well as some neglected disease pathogens [16] .", [["emerging pandemic threats", "PROBLEM", 48, 73], ["some neglected disease pathogens", "PROBLEM", 85, 117]]], ["Out of this proposal emerged a new initiative, known as the Coalition for Epidemic Preparedness Innovations (CEPI), an initiative linked to WHO that would focus on gaps in product development resulting from market failure.Financing new vaccines: blue marble health as an alternative to new global fundsClearly, there is need for economic and political innovation at a level that is commensurate with the scientific innovation needed to develop vaccines.", [["market failure", "PROBLEM", 207, 221], ["economic and political innovation", "PROBLEM", 329, 362], ["vaccines", "TREATMENT", 444, 452], ["market failure", "OBSERVATION", 207, 221]]], ["Both CEPI and the Plotkin et al. proposal represent one approach to this problem, if it can overcome the multiple complexities associated with the launch and administration of a fund.", [["Both CEPI", "TREATMENT", 0, 9], ["the Plotkin et al", "TREATMENT", 14, 31]]], ["Such complexities include the fact that the US Government is already the largest contributor to neglected disease R&D according to the G-FINDER Report, together with previous findings that it remains highly uncertain the US Government could tapped again for an additional research and development funds [17] .", [["R&D", "DISEASE", 114, 117], ["neglected disease R&D", "PROBLEM", 96, 117]]], ["Also of concern are the governance and distribution mechanisms of a global vaccine development fund, including how the list of vaccines is prioritized, and whether the scientists and administrators from donor Table 1 The public health impact of the ''new\" neglected and emerging disease threats.Financing new vaccines: blue marble health as an alternative to new global fundsPublic health impact 17 Neglected tropical diseases in 2013 [2] [3] [4] H1N1 2009-10 Influenza epidemic [8, 9] Ebola in West Africa West African 2014-15 [10] SARS and MERS CoV in 2012-6 [11] countries would be willing to cede control of funds to an international entity in Geneva or elsewhere.Financing new vaccines: blue marble health as an alternative to new global fundsAs an alternative or complement to a global vaccine fund, I proposed building on the concept of blue marble health, which recognizes that most of the world's neglected and emerging infections actually occur among the poor living in G20 countries [1] .", [["Neglected tropical diseases", "DISEASE", 399, 426], ["Influenza", "DISEASE", 460, 469], ["Ebola", "DISEASE", 486, 491], ["SARS", "DISEASE", 533, 537], ["infections", "DISEASE", 929, 939], ["Ebola", "ORGANISM", 486, 491], ["MERS CoV", "SPECIES", 542, 550], ["vaccines", "TREATMENT", 127, 135], ["emerging disease threats", "PROBLEM", 270, 294], ["Neglected tropical diseases", "PROBLEM", 399, 426], ["H1N1", "TEST", 447, 451], ["Influenza epidemic", "TEST", 460, 478], ["MERS CoV", "TEST", 542, 550], ["emerging infections", "PROBLEM", 920, 939], ["blue marble", "OBSERVATION", 844, 855]]], ["Specifically, national funds established in each of the G20 nations could support indigenous scientists and research institutes and incentivize them to partner with international industrial manufacturers and the half-dozen vaccine non-profit product development partnerships (PDPs), which are specifically focused on NTD and other neglected disease vaccines [1, 6] .", [["international industrial manufacturers", "TREATMENT", 165, 203], ["the half-dozen vaccine", "TREATMENT", 208, 230], ["NTD", "PROBLEM", 317, 320], ["other neglected disease vaccines", "PROBLEM", 325, 357]]], ["In this blue marble health model each national fund would similarly promote indigenous scientists and manufacturers, while simultaneously providing support for new neglected disease vaccines [1] .Financing new vaccines: blue marble health as an alternative to new global fundsThe possibility remains that parallel financial mechanisms -(1) a global vaccine development fund and (2) national funds in the blue marble health nations -could co-exist and work together (Fig. 2) .", [["new neglected disease vaccines", "TREATMENT", 160, 190]]], ["The former would focus on emergency zoonotic pandemic threats such as Ebola, Nipah, MERS Cov, Lassa Fever influenza, and even some arbovirus infections such as Zika and West Nile Virus infections, while the latter would emphasize vaccines for chronic and debilitating vector-borne NTDs such as cutaneous and visceral leishmaniasis, Chagas disease, schistosomaisis, onchocerciasis, and food-borne trematodiases, as well as some of the arbovirus infections.", [["cutaneous", "ANATOMY", 294, 303], ["zoonotic pandemic", "DISEASE", 36, 53], ["Ebola", "DISEASE", 70, 75], ["Nipah", "DISEASE", 77, 82], ["Lassa Fever influenza", "DISEASE", 94, 115], ["arbovirus infections", "DISEASE", 131, 151], ["Zika and West Nile Virus infections", "DISEASE", 160, 195], ["NTDs", "DISEASE", 281, 285], ["cutaneous and visceral leishmaniasis", "DISEASE", 294, 330], ["Chagas disease", "DISEASE", 332, 346], ["schistosomaisis", "DISEASE", 348, 363], ["onchocerciasis", "DISEASE", 365, 379], ["food-borne trematodiases", "DISEASE", 385, 409], ["arbovirus infections", "DISEASE", 434, 454], ["Ebola", "ORGANISM", 70, 75], ["Lassa Fever influenza", "ORGANISM", 94, 115], ["West Nile Virus", "ORGANISM", 169, 184], ["cutaneous", "ORGANISM_SUBDIVISION", 294, 303], ["Nipah", "SPECIES", 77, 82], ["Lassa Fever influenza", "SPECIES", 94, 115], ["Nile Virus", "SPECIES", 174, 184], ["West Nile Virus", "SPECIES", 169, 184], ["Ebola", "PROBLEM", 70, 75], ["Nipah", "PROBLEM", 77, 82], ["Lassa Fever influenza", "PROBLEM", 94, 115], ["some arbovirus infections", "PROBLEM", 126, 151], ["Zika", "PROBLEM", 160, 164], ["West Nile Virus infections", "PROBLEM", 169, 195], ["vaccines", "TREATMENT", 230, 238], ["chronic and debilitating vector", "PROBLEM", 243, 274], ["borne NTDs", "PROBLEM", 275, 285], ["cutaneous and visceral leishmaniasis", "PROBLEM", 294, 330], ["Chagas disease", "PROBLEM", 332, 346], ["schistosomaisis", "PROBLEM", 348, 363], ["onchocerciasis", "PROBLEM", 365, 379], ["food-borne trematodiases", "PROBLEM", 385, 409], ["the arbovirus infections", "PROBLEM", 430, 454], ["cutaneous", "ANATOMY", 294, 303], ["visceral", "ANATOMY", 308, 316], ["leishmaniasis", "OBSERVATION", 317, 330], ["Chagas disease", "OBSERVATION", 332, 346], ["onchocerciasis", "OBSERVATION", 365, 379], ["arbovirus infections", "OBSERVATION", 434, 454]]], ["Both mechanisms are essential in order to prevent the unacceptable situation in which the sole development of vaccines is focused on preventing pandemic threats of concern to populations living in North America and Europe.Concluding remarksAs we soon enter the third decade of the 21st century it is apparent that modern Anthropocene forces together with poverty are promoting the dramatic rise of zoonotic pandemic threats, as well as vector borne NTDs.", [["pandemic", "DISEASE", 407, 415], ["NTDs", "DISEASE", 449, 453], ["the unacceptable situation", "PROBLEM", 50, 76], ["vaccines", "TREATMENT", 110, 118], ["modern Anthropocene forces", "TREATMENT", 314, 340], ["zoonotic pandemic threats", "PROBLEM", 398, 423], ["dramatic", "OBSERVATION_MODIFIER", 381, 389], ["rise", "OBSERVATION_MODIFIER", 390, 394], ["zoonotic", "OBSERVATION_MODIFIER", 398, 406]]], ["The concept of blue marble health finds that many of these diseases are now occurring mostly among the poor living in G20 economies.", [["blue marble", "ORGANISM", 15, 26], ["these diseases", "PROBLEM", 53, 67], ["blue marble", "OBSERVATION", 15, 26], ["diseases", "OBSERVATION", 59, 67]]], ["Beyond the scientific innovation, we will require extensive reform on how we finance next generation vaccines that would serve as countermeasures for such health, economic, and global security threats [18] .", [["generation vaccines", "TREATMENT", 90, 109]]], ["Dual funding mechanisms that address both pandemic threats and vector-borne NTDs may help to address this critical gap.", [["NTDs", "DISEASE", 76, 80], ["Dual funding mechanisms", "PROBLEM", 0, 23], ["this critical gap", "PROBLEM", 101, 118]]]], "8e29b50eee567c662fe77a4ffbd4b52ae72d7867": [["INTRODUCTIONInfectious disease outbreaks are relatively common, (World Health Organization Accessed 26.03.2020) often prompting an international response involving thousands of healthcare workers (HCWs) (Brooks et al. 2018) .", [["INTRODUCTIONInfectious disease outbreaks", "PROBLEM", 0, 40]]], ["Providing frontline healthcare during infectious outbreaks increases the risk of HCWs developing mental health problems, both short and longterm (Maunder et al. 2006) .", [["mental health problems", "PROBLEM", 97, 119]]], ["It has been suggested that specific occupational factors are associated with psychological outcomes of HCWs during an infectious disease outbreak.INTRODUCTIONWorking in a high-risk environment, adhering to quarantine, job-related stress, and belonging to a specific cadre were all considered to aggravate psychological outcomes.", [["an infectious disease outbreak", "PROBLEM", 115, 145], ["infectious", "OBSERVATION_MODIFIER", 118, 128]]], ["Perceived safety, namely through access to protective equipment, and specialised training, mitigated those outcomes (Brooks et al. 2017) .INTRODUCTIONDuring December 2019 a new infectious disease outbreak was reported in Wuhan, Hubei province, China (C. , which was named COVID-19 (World Health Organization 2020).", [["infectious disease", "DISEASE", 177, 195], ["a new infectious disease outbreak", "PROBLEM", 171, 204], ["new", "OBSERVATION_MODIFIER", 173, 176], ["infectious", "OBSERVATION_MODIFIER", 177, 187]]], ["The World Health Organization (WHO) declared COVID-19 a pandemic by March 11th 2020, and by August 2020 it had spread to most countries and territories, with almost 20 million known cases and a death toll of over 730,000 people ('World Health Organization.", [["death", "DISEASE", 194, 199], ["people", "ORGANISM", 221, 227], ["people", "SPECIES", 221, 227]]], ["\"Coronavirus disease 2019 .", [["Coronavirus disease", "PROBLEM", 1, 20], ["Coronavirus disease", "OBSERVATION", 1, 20]]], ["Early anecdotal evidence from Wuhan showed how this unprecedented situation impacted the mental health of frontline HCWs, who reported mental problems such as anxiety, depressive symptoms, anger, and fear (L. ).", [["anxiety", "DISEASE", 159, 166], ["depressive symptoms", "DISEASE", 168, 187], ["anger", "DISEASE", 189, 194], ["mental problems", "PROBLEM", 135, 150], ["anxiety", "PROBLEM", 159, 166], ["depressive symptoms", "PROBLEM", 168, 187]]], ["These problems cannot only have a long-lasting effect on the mental health of HCWs, (Maunder et al. 2006 ) but also hinder the urgent response to COVID-19, by jeopardising attention and decision-making (L. .", [["COVID-19", "CHEMICAL", 146, 154], ["COVID", "TEST", 146, 151]]], ["Tackling the mental health of HCWs during this pandemic is essential, and will strengthen healthcare systems' capacity .INTRODUCTIONPrevious systematic reviews have explored social and occupational factors associated with psychological outcomes in HCW during an infectious disease outbreak (Brooks et al. 2018) , and their perceptions of risk and use of coping strategies towards emerging respiratory infectious diseases (Koh et al. 2011) .", [["respiratory infectious diseases", "DISEASE", 389, 420], ["coping strategies", "TREATMENT", 354, 371], ["emerging respiratory infectious diseases", "PROBLEM", 380, 420], ["infectious", "OBSERVATION_MODIFIER", 262, 272]]], ["A number of recent systematic reviews have examined the psychological and mental impact of COVID-19 on medical staff and other HCWs (Garcia-Iglesias et al. 2020 , Kisely et al. 2020 , Pan et al. 2020 , Pappa et al. 2020 , Shaukat et al. 2020 , some of them focussing on specific mental health problems such as post-traumatic stress disorder (PTSD) (Carmassi et al. 2020) or anxiety (Pan et al. 2020) .", [["COVID-19", "CHEMICAL", 91, 99], ["post-traumatic stress disorder", "DISEASE", 310, 340], ["PTSD", "DISEASE", 342, 346], ["anxiety", "DISEASE", 374, 381], ["post-traumatic stress disorder", "PROBLEM", 310, 340], ["PTSD", "PROBLEM", 342, 346], ["anxiety", "PROBLEM", 374, 381]]], ["However, given the exponential proliferation of studies on this area during the last months, there is a need to synthesise the current body of knowledge.", [["body", "ORGANISM_SUBDIVISION", 135, 139], ["exponential", "OBSERVATION_MODIFIER", 19, 30], ["proliferation", "OBSERVATION_MODIFIER", 31, 44]]], ["Moreover, the evidence base concerning the effectiveness of the interventions to ameliorate such impact has not been systematically assessed and reported.INTRODUCTIONThe aim of this rapid systematic literature review is threefold: i) to examine the impact of health emergencies caused by a viral pandemic or epidemic outbreak on HCWs mental health;INTRODUCTIONii) to identify factors associated with worse impact, and iii) to assess the effectiveness of interventions to reduce such impact.METHODSWe conducted a rapid systematic review following WHO guidelines (Tricco et al. 2017 ) andMETHODSCochrane's recommendations for Rapid Reviews in response to COVID-19 (''Cochrane's work on Rapid Reviews in response to COVID-19'.", [["viral pandemic", "DISEASE", 290, 304], ["COVID-19", "CHEMICAL", 653, 661], ["the interventions", "TREATMENT", 60, 77], ["a viral pandemic", "PROBLEM", 288, 304], ["interventions", "TREATMENT", 454, 467], ["such impact", "PROBLEM", 478, 489], ["COVID", "TEST", 653, 658], ["COVID", "TEST", 713, 718], ["base", "OBSERVATION_MODIFIER", 23, 27]]], ["Accessed 26METHODSMarch 2020' Cochrane 2020)(''Cochrane's work on Rapid Reviews in response to COVID-19'.", [["COVID", "TEST", 95, 100]]], ["We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for planning, conducting and reporting this study (Moher et al. 2009 ).Data Sources and SearchesWe designed specific search strategies for biomedical databases (MEDLINE/Ovid, EMBASE/Elsevier, and PsycInfo/EBSCO), combining MeSH terms and free-text keywords (Online Appendix 1).", [["Systematic Reviews", "TEST", 46, 64], ["this study", "TEST", 142, 152]]], ["We searched databases from inception to 3 rd August 2020, and checked the list of included studies of relevant systematic reviews (Shaukat et al. 2020 , Pappa et al. 2020 , Pan et al. 2020 , Kisely et al. 2020 , Garcia-Iglesias et al. 2020 , Carmassi et al. 2020 , Brooks et al. 2018 to identify potential additional studies.", [["additional studies", "TEST", 306, 324]]], ["We used EndNote X8\u2122 to create a bibliographical database, and Rayyan to screen relevant records (Ouzzani et al. 2016 ).Selection criteriaWe included empirical studies examining the impact on mental health of viral epidemic outbreaks on HCWs, and studies about interventions to reduce such impact.", [["empirical studies", "TEST", 149, 166], ["interventions", "TREATMENT", 260, 273]]], ["We included observational (cross-sectional, case-control, and cohort studies), and experimental studies (non-controlled before-after studies, controlled before-after studies, non-randomised controlled trials, and randomised controlled trials).", [["cohort studies", "TEST", 62, 76], ["experimental studies", "TEST", 83, 103], ["studies", "TEST", 133, 140], ["studies", "TEST", 166, 173], ["non-randomised controlled trials", "TREATMENT", 175, 207], ["randomised controlled trials", "TREATMENT", 213, 241]]], ["We included studies on any type of health emergency caused by a viral epidemic outbreak or pandemic, and examining its impact on HCWs mental health during or after the crisis.", [["a viral epidemic outbreak", "PROBLEM", 62, 87], ["pandemic", "PROBLEM", 91, 99], ["the crisis", "PROBLEM", 164, 174]]], ["For intervention studies, we included also those that examined interventions to protect mental health of HCWs prior, during or after the outbreak onset.", [["intervention studies", "TEST", 4, 24], ["interventions", "TREATMENT", 63, 76]]], ["All types of settings and healthcare professionals were accepted for inclusion.Selection criteriaWe included studies measuring any type of mental health problem or psychiatric morbidity.Selection criteriaWe excluded systematic reviews, narrative reviews, thesis, editorials, protocols, letters to the editor, and studies published in preprint servers but not in peer reviewed journals.", [["psychiatric", "DISEASE", 164, 175], ["Selection criteriaWe", "TEST", 79, 99], ["studies", "TEST", 109, 116], ["mental health problem", "PROBLEM", 139, 160], ["psychiatric morbidity", "PROBLEM", 164, 185]]], ["We also excluded studies published in languages other than English, Spanish or Portuguese.Study SelectionOne reviewer (of IRC, MJSR, MAFR, RZC, DGB) screened the retrieved references at title and abstract against the selection criteria.", [["studies", "TEST", 17, 24], ["IRC", "TEST", 122, 125], ["MJSR", "TEST", 127, 131], ["MAFR", "TEST", 133, 137]]], ["We solved disagreements by consensus or by involving a third reviewer if needed.Data Extraction and Quality AssessmentWe used structured forms to extract relevant data, such as country, health emergency, setting, population, epidemiological design, number of participants, mental health conditions, clinical outcomes and their measurement tools, and main study results.", [["participants", "SPECIES", 259, 271], ["Data Extraction", "TEST", 80, 95], ["their measurement tools", "TEST", 321, 344], ["main study", "TEST", 350, 360]]], ["For observational studies addressing the impact of health emergencies on HCWs mental health, we extracted the prevalence rate of the mental conditions examined in terms of the number of professionals suffering the condition (numerator) out of the total number of study participants (denominator).", [["participants", "SPECIES", 269, 281], ["observational studies", "TEST", 4, 25]]], ["For intervention studies (i.e., randomised and non-randomised trials), we extracted data about the characteristics of the intervention as well as that reported also for observational studies.Data Extraction and Quality AssessmentWe assessed the risk of bias of observational studies (i.e., cross-sectional, case-control, and cohort studies) by using the set of tools developed by Evidence Partners (McMaster University) (Partners) ; whereas ROBINS I (Sterne et al. 2016 ) was applied to uncontrolled trials.Data Extraction and Quality AssessmentFor all studies one reviewer (of MJSR, MAFR, AC, DF, JM, GP, RZC) extracted all the data and assessed the risk of bias, while a second reviewer cross-checked the information for accuracy and completeness.Data Synthesis and AnalysisWe conducted a narrative and tabulated synthesis of the results, classifying the studies according to the type of study (i.e., impact of infectious disease outbreaks on HCWs mental health, or interventions to reduce such impact), and timing of data collection (i.e., before, during, or after the outbreak -based on the studies\u00b4 own definition).", [["infectious disease outbreaks", "DISEASE", 913, 941], ["intervention studies", "TEST", 4, 24], ["the intervention", "TREATMENT", 118, 134], ["observational studies", "TEST", 169, 190], ["Data Extraction", "TEST", 191, 206], ["observational studies", "TEST", 261, 282], ["cohort studies", "TEST", 325, 339], ["Data Extraction", "TEST", 507, 522], ["all studies", "TEST", 549, 560], ["MJSR", "TEST", 578, 582], ["MAFR", "TEST", 584, 588], ["accuracy", "TEST", 723, 731], ["the studies", "TEST", 853, 864], ["study", "TEST", 890, 895], ["infectious disease outbreaks", "PROBLEM", 913, 941], ["interventions", "TREATMENT", 968, 981], ["data collection", "TEST", 1020, 1035], ["the studies", "TEST", 1091, 1102], ["infectious", "OBSERVATION_MODIFIER", 913, 923]]], ["We adapted a taxonomy proposed in a previous study (Brooks et al. 2018 ) to classify risk factors as social, occupational and sociodemographic.Data Synthesis and AnalysisFor studies about the impact of outbreaks on mental health, we used the STATA command \"metaprop\" (Nyaga et al. 2014) to pool estimates of proportions with corresponding 95% confidence intervals.", [["a previous study", "TEST", 34, 50], ["Data Synthesis", "TEST", 143, 157], ["Analysis", "TEST", 162, 170]]], ["We conducted subgroup analyses to explore potential differences in the prevalence of mental health disorders during vs. after the outbreak.", [["mental health disorders", "PROBLEM", 85, 108]]], ["Heterogeneity was quantified by the I 2 statistic, where I 2 >50% was deemed as substantial heterogeneity ).Data Synthesis and AnalysisPublication bias was examined with funnel plots and presence of asymmetry tested with Begg (Begg and Mazumdar 1994) and Egger tests (Egger et al. 1997) .", [["Data Synthesis", "TEST", 108, 122], ["AnalysisPublication bias", "TEST", 127, 151], ["funnel plots", "TEST", 170, 182], ["asymmetry", "PROBLEM", 199, 208], ["Begg (Begg", "TREATMENT", 221, 231], ["Egger tests", "TEST", 255, 266], ["substantial", "OBSERVATION_MODIFIER", 80, 91], ["heterogeneity", "OBSERVATION", 92, 105]]], ["We used Stata, version 12.0 to conduct meta-analyses.", [["Stata, version", "TREATMENT", 8, 22]]], ["Although we initially planned to pool the results from interventions to reduce mental health problems, this was finally not possible due to the scarcity of available data.", [["interventions", "TREATMENT", 55, 68], ["mental health problems", "PROBLEM", 79, 101]]], ["Instead, we conducted a narrative and tabulated synthesis of the interventions and main results.GRADE and 'Summary of findings' tablesWe used the GRADE approach (Sch\u00fcnemann et al. 2019) to assess the quality of evidence related to the outcomes included in this rapid review.", [["the interventions", "TREATMENT", 61, 78], ["the GRADE approach", "TREATMENT", 142, 160]]], ["For assessments of the overall quality of evidence for each outcome, we downgraded the evidence from 'high quality' by one level for serious, or by two levels for very serious, study limitations (risk of bias), indirectness of evidence, inconsistency, imprecision of effect estimates, or potential publication bias (Sch\u00fcnemann et al. 2019 ).Search resultsThe search resulted in a total of 3,479 records.", [["assessments", "TEST", 4, 15]]], ["We excluded 2,877 records based on title and abstract screening.", [["abstract screening", "TEST", 45, 63]]], ["After including seven additional studies identified from manual searches, 117 published studies met the inclusion criteria for this systematic rapid review.", [["seven additional studies", "TEST", 16, 40], ["manual searches", "TEST", 57, 72], ["published studies", "TEST", 78, 95], ["this systematic rapid review", "TEST", 127, 155]]], ["Figure 1 illustrates the selection process of the included studies.", [["the included studies", "TEST", 46, 66]]], ["Online Appendix 2 presents the excluded studies.Search results[ Figure 1 about here]Characteristics of the studiesThis systematic review included 119,189 participants (total).", [["participants", "SPECIES", 154, 166], ["the excluded studies", "TEST", 27, 47], ["the studies", "TEST", 103, 114]]], ["Most of the studies (65%) were conducted in Asian countries (excluding Middle East countries), including China (43%), Taiwan (8%), and Singapore (7%), among others.", [["the studies", "TEST", 8, 19]]], ["13% of the studies were conducted in Northern American countries, and 12% in Middle East Countries.", [["the studies", "TEST", 7, 18]]], ["The mean number of participants was 1,036 (range 26 to 21,199).", [["participants", "ORGANISM", 19, 31], ["participants", "SPECIES", 19, 31], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Around half of the studies (52%) examined the impact of COVID-19, followed by Severe Acute Respiratory Syndrome (SARS epidemic) (35%).", [["Acute Respiratory Syndrome", "DISEASE", 85, 111], ["SARS", "DISEASE", 113, 117], ["the studies", "TEST", 15, 26], ["COVID", "TEST", 56, 61], ["Severe Acute Respiratory Syndrome", "PROBLEM", 78, 111], ["SARS epidemic)", "PROBLEM", 113, 127], ["Severe", "OBSERVATION_MODIFIER", 78, 84], ["Acute", "OBSERVATION_MODIFIER", 85, 90], ["Respiratory Syndrome", "OBSERVATION", 91, 111]]], ["Most studies were conducted during the viral epidemic outbreaks (74%).", [["Most studies", "TEST", 0, 12], ["the viral epidemic outbreaks", "PROBLEM", 35, 63]]], ["General HCWs was the most common studied group (73%), whereas a minority of studies focused in specific types of HCWs (nurses (15%) and physicians (12%)).Characteristics of the studiesAnxiety (62%) and depression (54%) were the mental health conditions most frequently examined, followed by acute stress disorder (33%) and PTSD (31%).", [["Anxiety", "DISEASE", 184, 191], ["depression", "DISEASE", 202, 212], ["acute stress disorder", "DISEASE", 291, 312], ["PTSD", "DISEASE", 323, 327], ["the studies", "TEST", 173, 184], ["Anxiety", "TEST", 184, 191], ["depression", "PROBLEM", 202, 212], ["acute stress disorder", "PROBLEM", 291, 312], ["PTSD", "PROBLEM", 323, 327]]], ["The majority followed a cross-sectional design (91%).", [["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["84% did use validated instruments to evaluate mental health.", [["validated instruments", "TREATMENT", 12, 33]]], ["The characteristics of the included studies are summarised in Table 1.", [["the included studies", "TEST", 23, 43]]], ["[ Table 1 around here]Risk of bias assessmentThe results of the risk of bias assessment are provided in Online Appendix 3.", [["bias assessment", "TEST", 30, 45], ["bias assessment", "TEST", 72, 87], ["bias", "OBSERVATION", 30, 34]]], ["In general, main risks of bias in the 106 cross-sectional studies were low response rate (high risk of bias in 10% of the studies) and selection bias (10%).", [["low response rate", "PROBLEM", 71, 88], ["the studies", "TEST", 118, 129], ["selection bias", "TEST", 135, 149]]], ["The main sources of bias across the eight cohort studies were related to low confidence that the outcome of interest was not present at start of the study (38%) and to potential selection bias (25%).", [["the eight cohort studies", "TEST", 32, 56], ["the study", "TEST", 145, 154], ["potential selection bias", "TEST", 168, 192], ["main", "OBSERVATION_MODIFIER", 4, 8], ["bias", "OBSERVATION", 20, 24]]], ["Main sources of bias of the two uncontrolled before-after studies were bias in selection of participants, and bias in outcome measurement.", [["participants", "SPECIES", 92, 104], ["bias", "TEST", 16, 20], ["studies", "TEST", 58, 65], ["bias in outcome measurement", "TEST", 110, 137], ["bias", "OBSERVATION", 16, 20], ["two", "OBSERVATION_MODIFIER", 28, 31], ["uncontrolled", "OBSERVATION_MODIFIER", 32, 44]]], ["The case-control study did not present serious risks of bias.Prevalence of mental health problems in HCWs during and after viral epidemic outbreaks113 studies examined the mental health problems among frontline HCWs during and/or after an viral epidemic outbreak.", [["The case-control study", "TEST", 0, 22], ["mental health problems", "PROBLEM", 75, 97], ["viral epidemic outbreaks", "PROBLEM", 123, 147], ["an viral epidemic outbreak", "PROBLEM", 236, 262]]], ["The individual study characteristics and results are detailed in Online Appendix 4.", [["The individual study", "TEST", 0, 20]]], ["The great majority of them reported clinically significant mental health symptoms, most frequently PTSD, anxiety, depression, acute stress and burnout.", [["PTSD", "DISEASE", 99, 103], ["anxiety", "DISEASE", 105, 112], ["depression", "DISEASE", 114, 124], ["burnout", "DISEASE", 143, 150], ["significant mental health symptoms", "PROBLEM", 47, 81], ["PTSD", "PROBLEM", 99, 103], ["anxiety", "PROBLEM", 105, 112], ["depression", "PROBLEM", 114, 124], ["acute stress and burnout", "PROBLEM", 126, 150], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["stress", "OBSERVATION", 132, 138]]], ["Prevalence forest plots are shown in Figures 2 to 6 .", [["Prevalence forest plots", "TREATMENT", 0, 23]]], ["For clinically significant symptoms of mental health disorders, the pooled prevalence was higher for acute stress (40%, 95%CI 39 to 41%, I2 0%; 9 studies, 6,949 participants ), followed by anxiety (30%, 95%CI 30 to 31%, I2 0%; 32 studies, 43,751 participants), burnout (28%, 95%CI 26 to 31%, 3 studies, 1,168 participants)), depression (24%, 95%CI 24 to 25%, I2 0%; 31 studies, 61,463 participants)), and post-traumatic stress disorder (13%, 95%CI 13 to 14%, I2 0%; 16 studies, 24,540 participants)).", [["anxiety", "DISEASE", 189, 196], ["burnout", "DISEASE", 261, 268], ["depression", "DISEASE", 325, 335], ["post-traumatic stress disorder", "DISEASE", 405, 435], ["participants", "SPECIES", 161, 173], ["participants", "SPECIES", 246, 258], ["participants", "SPECIES", 309, 321], ["participants", "SPECIES", 385, 397], ["participants", "SPECIES", 485, 497], ["clinically significant symptoms", "PROBLEM", 4, 35], ["mental health disorders", "PROBLEM", 39, 62], ["acute stress", "PROBLEM", 101, 113], ["CI", "TEST", 123, 125], ["I2", "TEST", 137, 139], ["studies", "TEST", 146, 153], ["anxiety", "TEST", 189, 196], ["CI", "TEST", 206, 208], ["I2", "TEST", 220, 222], ["studies", "TEST", 230, 237], ["burnout", "TEST", 261, 268], ["CI", "TEST", 278, 280], ["studies", "TEST", 294, 301], ["depression", "PROBLEM", 325, 335], ["CI", "TEST", 345, 347], ["I2", "TEST", 359, 361], ["studies", "TEST", 369, 376], ["post-traumatic stress disorder", "PROBLEM", 405, 435], ["CI", "TEST", 445, 447], ["I2", "TEST", 459, 461], ["studies", "TEST", 469, 476], ["post-traumatic stress disorder", "OBSERVATION", 405, 435]]], ["Subgroup analyses showed higher prevalence of depression (46%, 95%CI 43 to 48%) and of anxiety (30%, 95% 29 to 30%) after the outbreaks than during the outbreaks (24%, 95%CI 24 to 24%, and 30%, 95%CI 29 to 30%, respectively).", [["depression", "DISEASE", 46, 56], ["anxiety", "DISEASE", 87, 94], ["Subgroup analyses", "TEST", 0, 17], ["depression", "PROBLEM", 46, 56], ["CI", "TEST", 66, 68], ["anxiety", "PROBLEM", 87, 94], ["CI", "TEST", 171, 173], ["CI", "TEST", 197, 199], ["higher prevalence", "OBSERVATION_MODIFIER", 25, 42]]], ["No relevant differences were observed for the rest of mental health symptoms.", [["mental health symptoms", "PROBLEM", 54, 76]]], ["According to exploratory subgroup analyses by gender (Online Appendix 5), female HCWs experienced higher prevalence of PTSD (30%, 95%CI 28 to 31%) and anxiety (26%, 95%CI 25 to 27%) than their male counterparts (16%, 95%CI 13 to 14%, and;Prevalence of mental health problems in HCWs during and after viral epidemic outbreaks21%, 95%CI 19 to 23%, respectively).", [["PTSD", "DISEASE", 119, 123], ["anxiety", "DISEASE", 151, 158], ["HCWs", "ORGANISM", 81, 85], ["exploratory subgroup analyses", "TEST", 13, 42], ["PTSD", "PROBLEM", 119, 123], ["CI", "TEST", 133, 135], ["anxiety", "PROBLEM", 151, 158], ["CI", "TEST", 168, 170], ["CI", "TEST", 220, 222], ["mental health problems", "PROBLEM", 252, 274], ["CI", "TEST", 332, 334]]], ["The prevalence of depression was very similar in male and female HCWs (23% in both cases).", [["depression", "DISEASE", 18, 28], ["depression", "PROBLEM", 18, 28], ["depression", "OBSERVATION", 18, 28]]], ["No data was available to examine potential gender differences in the prevalence of the rest of burnout and acute stress disorders.", [["burnout", "DISEASE", 95, 102], ["acute stress disorders", "DISEASE", 107, 129], ["acute stress disorders", "PROBLEM", 107, 129], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["stress disorders", "OBSERVATION", 113, 129]]], ["Begg's and Egger's tests suggested the absence of publication bias for all the meta-analyses conducted.Prevalence of mental health problems in HCWs during and after viral epidemic outbreaks[ Figures 2-6 around here]Risk factors for mental health problems in HCWs during and after viral epidemic outbreaksSeventy studies examined occupational, sociodemographic and social factors associated with the likelihood of developing mental health problems while providing frontline healthcare during an infectious disease outbreak (Online Appendix 4).Risk factors for mental health problems in HCWs during and after viral epidemic outbreaksThe main occupational factors were working in a high-risk environment, higher perception of threat and risk, specialised training received, and specific occupational role.", [["infectious disease", "DISEASE", 494, 512], ["Begg's and Egger's tests", "TEST", 0, 24], ["mental health problems", "PROBLEM", 117, 139], ["viral epidemic outbreaks", "PROBLEM", 165, 189], ["Risk factors", "PROBLEM", 215, 227], ["mental health problems", "PROBLEM", 232, 254], ["viral epidemic outbreaks", "PROBLEM", 280, 304], ["Seventy studies", "TEST", 304, 319], ["mental health problems", "PROBLEM", 424, 446], ["an infectious disease outbreak", "PROBLEM", 491, 521], ["Risk factors", "PROBLEM", 542, 554], ["mental health problems", "PROBLEM", 559, 581], ["viral epidemic outbreaks", "PROBLEM", 607, 631], ["infectious", "OBSERVATION_MODIFIER", 494, 504], ["main", "OBSERVATION_MODIFIER", 635, 639], ["occupational factors", "OBSERVATION", 640, 660]]], ["Working in a high risk environment was associated with different mental health problems, namely depression , Chatterjee et al. 2020 , Elbay et al. 2020 , Ni et al. 2020 , Huajun Wang et al. 2020 , Wu et al. 2008 , anxiety , Li et al. 2015 , Matsuishi et al. 2012 , Verma et al. 2004 , Dosil Santamaria et al. 2020 , Elbay et al. 2020 , Ni et al. 2020 , Que et al. 2020 , Huajun Wang et al. 2020 ), PTSD (Bukhari et al. 2016 , Styra et al. 2008 , Tang et al. 2017 , Wu et al. 2009 , Wu et al. 2008 , and burnout (Tolomiczenko et al. 2005) .", [["depression", "DISEASE", 96, 106], ["anxiety", "DISEASE", 214, 221], ["PTSD", "DISEASE", 398, 402], ["different mental health problems", "PROBLEM", 55, 87], ["depression", "PROBLEM", 96, 106], ["anxiety", "PROBLEM", 214, 221], ["PTSD", "PROBLEM", 398, 402]]], ["The definition of high risk environment varied across studies, but usually included being in direct contact with infected patients, either providing care (Bukhari et al. 2016 , Verma et al. 2004 or being responsible for cleaning and disinfection (Li et al. 2015) .Risk factors for mental health problems in HCWs during and after viral epidemic outbreaksLikewise, higher perception of threat and risk was also associated with a higher prevalence of a number of different mental health problems, including depression (Liu et al. 2012) , anxiety (Alsubaie et al. 2019 ) and PTSD (Maunder et al. 2004 , Styra et al. 2008 , Wu et al. 2009 ).", [["depression", "DISEASE", 504, 514], ["anxiety", "DISEASE", 535, 542], ["PTSD", "DISEASE", 571, 575], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["high risk environment", "PROBLEM", 18, 39], ["Risk factors", "PROBLEM", 264, 276], ["mental health problems", "PROBLEM", 281, 303], ["viral epidemic outbreaks", "PROBLEM", 329, 353], ["different mental health problems", "PROBLEM", 460, 492], ["depression", "PROBLEM", 504, 514], ["anxiety", "PROBLEM", 535, 542], ["PTSD", "PROBLEM", 571, 575], ["high risk", "OBSERVATION_MODIFIER", 18, 27], ["higher", "OBSERVATION_MODIFIER", 363, 369]]], ["Lack of specialised training was a risk factor for anxiety (Matsuishi et al. 2012 , Wong et al. 2007 , \u00c7ali\u015fkan and Dost 2020 , PTSD (Tang et al. 2017) , and burnout (Maunder et al. 2004) .", [["anxiety", "DISEASE", 51, 58], ["PTSD", "DISEASE", 128, 132], ["anxiety", "PROBLEM", 51, 58], ["PTSD", "PROBLEM", 128, 132]]], ["Some of the studies that recruited more than one cadre reported that specific HCWs were at higher risk of developing mental health problems.", [["HCWs", "ORGANISM", 78, 82], ["the studies", "TEST", 8, 19], ["developing mental health problems", "PROBLEM", 106, 139]]], ["A number of studies found that nurses were more likely to develop PTSD (Tang et al. 2017 , Barello et al. 2020 , Song et al. 2020 ), anxiety , stress (Hui , and burnout (Tolomiczenko et al. 2005) , whereas one study (Austria-Corrales et al. 2011) reported that resident pulmonologists were at higher risk of burnout.Risk factors for mental health problems in HCWs during and after viral epidemic outbreaksOther occupational risk factors for PTSD were job stress (Maunder et al. 2004) , and less job experience (Tang et al. 2017) , whereas lower levels of organisational support increased the risk of burnout (Marjanovic et al. 2007 ).Risk factors for mental health problems in HCWs during and after viral epidemic outbreaksIn terms of sociodemographic factors, younger age was a risk factor for depression (Khanna et al. 2020) , anxiety (Yildirim et al. 2020) , PTSD (Tang et al. 2017 , Sim et al. 2004 ) and burnout (Austria-Corrales et al. 2011) .", [["PTSD", "DISEASE", 66, 70], ["anxiety", "DISEASE", 133, 140], ["burnout", "DISEASE", 161, 168], ["burnout", "DISEASE", 308, 315], ["PTSD", "DISEASE", 441, 445], ["burnout", "DISEASE", 600, 607], ["depression", "DISEASE", 795, 805], ["anxiety", "DISEASE", 829, 836], ["PTSD", "DISEASE", 862, 866], ["pulmonologists", "ORGANISM", 270, 284], ["PTSD", "PROBLEM", 66, 70], ["anxiety", "PROBLEM", 133, 140], ["burnout", "PROBLEM", 308, 315], ["Risk factors", "PROBLEM", 316, 328], ["mental health problems", "PROBLEM", 333, 355], ["viral epidemic outbreaks", "PROBLEM", 381, 405], ["PTSD", "PROBLEM", 441, 445], ["organisational support", "TREATMENT", 555, 577], ["burnout", "PROBLEM", 600, 607], ["Risk factors", "PROBLEM", 634, 646], ["mental health problems", "PROBLEM", 651, 673], ["viral epidemic outbreaks", "PROBLEM", 699, 723], ["depression", "PROBLEM", 795, 805], ["anxiety", "PROBLEM", 829, 836], ["PTSD", "PROBLEM", 862, 866], ["burnout", "OBSERVATION", 308, 315]]], ["Female gender was consistently associated with higher levels of depression (Dosil Santamaria et al. 2020 , Kurt et al. 2020 , Elbay et al. 2020 , Yildirim et al. 2020 , stress (Z. , Badahdah et al. 2020 , Elbay et al. 2020 ), anxiety (Dosil Santamaria et al. 2020 , Lijun Kang et al. 2020 , Kurt et al. 2020 , Badahdah et al. 2020 , Corbett et al. 2020 , Elbay et al. 2020 , Yildirim et al. 2020 ) and burnout (Tolomiczenko et al. 2005) , whereas no consistent associations were found for PTSD.Risk factors for mental health problems in HCWs during and after viral epidemic outbreaksFeelings of social rejection or isolation and higher impact of the outbreak on daily life (Styra et al. 2008) increased the likelihood of developing PTSD, depression (Chatterjee et al. 2020) , stress(Z. , and anxiety (Que et al. 2020) .", [["depression", "DISEASE", 64, 74], ["anxiety", "DISEASE", 226, 233], ["burnout", "DISEASE", 402, 409], ["PTSD", "DISEASE", 489, 493], ["PTSD", "DISEASE", 732, 736], ["depression", "DISEASE", 738, 748], ["anxiety", "DISEASE", 792, 799], ["depression", "PROBLEM", 64, 74], ["anxiety", "PROBLEM", 226, 233], ["PTSD", "PROBLEM", 489, 493], ["Risk factors", "PROBLEM", 494, 506], ["mental health problems", "PROBLEM", 511, 533], ["viral epidemic outbreaks", "PROBLEM", 559, 583], ["social rejection", "PROBLEM", 595, 611], ["isolation", "TREATMENT", 615, 624], ["PTSD", "PROBLEM", 732, 736], ["depression", "PROBLEM", 738, 748], ["anxiety", "PROBLEM", 792, 799], ["social rejection", "OBSERVATION", 595, 611], ["PTSD", "OBSERVATION", 732, 736]]], ["Lack of family and friends support were associated with burnout (Kim and Choi 2016) .", [["burnout", "DISEASE", 56, 63]]], ["In addition, stigmatisation (Koh et al. 2005) , social rejection , and lower levels of social support were identified as risk factors for stress ).Interventions to reduce the mental health impact of viral epidemic outbreaks in HCWsFour studies (Aiello et al. 2011 , Maunder et al. 2010 , Chen et al. 2006 described four different interventions to reduce the mental health impact of viral epidemic outbreaks in HCWs (Online Appendix 6).", [["viral epidemic outbreaks", "DISEASE", 199, 223], ["viral epidemic outbreaks", "DISEASE", 382, 406], ["stigmatisation", "PROBLEM", 13, 27], ["social rejection", "PROBLEM", 48, 64], ["social support", "TREATMENT", 87, 101], ["stress", "PROBLEM", 138, 144], ["Interventions", "TREATMENT", 147, 160], ["Four studies", "TEST", 231, 243], ["rejection", "OBSERVATION", 55, 64], ["viral", "OBSERVATION_MODIFIER", 199, 204]]], ["Two studies in Canada evaluated two educational interventions for improving HCWs mental health by increasing resilience (Aiello et al. 2011 , Maunder et al. 2010 ).", [["Two studies", "TEST", 0, 11], ["educational interventions", "TREATMENT", 36, 61]]], ["Aiello and colleagues (Aiello et al. 2011) conducted a cross-sectional study to evaluate an educational intervention targeted to HCWs during the SARS epidemic, which consisted of a face-to-face group training session based on Folkman and Greer's model of coping (Folkman and Greer 2000) .", [["SARS", "DISEASE", 145, 149], ["a cross-sectional study", "TEST", 53, 76], ["an educational intervention", "TREATMENT", 89, 116], ["the SARS epidemic", "PROBLEM", 141, 158]]], ["The session focused on stressors associated with pandemic influenza and on organisational and individual approaches to building resilience and reducing stress.", [["influenza", "DISEASE", 58, 67], ["pandemic influenza", "PROBLEM", 49, 67]]], ["While most participants did not feel prepared to deal confidently with the pandemic before the session (35%), there was a higher proportion of participants who felt better able to cope after the session (76%).", [["participants", "SPECIES", 11, 23], ["participants", "SPECIES", 143, 155]]], ["Maunder and colleagues conducted an uncontrolled before-after study to explore the impact of a computerassisted resilience training to prepare HCWs for a potential pandemic influenza (Maunder et al. 2010 ).", [["influenza", "DISEASE", 173, 182], ["a computerassisted resilience training", "TREATMENT", 93, 131], ["a potential pandemic influenza", "PROBLEM", 152, 182]]], ["The intervention improved confidence in support and training, pandemic self-efficacy and interpersonal problems (p<0.05).", [["support and training", "TREATMENT", 40, 60], ["interpersonal problems", "PROBLEM", 89, 111]]], ["One cross-sectional study examined the impact of exercise interventions to relieve psychological stress and improve sleep status for frontline medical staff in the fight against COVID-19 in China .", [["One cross-sectional study", "TEST", 0, 25], ["exercise interventions", "TREATMENT", 49, 71], ["psychological stress", "PROBLEM", 83, 103], ["COVID", "TEST", 178, 183]]], ["In comparison with the control group, participants in the intervention group experienced higher levels of anxiety (45.89\u00b11.12 vs 41.02\u00b11.15; p=0.056), depression (50.13\u00b11.81 vs 36.11\u00b12.06; p=0.04), and PTSD (50.13\u00b11.813 vs 29.89 \u00b11.97; p=0.03).", [["anxiety", "DISEASE", 106, 113], ["depression", "DISEASE", 151, 161], ["PTSD", "DISEASE", 202, 206], ["participants", "SPECIES", 38, 50], ["anxiety", "PROBLEM", 106, 113], ["vs", "TEST", 126, 128], ["p", "TEST", 141, 142], ["depression", "PROBLEM", 151, 161], ["vs", "TEST", 174, 176], ["p", "TEST", 189, 190], ["PTSD", "TEST", 202, 206], ["vs", "TEST", 220, 222], ["p", "TEST", 236, 237]]], ["We have very low confidence on the evidence of educational interventions for preventing the psychological impact of viral epidemic outbreaks in HCWs due to the study design (uncontrolled before-after studies) and very serious risk of bias regarding confounding and measurement of outcomes (Online Appendix 7).Interventions to reduce the mental health impact of viral epidemic outbreaks in HCWsOne uncontrolled before-after study in Taiwan (Chen et al. 2006 ) evaluated the effects of a multifaceted intervention to prevent depression and anxiety in hospital nurses during the SARS epidemic.", [["viral epidemic outbreaks", "DISEASE", 361, 385], ["depression", "DISEASE", 523, 533], ["anxiety", "DISEASE", 538, 545], ["SARS", "DISEASE", 576, 580], ["educational interventions", "TREATMENT", 47, 72], ["the study", "TEST", 156, 165], ["studies", "TEST", 200, 207], ["Interventions", "TREATMENT", 309, 322], ["a multifaceted intervention", "TREATMENT", 484, 511], ["depression", "PROBLEM", 523, 533], ["anxiety", "PROBLEM", 538, 545], ["the SARS epidemic", "PROBLEM", 572, 589]]], ["The intervention included in-service training, manpower allocation, gathering sufficient protective equipment, and establishment of a mental health team.", [["manpower allocation", "TREATMENT", 47, 66]]], ["The authors observed statistically significant improvements in nurses' anxiety and depression along with sleep quality at two weeks follow-up.", [["anxiety", "DISEASE", 71, 78], ["depression", "DISEASE", 83, 93], ["' anxiety", "PROBLEM", 69, 78], ["depression", "PROBLEM", 83, 93], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["improvements", "OBSERVATION_MODIFIER", 47, 59]]], ["Our confidence on the evidence for multifaceted interventions for preventing the psychological impact during viral epidemic outbreaks in HCWs was very low (Online Appendix 7) due to limitations in the study design (uncontrolled before after studies) and very serious risk of bias (high risk of selection bias and high risk of bias in measurement of outcomes).Summary of findingsIn this timely systematic rapid review, we synthesized evidence from 117 studies examining the impact on mental health of providing frontline healthcare during viral epidemic outbreaks.Summary of findingsResults showed that HCWs commonly present high levels of anxiety, depression, and PTSD, both during and after the outbreaks.", [["anxiety", "DISEASE", 639, 646], ["depression", "DISEASE", 648, 658], ["PTSD", "DISEASE", 664, 668], ["multifaceted interventions", "TREATMENT", 35, 61], ["the psychological impact", "PROBLEM", 77, 101], ["viral epidemic outbreaks", "PROBLEM", 109, 133], ["the study", "TEST", 197, 206], ["studies", "TEST", 241, 248], ["bias", "PROBLEM", 275, 279], ["selection bias", "PROBLEM", 294, 308], ["117 studies", "TEST", 447, 458], ["viral epidemic outbreaks", "PROBLEM", 538, 562], ["anxiety", "PROBLEM", 639, 646], ["depression", "PROBLEM", 648, 658], ["PTSD", "PROBLEM", 664, 668]]], ["We identified a broad number of risk factors for these conditions, including sociodemographic factors such as younger age and female gender, and social factors such as lack of social support, social rejection or isolation and stigmatization.Summary of findingsOccupational factors entailed working in a high-risk environment (frontline staff), specific occupational roles (e.g., nurse), and having lower levels of specialized training, preparedness and job experience.", [["stigmatization", "DISEASE", 226, 240], ["findingsOccupational factors", "PROTEIN", 252, 280], ["these conditions", "PROBLEM", 49, 65], ["social support", "TREATMENT", 176, 190], ["social rejection", "TREATMENT", 192, 208], ["isolation", "TREATMENT", 212, 221], ["findingsOccupational factors", "PROBLEM", 252, 280], ["broad", "OBSERVATION_MODIFIER", 16, 21], ["rejection", "OBSERVATION", 199, 208]]], ["In contrast with the high number of studies examining impact on mental health, there is limited evidence regarding the impact of interventions to reduce mental health problems in this particularly vulnerable population, and overall its certainty is very low, mainly due to study design and serious risk of bias.Discussion of the main findingsSome of the risk factors associated with mental health problems while providing frontline care during viral epidemic outbreaks cannot be modified.", [["interventions", "TREATMENT", 129, 142], ["mental health problems", "PROBLEM", 153, 175], ["mental health problems", "PROBLEM", 383, 405], ["frontline care", "TREATMENT", 422, 436], ["viral epidemic outbreaks", "PROBLEM", 444, 468]]], ["In this way, working in a high risk environment increases the risk of developing clinically significant symptoms, namely depression , Chatterjee et al. 2020 , Elbay et al. 2020 , Ni et al. 2020 , anxiety , Li et al. 2015 , Matsuishi et al. 2012 , Verma et al. 2004 , Dosil Santamaria et al. 2020 , Elbay et al. 2020 , Ni et al. 2020 , Que et al. 2020 , Huajun Wang et al. 2020 , PTSD (Bukhari et al. 2016 , Tang et al. 2017 , Wu et al. 2009 , Styra et al. 2008 , Wu et al. 2008 , and burnout (Tolomiczenko et al. 2005) .", [["depression", "DISEASE", 121, 131], ["anxiety", "DISEASE", 196, 203], ["PTSD", "DISEASE", 379, 383], ["clinically significant symptoms", "PROBLEM", 81, 112], ["depression", "PROBLEM", 121, 131], ["anxiety", "PROBLEM", 196, 203], ["PTSD", "PROBLEM", 379, 383]]], ["Likewise, it seems like specific cadres are more likely to report mental health problems, namely PTSD (Tang et al. 2017) , and burnout (Austria-Corrales et al. 2011 , Tolomiczenko et al. 2005 ).Discussion of the main findingsHowever, this review also identified specific modifiable factors that can be addressed in advance and mitigate the risk brought by the aforementioned factors.", [["PTSD", "DISEASE", 97, 101], ["burnout", "DISEASE", 127, 134], ["mental health problems", "PROBLEM", 66, 88], ["PTSD", "PROBLEM", 97, 101], ["specific modifiable factors", "PROBLEM", 262, 289]]], ["Lack of specialized training was associated with anxiety, PTSD (Tang et al. 2017) , and burnout (Maunder et al. 2004) , and higher perception of threat and risk was associated with depression (Liu et al. 2012) , anxiety (Alsubaie et al. 2019) , and PTSD (Ho et al. 2005 , Maunder et al. 2004 , Styra et al. 2008 , Wu et al. 2009 ).", [["anxiety", "DISEASE", 49, 56], ["PTSD", "DISEASE", 58, 62], ["burnout", "DISEASE", 88, 95], ["depression", "DISEASE", 181, 191], ["anxiety", "DISEASE", 212, 219], ["PTSD", "DISEASE", 249, 253], ["specialized training", "TREATMENT", 8, 28], ["anxiety", "PROBLEM", 49, 56], ["PTSD", "PROBLEM", 58, 62], ["depression", "PROBLEM", 181, 191], ["anxiety", "PROBLEM", 212, 219], ["PTSD", "PROBLEM", 249, 253]]], ["Long-term institutional preparedness is possible for both factors, through the development and implementation of specialized training that includes infection prevention, diagnostics, patient care, staff, and communication (de Rooij et al. 2020) .Discussion of the main findingsContinuous communication between HCWs and managers, including the provision of up-todate facts about the progression of the outbreak, can convey institutional support (Marjanovic et al. 2007) , and promote the acquisition of knowledge and confidence for those HCWs who have less job experience (Tang et al. 2017) .", [["infection", "DISEASE", 148, 157], ["patient", "ORGANISM", 183, 190], ["patient", "SPECIES", 183, 190], ["specialized training", "TREATMENT", 113, 133], ["infection prevention", "TREATMENT", 148, 168], ["infection", "OBSERVATION", 148, 157]]], ["The proliferation of online mobile-based technologies could play an essential role in promoting connectedness and decrease the feelings of isolation and stigmatization (Gon\u00e7alves-Bradley et al. 2018) , and can also be used for informal contacts between HCWs who are quarantined.Discussion of the main findingsAlthough very limited, evidence from intervention studies indicates that educational interventions have the potential to increase knowledge and resilience (Aiello et al. 2011 , Maunder et al. 2010 , even when implemented during an outbreak (Chen et al. 2006 ).Strengths and limitations of the reviewThis is a timely and comprehensive rapid review of the current literature on the impact of viral epidemic outbreaks on the mental health of HCWs.", [["intervention studies", "TEST", 346, 366], ["educational interventions", "TREATMENT", 382, 407], ["proliferation", "OBSERVATION_MODIFIER", 4, 17]]], ["We examined three relevant areas, namely the prevalence of mental health problems, factors associated with an increased likelihood of developing those problems, and the effects of interventions to improve mental health of HCWs.", [["mental health problems", "PROBLEM", 59, 81], ["interventions", "TREATMENT", 180, 193], ["increased", "OBSERVATION_MODIFIER", 110, 119]]], ["We followed the highest methodological standards when undertaking the current rapid review (Tricco et al. 2017) , and we used the GRADE approach to evaluate the certainty of the evidence, in order to facilitate evidence-informed decision making processes.", [["the GRADE approach", "TREATMENT", 126, 144]]], ["Moreover, the initial screening was undertaken by a single reviewer.", [["the initial screening", "TEST", 10, 31]]], ["Therefore, we cannot discard that relevant references may have been missed out.Limitations of available evidence and future research needsDespite the large number of studies identified in this systematic review, only four studies assessed the efficacy of interventions to ameliorate the impact of health emergencies on mental health of HCWs.", [["studies", "TEST", 166, 173], ["four studies", "TEST", 217, 229], ["interventions", "TREATMENT", 255, 268], ["large", "OBSERVATION_MODIFIER", 150, 155]]], ["None of them was a randomized controlled trial.", [["a randomized controlled trial", "TREATMENT", 17, 46]]], ["During the last six months (since the onset of the COVID-19 pandemic) we have witnessed a proliferation of a large volume of studies examining the impact of COVID-19 on HCWs\u00b4 mental health.", [["COVID-19", "CHEMICAL", 157, 165], ["the COVID", "TEST", 47, 56], ["COVID", "TEST", 157, 162], ["large", "OBSERVATION_MODIFIER", 109, 114]]], ["To make progress in this area, future studies should address these limitations of the available literature.Limitations of available evidence and future research needsThe use of validated measurement tools and more representative sample sizes are warranted in order to strengthen the quality of future cross-sectional studies.", [["future studies", "TEST", 31, 45], ["validated measurement tools", "TEST", 177, 204]]], ["Robust trials are however much more needed to identify effective interventions to reduce mental health problems in HCWs.", [["effective interventions", "TREATMENT", 55, 78], ["mental health problems", "PROBLEM", 89, 111]]], ["Intervention studies should adhere to international reporting standards such as CONSORT (de Rooij et al. 2020) and TIDieR (Hoffmann et al. 2014 ).ConclusionsAs observed in our review, the mental health burden for HCWs during pandemics is especially high both during and after the outbreak.", [["Intervention studies", "TEST", 0, 20], ["pandemics", "PROBLEM", 225, 234], ["high", "OBSERVATION_MODIFIER", 249, 253]]], ["We urge governments, policy-makers and relevant stakeholders to monitor and follow these outcomes and conduct scientifically sound interventional research, in order to mitigate mental health impact on HCWs.ConclusionsThe physical health of HCWs is already at stake from the virus, and once we tackle the current pandemic, we will need to heal the healers, not only for the sake of having a prepared and resilient work-force, but to honour their tremendous sacrifices.", [["HCWs", "ORGANISM", 240, 244], ["the virus", "PROBLEM", 270, 279]]], ["If we want to address these concerns and be able to mitigate its impact, we need to act soon.ContributorsIRC, IRP and MJSR had the idea for the study.", [["ContributorsIRC", "PROTEIN", 93, 108], ["IRP", "PROTEIN", 110, 113], ["MJSR", "DNA", 118, 122], ["the study", "TEST", 140, 149]]], ["IRC, MJSR, MAFR, RZC, DGB screened abstracts and full texts.", [["IRC", "TEST", 0, 3], ["MJSR", "TEST", 5, 9]]], ["MJSR, MAFR, AC, DFN, JM, GP, RZ, DGB acquired data, and assessed risk of bias in studies.", [["MAFR", "PROTEIN", 6, 10], ["MJSR", "TEST", 0, 4], ["MAFR", "TEST", 6, 10], ["AC", "TEST", 12, 14], ["GP", "TEST", 25, 27], ["RZ", "TEST", 29, 31], ["bias in studies", "TEST", 73, 88], ["JM", "ANATOMY", 21, 23]]], ["IRC did the data analysis.", [["the data analysis", "TEST", 8, 25]]], ["All authors interpreted the data analysis.", [["the data analysis", "TEST", 24, 41]]], ["IRC and DGB wrote the manuscript, with revisions from all authors.", [["IRC", "PROBLEM", 0, 3], ["revisions", "TREATMENT", 39, 48]]]], "2ad6066a47fc8fed46abea8e3c7058955f4dd5d8": [["INTRODUCTIONAn outbreak of severe acute respiratory syndrome (SARS) swept the world in early 2003, spreading from China to several countries in different continents, and causing more than 8,000 cases with roughly 14%-18% mortality rate [Donnelly et al., 2004] .", [["acute respiratory syndrome", "DISEASE", 34, 60], ["SARS", "DISEASE", 62, 66], ["severe acute respiratory syndrome", "PROBLEM", 27, 60], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["respiratory syndrome", "OBSERVATION", 40, 60]]], ["A new Coronavirus (SARS-CoV) is the etiological agent of this syndrome, accordingly, molecular, virological, and serological tests have been developed for its identification Poon et al., 2004b] .", [["SARS", "DISEASE", 19, 23], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 6, 17], ["SARS-CoV", "ORGANISM", 19, 27], ["SARS-CoV", "SPECIES", 19, 27], ["A new Coronavirus (SARS", "PROBLEM", 0, 23], ["this syndrome", "PROBLEM", 57, 70], ["serological tests", "TEST", 113, 130], ["new", "OBSERVATION_MODIFIER", 2, 5], ["Coronavirus", "OBSERVATION", 6, 17]]], ["Although retrospective in nature, serological tests are of utmost importance either to confirm or rule out infection by the virus and for seroprevalence studies.", [["infection", "DISEASE", 107, 116], ["serological tests", "TEST", 34, 51], ["infection", "PROBLEM", 107, 116], ["the virus", "PROBLEM", 120, 129], ["seroprevalence studies", "TEST", 138, 160], ["infection", "OBSERVATION", 107, 116]]], ["In this context, the viral nucleocapsid protein N and the membrane protein M are recognized as useful antigens to monitor antibody response in other coronavirus infections [Ndifuna et al., 1998; Chen et al., 2003; Elia et al., 2003] .", [["membrane", "ANATOMY", 58, 66], ["coronavirus infections", "DISEASE", 149, 171], ["nucleocapsid protein N", "GENE_OR_GENE_PRODUCT", 27, 49], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["coronavirus", "ORGANISM", 149, 160], ["viral nucleocapsid protein N", "PROTEIN", 21, 49], ["membrane protein M", "PROTEIN", 58, 76], ["the viral nucleocapsid protein N", "PROBLEM", 17, 49], ["the membrane protein M", "PROBLEM", 54, 76], ["antibody response", "TEST", 122, 139], ["other coronavirus infections", "PROBLEM", 143, 171]]], ["The N and M antigen have been also used to detect anti-SARS-CoV antibodies.", [["M antigen", "GENE_OR_GENE_PRODUCT", 10, 19], ["anti-SARS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 50, 74], ["N and M antigen", "PROTEIN", 4, 19], ["anti-SARS-CoV antibodies", "PROTEIN", 50, 74], ["anti-SARS-CoV", "SPECIES", 50, 63], ["The N and M antigen", "TEST", 0, 19], ["anti-SARS", "TEST", 50, 59], ["CoV antibodies", "TEST", 60, 74]]], ["Despite intense research in this area [Ndifuna et al., 1998; Che et al., 2003; Shi et al., 2003 Shi et al., , 2004a Leung et al., 2004; Liu et al., 2004; Woo et al., 2004; Wu et al., 2004] , the need for further improvements of SARS serology is widely recognized [Poon et al., 2004a] .INTRODUCTIONRecombinant proteins are potentially inexpensive, safe, and easy to standardize serological reagents.", [["SARS", "DISEASE", 228, 232], ["SARS serology", "TEST", 228, 241], ["intense", "OBSERVATION_MODIFIER", 8, 15]]], ["They also represent the safest way to prepare the viral antigens since they can be obtained without propagation of live virus, a fact of considerable importance in view of the recognized capacity of SARS-CoV to infect laboratory workers.", [["live virus", "ORGANISM", 115, 125], ["SARS-CoV", "ORGANISM", 199, 207], ["viral antigens", "PROTEIN", 50, 64], ["SARS-CoV", "SPECIES", 199, 207], ["the viral antigens", "PROBLEM", 46, 64], ["live virus", "PROBLEM", 115, 125]]], ["Thus, for SARS diagnosis and seroprevalence studies, an in-house ELISA was developed in our laboratory acting as National Reference Center for Infectious Emergences.", [["SARS", "DISEASE", 10, 14], ["Infectious Emergences", "DISEASE", 143, 164], ["SARS diagnosis", "TEST", 10, 24], ["seroprevalence studies", "TEST", 29, 51]]], ["The assay is based on the use of SARS-CoV recombinant N and M structural proteins as coating antigens.", [["SARS-CoV recombinant N and M structural proteins", "PROTEIN", 33, 81], ["coating antigens", "PROTEIN", 85, 101], ["SARS-CoV", "SPECIES", 33, 41], ["The assay", "TEST", 0, 9], ["SARS", "PROBLEM", 33, 37], ["CoV recombinant N and M structural proteins", "TREATMENT", 38, 81]]], ["Purified N and M proteins were also used to generate specific polyclonal antibodies for detection of SARS-CoV and its antigens in clinical specimens.Recombinant DNA ManipulationThe N and M full-length genes were generated by RT-PCR technology from a 10 ml sample containing heat and gamma-irradiated cell culture supernatant of Vero E6 cells infected with the SARS-CoV isolate Frankfurt 1 [Thiel et al., 2003] .", [["specimens", "ANATOMY", 139, 148], ["sample", "ANATOMY", 256, 262], ["cell", "ANATOMY", 300, 304], ["supernatant", "ANATOMY", 313, 324], ["Vero E6 cells", "ANATOMY", 328, 341], ["SARS", "DISEASE", 360, 364], ["SARS-CoV", "ORGANISM", 101, 109], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["cell", "CELL", 300, 304], ["Vero E6 cells", "CELL", 328, 341], ["SARS-CoV", "ORGANISM", 360, 368], ["N and M proteins", "PROTEIN", 9, 25], ["polyclonal antibodies", "PROTEIN", 62, 83], ["N and M full-length genes", "DNA", 181, 206], ["Vero E6 cells", "CELL_LINE", 328, 341], ["SARS-CoV", "SPECIES", 101, 109], ["Vero E6", "SPECIES", 328, 335], ["SARS-CoV", "SPECIES", 360, 368], ["Purified N and M proteins", "TEST", 0, 25], ["specific polyclonal antibodies", "TEST", 53, 83], ["SARS", "PROBLEM", 101, 105], ["CoV", "PROBLEM", 106, 109], ["clinical specimens", "TEST", 130, 148], ["Recombinant DNA Manipulation", "TREATMENT", 149, 177], ["The N and M full-length genes", "TREATMENT", 177, 206], ["a 10 ml sample containing heat", "TREATMENT", 248, 278], ["gamma-irradiated cell culture", "TEST", 283, 312], ["Vero E6 cells", "PROBLEM", 328, 341], ["the SARS", "TEST", 356, 364], ["DNA Manipulation", "OBSERVATION", 161, 177]]], ["The oligonucleotides used are listed in Table I .", [["The oligonucleotides", "TREATMENT", 0, 20], ["oligonucleotides", "OBSERVATION", 4, 20]]], ["The BamHI and PstI sequences were added at the 5 0 -ends of each forward (FW) and reverse (RV) primers, respectively.", [["BamHI", "GENE_OR_GENE_PRODUCT", 4, 9], ["PstI", "GENE_OR_GENE_PRODUCT", 14, 18], ["BamHI and PstI sequences", "DNA", 4, 28], ["5 0 -ends", "DNA", 47, 56], ["forward (FW) and reverse (RV) primers", "DNA", 65, 102], ["The BamHI and PstI sequences", "TEST", 0, 28]]], ["The BamHI-PstI restricted cDNAs were cloned in pQE-30 (QIAGEN) and introduced by transformation in the JM109 Escherichia coli cells, obtaining the constructs p-N and p-M, respectively.", [["cells", "ANATOMY", 126, 131], ["BamHI", "GENE_OR_GENE_PRODUCT", 4, 9], ["PstI", "GENE_OR_GENE_PRODUCT", 10, 14], ["pQE-30", "GENE_OR_GENE_PRODUCT", 47, 53], ["QIAGEN", "ORGANISM", 55, 61], ["JM109 Escherichia coli cells", "CELL", 103, 131], ["BamHI-PstI restricted cDNAs", "DNA", 4, 31], ["pQE", "DNA", 47, 50], ["JM109 Escherichia coli cells", "CELL_LINE", 103, 131], ["Escherichia coli", "SPECIES", 109, 125], ["JM109", "SPECIES", 103, 108], ["Escherichia coli", "SPECIES", 109, 125], ["The BamHI-PstI restricted cDNAs", "TREATMENT", 0, 31], ["the JM109 Escherichia coli cells", "PROBLEM", 99, 131]]], ["The proteins were expressed as N-terminal MRGS(H)6 tag proteins.", [["N-", "CHEMICAL", 31, 33], ["N-terminal MRGS(H)6 tag proteins", "PROTEIN", 31, 63], ["N-terminal MRGS", "TEST", 31, 46]]], ["The NH2-terminus (1-117 amino acids, aa), the central-domain (110-340 aa), and the COOH-terminus (333-422 aa) of the N protein, and the cytoplasmic-domain (138-222 aa) of the M protein, were also cloned in pQE-30 obtaining the constructs p-N1, p-N2, p-N3, and p-M2, respectively.", [["cytoplasmic", "ANATOMY", 136, 147], ["NH2", "CHEMICAL", 4, 7], ["amino acids", "CHEMICAL", 24, 35], ["COOH", "CHEMICAL", 83, 87], ["amino acids", "AMINO_ACID", 24, 35], ["cytoplasmic", "ORGANISM_SUBSTANCE", 136, 147], ["NH2", "PROTEIN", 4, 7], ["central-domain", "PROTEIN", 46, 60], ["COOH-terminus", "PROTEIN", 83, 96], ["333-422 aa", "PROTEIN", 98, 108], ["N protein", "PROTEIN", 117, 126], ["cytoplasmic-domain", "PROTEIN", 136, 154], ["138-222 aa", "PROTEIN", 156, 166], ["M protein", "PROTEIN", 175, 184], ["pQE", "PROTEIN", 206, 209], ["M2", "DNA", 262, 264], ["The NH2-terminus", "TEST", 0, 16], ["amino acids", "TEST", 24, 35], ["aa", "TEST", 37, 39], ["the N protein", "TEST", 113, 126], ["the M protein", "TEST", 171, 184], ["central", "ANATOMY_MODIFIER", 46, 53]]], ["Numbers refer to the N (AAP33707) and M (AAP33701) EMBL sequences.Protein PurificationThe recombinant proteins were purified by affinity chromatography on Ni-NTA resin using a denaturing protocol according to the manufacture instructions (The QIAexpressionist).", [["AAP33707", "CHEMICAL", 24, 32], ["AAP33701", "CHEMICAL", 41, 49], ["Ni-NTA", "CHEMICAL", 155, 161], ["Ni-NTA", "CHEMICAL", 155, 161], ["Ni-NTA resin", "SIMPLE_CHEMICAL", 155, 167], ["recombinant proteins", "PROTEIN", 90, 110], ["EMBL sequences", "TEST", 51, 65], ["Protein Purification", "TEST", 66, 86], ["The recombinant proteins", "TEST", 86, 110], ["affinity chromatography", "TEST", 128, 151], ["Ni-NTA resin", "TREATMENT", 155, 167], ["a denaturing protocol", "TREATMENT", 174, 195], ["The QIAexpressionist)", "TREATMENT", 239, 260]]], ["All proteins were solubilized by 8 M urea in PBS, except the protein N, which was solubilized by 6 M guanidine hydrochloride in PBS.", [["urea", "CHEMICAL", 37, 41], ["6 M guanidine hydrochloride", "CHEMICAL", 97, 124], ["urea", "CHEMICAL", 37, 41], ["guanidine hydrochloride", "CHEMICAL", 101, 124], ["urea", "SIMPLE_CHEMICAL", 37, 41], ["PBS", "SIMPLE_CHEMICAL", 45, 48], ["6 M guanidine hydrochloride", "SIMPLE_CHEMICAL", 97, 124], ["PBS", "SIMPLE_CHEMICAL", 128, 131], ["the protein N", "TREATMENT", 57, 70], ["guanidine hydrochloride in PBS", "TREATMENT", 101, 131]]], ["Protein purity and quantity were analyzed by SDS-PAGE followed by staining with Coomassie blue and by standard method (Lowry), respectively.", [["Coomassie blue", "CHEMICAL", 80, 94], ["Coomassie blue", "CHEMICAL", 80, 94], ["Coomassie blue", "SIMPLE_CHEMICAL", 80, 94], ["Coomassie blue", "SPECIES", 80, 94], ["Protein purity", "TEST", 0, 14], ["Coomassie blue", "TEST", 80, 94]]], ["Protein identity was confirmed by Western blotting using the anti poly-histidine antibody (Sigma-Aldrich, St. Louis, MO).Human SeraThe six SARS-CoV-positive sera were collected at the Robert Koch Institute in Berlin, Italy acting within the European Network for Diagnostics of Imported Viral Diseases (ENVID).", [["sera", "ANATOMY", 157, 161], ["poly-histidine", "CHEMICAL", 66, 80], ["Imported Viral Diseases", "DISEASE", 277, 300], ["poly-histidine", "CHEMICAL", 66, 80], ["poly-histidine antibody", "SIMPLE_CHEMICAL", 66, 89], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 91, 104], ["St. Louis", "ORGANISM", 106, 115], ["MO", "ORGANISM", 117, 119], ["Human", "ORGANISM", 121, 126], ["SARS-CoV", "ORGANISM", 139, 147], ["sera", "ORGANISM_SUBSTANCE", 157, 161], ["anti poly-histidine antibody", "PROTEIN", 61, 89], ["Human", "SPECIES", 121, 126], ["Human", "SPECIES", 121, 126], ["SARS-CoV", "SPECIES", 139, 147], ["Protein identity", "TEST", 0, 16], ["the anti poly-histidine antibody", "TREATMENT", 57, 89], ["Human SeraThe six SARS", "TEST", 121, 143], ["positive sera", "PROBLEM", 148, 161], ["Imported Viral Diseases", "PROBLEM", 277, 300], ["Viral Diseases", "OBSERVATION", 286, 300]]], ["All 6 sera were from patients with confirmed SARS according to the WHO criteria, and had documented titres in immunofluorescence, ELISA, and neutralization assay.", [["sera", "ANATOMY", 6, 10], ["SARS", "DISEASE", 45, 49], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["All 6 sera", "TEST", 0, 10], ["SARS", "PROBLEM", 45, 49], ["immunofluorescence", "TEST", 110, 128], ["ELISA", "TEST", 130, 135], ["neutralization assay", "TEST", 141, 161]]], ["They were used for quality control of different serological assays performed in different European laboratories acting as National Reference Centers for SARS diagnosis.", [["SARS", "DISEASE", 153, 157], ["different serological assays", "TEST", 38, 66]]], ["Sera from 20 healthy donors and 73 patients affected by viral (non-SARS) or bacterial acute respiratory syndromes served as controls.ELISAThe SARS-CoV recombinant proteins (0.125 mg/well), in denatured form, were adsorbed in carbonate buffer (pH 9.4) into 96-well microtiter plates overnight at 48C, then incubated with twofold dilutions of each serum, starting from a 1:600 and 1:2,000 dilutions for N1, N2, N3, and M2-based and N-based ELISA, respectively.", [["Sera", "ANATOMY", 0, 4], ["respiratory", "ANATOMY", 92, 103], ["serum", "ANATOMY", 346, 351], ["SARS", "DISEASE", 67, 71], ["acute respiratory syndromes", "DISEASE", 86, 113], ["carbonate", "CHEMICAL", 225, 234], ["N2", "CHEMICAL", 405, 407], ["N3", "CHEMICAL", 409, 411], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["donors", "ORGANISM", 21, 27], ["patients", "ORGANISM", 35, 43], ["carbonate", "SIMPLE_CHEMICAL", 225, 234], ["48C", "SIMPLE_CHEMICAL", 295, 298], ["serum", "ORGANISM_SUBSTANCE", 346, 351], ["N3", "SIMPLE_CHEMICAL", 409, 411], ["SARS-CoV recombinant proteins", "PROTEIN", 142, 171], ["patients", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 142, 150], ["Sera", "TEST", 0, 4], ["viral (non-SARS)", "PROBLEM", 56, 72], ["bacterial acute respiratory syndromes", "PROBLEM", 76, 113], ["CoV recombinant proteins", "TREATMENT", 147, 171], ["carbonate buffer", "TREATMENT", 225, 241], ["pH", "TEST", 243, 245], ["microtiter plates", "TEST", 264, 281], ["N1", "TEST", 401, 403], ["N2", "TEST", 405, 407], ["N3", "TEST", 409, 411], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["respiratory syndromes", "OBSERVATION", 92, 113], ["N3", "ANATOMY_MODIFIER", 409, 411], ["M2", "ANATOMY_MODIFIER", 417, 419]]], ["Incubation with primary and secondary antibody was performed at 378C for 1 hr.", [["primary and secondary antibody", "TREATMENT", 16, 46]]], ["The antigen-antibody complexes were detected by a goat anti-human Ig (IgM, IgG, IgA, H \u00fe L) peroxidase-conjugated (Southern Biotechnology Association Inc., Birmingham, AL), using the TMB (Vector Laboratories Inc., Burlinghame, CA) as substrate.", [["TMB", "CHEMICAL", 183, 186], ["Ig", "GENE_OR_GENE_PRODUCT", 66, 68], ["IgM", "GENE_OR_GENE_PRODUCT", 70, 73], ["IgG", "GENE_OR_GENE_PRODUCT", 75, 78], ["IgA", "GENE_OR_GENE_PRODUCT", 80, 83], ["H \u00fe L", "SIMPLE_CHEMICAL", 85, 90], ["peroxidase", "SIMPLE_CHEMICAL", 92, 102], ["antigen-antibody complexes", "PROTEIN", 4, 30], ["goat anti-human Ig", "PROTEIN", 50, 68], ["IgM", "PROTEIN", 70, 73], ["IgG", "PROTEIN", 75, 78], ["IgA", "PROTEIN", 80, 83], ["H \u00fe L", "PROTEIN", 85, 90], ["peroxidase", "PROTEIN", 92, 102], ["goat", "SPECIES", 50, 54], ["goat", "SPECIES", 50, 54], ["The antigen-antibody complexes", "TEST", 0, 30], ["a goat anti-human Ig", "TEST", 48, 68], ["IgM", "TEST", 70, 73], ["IgG", "TEST", 75, 78], ["IgA", "TEST", 80, 83], ["peroxidase", "TEST", 92, 102]]], ["Optical density was read at 450 nm.Mouse and Rabbit Immune SeraHyperimmune mouse sera were produced by intraperitoneal immunization in CD1 mice (4-8 weeks old) as previously described in Di Bonito et al. [1999] , using 10 mg of purified proteins per mouse.", [["sera", "ANATOMY", 81, 85], ["intraperitoneal", "ANATOMY", 103, 118], ["Mouse", "ORGANISM", 35, 40], ["Rabbit", "ORGANISM", 45, 51], ["mouse", "ORGANISM", 75, 80], ["sera", "ORGANISM_SUBSTANCE", 81, 85], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 118], ["CD1 mice", "ORGANISM", 135, 143], ["mouse", "ORGANISM", 250, 255], ["purified proteins", "PROTEIN", 228, 245], ["Mouse", "SPECIES", 35, 40], ["Rabbit", "SPECIES", 45, 51], ["mouse", "SPECIES", 75, 80], ["mice", "SPECIES", 139, 143], ["mouse", "SPECIES", 250, 255], ["Mouse", "SPECIES", 35, 40], ["Rabbit", "SPECIES", 45, 51], ["mouse", "SPECIES", 75, 80], ["mice", "SPECIES", 139, 143], ["mouse", "SPECIES", 250, 255], ["Rabbit Immune SeraHyperimmune mouse sera", "TREATMENT", 45, 85], ["intraperitoneal immunization", "TREATMENT", 103, 131], ["density", "OBSERVATION", 8, 15], ["intraperitoneal", "ANATOMY", 103, 118]]], ["Purified proteins (100 mg per animal) were also inoculated intradermally four times, at 3-weeks interval, in albino New Zealand rabbits.", [["rabbits", "ORGANISM", 128, 135], ["Purified proteins", "PROTEIN", 0, 17], ["rabbits", "SPECIES", 128, 135], ["Purified proteins", "TREATMENT", 0, 17]]], ["The priming immunization was made with each antigen emulsified with Freund's complete adjuvant (0.5 ml/rabbit).", [["rabbit", "ORGANISM", 103, 109], ["rabbit", "SPECIES", 103, 109], ["rabbit", "SPECIES", 103, 109], ["The priming immunization", "TREATMENT", 0, 24], ["Freund's complete adjuvant", "TREATMENT", 68, 94]]], ["The first and second boosters contained antigen in Freund's incomplete adjuvant (0.5 ml/rabbit) while the final booster consisted in the blotting using the corresponding recombinant protein as antigen.Immunocytochemical AssaySlides containing biochips of SARS-CoV infected and uninfected cells (Euroimmun Italia, Padova, Italy) were treated with 10% fetal calf serum in PBS for 30 min to remove aspecific reaction.", [["cells", "ANATOMY", 288, 293], ["fetal calf serum", "ANATOMY", 350, 366], ["SARS-CoV infected", "DISEASE", 255, 272], ["Freund", "ORGANISM", 51, 57], ["rabbit", "ORGANISM", 88, 94], ["SARS-CoV", "ORGANISM", 255, 263], ["cells", "CELL", 288, 293], ["fetal calf", "ORGANISM_SUBSTANCE", 350, 360], ["serum", "ORGANISM_SUBSTANCE", 361, 366], ["recombinant protein", "PROTEIN", 170, 189], ["uninfected cells", "CELL_TYPE", 277, 293], ["rabbit", "SPECIES", 88, 94], ["calf", "SPECIES", 356, 360], ["rabbit", "SPECIES", 88, 94], ["SARS-CoV", "SPECIES", 255, 263], ["antigen in Freund's incomplete adjuvant", "TREATMENT", 40, 79], ["the final booster", "TREATMENT", 102, 119], ["the blotting", "TEST", 133, 145], ["Immunocytochemical AssaySlides", "TEST", 201, 231], ["SARS", "PROBLEM", 255, 259], ["CoV infected", "PROBLEM", 260, 272], ["uninfected cells", "PROBLEM", 277, 293], ["10% fetal calf serum in PBS", "TREATMENT", 346, 373], ["aspecific reaction", "PROBLEM", 395, 413], ["CoV", "OBSERVATION_MODIFIER", 260, 263], ["infected", "OBSERVATION_MODIFIER", 264, 272], ["uninfected cells", "OBSERVATION", 277, 293]]], ["Rabbit and mouse anti-sera were serially diluted at 1:100 to 1:25,000 and 1:100 to 1:10,000, respectively in PBS 1% non-fat dry milk and incubated with the cell samples for 1 hr at room temperature.", [["anti-sera", "ANATOMY", 17, 26], ["milk", "ANATOMY", 128, 132], ["cell samples", "ANATOMY", 156, 168], ["Rabbit", "ORGANISM", 0, 6], ["mouse", "ORGANISM", 11, 16], ["anti-sera", "GENE_OR_GENE_PRODUCT", 17, 26], ["milk", "ORGANISM_SUBSTANCE", 128, 132], ["cell samples", "CELL", 156, 168], ["Rabbit", "SPECIES", 0, 6], ["mouse", "SPECIES", 11, 16], ["Rabbit", "SPECIES", 0, 6], ["mouse", "SPECIES", 11, 16], ["Rabbit and mouse anti-sera", "TREATMENT", 0, 26], ["PBS", "TEST", 109, 112], ["the cell samples", "TREATMENT", 152, 168]]], ["Antigen-antibody complexes were revealed by a detection system using the labeled polymer method (DAKO EnVision TM \u00fe System, 3-amino-9-ethilcarbazole, Horseradish Peroxidase, Carpinteria, CA).", [["3-amino-9-ethilcarbazole", "CHEMICAL", 124, 148], ["3-amino-9-ethilcarbazole", "CHEMICAL", 124, 148], ["3-amino-9-ethilcarbazole", "SIMPLE_CHEMICAL", 124, 148], ["Horseradish Peroxidase", "SIMPLE_CHEMICAL", 150, 172], ["CA", "GENE_OR_GENE_PRODUCT", 187, 189], ["Antigen-antibody complexes", "PROTEIN", 0, 26], ["Horseradish Peroxidase", "PROTEIN", 150, 172], ["Horseradish", "SPECIES", 150, 161], ["Antigen-antibody complexes", "TEST", 0, 26], ["System", "TEST", 116, 122], ["amino", "TEST", 126, 131], ["ethilcarbazole", "TREATMENT", 134, 148], ["Horseradish Peroxidase", "TREATMENT", 150, 172]]], ["Samples were observed under the light microscope (Leitz, Germany) at a total magnification indicated in the legend of the Figure 4 .RESULTS AND DISCUSSIONN and M structural SARS-CoV proteins were chosen to develop an ELISA test to detect specific antiviral antibodies.", [["Samples", "ANATOMY", 0, 7], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 173, 181], ["CoV proteins", "PROTEIN", 178, 190], ["antiviral antibodies", "PROTEIN", 247, 267], ["Samples", "TEST", 0, 7], ["the light microscope", "TEST", 28, 48], ["a total magnification", "TREATMENT", 69, 90], ["CoV proteins", "PROBLEM", 178, 190], ["an ELISA test", "TEST", 214, 227], ["specific antiviral antibodies", "PROBLEM", 238, 267]]], ["The N and M full-length genes were amplified from heat and gamma-irradiated cell culture supernatant of Vero E6 cells infected with the SARS-CoV isolate Frankfurt 1.", [["cell culture supernatant", "ANATOMY", 76, 100], ["Vero E6 cells", "ANATOMY", 104, 117], ["SARS", "DISEASE", 136, 140], ["cell", "CELL", 76, 80], ["Vero E6 cells", "CELL", 104, 117], ["SARS-CoV", "ORGANISM", 136, 144], ["N and M full-length genes", "DNA", 4, 29], ["Vero E6 cells", "CELL_LINE", 104, 117], ["Vero E6", "SPECIES", 104, 111], ["SARS-CoV", "SPECIES", 136, 144], ["gamma-irradiated cell culture", "TEST", 59, 88], ["Vero E6 cells", "PROBLEM", 104, 117]]], ["The amplified cDNAs were cloned in the expression vector pQE-30 (QIAGEN), obtaining the p-N and p-M constructs, respectively.", [["amplified cDNAs", "DNA", 4, 19], ["expression vector pQE-30", "DNA", 39, 63], ["p-N and p-M constructs", "DNA", 88, 110], ["The amplified cDNAs", "TREATMENT", 0, 19], ["the p-N and p-M constructs", "TREATMENT", 84, 110]]], ["The C-terminus, extra-membrane tail of the M protein (138-222 amino acids) was cloned and sequenced (Fig. 1, panel a) .", [["extra-membrane tail", "ANATOMY", 16, 35], ["amino acids", "CHEMICAL", 62, 73], ["C", "CHEMICAL", 4, 5], ["amino acids", "CHEMICAL", 62, 73], ["C-terminus", "GENE_OR_GENE_PRODUCT", 4, 14], ["amino acids", "AMINO_ACID", 62, 73], ["C-terminus", "PROTEIN", 4, 14], ["extra-membrane tail", "PROTEIN", 16, 35], ["M protein", "PROTEIN", 43, 52], ["138-222 amino acids", "PROTEIN", 54, 73], ["The C-terminus", "TEST", 0, 14], ["the M protein", "TEST", 39, 52], ["amino acids", "TEST", 62, 73], ["extra-membrane tail", "ANATOMY", 16, 35]]], ["The deduced amino acid sequences of each insert were compared with the N and M sequences of the SARS-CoV Frankfurt 1 isolate revealing a 100% amino acid identity, thus assuring that the cloning methods had no inserted spurious amino acid variations.", [["amino acid", "CHEMICAL", 12, 22], ["amino acid", "CHEMICAL", 142, 152], ["amino acid", "CHEMICAL", 227, 237], ["amino acid", "CHEMICAL", 12, 22], ["amino acid", "CHEMICAL", 142, 152], ["amino acid", "CHEMICAL", 227, 237], ["amino acid", "AMINO_ACID", 12, 22], ["amino acid", "AMINO_ACID", 142, 152], ["amino acid", "AMINO_ACID", 227, 237], ["N and M sequences", "DNA", 71, 88], ["SARS-CoV Frankfurt 1", "SPECIES", 96, 116], ["The deduced amino acid sequences", "TEST", 0, 32], ["the SARS", "TEST", 92, 100], ["a 100% amino acid identity", "PROBLEM", 135, 161], ["the cloning methods", "TEST", 182, 201], ["spurious amino acid variations", "PROBLEM", 218, 248], ["acid variations", "OBSERVATION", 233, 248]]], ["While the whole protein M could not be generated, probably for its toxicity in E. coli, the recombinant M2 fragment as well as the full length N protein were successfully expressed in E. coli (Fig. 1, panel b) .", [["toxicity", "DISEASE", 67, 75], ["E. coli", "ORGANISM", 79, 86], ["M2", "GENE_OR_GENE_PRODUCT", 104, 106], ["E. coli", "ORGANISM", 184, 191], ["protein M", "PROTEIN", 16, 25], ["recombinant M2 fragment", "PROTEIN", 92, 115], ["N protein", "PROTEIN", 143, 152], ["E. coli", "SPECIES", 79, 86], ["E. coli", "SPECIES", 184, 191], ["E. coli", "SPECIES", 79, 86], ["E. coli", "SPECIES", 184, 191], ["the whole protein M", "TEST", 6, 25], ["its toxicity", "PROBLEM", 63, 75], ["E. coli", "PROBLEM", 79, 86], ["the recombinant M2 fragment", "PROBLEM", 88, 115], ["the full length N protein", "TEST", 127, 152], ["E. coli", "PROBLEM", 184, 191], ["E. coli", "OBSERVATION", 79, 86], ["recombinant", "OBSERVATION_MODIFIER", 92, 103], ["M2 fragment", "OBSERVATION", 104, 115], ["E. coli", "OBSERVATION", 184, 191]]], ["Recombinant proteins were purified and used as coating antigens in ELISA set up to analyze the 6 SARS-positive human sera.", [["sera", "ANATOMY", 117, 121], ["human", "ORGANISM", 111, 116], ["sera", "ORGANISM_SUBSTANCE", 117, 121], ["Recombinant proteins", "PROTEIN", 0, 20], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["Recombinant proteins", "PROBLEM", 0, 20], ["coating antigens", "TEST", 47, 63], ["ELISA", "TEST", 67, 72]]], ["Twenty human sera from healthy blood donors and 73 SARS-negative sera from patients affected by acute respiratory syndromes with viral (non-SARS) or bacterial etiology were used as negative controls.", [["sera", "ANATOMY", 13, 17], ["blood", "ANATOMY", 31, 36], ["sera", "ANATOMY", 65, 69], ["respiratory", "ANATOMY", 102, 113], ["SARS", "DISEASE", 51, 55], ["acute respiratory syndromes", "DISEASE", 96, 123], ["SARS", "DISEASE", 140, 144], ["human", "ORGANISM", 7, 12], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["blood donors", "ORGANISM_SUBSTANCE", 31, 43], ["sera", "ORGANISM_SUBSTANCE", 65, 69], ["patients", "ORGANISM", 75, 83], ["human", "SPECIES", 7, 12], ["patients", "SPECIES", 75, 83], ["human", "SPECIES", 7, 12], ["blood donors", "TEST", 31, 43], ["SARS", "TEST", 51, 55], ["acute respiratory syndromes", "PROBLEM", 96, 123], ["viral (non-SARS", "PROBLEM", 129, 144], ["bacterial etiology", "PROBLEM", 149, 167], ["acute", "OBSERVATION_MODIFIER", 96, 101], ["respiratory syndromes", "OBSERVATION", 102, 123]]], ["All sera from SARS patients showed a strong positive reaction against N and M2 antigen.", [["sera", "ANATOMY", 4, 8], ["SARS", "DISEASE", 14, 18], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["patients", "ORGANISM", 19, 27], ["M2 antigen", "GENE_OR_GENE_PRODUCT", 76, 86], ["N and M2 antigen", "PROTEIN", 70, 86], ["patients", "SPECIES", 19, 27], ["All sera", "TEST", 0, 8], ["a strong positive reaction", "PROBLEM", 35, 61]]], ["In contrast, no positive reaction was observed in any serum from non-SARS subjects with the dilution cut-off considered, suggesting a high specificity of the test.", [["serum", "ANATOMY", 54, 59], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["positive reaction", "PROBLEM", 16, 33], ["any serum from non-SARS subjects", "PROBLEM", 50, 82], ["the dilution", "TEST", 88, 100], ["the test", "TEST", 154, 162], ["no", "UNCERTAINTY", 13, 15], ["positive", "OBSERVATION_MODIFIER", 16, 24], ["reaction", "OBSERVATION", 25, 33]]], ["Figure 2 particularly shows the titration curves of the 6 SARS serum samples obtained by ELISA with the use of M2 (panel a) and the whole N antigen (panel b).", [["serum samples", "ANATOMY", 63, 76], ["SARS", "DISEASE", 58, 62], ["serum samples", "ORGANISM_SUBSTANCE", 63, 76], ["N antigen", "GENE_OR_GENE_PRODUCT", 138, 147], ["M2", "PROTEIN", 111, 113], ["N antigen", "PROTEIN", 138, 147], ["the titration curves", "TEST", 28, 48], ["the 6 SARS serum samples", "TEST", 52, 76], ["ELISA", "TEST", 89, 94], ["the whole N antigen", "TEST", 128, 147]]], ["It also shows that the anti-M2 antibody titre was generally lower than the anti-N titre, nonetheless, the anti-M2 response showed particularly low inter-subject variability, as compared to the anti-N response.", [["anti-M2 antibody", "GENE_OR_GENE_PRODUCT", 23, 39], ["anti-M2", "GENE_OR_GENE_PRODUCT", 106, 113], ["anti-M2 antibody", "PROTEIN", 23, 39], ["the anti-M2 antibody titre", "TEST", 19, 45], ["the anti-M2 response", "TEST", 102, 122], ["particularly low inter-subject variability", "PROBLEM", 130, 172], ["low inter-subject", "OBSERVATION", 143, 160]]], ["The mean OD reading values of the six SARS sera tested against either M2 or N antigens, at the dilution of 1: 600 and 1:2,000, respectively, are shown in Figure 2 , panel c, together with the values of the 93 non-SARS subjects (OD < 0.2).", [["sera", "ANATOMY", 43, 47], ["SARS", "DISEASE", 38, 42], ["SARS", "DISEASE", 213, 217], ["sera", "ORGANISM_SUBSTANCE", 43, 47], ["M2", "PROTEIN", 70, 72], ["N antigens", "PROTEIN", 76, 86], ["The mean OD reading values", "TEST", 0, 26], ["the six SARS sera", "TEST", 30, 47], ["the dilution", "TEST", 91, 103], ["panel c", "TEST", 165, 172], ["the values", "TEST", 188, 198], ["SARS subjects", "TEST", 213, 226], ["OD", "TEST", 228, 230]]], ["All hightitre ELISA results were confirmed by Western blotting showing the expected immuno-reactive viral protein band (data not shown).", [["immuno-reactive viral protein band", "PROTEIN", 84, 118], ["All hightitre ELISA", "TEST", 0, 19], ["Western blotting", "TEST", 46, 62], ["the expected immuno-reactive viral protein band", "PROBLEM", 71, 118]]], ["Three N fragments (N1, N2, N3) were also expressed as described in Methods (Fig. 1, panel a) .", [["N2", "CHEMICAL", 23, 25], ["N3", "CHEMICAL", 27, 29], ["N fragments", "DNA", 6, 17], ["fragments", "OBSERVATION", 8, 17]]], ["The deduced protein sequences of each N fragment were compared with the N sequences of the SARS-CoV Frankfurt 1 isolate revealing a 100% amino acid identity with the exception of the p-N2 construct where the Tyr at position 248 was replaced by Ala.", [["amino acid", "CHEMICAL", 137, 147], ["Tyr", "CHEMICAL", 208, 211], ["amino acid", "CHEMICAL", 137, 147], ["p-N2", "CHEMICAL", 183, 187], ["Tyr", "CHEMICAL", 208, 211], ["Ala", "CHEMICAL", 244, 247], ["amino acid", "AMINO_ACID", 137, 147], ["Tyr", "AMINO_ACID", 208, 211], ["Ala", "AMINO_ACID", 244, 247], ["N fragment", "PROTEIN", 38, 48], ["N sequences", "DNA", 72, 83], ["p-N2 construct", "DNA", 183, 197], ["SARS-CoV Frankfurt 1", "SPECIES", 91, 111], ["The deduced protein sequences", "TEST", 0, 29], ["each N fragment", "PROBLEM", 33, 48], ["the N sequences", "TEST", 68, 83], ["the SARS", "TEST", 87, 95], ["a 100% amino acid identity", "PROBLEM", 130, 156], ["the p-N2 construct", "TREATMENT", 179, 197], ["fragment", "OBSERVATION", 40, 48], ["N2 construct", "OBSERVATION", 185, 197], ["Ala", "OBSERVATION_MODIFIER", 244, 247]]], ["The three N fragments were purified and used as coating antigen in ELISA to analyze the six SARS-CoV reference sera (Fig. 3) .", [["sera", "ANATOMY", 111, 115], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["N fragments", "DNA", 10, 21], ["SARS-CoV", "SPECIES", 92, 100], ["The three N fragments", "TREATMENT", 0, 21], ["coating antigen", "TEST", 48, 63], ["fragments", "OBSERVATION", 12, 21]]], ["In all cases, clear-cut positive reactions of the six SARS-positive human sera were detected.", [["sera", "ANATOMY", 74, 78], ["SARS", "DISEASE", 54, 58], ["human", "ORGANISM", 68, 73], ["sera", "ORGANISM_SUBSTANCE", 74, 78], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["the six SARS", "TEST", 46, 58], ["positive human sera", "PROBLEM", 59, 78]]], ["In particular, the central N portion (N2) (panel b), demonstrated high levels of positive reaction, with an OD average value (at the dilution of 1:2,000) of 1.8 AE 0.6, with respect to the negative sera 0.05 AE 0.04.", [["N2", "CHEMICAL", 38, 40], ["sera", "ORGANISM_SUBSTANCE", 198, 202], ["panel b)", "TEST", 43, 51], ["high levels of positive reaction", "PROBLEM", 66, 98], ["the dilution", "TEST", 129, 141], ["sera", "TEST", 198, 202], ["central", "ANATOMY_MODIFIER", 19, 26], ["high", "OBSERVATION_MODIFIER", 66, 70], ["positive reaction", "OBSERVATION", 81, 98]]], ["The N1 and N3 proteins generated a lower positive reaction, reaching at the 1:600 dilution the OD average values of 0.6 AE 0.1 (negative sera mean values: 0.07 AE 0.05) and 0.7 AE 0.3 (negative sera mean values: 0.09 AE 0.07), respectively.", [["sera", "ANATOMY", 194, 198], ["N1 and N3 proteins", "PROTEIN", 4, 22], ["The N1 and N3 proteins", "TEST", 0, 22], ["a lower positive reaction", "PROBLEM", 33, 58], ["AE", "TEST", 120, 122], ["sera mean values", "TEST", 137, 153], ["AE", "TEST", 160, 162], ["AE", "TEST", 177, 179], ["sera mean values", "TEST", 194, 210], ["lower", "OBSERVATION_MODIFIER", 35, 40], ["positive reaction", "OBSERVATION", 41, 58]]], ["The specificity of the this ELISA assay (Fig. 2 , panel e; Fig. 3 , panel d) would appear to be rather high as no positive reaction was observed in the N-and N2-based ELISA at the 1:2,000 dilution and only two out of the 93 SARS-negative sera showed a weak positive reaction against all antigens at the 1:600 dilution, reading however twofold lower than the mean SARS-positive sera values.", [["sera", "ANATOMY", 238, 242], ["sera", "ANATOMY", 377, 381], ["N2", "CHEMICAL", 158, 160], ["sera", "ORGANISM_SUBSTANCE", 238, 242], ["sera", "ORGANISM_SUBSTANCE", 377, 381], ["antigens", "PROTEIN", 287, 295], ["the this ELISA assay", "TEST", 19, 39], ["panel e; Fig. 3 , panel d)", "TEST", 50, 76], ["positive reaction", "PROBLEM", 114, 131], ["the 93 SARS", "TEST", 217, 228], ["a weak positive reaction", "PROBLEM", 250, 274], ["the mean SARS", "TEST", 354, 367], ["positive sera values", "PROBLEM", 368, 388]]], ["No positive reaction with any non-SARS sera was however observed at 1:1,200 dilution.RESULTS AND DISCUSSIONThe results described above, showing high immunogenicity of the N and M proteins in SARS patients, prompted us to produce polyclonal antibodies against the recombinant proteins, to be used for the detection of viral antigens.", [["sera", "ANATOMY", 39, 43], ["SARS", "DISEASE", 191, 195], ["sera", "ORGANISM_SUBSTANCE", 39, 43], ["patients", "ORGANISM", 196, 204], ["N and M proteins", "PROTEIN", 171, 187], ["polyclonal antibodies", "PROTEIN", 229, 250], ["recombinant proteins", "PROTEIN", 263, 283], ["viral antigens", "PROTEIN", 317, 331], ["patients", "SPECIES", 196, 204], ["positive reaction", "PROBLEM", 3, 20], ["any non-SARS sera", "PROBLEM", 26, 43], ["polyclonal antibodies", "TREATMENT", 229, 250], ["the recombinant proteins", "TREATMENT", 259, 283], ["viral antigens", "PROBLEM", 317, 331], ["positive", "OBSERVATION_MODIFIER", 3, 11], ["reaction", "OBSERVATION", 12, 20]]], ["Thus, all the five SARS-CoV recombinant proteins were purified and inoculated either in rabbit or in mice in order to generate specific hyperimmune sera.", [["sera", "ANATOMY", 148, 152], ["SARS-CoV", "ORGANISM", 19, 27], ["rabbit", "ORGANISM", 88, 94], ["mice", "ORGANISM", 101, 105], ["hyperimmune", "ORGANISM", 136, 147], ["sera", "ORGANISM_SUBSTANCE", 148, 152], ["SARS-CoV recombinant proteins", "PROTEIN", 19, 48], ["rabbit", "SPECIES", 88, 94], ["mice", "SPECIES", 101, 105], ["SARS-CoV", "SPECIES", 19, 27], ["rabbit", "SPECIES", 88, 94], ["mice", "SPECIES", 101, 105], ["CoV recombinant proteins", "TREATMENT", 24, 48]]], ["All viral proteins showed high immunogenicity in both animal species, inducing specific antibodies, reactive both in ELISA and Western blotting (data not shown).", [["viral proteins", "PROTEIN", 4, 18], ["specific antibodies", "PROTEIN", 79, 98], ["All viral proteins", "TEST", 0, 18], ["high immunogenicity in both animal species", "PROBLEM", 26, 68], ["specific antibodies", "PROBLEM", 79, 98], ["Western blotting", "TEST", 127, 143], ["high immunogenicity", "OBSERVATION", 26, 45], ["animal species", "OBSERVATION", 54, 68], ["reactive", "OBSERVATION_MODIFIER", 100, 108]]], ["The specificity of the sera was examined further by an immunocytochemical assay on slides containing a mixing of mock and SARS-CoV-infected cell.", [["sera", "ANATOMY", 23, 27], ["cell", "ANATOMY", 140, 144], ["sera", "ORGANISM_SUBSTANCE", 23, 27], ["SARS-CoV", "ORGANISM", 122, 130], ["cell", "CELL", 140, 144], ["SARS-CoV", "SPECIES", 122, 130], ["an immunocytochemical assay", "TEST", 52, 79], ["a mixing of mock", "TREATMENT", 101, 117], ["SARS", "PROBLEM", 122, 126], ["infected cell", "PROBLEM", 131, 144], ["infected cell", "OBSERVATION", 131, 144]]], ["All sera showed strong reactivity against the infected cells, with a comparable pattern of cellular staining.", [["sera", "ANATOMY", 4, 8], ["cells", "ANATOMY", 55, 60], ["cellular", "ANATOMY", 91, 99], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["cells", "CELL", 55, 60], ["cellular", "CELL", 91, 99], ["infected cells", "CELL_TYPE", 46, 60], ["All sera", "TEST", 0, 8], ["the infected cells", "PROBLEM", 42, 60], ["cellular staining", "PROBLEM", 91, 108], ["infected cells", "OBSERVATION", 46, 60], ["cellular staining", "OBSERVATION", 91, 108]]], ["In Figure 4 the immunocytochemical assays obtained with the anti-N and anti-M2 rabbit sera at the dilution of 1:1,600, are shown.", [["sera", "ANATOMY", 86, 90], ["anti-N", "SIMPLE_CHEMICAL", 60, 66], ["rabbit", "ORGANISM", 79, 85], ["sera", "ORGANISM_SUBSTANCE", 86, 90], ["anti-N", "PROTEIN", 60, 66], ["rabbit", "SPECIES", 79, 85], ["rabbit", "SPECIES", 79, 85], ["the immunocytochemical assays", "TEST", 12, 41], ["the anti-N and anti-M2 rabbit sera", "TREATMENT", 56, 90]]], ["In particular, the anti-N and anti-M2 rabbit sera could still detect viral antigen at the 1:25,000 dilution (data not shown).", [["sera", "ANATOMY", 45, 49], ["anti-N", "SIMPLE_CHEMICAL", 19, 25], ["rabbit", "ORGANISM", 38, 44], ["sera", "ORGANISM_SUBSTANCE", 45, 49], ["anti-N", "PROTEIN", 19, 25], ["viral antigen", "PROTEIN", 69, 82], ["rabbit", "SPECIES", 38, 44], ["rabbit", "SPECIES", 38, 44], ["the anti-N and anti-M2 rabbit sera", "TEST", 15, 49], ["viral antigen", "TEST", 69, 82]]], ["The anti-SARS-CoV murine sera generally showed a lower titre, irrespective of the antigen used (1:10,000).", [["sera", "ANATOMY", 25, 29], ["anti-SARS-CoV", "ORGANISM", 4, 17], ["murine", "ORGANISM", 18, 24], ["sera", "ORGANISM_SUBSTANCE", 25, 29], ["murine", "SPECIES", 18, 24], ["anti-SARS-CoV", "SPECIES", 4, 17], ["The anti-SARS", "TEST", 0, 13], ["CoV murine sera", "TEST", 14, 29], ["a lower titre", "PROBLEM", 47, 60]]], ["Both animal sera showed no cross-reactivity with other human Coronavirus (data not shown).RESULTS AND DISCUSSIONThe low number of available SARS-positive sera would preclude a sound assessment of the sensitivity and diagnostic efficiency of the described in-house ELISA test.", [["sera", "ANATOMY", 12, 16], ["sera", "ANATOMY", 154, 158], ["SARS", "DISEASE", 140, 144], ["sera", "ORGANISM_SUBSTANCE", 12, 16], ["human", "ORGANISM", 55, 60], ["sera", "ORGANISM_SUBSTANCE", 154, 158], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["Both animal sera", "TEST", 0, 16], ["cross-reactivity", "PROBLEM", 27, 43], ["other human Coronavirus", "PROBLEM", 49, 72], ["available SARS-positive sera", "PROBLEM", 130, 158], ["a sound assessment", "TEST", 174, 192], ["the sensitivity", "TEST", 196, 211], ["low number", "OBSERVATION_MODIFIER", 116, 126]]], ["While our studies clearly warrant further, extended investigation, we would like to emphasize here the effectiveness of recombinant antigen-based ELISA tests, in particular with the use of the novel N2 and M2 antigen for the detection SARS-CoV-antibodies.", [["M2 antigen", "GENE_OR_GENE_PRODUCT", 206, 216], ["recombinant antigen", "PROTEIN", 120, 139], ["novel N2 and M2 antigen", "PROTEIN", 193, 216], ["SARS-CoV-antibodies", "PROTEIN", 235, 254], ["SARS-CoV", "SPECIES", 235, 243], ["our studies", "TEST", 6, 17], ["recombinant antigen", "TEST", 120, 139], ["based ELISA tests", "TEST", 140, 157], ["the novel N2", "TREATMENT", 189, 201], ["the detection SARS", "TEST", 221, 239], ["CoV-antibodies", "TEST", 240, 254]]], ["In addition, our recombinant proteins have been found to be useful for the generation of hyperimmune sera to use for the detection of viral antigens in clinical specimens.", [["sera", "ANATOMY", 101, 105], ["specimens", "ANATOMY", 161, 170], ["hyperimmune", "ORGANISM", 89, 100], ["sera", "ORGANISM_SUBSTANCE", 101, 105], ["recombinant proteins", "PROTEIN", 17, 37], ["viral antigens", "PROTEIN", 134, 148], ["our recombinant proteins", "TEST", 13, 37], ["hyperimmune sera", "TREATMENT", 89, 105], ["the detection", "TEST", 117, 130], ["viral antigens in clinical specimens", "PROBLEM", 134, 170]]], ["Overall, our results strongly suggest the effectiveness of recombinant antigens M and N in laboratory diagnosis of SARS and invite to further, more extensive investigations to validate our methods.", [["SARS", "DISEASE", 115, 119], ["recombinant antigens", "PROTEIN", 59, 79], ["SARS", "PROBLEM", 115, 119], ["extensive investigations", "TEST", 148, 172]]]], "89493b0cde3ffb76589791bd318f2227c58193a3": [["Since its initial description at the end of December 2019, the new severe acute respiratory syndrome (SARS)-CoV2 epidemic has become a rapidly evolving pandemic.", [["acute respiratory syndrome (SARS)-CoV2 epidemic", "DISEASE", 74, 121], ["the new severe acute respiratory syndrome", "PROBLEM", 59, 100], ["CoV2 epidemic", "PROBLEM", 108, 121], ["pandemic", "PROBLEM", 152, 160], ["new", "OBSERVATION_MODIFIER", 63, 66], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["respiratory syndrome", "OBSERVATION", 80, 100], ["rapidly", "OBSERVATION_MODIFIER", 135, 142], ["evolving", "OBSERVATION_MODIFIER", 143, 151], ["pandemic", "OBSERVATION", 152, 160]]], ["1 Following the WHO recommendation, governments worldwide declared quarantine status and containments to prevent the spreading of the disease.", [["containments", "TREATMENT", 89, 101], ["the disease", "PROBLEM", 130, 141], ["disease", "OBSERVATION", 134, 141]]], ["At the time of writing, more than 3.5 billion people (half of humanity) are under containment because of coronavirus restrictions 2 in either their movement, or limitations in the availbility of everyday items.", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52], ["coronavirus restrictions", "PROBLEM", 105, 129], ["coronavirus", "OBSERVATION", 105, 116]]], ["The 20th century saw massive international treaties favouring both circulation of goods (eg, North American Free Trade Agreement, Association of South East Asian Nations and Economic Community Of West African States) and people (Schengen Area).", [["people", "ORGANISM", 221, 227], ["people", "SPECIES", 221, 227], ["massive international treaties", "PROBLEM", 21, 51], ["massive", "OBSERVATION_MODIFIER", 21, 28]]], ["The number of international air travellers has multiplied by 10 in less than 50 years.", [["international air travellers", "PROBLEM", 14, 42], ["number", "OBSERVATION_MODIFIER", 4, 10], ["air travellers", "OBSERVATION", 28, 42]]], ["In this context, containment imposed by the SARS-CoV-2 pandemic is triggering psychological distress.", [["SARS", "DISEASE", 44, 48], ["psychological distress", "DISEASE", 78, 100], ["SARS-CoV-2", "ORGANISM", 44, 54], ["psychological distress", "PROBLEM", 78, 100]]], ["Looking at evidence-based data regarding submariners, the specific containment of submariners provides conflicting results for stress.", [["stress", "PROBLEM", 127, 133]]], ["Even if a first study showed higher stress levels in the Royal Navy submariners than in the Royal Navy surface fleet, 4 a 2-year cohort study did not confirm those results.", [["a first study", "TEST", 8, 21], ["higher stress levels", "PROBLEM", 29, 49], ["cohort study", "TEST", 129, 141]]], ["5 Moreover, despite not seeing the natural sunlight that synchronises the circadian rhythm, there was no alteration of the sleep and wake patterns during a 70-day routine mission, with sleep monitored by polysomnography.", [["alteration of the sleep", "PROBLEM", 105, 128], ["polysomnography", "TEST", 204, 219], ["circadian rhythm", "OBSERVATION", 74, 90]]]], "PMC7172324": [["IntroductionNoroviruses (NoVs) are one of the most common causes of foodborne viral gastroenteritis, infecting over 250 million people worldwide every year.", [["foodborne viral gastroenteritis", "DISEASE", 68, 99], ["NoVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["foodborne viral gastroenteritis", "PROBLEM", 68, 99], ["foodborne viral gastroenteritis", "OBSERVATION", 68, 99]]], ["Symptoms typically last 24 to 48 h, but complications can occur in immunocompromised patients, resulting in an estimated 200,000 deaths per year mainly among elderly people and young children in developing countries (Patel et al., 2008, Robilotti et al., 2015).", [["deaths", "DISEASE", 129, 135], ["patients", "ORGANISM", 85, 93], ["people", "ORGANISM", 166, 172], ["children", "ORGANISM", 183, 191], ["patients", "SPECIES", 85, 93], ["people", "SPECIES", 166, 172], ["children", "SPECIES", 183, 191], ["Symptoms", "PROBLEM", 0, 8]]], ["NoVs are positive-stranded RNA viruses belonging to the family Caliciviridae and, similar to other RNA viruses, they exhibit extremely high levels of genetic diversity (Debbink et al., 2012).", [["NoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 63, 76], ["NoVs", "DNA", 0, 4], ["stranded RNA viruses", "PROBLEM", 18, 38], ["Caliciviridae", "TREATMENT", 63, 76], ["other RNA viruses", "PROBLEM", 93, 110], ["positive", "OBSERVATION", 9, 17], ["stranded RNA", "OBSERVATION_MODIFIER", 18, 30], ["viruses", "OBSERVATION", 103, 110]]], ["NoVs have evolved into seven highly divergent genogroups (GI\u2013GVII), which are in turn divided into genotypes.", [["NoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["GI\u2013GVII", "GENE_OR_GENE_PRODUCT", 58, 65], ["NoVs", "PROTEIN", 0, 4], ["NoVs", "PROBLEM", 0, 4]]], ["The prototypic Norwalk virus belongs to genotype GI.1, but GII.4 has become the most prevalent genotype in the last decades, being responsible for the majority of outbreaks (White, 2014).", [["Norwalk virus", "ORGANISM", 15, 28], ["prototypic Norwalk virus", "SPECIES", 4, 28], ["The prototypic Norwalk virus", "TREATMENT", 0, 28], ["GII.4", "PROBLEM", 59, 64], ["most prevalent", "OBSERVATION_MODIFIER", 80, 94]]], ["The most variable NoV genome regions are located in the surface-exposed P2 domain of the capsid (VP1) protein, which determines antibody escape (Lindesmith et al., 2008, White, 2014).", [["surface", "ANATOMY", 56, 63], ["surface", "CELLULAR_COMPONENT", 56, 63], ["VP1", "GENE_OR_GENE_PRODUCT", 97, 100], ["NoV genome regions", "DNA", 18, 36], ["P2 domain", "DNA", 72, 81], ["capsid (VP1) protein", "PROTEIN", 89, 109], ["the capsid (VP1) protein", "PROBLEM", 85, 109], ["antibody escape", "PROBLEM", 128, 143], ["most", "OBSERVATION_MODIFIER", 4, 8], ["variable", "OBSERVATION_MODIFIER", 9, 17], ["NoV genome", "OBSERVATION", 18, 28], ["regions", "ANATOMY_MODIFIER", 29, 36], ["surface", "OBSERVATION_MODIFIER", 56, 63], ["capsid", "ANATOMY_MODIFIER", 89, 95], ["antibody escape", "OBSERVATION", 128, 143]]], ["Differences in genetic diversity and evolution rates among NoV genotypes have been attributed to multiple factors, including random genetic drift, receptor usage, the structural plasticity of the VP1 protein, and replication fidelity (Bull and White, 2011, Donaldson et al., 2010).", [["NoV", "ORGANISM", 59, 62], ["VP1", "GENE_OR_GENE_PRODUCT", 196, 199], ["VP1 protein", "PROTEIN", 196, 207], ["NoV genotypes", "PROBLEM", 59, 72], ["multiple factors", "PROBLEM", 97, 113], ["random genetic drift", "PROBLEM", 125, 145], ["receptor usage", "TREATMENT", 147, 161], ["the VP1 protein", "TEST", 192, 207], ["diversity", "OBSERVATION_MODIFIER", 23, 32], ["VP1 protein", "ANATOMY", 196, 207]]], ["However, and despite its purported importance for evolution, immune escape, and the development of efficient control strategies, the rate of spontaneous mutation of human NoVs has not been experimentally determined.IntroductionThe genetic diversity of RNA viruses is ultimately driven by their extremely high rates of spontaneous mutation, which are orders of magnitude higher than those of DNA-based microorganisms and range from 10\u2212 6 to 10\u2212 4 per nucleotide per round of copying (Lauring et al., 2013, Sanju\u00e1n et al., 2010).", [["nucleotide", "CHEMICAL", 450, 460], ["human", "ORGANISM", 165, 170], ["NoVs", "GENE_OR_GENE_PRODUCT", 171, 175], ["DNA", "CELLULAR_COMPONENT", 391, 394], ["human NoVs", "PROTEIN", 165, 175], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 165, 170], ["immune escape", "PROBLEM", 61, 74], ["efficient control strategies", "TREATMENT", 99, 127], ["spontaneous mutation of human NoVs", "PROBLEM", 141, 175], ["RNA viruses", "PROBLEM", 252, 263], ["spontaneous mutation", "PROBLEM", 318, 338], ["DNA", "TEST", 391, 394], ["RNA viruses", "OBSERVATION", 252, 263]]], ["Such high mutation rates are commonly attributed to the low replication fidelity of RNA virus polymerases, since these lack 3\u2032 exonuclease activity in all viral families examined except coronaviruses (Smith and Denison, 2013, Ulferts and Ziebuhr, 2011).", [["3\u2032 exonuclease", "GENE_OR_GENE_PRODUCT", 124, 138], ["RNA virus polymerases", "PROTEIN", 84, 105], ["exonuclease", "PROTEIN", 127, 138], ["Such high mutation rates", "PROBLEM", 0, 24], ["RNA virus polymerases", "PROBLEM", 84, 105], ["coronaviruses", "PROBLEM", 186, 199], ["low replication", "OBSERVATION_MODIFIER", 56, 71]]], ["However, editing of the viral genome by host-encoded proteins is another possible source of mutations.", [["viral genome", "DNA", 24, 36], ["host-encoded proteins", "PROTEIN", 40, 61], ["the viral genome", "PROBLEM", 20, 36], ["mutations", "PROBLEM", 92, 101], ["viral genome", "OBSERVATION", 24, 36]]], ["Double-stranded RNA-specific adenosine deaminases (ADAR) have been suggested to edit the genome of a variety of negative-stranded RNA viruses, including measles virus (Cattaneo et al., 1988), human parainfluenza virus (Murphy et al., 1991), respiratory syncytial virus (Mart\u00ednez and Melero, 2002), lymphocytic choriomeningitis virus (Zahn et al., 2007), and Rift Valley fever virus (Susp\u00e8ne et al., 2008), and the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3 cytidine deaminase family (APOBEC3) is known to edit HIV-1 (Desimmie et al., 2014, Moris et al., 2014, Santa-Marta et al., 2013), hepatitis B virus (Susp\u00e8ne et al., 2005), papillomaviruses (Vartanian et al., 2008), and herpesviruses (Susp\u00e8ne et al. 2011).", [["adenosine", "CHEMICAL", 29, 38], ["measles virus", "DISEASE", 153, 166], ["parainfluenza virus", "DISEASE", 198, 217], ["respiratory syncytial virus", "DISEASE", 241, 268], ["lymphocytic choriomeningitis virus", "DISEASE", 298, 332], ["Rift Valley fever", "DISEASE", 358, 375], ["cytidine", "CHEMICAL", 481, 489], ["hepatitis B", "DISEASE", 611, 622], ["adenosine", "CHEMICAL", 29, 38], ["cytidine", "CHEMICAL", 481, 489], ["adenosine deaminases", "GENE_OR_GENE_PRODUCT", 29, 49], ["ADAR", "GENE_OR_GENE_PRODUCT", 51, 55], ["measles virus", "ORGANISM", 153, 166], ["human", "ORGANISM", 192, 197], ["parainfluenza virus", "ORGANISM", 198, 217], ["respiratory syncytial virus", "ORGANISM", 241, 268], ["lymphocytic choriomeningitis virus", "ORGANISM", 298, 332], ["Rift Valley fever virus", "ORGANISM", 358, 381], ["apolipoprotein B", "GENE_OR_GENE_PRODUCT", 414, 430], ["catalytic polypeptide-like 3 cytidine deaminase", "GENE_OR_GENE_PRODUCT", 452, 499], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 508, 515], ["HIV-1", "ORGANISM", 534, 539], ["hepatitis B virus", "ORGANISM", 611, 628], ["papillomaviruses", "ORGANISM", 653, 669], ["herpesviruses", "ORGANISM", 700, 713], ["adenosine deaminases", "PROTEIN", 29, 49], ["ADAR", "PROTEIN", 51, 55], ["apolipoprotein B mRNA editing enzyme", "PROTEIN", 414, 450], ["catalytic polypeptide-like 3 cytidine deaminase family", "PROTEIN", 452, 506], ["APOBEC3", "PROTEIN", 508, 515], ["measles virus", "SPECIES", 153, 166], ["human", "SPECIES", 192, 197], ["parainfluenza virus", "SPECIES", 198, 217], ["respiratory syncytial virus", "SPECIES", 241, 268], ["lymphocytic choriomeningitis virus", "SPECIES", 298, 332], ["Rift Valley fever virus", "SPECIES", 358, 381], ["HIV-1", "SPECIES", 534, 539], ["hepatitis B virus", "SPECIES", 611, 628], ["measles virus", "SPECIES", 153, 166], ["human parainfluenza virus", "SPECIES", 192, 217], ["respiratory syncytial virus", "SPECIES", 241, 268], ["lymphocytic choriomeningitis virus", "SPECIES", 298, 332], ["Rift Valley fever virus", "SPECIES", 358, 381], ["HIV-1", "SPECIES", 534, 539], ["hepatitis B virus", "SPECIES", 611, 628], ["Double-stranded RNA", "TREATMENT", 0, 19], ["stranded RNA viruses", "PROBLEM", 121, 141], ["measles virus", "PROBLEM", 153, 166], ["human parainfluenza virus", "PROBLEM", 192, 217], ["respiratory syncytial virus", "PROBLEM", 241, 268], ["lymphocytic choriomeningitis virus", "PROBLEM", 298, 332], ["Rift Valley fever virus", "PROBLEM", 358, 381], ["the apolipoprotein B mRNA", "TEST", 410, 435], ["enzyme", "TEST", 444, 450], ["catalytic polypeptide", "TEST", 452, 473], ["Santa", "TEST", 584, 589], ["hepatitis B virus", "PROBLEM", 611, 628], ["papillomaviruses", "PROBLEM", 653, 669], ["stranded RNA", "OBSERVATION_MODIFIER", 7, 19], ["adenosine deaminases", "OBSERVATION", 29, 49], ["stranded RNA viruses", "OBSERVATION", 121, 141], ["parainfluenza virus", "OBSERVATION", 198, 217], ["respiratory syncytial", "ANATOMY", 241, 262], ["lymphocytic choriomeningitis", "OBSERVATION", 298, 326], ["hepatitis", "ANATOMY", 611, 620]]], ["In HIV-1, 98% of spontaneous mutations in vivo are produced by APOBEC3, whereas only 2% are attributable to the viral reverse transcriptase (Cuevas et al., 2015), but the relative contribution of the viral polymerase and host-mediated editing is unknown for most other viruses.IntroductionHere, we have analyzed the intra-patient genetic diversity of a region of the NoV capsid VP1 by performing ultra-deep sequencing of stool samples obtained from infected patients.", [["stool samples", "ANATOMY", 421, 434], ["HIV-1", "ORGANISM", 3, 8], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 63, 70], ["NoV capsid", "ORGANISM", 367, 377], ["VP1", "ORGANISM", 378, 381], ["stool samples", "ORGANISM_SUBSTANCE", 421, 434], ["patients", "ORGANISM", 458, 466], ["APOBEC3", "PROTEIN", 63, 70], ["viral reverse transcriptase", "PROTEIN", 112, 139], ["viral polymerase", "PROTEIN", 200, 216], ["NoV capsid VP1", "PROTEIN", 367, 381], ["HIV-1", "SPECIES", 3, 8], ["patients", "SPECIES", 458, 466], ["HIV-1", "SPECIES", 3, 8], ["HIV", "TEST", 3, 6], ["spontaneous mutations", "PROBLEM", 17, 38], ["the viral polymerase", "PROBLEM", 196, 216], ["host-mediated editing", "PROBLEM", 221, 242], ["most other viruses", "PROBLEM", 258, 276], ["the NoV capsid VP1", "PROBLEM", 363, 381], ["ultra", "TEST", 396, 401], ["stool samples", "TEST", 421, 434], ["viral polymerase", "OBSERVATION", 200, 216]]], ["Unexpectedly, we found a small number of hyper-mutated sequences carrying large numbers of A-to-G or U-to-C base transitions that were not attributable to sequencing errors.", [["hyper-mutated sequences", "DNA", 41, 64], ["hyper-mutated sequences", "PROBLEM", 41, 64], ["U-to-C base transitions", "PROBLEM", 101, 124], ["small", "OBSERVATION_MODIFIER", 25, 30], ["number", "OBSERVATION_MODIFIER", 31, 37], ["hyper", "OBSERVATION", 41, 46], ["large", "OBSERVATION_MODIFIER", 74, 79], ["numbers", "OBSERVATION_MODIFIER", 80, 87], ["base", "ANATOMY_MODIFIER", 108, 112], ["not attributable to", "UNCERTAINTY", 135, 154]]], ["1/1000 (J\u00fcnemann et al., 2013), it is extremely improbable to find multiple mutations in a single read.", [["multiple mutations", "PROBLEM", 67, 85]]], ["The natural genetic diversity of NoVs has been studied previously within individual patients (Nilsson et al., 2003, Obara et al., 2008, Vega et al., 2014), within defined outbreaks (Dingle, 2004, Holzknecht et al., 2015, Sasaki et al., 2006), or at larger geographic and temporal scales (Bodhidatta et al., 2015, Carlsson et al., 2009, Cotten et al., 2014, Kobayashi et al., 2015, Vega et al., 2014).", [["NoVs", "GENE_OR_GENE_PRODUCT", 33, 37], ["patients", "ORGANISM", 84, 92], ["NoVs", "DNA", 33, 37], ["patients", "SPECIES", 84, 92], ["temporal", "ANATOMY_MODIFIER", 271, 279]]], ["However, this diversity depends on multiple factors other than spontaneous mutation rates, including natural selection, the number of replication rounds elapsed and random genetic drift, among others.", [["multiple factors", "PROBLEM", 35, 51], ["spontaneous mutation rates", "PROBLEM", 63, 89], ["natural selection", "TREATMENT", 101, 118], ["random genetic drift", "PROBLEM", 165, 185], ["replication", "OBSERVATION_MODIFIER", 134, 145], ["genetic drift", "OBSERVATION", 172, 185]]], ["To discard these confounders and focus on spontaneous mutations, we used a cell culture system in which human cells are transfected with an infectious cDNA clone (Asanaka et al., 2005, Katayama et al., 2014).", [["cell", "ANATOMY", 75, 79], ["cells", "ANATOMY", 110, 115], ["cell", "CELL", 75, 79], ["human", "ORGANISM", 104, 109], ["cells", "CELL", 110, 115], ["clone", "CELL", 156, 161], ["human cells", "CELL_TYPE", 104, 115], ["infectious cDNA clone", "DNA", 140, 161], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["spontaneous mutations", "PROBLEM", 42, 63], ["a cell culture system", "TEST", 73, 94]]], ["Since these cells do not support viral attachment and entry, this system restricts viral replication to a single infection cycle.", [["cells", "ANATOMY", 12, 17], ["infection", "DISEASE", 113, 122], ["cells", "CELL", 12, 17], ["viral attachment", "PROBLEM", 33, 49], ["this system", "TREATMENT", 61, 72], ["viral replication", "TREATMENT", 83, 100], ["a single infection cycle", "TREATMENT", 104, 128], ["viral replication", "OBSERVATION", 83, 100], ["infection", "OBSERVATION", 113, 122]]], ["Whereas this is generally viewed as a limitation, single-cycle viral replication was convenient for the purpose of mutation rate estimation, because it allowed us to minimize the effects of selection and other evolutionary factors.", [["single-cycle viral replication", "TREATMENT", 50, 80], ["mutation rate estimation", "TEST", 115, 139], ["other evolutionary factors", "PROBLEM", 204, 230]]], ["This approach allowed us to observe hundreds of sequences carrying multiple U-to-C or A-to-G substitutions each, suggesting that a large fraction of all spontaneous mutations corresponds to hyper-mutation events.", [["hyper-mutation", "DISEASE", 190, 204], ["U-to-C", "GENE_OR_GENE_PRODUCT", 76, 82], ["a large fraction", "PROBLEM", 129, 145], ["all spontaneous mutations", "PROBLEM", 149, 174], ["hyper-mutation events", "PROBLEM", 190, 211], ["large", "OBSERVATION_MODIFIER", 131, 136], ["fraction", "OBSERVATION", 137, 145], ["spontaneous mutations", "OBSERVATION", 153, 174]]], ["Based on the sequence context of the observed changes, we propose that NoV hyper-mutation might be driven by ADAR-mediated editing of the viral genomic RNA of either polarity during replication.RT-PCR of stool samples ::: MethodsViral RNA was extracted from 20% stool suspensions in PBS using the Trizol LS reagent (Invitrogen), eluted in diethyl pyrocarbonate-treated water containing RNasin (Promega) and stored at \u2212 70 \u00b0C. RT was performed using Superscript III (Invitrogen) and random hexamers for 10 min at 25 \u00b0C, 45 min at 50 \u00b0C and 15 min at 70 \u00b0C. PCR was done with Phusion High-Fidelity DNA polymerase following manufacturer's recommendations and specific primers degenerated either for purines or pyrimidines at a final concentration of 200 \u03bcM.", [["stool samples", "ANATOMY", 204, 217], ["diethyl pyrocarbonate", "CHEMICAL", 339, 360], ["RNasin", "CHEMICAL", 386, 392], ["purines", "CHEMICAL", 696, 703], ["pyrimidines", "CHEMICAL", 707, 718], ["diethyl pyrocarbonate", "CHEMICAL", 339, 360], ["purines", "CHEMICAL", 696, 703], ["pyrimidines", "CHEMICAL", 707, 718], ["NoV", "GENE_OR_GENE_PRODUCT", 71, 74], ["ADAR", "GENE_OR_GENE_PRODUCT", 109, 113], ["Invitrogen", "SIMPLE_CHEMICAL", 316, 326], ["diethyl pyrocarbonate", "SIMPLE_CHEMICAL", 339, 360], ["water", "SIMPLE_CHEMICAL", 369, 374], ["RNasin", "SIMPLE_CHEMICAL", 386, 392], ["Promega", "ORGANISM", 394, 401], ["DNA", "CELLULAR_COMPONENT", 596, 599], ["purines", "SIMPLE_CHEMICAL", 696, 703], ["pyrimidines", "SIMPLE_CHEMICAL", 707, 718], ["ADAR", "PROTEIN", 109, 113], ["viral genomic RNA", "RNA", 138, 155], ["MethodsViral RNA", "RNA", 222, 238], ["Superscript III", "DNA", 449, 464], ["Phusion High-Fidelity DNA polymerase", "PROTEIN", 574, 610], ["NoV hyper-mutation", "PROBLEM", 71, 89], ["RT-PCR of stool samples", "TEST", 194, 217], ["MethodsViral RNA", "TREATMENT", 222, 238], ["the Trizol LS reagent (Invitrogen)", "TREATMENT", 293, 327], ["eluted in diethyl pyrocarbonate", "TREATMENT", 329, 360], ["RNasin (Promega)", "TREATMENT", 386, 402], ["Superscript III (Invitrogen)", "TREATMENT", 449, 477], ["random hexamers", "TREATMENT", 482, 497], ["PCR", "TEST", 556, 559], ["Phusion", "TEST", 574, 581], ["manufacturer's recommendations", "TREATMENT", 621, 651], ["specific primers", "TREATMENT", 656, 672], ["pyrimidines", "TREATMENT", 707, 718], ["viral genomic RNA", "OBSERVATION", 138, 155], ["stool", "OBSERVATION", 204, 209]]], ["For VP1 region 1, two pairs of primers with different degeneration were used: primers 5\u2032-AyGAAGAyGGCGyCGAGyGACG-3\u2032 (forward, nucleotides 5085\u20135106 in accession JX459908) and 5\u2032-GGrrrrTTTGGTGGGrCTGCTGC-3\u2032 (reverse, nucleotides 5448\u20135470 in accession JX459908) were designed to account for U-to-C mutations in plus-strand RNA, and primers 5\u2032-rTGrrGrTGGCGTCGrGTGrCG-3\u2032 (forward) and 5\u2032-GGAAAAyyyGGyGGGACyGCyGC-3\u2032 (reverse) were designed to account for A-to-G mutations in plus-strand RNA.", [["VP1 region 1", "GENE_OR_GENE_PRODUCT", 4, 16], ["5\u2032-GGrrrrTTTGGTGGGrCTGCTGC-3", "GENE_OR_GENE_PRODUCT", 174, 202], ["U-to-C", "GENE_OR_GENE_PRODUCT", 288, 294], ["5\u2032-GGAAAAyyyGGyGGGACyGCyGC-3", "GENE_OR_GENE_PRODUCT", 380, 408], ["VP1 region 1", "DNA", 4, 16], ["primers 5\u2032-AyGAAGAyGGCGyCGAGyGACG-3\u2032", "DNA", 78, 114], ["forward, nucleotides 5085\u20135106", "DNA", 116, 146], ["5\u2032-GGrrrrTTTGGTGGGrCTGCTGC-3\u2032", "DNA", 174, 203], ["reverse, nucleotides 5448\u20135470", "DNA", 205, 235], ["accession JX459908", "DNA", 239, 257], ["U-to-C mutations", "DNA", 288, 304], ["5\u2032", "DNA", 337, 339], ["rTGrrGrTGGCGTCGrGTGrCG", "DNA", 340, 362], ["3\u2032", "DNA", 363, 365], ["plus-strand RNA", "RNA", 469, 484], ["VP1 region", "PROBLEM", 4, 14], ["different degeneration", "PROBLEM", 44, 66], ["primers", "TEST", 78, 85], ["AyGAAGAyGGCGyCGAGyGACG", "TEST", 89, 111], ["nucleotides", "TEST", 125, 136], ["GGrrrrTTTGGTGGGrCTGCTGC", "TEST", 177, 200], ["nucleotides", "TEST", 214, 225], ["U", "TEST", 288, 289], ["C mutations", "PROBLEM", 293, 304], ["strand RNA", "TEST", 313, 323], ["primers", "TEST", 329, 336], ["rTGrrGrTGGCGTCGrGTGrCG", "TEST", 340, 362], ["GGAAAAyyyGGyGGGACyGCyGC", "TEST", 383, 406], ["different", "OBSERVATION_MODIFIER", 44, 53], ["degeneration", "OBSERVATION", 54, 66], ["strand RNA", "OBSERVATION", 474, 484]]], ["For region 2, the degenerate primer pairs were 5\u2032-CAAGAyyCCCCAyyCCyyyGG-3\u2032 (forward, nucleotides 5803\u20135823 in accession JX459908) and 5\u2032-GGrTGrCrCCGrCTGGGGTG-3\u2032 (reverse, nucleotides 6233\u20136252 in accession JX459908), and 5\u2032-CrrGrTTCCCCrTTCCTTTGG-3\u2032 (forward) and 5\u2032-GGAyGACACCGACyGGGGyG-3\u2032 (reverse), respectively.", [["nucleotides", "CHEMICAL", 85, 96], ["nucleotides", "CHEMICAL", 171, 182], ["5\u2032-GGrTGrCrCCGrCTGGGGTG-3", "GENE_OR_GENE_PRODUCT", 134, 159], ["degenerate primer pairs", "DNA", 18, 41], ["5\u2032-CAAGAyyCCCCAyyCCyyyGG-3\u2032", "DNA", 47, 74], ["forward, nucleotides 5803\u20135823", "DNA", 76, 106], ["reverse, nucleotides 6233\u20136252", "DNA", 162, 192], ["3\u2032", "DNA", 246, 248], ["the degenerate primer pairs", "TEST", 14, 41], ["CAAGAyyCCCCAyyCCyyyGG", "TEST", 50, 71], ["nucleotides", "TEST", 85, 96], ["GGrTGrCrCCGrCTGGGGTG", "TEST", 137, 157], ["nucleotides", "TEST", 171, 182], ["CrrGrTTCCCCrTTCCTTTGG", "TEST", 224, 245], ["GGAyGACACCGACyGGGGyG", "TEST", 266, 286]]], ["PCR conditions were 98 \u00b0C 30 s, 35 cycles of 98 \u00b0C 10 s, 68 \u00b0C 30 s, 72 \u00b0C 1 min, and a final elongation step at 72 \u00b0C 5 min.Transfection assays ::: MethodsA previously described Norwalk virus infectious cDNA clone (Asanaka et al., 2005) was obtained after an MTA with Dr. M. K. Estes (Baylor College of Medicine, Houston), cloned in Escherichia coli by the heat shock method, and purified by midiprep using the PureLink HiPure Plasmid Midiprep kit (Invitrogen).", [["Norwalk virus", "ORGANISM", 179, 192], ["Escherichia coli", "ORGANISM", 334, 350], ["Norwalk virus infectious cDNA clone", "DNA", 179, 214], ["PureLink HiPure Plasmid Midiprep kit", "PROTEIN", 412, 448], ["Escherichia coli", "SPECIES", 334, 350], ["Escherichia coli", "SPECIES", 334, 350], ["PCR conditions", "TEST", 0, 14], ["cycles", "TEST", 35, 41], ["\u00b0C", "TEST", 48, 50], ["\u00b0C", "TEST", 60, 62], ["\u00b0C", "TEST", 72, 74], ["MethodsA", "TREATMENT", 149, 157], ["Norwalk virus infectious cDNA clone", "PROBLEM", 179, 214], ["Escherichia coli", "PROBLEM", 334, 350], ["the heat shock method", "TREATMENT", 354, 375], ["midiprep", "TREATMENT", 393, 401], ["the PureLink HiPure Plasmid Midiprep kit (Invitrogen)", "TREATMENT", 408, 461], ["Escherichia coli", "OBSERVATION", 334, 350]]], ["Human embryonic kidney cells HEK293 were obtained from the American Tissue Culture Collection (ATCC CRL-11,268) and cultured in DMEM F12 (Dulbecco's modified Eagle medium) supplemented with 10% FBS and antibiotics at 37 \u00b0C under 5% CO2.", [["embryonic kidney cells HEK293", "ANATOMY", 6, 35], ["FBS", "ANATOMY", 194, 197], ["ATCC CRL-11,268", "CHEMICAL", 95, 110], ["FBS", "CHEMICAL", 194, 197], ["CO2", "CHEMICAL", 232, 235], ["CO2", "CHEMICAL", 232, 235], ["Human", "ORGANISM", 0, 5], ["embryonic kidney cells HEK293", "CELL", 6, 35], ["ATCC CRL-11,268", "CELL", 95, 110], ["DMEM F12", "CELL", 128, 136], ["FBS", "ORGANISM_SUBSTANCE", 194, 197], ["CO2", "SIMPLE_CHEMICAL", 232, 235], ["Human embryonic kidney cells HEK293", "CELL_LINE", 0, 35], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["ATCC CRL-11,268", "SPECIES", 95, 110], ["F12", "SPECIES", 133, 136], ["Human embryonic kidney cells HEK293", "TEST", 0, 35], ["Culture Collection", "TEST", 75, 93], ["ATCC CRL", "TEST", 95, 103], ["Dulbecco's modified Eagle medium", "TREATMENT", 138, 170], ["10% FBS", "TREATMENT", 190, 197], ["antibiotics", "TREATMENT", 202, 213], ["kidney", "ANATOMY", 16, 22], ["cells HEK293", "OBSERVATION", 23, 35]]], ["Norovirus was recovered from the cDNA clone as described previously (Asanaka et al., 2005).", [["Norovirus", "DISEASE", 0, 9], ["Norovirus", "ORGANISM", 0, 9], ["cDNA clone", "DNA", 33, 43], ["Norovirus", "PROBLEM", 0, 9], ["the cDNA clone", "PROBLEM", 29, 43]]], ["Briefly, approximately 105 HEK293 cells (80% confluence) were infected with a recombinant vaccinia virus expressing bacteriophage T7 RNA polymerase at a multiplicity of infection of 10 plaque-forming units per cell and, after 1 h incubation, the inoculum was washed and cells were transfected with 0.5 \u03bcg of the infectious cDNA clone using Lipofectamine LTX Reagent (Invitrogen), following manufacturer's instructions.", [["HEK293 cells", "ANATOMY", 27, 39], ["plaque", "ANATOMY", 185, 191], ["cell", "ANATOMY", 210, 214], ["cells", "ANATOMY", 270, 275], ["infection", "DISEASE", 169, 178], ["HEK293 cells", "CELL", 27, 39], ["vaccinia virus", "ORGANISM", 90, 104], ["cell", "CELL", 210, 214], ["cells", "CELL", 270, 275], ["HEK293 cells", "CELL_LINE", 27, 39], ["bacteriophage T7 RNA polymerase", "PROTEIN", 116, 147], ["infectious cDNA clone", "DNA", 312, 333], ["vaccinia virus", "SPECIES", 90, 104], ["HEK293 cells", "TEST", 27, 39], ["a recombinant vaccinia virus expressing bacteriophage T7 RNA polymerase", "PROBLEM", 76, 147], ["infection of 10 plaque", "PROBLEM", 169, 191], ["the inoculum", "TREATMENT", 242, 254], ["the infectious cDNA clone", "TREATMENT", 308, 333], ["Lipofectamine LTX Reagent", "TREATMENT", 340, 365], ["infection", "OBSERVATION", 169, 178]]], ["After 5 h incubation at 37 \u00b0C, vaccinia replication was inhibited with 25 \u03bcg/mL AraC (arabinofuranosyl cytidine) and cells were incubated for 48 h.", [["cells", "ANATOMY", 117, 122], ["AraC", "CHEMICAL", 80, 84], ["arabinofuranosyl cytidine", "CHEMICAL", 86, 111], ["AraC", "CHEMICAL", 80, 84], ["arabinofuranosyl cytidine)", "CHEMICAL", 86, 112], ["vaccinia", "ORGANISM", 31, 39], ["AraC", "SIMPLE_CHEMICAL", 80, 84], ["arabinofuranosyl cytidine", "SIMPLE_CHEMICAL", 86, 111], ["cells", "CELL", 117, 122], ["vaccinia", "SPECIES", 31, 39], ["vaccinia replication", "TREATMENT", 31, 51], ["AraC (arabinofuranosyl cytidine", "TREATMENT", 80, 111], ["cells", "TREATMENT", 117, 122]]], ["A plasmid containing a green-fluorescent-protein (GFP) was transfected under the same conditions as a control.RT-PCR of NoV RNA extracted from HEK293 cells ::: MethodsAfter 48 h incubation, RNA was extracted from transfected cultures using TRIzol (Invitrogen) followed by chloroform and isopropanol purification, and washed with 75% ethanol.", [["plasmid", "ANATOMY", 2, 9], ["HEK293 cells", "ANATOMY", 143, 155], ["cultures", "ANATOMY", 225, 233], ["chloroform", "CHEMICAL", 272, 282], ["isopropanol", "CHEMICAL", 287, 298], ["ethanol", "CHEMICAL", 333, 340], ["chloroform", "CHEMICAL", 272, 282], ["isopropanol", "CHEMICAL", 287, 298], ["ethanol", "CHEMICAL", 333, 340], ["green-fluorescent-protein", "GENE_OR_GENE_PRODUCT", 23, 48], ["GFP", "GENE_OR_GENE_PRODUCT", 50, 53], ["NoV", "ORGANISM", 120, 123], ["HEK293 cells", "CELL", 143, 155], ["TRIzol", "ORGANISM", 240, 246], ["chloroform", "SIMPLE_CHEMICAL", 272, 282], ["isopropanol", "SIMPLE_CHEMICAL", 287, 298], ["ethanol", "SIMPLE_CHEMICAL", 333, 340], ["green-fluorescent-protein", "PROTEIN", 23, 48], ["GFP", "PROTEIN", 50, 53], ["NoV RNA", "RNA", 120, 127], ["HEK293 cells", "CELL_LINE", 143, 155], ["transfected cultures", "CELL_LINE", 213, 233], ["NoV", "SPECIES", 120, 123], ["A plasmid", "TREATMENT", 0, 9], ["RT-PCR", "TEST", 110, 116], ["MethodsAfter", "TREATMENT", 160, 172], ["transfected cultures", "TEST", 213, 233], ["TRIzol (Invitrogen)", "TREATMENT", 240, 259], ["chloroform", "TREATMENT", 272, 282], ["isopropanol purification", "TREATMENT", 287, 311], ["NoV RNA", "OBSERVATION", 120, 127], ["HEK293 cells", "OBSERVATION", 143, 155]]], ["In order to digest any remaining DNA, samples were treated with 1 U/\u03bcg RNase-free DNase I (Thermo Scientific) for 30 min at 37 \u00b0C. DNase I was heat-inactivated (10 min at 65 \u00b0C) and the RNA was column-purified using NucleoSpin RNA Clean-up XS kit (Macherey-Nagel).", [["samples", "ANATOMY", 38, 45], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["RNase", "GENE_OR_GENE_PRODUCT", 71, 76], ["DNase I", "GENE_OR_GENE_PRODUCT", 82, 89], ["DNase I", "GENE_OR_GENE_PRODUCT", 131, 138], ["RNase", "PROTEIN", 71, 76], ["DNase I", "PROTEIN", 82, 89], ["DNase I", "PROTEIN", 131, 138], ["any remaining DNA", "PROBLEM", 19, 36], ["1 U/\u03bcg RNase", "TREATMENT", 64, 76], ["NucleoSpin RNA", "TREATMENT", 216, 230]]], ["Purified RNA was reverse-transcribed using Accuscript High Fidelity Reverse Transcriptase (Agilent Technologies) and a sequence-specific primer.", [["a sequence", "TEST", 117, 127], ["RNA", "OBSERVATION", 9, 12]]], ["Negative-strand RNA was reverse-transcribed using the following primer 5\u2032-ATTACTCTCTGTGCACTGTCTG-3\u2032 (nucleotides 4790\u20134811 in accession NC_001959), whereas positive-strand RNA was reverse-transcribed using primer 5\u2032-CAGTGTAGAAGAGGCTGTTGAA-3\u2032 (nucleotides 7501\u20137522 in accession NC_001959).", [["nucleotides 4790\u20134811", "CHEMICAL", 101, 122], ["Negative-strand RNA", "RNA", 0, 19], ["primer 5\u2032-ATTACTCTCTGTGCACTGTCTG-3\u2032", "DNA", 64, 99], ["nucleotides 4790\u20134811", "DNA", 101, 122], ["positive-strand RNA", "RNA", 156, 175], ["primer 5\u2032-CAGTGTAGAAGAGGCTGTTGAA-3\u2032", "DNA", 206, 241], ["nucleotides 7501\u20137522", "DNA", 243, 264], ["strand RNA", "PROBLEM", 9, 19], ["ATTACTCTCTGTGCACTGTCTG", "TEST", 74, 96], ["nucleotides", "TEST", 101, 112], ["accession NC", "TEST", 126, 138], ["strand RNA", "PROBLEM", 165, 175], ["CAGTGTAGAAGAGGCTGTTGAA", "TEST", 216, 238], ["strand RNA", "OBSERVATION_MODIFIER", 9, 19]]], ["The VP1 gene was then PCR-amplified using Phusion High Fidelity DNA polymerase (New England Biolabs) and primers 5\u2032-GACGCyACAyCAAGCGyGG-3\u2032 (forward, nucleotides 5376\u20135394 in accession NC_001959) and 5\u2032-CTCrTGTTrCCrrCCCrrCC-3\u2032 (reverse, nucleotides 5661\u20135680 in accession NC_001959).", [["nucleotides", "CHEMICAL", 236, 247], ["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["Biolabs", "GENE_OR_GENE_PRODUCT", 92, 99], ["5\u2032-CTCrTGTTrCCrrCCCrrCC-3", "GENE_OR_GENE_PRODUCT", 199, 224], ["VP1 gene", "DNA", 4, 12], ["Phusion High Fidelity DNA polymerase", "PROTEIN", 42, 78], ["New England Biolabs", "PROTEIN", 80, 99], ["primers 5\u2032-GACGCyACAyCAAGCGyGG-3\u2032", "DNA", 105, 138], ["forward, nucleotides 5376\u20135394", "DNA", 140, 170], ["5\u2032-CTCrTGTTrCCrrCCCrrCC-3\u2032", "DNA", 199, 225], ["reverse, nucleotides 5661\u20135680", "DNA", 227, 257], ["The VP1 gene", "TREATMENT", 0, 12], ["PCR", "TEST", 22, 25], ["Phusion", "TEST", 42, 49], ["High Fidelity DNA polymerase", "PROBLEM", 50, 78], ["New England Biolabs", "TEST", 80, 99], ["primers", "TEST", 105, 112], ["GACGCyACAyCAAGCGyGG", "TEST", 116, 135], ["nucleotides", "TEST", 149, 160], ["NC", "TEST", 184, 186], ["CTCrTGTTrCCrrCCCrrCC", "TEST", 202, 222], ["nucleotides", "TREATMENT", 236, 247]]], ["The PCR conditions used were 98 \u00b0C 30 s, 35 cycles at 98 \u00b0C 10 s, 59 \u00b0C 30 s, and 72 \u00b0C 1 min, and a final extension at 72 \u00b0C 10 min.", [["The PCR conditions", "TEST", 0, 18]]], ["Controls were carried out in which the PCR was performed without RT step to ensure that no remaining DNA from the infectious clone was amplified.", [["clone", "ANATOMY", 125, 130], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["clone", "CELL", 125, 130], ["the PCR", "TEST", 35, 42], ["RT step", "TREATMENT", 65, 72], ["remaining DNA", "PROBLEM", 91, 104], ["the infectious clone", "PROBLEM", 110, 130], ["infectious clone", "OBSERVATION", 114, 130]]], ["To control for strand-specific amplification, transfection supernatants were cleaned by centrifugation at 16,000 \u00d7 g, 15 min, 4 \u00b0C to separate free virions containing plus-strand genomes from cellular pellets, used for RNA extraction, and the RT step was performed with the same primer used for amplification of minus strands.", [["supernatants", "ANATOMY", 59, 71], ["cellular pellets", "ANATOMY", 192, 208], ["cellular", "CELL", 192, 200], ["plus-strand genomes", "DNA", 167, 186], ["strand-specific amplification", "PROBLEM", 15, 44], ["transfection supernatants", "TREATMENT", 46, 71], ["free virions", "TREATMENT", 143, 155], ["cellular pellets", "TREATMENT", 192, 208], ["RNA extraction", "TREATMENT", 219, 233], ["the RT step", "TEST", 239, 250], ["the same primer", "TREATMENT", 270, 285], ["minus strands", "PROBLEM", 312, 325], ["free virions", "OBSERVATION", 143, 155], ["strand genomes", "OBSERVATION", 172, 186], ["cellular pellets", "OBSERVATION", 192, 208], ["minus strands", "OBSERVATION", 312, 325]]], ["As expected, these controls did not yield any visible PCR product.", [["any visible PCR product", "PROBLEM", 42, 65]]], ["To obtain a shorter product for Illumina sequencing, a secondary PCR of the indicated size was done with the following cycling conditions: 98 \u00b0C 30 s, 40 cycles of 98 \u00b0C 10 s, 60 \u00b0C 30s, 72 \u00b0C 1 min, and a final extension at 72 \u00b0C 5 min.Illumina sequencing ::: MethodsPCR products were sequenced in an Illumina Miseq machine using paired-end libraries.", [["Illumina Miseq machine", "DNA", 302, 324], ["paired-end libraries", "DNA", 331, 351], ["Illumina sequencing", "TEST", 32, 51], ["a secondary PCR", "TEST", 53, 68], ["\u00b0C", "TEST", 167, 169], ["\u00b0C", "TEST", 179, 181], ["MethodsPCR products", "TREATMENT", 261, 280], ["an Illumina Miseq machine", "TREATMENT", 299, 324], ["paired-end libraries", "TREATMENT", 331, 351], ["size", "OBSERVATION_MODIFIER", 86, 90]]], ["The quality of the run was first evaluated with FastQC software 0.10.1 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc).", [["FastQC software", "TEST", 48, 63]]], ["For clinical samples, a base calling pipeline was run to define a consensus reference sequence for each sample.", [["samples", "ANATOMY", 13, 20], ["consensus reference sequence", "DNA", 66, 94], ["clinical samples", "TEST", 4, 20], ["each sample", "TEST", 99, 110]]], ["To do this, Illumina adapters and PCR primers were cut with Cutadapt software (Marcel, 2011), fastq files were trimmed using Prinseq-lite version 0.20.4 (Schmieder and Edwards, 2011), mapping was done using the Mem algorithm from Bwa 0.7.12 (http://arxiv.org/abs/1303.3997), SAM files were converted to BAM format, sorted and indexed using SAMtools software package (Li et al., 2009), and sequence variants relative to a common reference were called with VarScan 2.3.7 (Koboldt et al., 2013) using SAMtools mpileup data as input.", [["Illumina adapters", "DNA", 12, 29], ["PCR primers", "DNA", 34, 45], ["fastq files", "DNA", 94, 105], ["Mem algorithm", "DNA", 211, 224], ["Bwa 0.7.12", "DNA", 230, 240], ["SAM files", "DNA", 275, 284], ["Illumina adapters", "TREATMENT", 12, 29], ["PCR primers", "TEST", 34, 45], ["the Mem algorithm", "TEST", 207, 224], ["Bwa", "TEST", 230, 233], ["SAM files", "TEST", 275, 284], ["VarScan", "TREATMENT", 455, 462]]], ["For each sample, nucleotide changes detected at a frequency higher than 0.5 were used to construct the sample-specific reference sequence.", [["sample", "ANATOMY", 9, 15], ["nucleotide", "CHEMICAL", 17, 27], ["nucleotide", "CHEMICAL", 17, 27], ["each sample", "TEST", 4, 15], ["nucleotide changes", "PROBLEM", 17, 35], ["the sample", "TEST", 99, 109]]], ["For subsequent steps, paired-end Illumina reads were merged using PANDAseq (Masella et al., 2012) and an initial trimming of these merged fastq files was performed with Prinseq-lite version 0.20.4.", [["fastq files", "DNA", 138, 149], ["Prinseq-lite version", "TREATMENT", 169, 189]]], ["Trimmed fastq files were converted into fasta and standalone blast pair-wise alignments (Camacho et al., 2009) were obtained to map reads and to obtain the number of mutations relative to the reference sequence of the sample.", [["Trimmed fastq files", "DNA", 0, 19], ["mutations", "PROBLEM", 166, 175]]], ["Since the number of reads was variable, 100,000 reads were randomly chosen for each PCR.", [["each PCR", "TEST", 79, 87]]], ["To obtain a refined set of mutated reads, a final quality filter was applied, such that only reads with average Phred quality score higher than 28 for the specific mutated positions were considered.", [["a final quality filter", "TREATMENT", 42, 64], ["Phred quality score", "TEST", 112, 131]]], ["This filter removed less than 5% of the original reads in all samples.", [["samples", "ANATOMY", 62, 69], ["This filter", "TREATMENT", 0, 11]]], ["Specific Shell, Python, Perl and R scripts were written for these analyses.Molecular cloning and Sanger sequencing of PCR products ::: MethodsPCR products were gel-purified and cloned using CloneJET PCR cloning kit (Thermo Scientific) in E. coli by the heat shock method.", [["shock", "DISEASE", 258, 263], ["E. coli", "ORGANISM", 238, 245], ["PCR products", "DNA", 118, 130], ["E. coli", "SPECIES", 238, 245], ["E. coli", "SPECIES", 238, 245], ["Perl and R scripts", "TREATMENT", 24, 42], ["these analyses", "TEST", 60, 74], ["MethodsPCR products", "TREATMENT", 135, 154], ["CloneJET PCR", "TREATMENT", 190, 202], ["E. coli", "PROBLEM", 238, 245], ["the heat shock method", "TREATMENT", 249, 270]]], ["Transformant colonies were PCR-amplified using Taq DNA polymerase and CloneJET-specific primers (forward 5\u2032-CGACTCACTATAGGGAGAGCGGC-3\u2032; reverse 5\u2032-AAGAACATCGATTTTCCATGGCAG-3\u2032) under the following conditions: 95 \u00b0C 5 min, 35 cycles of 95 \u00b0C 30 s, 60 \u00b0C 30 s, 72 \u00b0C 2 min, and a final extension at 72 \u00b0C 5 min.", [["colonies", "ANATOMY", 13, 21], ["Taq", "GENE_OR_GENE_PRODUCT", 47, 50], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["Taq DNA polymerase and CloneJET-specific primers", "DNA", 47, 95], ["reverse 5\u2032-AAGAACATCGATTTTCCATGGCAG-3\u2032", "DNA", 136, 174], ["Transformant colonies", "TEST", 0, 21], ["PCR", "TEST", 27, 30], ["Taq DNA polymerase", "TEST", 47, 65], ["CloneJET", "TEST", 70, 78], ["specific primers", "TEST", 79, 95], ["CGACTCACTATAGGGAGAGCGGC", "TEST", 108, 131], ["AAGAACATCGATTTTCCATGGCAG", "TEST", 147, 171]]], ["Colony PCR products were column-purified and sequenced by the Sanger method.", [["Colony PCR products", "TEST", 0, 19], ["column", "OBSERVATION_MODIFIER", 25, 31]]], ["Sequence chromatograms were analyzed using the Staden software (http://staden.sourceforge.net).Ultra-deep sequencing reveals NoV hyper-mutants in clinical samples ::: ResultsWe used 16 stool samples from patients acutely infected with NoV GII.4 to amplify by RT-PCR a 386-base region encompassing nucleotides 1 to 386 of the VP1 gene (reference sequence: GenBank JX459908; Fig. 1A).", [["samples", "ANATOMY", 155, 162], ["stool samples", "ANATOMY", 185, 198], ["NoV", "ORGANISM", 125, 128], ["patients", "ORGANISM", 204, 212], ["VP1", "GENE_OR_GENE_PRODUCT", 325, 328], ["NoV hyper-mutants", "PROTEIN", 125, 142], ["386-base region", "DNA", 268, 283], ["nucleotides 1 to 386", "DNA", 297, 317], ["VP1 gene", "DNA", 325, 333], ["patients", "SPECIES", 204, 212], ["NoV GII.4", "SPECIES", 235, 244], ["Sequence chromatograms", "TEST", 0, 22], ["Ultra-deep sequencing", "TEST", 95, 116], ["NoV hyper-mutants", "PROBLEM", 125, 142], ["stool samples", "TEST", 185, 198], ["RT", "TEST", 259, 261], ["PCR", "TEST", 262, 265], ["nucleotides", "TEST", 297, 308], ["base", "ANATOMY_MODIFIER", 272, 276]]], ["The RT-PCR was successful in 11/16 samples.", [["samples", "ANATOMY", 35, 42], ["The RT-PCR", "TEST", 0, 10]]], ["Of these, eight belonged to newborns or children under the age of three, two to adults, and for one sample there was no available age information.", [["newborns", "ORGANISM", 28, 36], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48]]], ["We performed paired-end Illumina sequencing of these PCR products with 100,000-fold coverage (i.e. 100,000 reads per patient).", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["these PCR products", "TREATMENT", 47, 65], ["fold coverage", "TREATMENT", 79, 92]]], ["For three patients, approximately one in 6000 reads contained large numbers of U-to-C or A-to-G base transitions (12\u201327 reads with 5\u201330 such mutations out of approx.", [["patients", "ORGANISM", 10, 18], ["U-to-C", "GENE_OR_GENE_PRODUCT", 79, 85], ["patients", "SPECIES", 10, 18], ["U", "TEST", 79, 80], ["such mutations", "PROBLEM", 136, 150], ["large", "OBSERVATION_MODIFIER", 62, 67]]], ["Reads with less than five mutations of such type were not considered as hyper-mutants.", [["hyper-mutants", "PROBLEM", 72, 85]]], ["Although the error rate of Illumina sequencing precludes analysis of low-frequency polymorphisms, it provides a powerful approach for detecting hyper-mutants.", [["Illumina sequencing", "TEST", 27, 46], ["low-frequency polymorphisms", "PROBLEM", 69, 96], ["hyper-mutants", "PROBLEM", 144, 157]]], ["In the most mutated read, 30 of the 86 U residues were substituted for C, a pattern that cannot be explained by sequencing error.", [["the 86 U residues", "TREATMENT", 32, 49], ["C", "PROBLEM", 71, 72], ["cannot be explained", "UNCERTAINTY", 89, 108]]], ["Interestingly, we found both U-to-C and A-to-G hyper-mutations, but these did not occur in the same reads.", [["U-to-C", "GENE_OR_GENE_PRODUCT", 29, 35], ["A-to-G", "GENE_OR_GENE_PRODUCT", 40, 46], ["U", "TEST", 29, 30], ["A-to-G hyper-mutations", "PROBLEM", 40, 62]]], ["To extend our analysis, we set out to amplify by RT-PCR another region encompassing nucleotides 719 to 1168 of VP1 (450 bases, although only the 409 bases excluding primer regions were considered for subsequent analysis), which maps to the hypervariable domain P2.", [["nucleotides 719 to 1168", "DNA", 84, 107], ["VP1", "DNA", 111, 114], ["409 bases", "DNA", 145, 154], ["primer regions", "DNA", 165, 179], ["hypervariable domain P2", "DNA", 240, 263], ["our analysis", "TEST", 10, 22], ["PCR", "TEST", 52, 55], ["nucleotides", "TEST", 84, 95], ["VP1", "TEST", 111, 114], ["the hypervariable domain P2", "PROBLEM", 236, 263]]], ["In two out of the three samples showing hyper-mutation in the first region, we also found hyper-mutated reads in the second region, with a maximum of 37 mutations in a single read.", [["samples", "ANATOMY", 24, 31], ["hyper-mutated reads", "DNA", 90, 109], ["hyper-mutation in the first region", "PROBLEM", 40, 74], ["hyper-mutated reads", "PROBLEM", 90, 109], ["hyper-mutation", "OBSERVATION", 40, 54], ["hyper", "OBSERVATION", 90, 95], ["second", "ANATOMY_MODIFIER", 117, 123], ["region", "ANATOMY_MODIFIER", 124, 130]]], ["Furthermore, one sample which failed to amplify for the first region also yielded hyper-mutated reads in the second region (Table 1).", [["hyper-mutated reads", "DNA", 82, 101], ["one sample", "TEST", 13, 23], ["hyper-mutated reads", "PROBLEM", 82, 101], ["hyper", "OBSERVATION", 82, 87], ["mutated reads", "OBSERVATION", 88, 101]]], ["Two of the samples showing hyper-mutation belonged to newborns, whereas the other two belonged to adults, with no significant association between age and hyper-mutation at this low sample size (Fisher's exact test, P= 0.547).", [["samples", "ANATOMY", 11, 18], ["sample", "ANATOMY", 181, 187], ["samples", "CANCER", 11, 18], ["newborns", "ORGANISM", 54, 62], ["the samples", "TEST", 7, 18], ["hyper-mutation", "PROBLEM", 27, 41], ["hyper-mutation", "PROBLEM", 154, 168], ["Fisher's exact test", "TEST", 194, 213], ["P", "TEST", 215, 216]]], ["Viruses carrying large numbers of mutations should not be viable and, thus, their population frequency should be strongly reduced by the action of purifying selection.", [["Viruses carrying large numbers of mutations", "PROBLEM", 0, 43], ["purifying selection", "TREATMENT", 147, 166], ["large", "OBSERVATION_MODIFIER", 17, 22], ["numbers", "OBSERVATION_MODIFIER", 23, 30]]], ["Therefore, albeit very rare, hyper-mutants may reflect a relevant mutational process in NoV.Massive hyper-mutation in a transfection system ::: ResultsTo minimize the effects of selection, we transfected a Norwalk virus infectious cDNA clone into HEK293 cells expressing the T7 RNA polymerase from a recombinant vaccinia virus (ATCC VR-2153).", [["HEK293 cells", "ANATOMY", 247, 259], ["ATCC VR-2153", "CHEMICAL", 328, 340], ["NoV", "ORGANISM", 88, 91], ["Norwalk virus", "ORGANISM", 206, 219], ["HEK293 cells", "CELL", 247, 259], ["vaccinia virus", "ORGANISM", 312, 326], ["ATCC VR-2153", "CELL", 328, 340], ["Norwalk virus infectious cDNA clone", "DNA", 206, 241], ["HEK293 cells", "CELL_LINE", 247, 259], ["T7 RNA polymerase", "PROTEIN", 275, 292], ["Norwalk virus", "SPECIES", 206, 219], ["vaccinia virus", "SPECIES", 312, 326], ["ATCC VR-2153", "SPECIES", 328, 340], ["hyper-mutants", "PROBLEM", 29, 42], ["Massive hyper-mutation", "PROBLEM", 92, 114], ["a Norwalk virus infectious cDNA clone", "PROBLEM", 204, 241], ["the T7 RNA polymerase", "PROBLEM", 271, 292], ["a recombinant vaccinia virus", "TREATMENT", 298, 326], ["ATCC VR", "TEST", 328, 335], ["hyper", "OBSERVATION", 29, 34], ["hyper-mutation", "OBSERVATION", 100, 114], ["T7", "ANATOMY", 275, 277]]], ["As previously described, this system supports NoV transcription, replication and encapsidation (Fig. 1B), but does not allow released virions to initiate a second infection cycle because HEK293T cells are not a natural cell target for the virus (Asanaka et al., 2005).", [["virions", "ANATOMY", 134, 141], ["HEK293T cells", "ANATOMY", 187, 200], ["cell", "ANATOMY", 219, 223], ["infection", "DISEASE", 163, 172], ["NoV", "ORGANISM", 46, 49], ["HEK293T cells", "CELL", 187, 200], ["cell", "CELL", 219, 223], ["HEK293T cells", "CELL_LINE", 187, 200], ["NoV transcription", "TREATMENT", 46, 63], ["a second infection cycle", "TREATMENT", 154, 178], ["HEK293T cells", "PROBLEM", 187, 200], ["the virus", "PROBLEM", 235, 244]]], ["After 48 h incubation, total RNA was extracted from cells, residual DNA was removed with DNAse I, a specific primer annealing to the minus-strand of the VP1 capsid gene was used for reverse transcription, and high-fidelity PCR amplification of a region encompassing positions 19 to 323 of the VP1 gene (305 bases, although only the 266 bases excluding primer regions were considered for subsequent analysis) was carried out.", [["cells", "ANATOMY", 52, 57], ["cells", "CELL", 52, 57], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["DNAse I", "GENE_OR_GENE_PRODUCT", 89, 96], ["VP1", "ORGANISM", 153, 156], ["VP1", "GENE_OR_GENE_PRODUCT", 293, 296], ["DNAse I", "PROTEIN", 89, 96], ["minus-strand", "DNA", 133, 145], ["VP1 capsid gene", "DNA", 153, 168], ["VP1 gene", "DNA", 293, 301], ["primer regions", "DNA", 352, 366], ["total RNA", "TREATMENT", 23, 32], ["residual DNA", "PROBLEM", 59, 71], ["DNAse I", "TREATMENT", 89, 96], ["the VP1 capsid gene", "TREATMENT", 149, 168], ["reverse transcription", "TREATMENT", 182, 203], ["subsequent analysis", "TEST", 387, 406], ["residual DNA", "OBSERVATION", 59, 71], ["VP1 capsid", "ANATOMY", 153, 163], ["high", "OBSERVATION_MODIFIER", 209, 213]]], ["For each of three independent transfection assays, we subjected the PCR products to paired-end Illumina sequencing with the same coverage as above.", [["PCR products", "DNA", 68, 80], ["the PCR products", "TREATMENT", 64, 80], ["the same coverage", "TREATMENT", 120, 137]]], ["Comparison of Illumina reads with the sequence of the infectious cDNA clone (reference sequence: GenBank NC_001959) revealed hundreds of sequences with multiple U-to-C substitutions.", [["U-to-C", "GENE_OR_GENE_PRODUCT", 161, 167], ["Illumina reads", "DNA", 14, 28], ["infectious cDNA clone", "DNA", 54, 75], ["U-to-C substitutions", "DNA", 161, 181], ["Illumina reads", "TEST", 14, 28], ["multiple U", "TEST", 152, 162]]], ["Some examples of U-to-C hyper-mutants are shown in Fig. 2.", [["U-to-C", "GENE_OR_GENE_PRODUCT", 17, 23], ["U-to-C hyper-mutants", "DNA", 17, 37], ["U", "TEST", 17, 18], ["C hyper-mutants", "PROBLEM", 22, 37]]], ["To objectively define hyper-mutated sequences, we analyzed the distribution of the number of U-to-C transitions among the 100,000 reads obtained for each replicate assay.", [["hyper-mutated sequences", "DNA", 22, 45], ["hyper-mutated sequences", "PROBLEM", 22, 45]]], ["The distribution clearly deviated from a Poisson model of rare random events, showing an excess of sequences with high mutation counts (Fig. 3A).", [["rare random events", "PROBLEM", 58, 76], ["an excess of sequences", "PROBLEM", 86, 108], ["high mutation counts", "PROBLEM", 114, 134], ["deviated", "OBSERVATION", 25, 33]]], ["Based on this, we defined hyper-mutated sequences as those carrying five or more mutations in the 266-base region studied.", [["hyper-mutated sequences", "DNA", 26, 49], ["266-base region", "DNA", 98, 113], ["hyper-mutated sequences", "PROBLEM", 26, 49], ["base", "ANATOMY_MODIFIER", 102, 106]]], ["However, the data also showed that hyper-mutation was not an all-or-nothing process and that the number of mutations per read varied continuously.", [["the data", "TEST", 9, 17], ["hyper-mutation", "PROBLEM", 35, 49]]], ["Regarding U-to-C substitutions, we found 1444 hyper-mutated reads (266, 481 and 697 reads for assays 1, 2 and 3, respectively), meaning that approximately one in every 200 reads (0.48%) contained U-to-C hyper-mutations (Table 2).", [["U-to-C", "GENE_OR_GENE_PRODUCT", 10, 16], ["U-to-C", "GENE_OR_GENE_PRODUCT", 196, 202], ["U-to-C substitutions", "DNA", 10, 30], ["1444 hyper-mutated reads", "DNA", 41, 65], ["assays", "TEST", 94, 100], ["U", "TEST", 196, 197]]], ["These carried 11,612 total U-to-C substitutions, the number of mutations per read varying from 5 to 31 out of the 88 U residues contained in the 266-base fragment.", [["U-to-C", "CHEMICAL", 27, 33], ["U-to-C", "GENE_OR_GENE_PRODUCT", 27, 33], ["266-base fragment", "DNA", 145, 162], ["total U", "TEST", 21, 28], ["C substitutions", "PROBLEM", 32, 47], ["base fragment", "OBSERVATION", 149, 162]]], ["Since sequences were derived from minus-strand RNA, U-to-C substitutions in the reference (plus-strand) genome sequence indicate that the negative-strand template RNA contained A-to-G substitutions.", [["U-to-C", "GENE_OR_GENE_PRODUCT", 52, 58], ["A-to-G", "SIMPLE_CHEMICAL", 177, 183], ["minus-strand RNA", "RNA", 34, 50], ["U-to-C substitutions", "DNA", 52, 72], ["reference (plus-strand) genome sequence", "DNA", 80, 119], ["negative-strand template RNA", "RNA", 138, 166], ["A-to-G substitutions", "DNA", 177, 197], ["U", "TEST", 52, 53], ["C substitutions", "PROBLEM", 57, 72], ["genome sequence", "TEST", 104, 119], ["strand template RNA", "PROBLEM", 147, 166]]], ["Ultra-deep sequencing also revealed some A-to-G hyper-mutated sequences in two of the three assays (indicating U-to-C changes in the negative-strand template), but these were 17 times less frequent (i.e. 1444/83 = 17.4) than the former (Table 2).", [["U-to-C", "GENE_OR_GENE_PRODUCT", 111, 117], ["A-to-G hyper-mutated sequences", "DNA", 41, 71], ["negative-strand template", "DNA", 133, 157], ["Ultra-deep sequencing", "TEST", 0, 21], ["some A-to-G hyper-mutated sequences", "PROBLEM", 36, 71], ["the three assays", "TEST", 82, 98], ["U", "TEST", 111, 112], ["C changes", "PROBLEM", 116, 125]]], ["A-to-G hyper-mutants may be a result of plus-strand carry-over amplification during RT-PCR or, alternatively, they may represent a different mutational process.Reproducible effect of sequence context on hyper-mutation ::: ResultsAnalysis of the location of mutations revealed a widespread distribution along the 266-base VP1 region.", [["266-base VP1 region", "DNA", 312, 331], ["strand carry", "PROBLEM", 45, 57], ["RT-PCR", "TEST", 84, 90], ["a different mutational process", "PROBLEM", 129, 159], ["mutations", "PROBLEM", 257, 266], ["may represent", "UNCERTAINTY", 115, 128], ["widespread", "OBSERVATION_MODIFIER", 278, 288], ["distribution", "OBSERVATION_MODIFIER", 289, 301], ["base", "ANATOMY_MODIFIER", 316, 320], ["VP1", "ANATOMY_MODIFIER", 321, 324], ["region", "ANATOMY_MODIFIER", 325, 331]]], ["Although all of the 88 U residues showed at least one U-to-C mutation at this high sequencing depth, mutation frequencies varied strongly across sites, the pattern of variation being highly reproducible between the three biological replicates (pairwise Spearman p> 0.850, p< 10\u2212 12; Fig. 3B).", [["U", "GENE_OR_GENE_PRODUCT", 23, 24], ["the 88 U residues", "TEST", 16, 33], ["C mutation", "PROBLEM", 59, 69], ["mutation frequencies", "PROBLEM", 101, 121], ["pairwise Spearman p", "TEST", 244, 263]]], ["A major determinant of the frequency of U-to-C mutation was the identity of the 3\u2032 neighboring base.", [["U-to-C", "GENE_OR_GENE_PRODUCT", 40, 46], ["3\u2032 neighboring base", "DNA", 80, 99], ["C mutation", "PROBLEM", 45, 55], ["base", "ANATOMY_MODIFIER", 95, 99]]], ["These counts clearly deviated from those of 3\u2032 neighbors of non-mutated bases (chi-square test: p< 10\u2212 12; Fig. 3C).", [["These counts", "TEST", 0, 12], ["chi-square test", "TEST", 79, 94], ["deviated", "OBSERVATION", 21, 29], ["bases", "ANATOMY_MODIFIER", 72, 77]]], ["After correcting for base composition, the 3\u2032 neighbor preferences for U-to-C hyper-mutation were A > U > G > C. Interestingly, A-to-G hyper-mutated sequences showed a marked bias in the 5\u2032 neighboring base such that, among the 638 total A-to-G mutations, the 5\u2032 neighbor was U in 379 cases, A in 204 cases, G in 14 cases, and C in 41 cases (p< 10\u2212 12; Fig. 3C).", [["U-to-C", "GENE_OR_GENE_PRODUCT", 71, 77], ["A-to-G", "GENE_OR_GENE_PRODUCT", 128, 134], ["A-to-G", "GENE_OR_GENE_PRODUCT", 238, 244], ["A-to-G hyper-mutated sequences", "DNA", 128, 158], ["5\u2032 neighbor", "DNA", 260, 271], ["U", "TEST", 71, 72], ["hyper-mutation", "TEST", 78, 92], ["A-to", "TEST", 128, 132], ["G hyper-mutated sequences", "TEST", 133, 158], ["a marked bias", "PROBLEM", 166, 179], ["G", "TEST", 308, 309], ["C", "TEST", 327, 328], ["marked", "OBSERVATION_MODIFIER", 168, 174], ["bias", "OBSERVATION", 175, 179], ["base", "ANATOMY_MODIFIER", 202, 206]]], ["Therefore, A-to-G hyper-mutation had 5\u2032 neighbor base preferences (U > A > C > G) which are exactly the reverse complement of those for U-to-C hyper-mutation.", [["A-to-G", "GENE_OR_GENE_PRODUCT", 11, 17], ["U-to-C", "GENE_OR_GENE_PRODUCT", 136, 142], ["U-to-C hyper-mutation", "DNA", 136, 157], ["U", "TEST", 136, 137], ["C hyper-mutation", "PROBLEM", 141, 157]]], ["This strongly suggests a common biochemical process underlying both U-to-C and A-to-G mutations, the type of change observed depending on whether hyper-mutation occurred in the minus or plus RNA strand, respectively.Contribution of hyper-mutation to the total NoV rate of spontaneous mutation ::: ResultsBased on the above data, the per-base probability of a U-to-C substitution due to hyper-mutation was (1.5 \u00b1 0.4) \u00d7 10\u2212 4, a value within the typical range of RNA virus rates of spontaneous mutation (Lauring et al., 2013, Sanju\u00e1n et al., 2010).", [["hyper-mutation", "DISEASE", 386, 400], ["U-to-C", "GENE_OR_GENE_PRODUCT", 68, 74], ["A-to-G", "GENE_OR_GENE_PRODUCT", 79, 85], ["U", "GENE_OR_GENE_PRODUCT", 359, 360], ["minus or plus RNA strand", "RNA", 177, 201], ["a common biochemical process", "PROBLEM", 23, 51], ["hyper-mutation", "PROBLEM", 146, 160], ["hyper-mutation", "PROBLEM", 232, 246], ["the above data", "TEST", 313, 327], ["a U", "TEST", 357, 360], ["C substitution", "PROBLEM", 364, 378], ["hyper-mutation", "TEST", 386, 400], ["a value", "TEST", 426, 433], ["spontaneous mutation", "PROBLEM", 481, 501], ["RNA virus", "OBSERVATION", 462, 471]]], ["To ascertain the contribution of hyper-mutation events to the total NoV mutation rate, we sought to estimate the total mutation rate from the above single-cycle transfection assays.", [["hyper-mutation events", "PROBLEM", 33, 54], ["the total mutation rate", "TEST", 109, 132], ["hyper", "OBSERVATION", 33, 38]]], ["Since the Illumina per-read accuracy is not high enough to reliably infer individual base substitutions at such low frequencies, we performed classical molecular cloning followed by Sanger sequencing.", [["the Illumina per-read accuracy", "TEST", 6, 36]]], ["Using RNA extracts from the above transfections, we amplified by high-fidelity RT-PCR the entire VP1 gene and obtained 64 molecular clones.", [["extracts", "ANATOMY", 10, 18], ["VP1", "GENE_OR_GENE_PRODUCT", 97, 100], ["clones", "CELL", 132, 138], ["VP1 gene", "DNA", 97, 105], ["RNA extracts", "TREATMENT", 6, 18], ["the above transfections", "TREATMENT", 24, 47]]], ["In total, we found 21 base substitutions in 136,032 bases, giving a mutation rate estimate of 1.5 \u00d7 10\u2212 4 per nucleotide per cell infection (Table 3), a value nearly identical to the hyper-mutation rate inferred by Illumina sequencing.", [["cell", "ANATOMY", 125, 129], ["infection", "DISEASE", 130, 139], ["nucleotide", "CHEMICAL", 110, 120], ["cell", "CELL", 125, 129], ["base substitutions", "TEST", 22, 40], ["a mutation rate estimate", "TEST", 66, 90], ["nucleotide per cell infection", "PROBLEM", 110, 139], ["a value", "TEST", 151, 158], ["the hyper-mutation rate", "PROBLEM", 179, 202], ["21 base", "OBSERVATION_MODIFIER", 19, 26], ["substitutions", "OBSERVATION_MODIFIER", 27, 40], ["bases", "ANATOMY_MODIFIER", 52, 57], ["cell infection", "OBSERVATION", 125, 139], ["hyper", "OBSERVATION", 183, 188]]], ["Furthermore, of the 21 mutations 18 were U-to-C base transitions found in a single, hyper-mutated clone.", [["clone", "ANATOMY", 98, 103], ["clone", "CELL", 98, 103], ["hyper-mutated clone", "CELL_LINE", 84, 103], ["U", "TEST", 41, 42], ["C base transitions", "PROBLEM", 46, 64], ["a single, hyper-mutated clone", "PROBLEM", 74, 103]]], ["Removing this single clone, the estimated mutation rate was 2.2 \u00d7 10\u2212 5, a value seven times lower than the estimated hyper-mutation rate.DiscussionOur results reveal that a large fraction of NoV spontaneous mutations is constituted by U-to-C and A-to-G substitutions occurring as bouts of mutations in the same RNA molecule.", [["clone", "CELL", 21, 26], ["U-to-C", "GENE_OR_GENE_PRODUCT", 236, 242], ["A-to-G", "GENE_OR_GENE_PRODUCT", 247, 253], ["RNA molecule", "PROTEIN", 312, 324], ["this single clone", "TREATMENT", 9, 26], ["the estimated mutation rate", "TEST", 28, 55], ["a value", "TEST", 73, 80], ["the estimated hyper-mutation rate", "TEST", 104, 137], ["a large fraction", "PROBLEM", 172, 188], ["NoV spontaneous mutations", "PROBLEM", 192, 217], ["U", "TEST", 236, 237], ["A-to-G substitutions", "PROBLEM", 247, 267], ["mutations in the same RNA molecule", "PROBLEM", 290, 324], ["large", "OBSERVATION_MODIFIER", 174, 179], ["fraction", "OBSERVATION_MODIFIER", 180, 188], ["spontaneous mutations", "OBSERVATION", 196, 217]]], ["We argue that, depending on whether the hyper-mutation takes place in the minus or plus strand, U-to-C or A-to-G changes are observed, respectively, in the (plus strand) genomic RNA.", [["U-to-C", "GENE_OR_GENE_PRODUCT", 96, 102], ["(plus strand) genomic RNA", "RNA", 156, 181], ["the hyper-mutation", "PROBLEM", 36, 54], ["strand) genomic RNA", "PROBLEM", 162, 181], ["genomic RNA", "OBSERVATION", 170, 181]]], ["A likely mechanism underlying these A-to-G mutations is ADAR, which edits adenosines to inosines that subsequently base-pair with cytosines (Samuel, 2011, Valente and Nishikura, 2005).", [["adenosines", "CHEMICAL", 74, 84], ["inosines", "CHEMICAL", 88, 96], ["cytosines", "CHEMICAL", 130, 139], ["adenosines", "CHEMICAL", 74, 84], ["inosines", "CHEMICAL", 88, 96], ["cytosines", "CHEMICAL", 130, 139], ["A-to-G", "GENE_OR_GENE_PRODUCT", 36, 42], ["ADAR", "GENE_OR_GENE_PRODUCT", 56, 60], ["adenosines", "SIMPLE_CHEMICAL", 74, 84], ["inosines", "SIMPLE_CHEMICAL", 88, 96], ["cytosines", "SIMPLE_CHEMICAL", 130, 139], ["ADAR", "PROTEIN", 56, 60], ["these A-to-G mutations", "PROBLEM", 30, 52], ["ADAR", "PROBLEM", 56, 60], ["likely", "UNCERTAINTY", 2, 8]]], ["A hallmark of ADAR 1 and 2 is that editing is more likely when the 5\u2032 neighbor of the editable base is A or U and, more precisely, the neighbor base preferences have been shown to be U > A > C > G (Dawson et al., 2004, Kuttan and Bass, 2012, Lehmann and Bass, 2000, Polson and Bass, 1994).", [["ADAR 1", "GENE_OR_GENE_PRODUCT", 14, 20], ["2", "GENE_OR_GENE_PRODUCT", 25, 26], ["A", "GENE_OR_GENE_PRODUCT", 103, 104], ["U", "GENE_OR_GENE_PRODUCT", 108, 109], ["ADAR 1 and 2", "DNA", 14, 26], ["5\u2032 neighbor", "DNA", 67, 78], ["editable base", "DNA", 86, 99], ["more likely", "UNCERTAINTY", 46, 57]]], ["Our sequence analysis shows these same preferences, thus supporting the involvement of ADAR in NoV hyper-mutation.", [["ADAR", "GENE_OR_GENE_PRODUCT", 87, 91], ["NoV", "ORGANISM", 95, 98], ["ADAR", "PROTEIN", 87, 91], ["Our sequence analysis", "TEST", 0, 21]]], ["Previous work has shown or suggested ADAR-mediated hyper-mutation in several viruses, but these were negative-strand viruses as opposed to NoVs (Samuel, 2011).", [["ADAR", "GENE_OR_GENE_PRODUCT", 37, 41], ["ADAR", "PROTEIN", 37, 41], ["ADAR-mediated hyper-mutation", "PROBLEM", 37, 65], ["several viruses", "PROBLEM", 69, 84], ["strand viruses", "PROBLEM", 110, 124], ["viruses", "OBSERVATION", 77, 84]]], ["Hyper-mutation should be carried out by the interferon-inducible p150 isoform of ADAR1, since this is the only ADAR form located in the cytoplasm (George et al., 2011) where NoVs replicate.", [["cytoplasm", "ANATOMY", 136, 145], ["Hyper-mutation", "DISEASE", 0, 14], ["p150", "GENE_OR_GENE_PRODUCT", 65, 69], ["ADAR1", "GENE_OR_GENE_PRODUCT", 81, 86], ["ADAR", "GENE_OR_GENE_PRODUCT", 111, 115], ["cytoplasm", "ORGANISM_SUBSTANCE", 136, 145], ["NoVs", "GENE_OR_GENE_PRODUCT", 174, 178], ["interferon", "PROTEIN", 44, 54], ["p150 isoform", "PROTEIN", 65, 77], ["ADAR1", "PROTEIN", 81, 86], ["ADAR form", "PROTEIN", 111, 120], ["NoVs", "PROTEIN", 174, 178], ["Hyper-mutation", "TEST", 0, 14], ["ADAR1", "PROBLEM", 81, 86]]], ["ADAR uses double-stranded RNA as a substrate and, therefore, the template RNA has to adopt a nearly perfect stem-like secondary structure or be a double-stranded replicative intermediate.", [["ADAR", "GENE_OR_GENE_PRODUCT", 0, 4], ["ADAR", "PROTEIN", 0, 4], ["double-stranded RNA", "RNA", 10, 29], ["template RNA", "RNA", 65, 77], ["double-stranded RNA", "TREATMENT", 10, 29], ["secondary structure", "PROBLEM", 118, 137], ["a double-stranded replicative intermediate", "TREATMENT", 144, 186]]], ["The secondary structure of the NoV genomic RNA has not been solved experimentally and, although in silico RNA folding shows limited reliability for long molecules, stem-like structures are simple enough to be confidently predicted.", [["stem-like structures", "ANATOMY", 164, 184], ["NoV genomic RNA", "RNA", 31, 46], ["the NoV genomic RNA", "PROBLEM", 27, 46], ["silico RNA folding", "PROBLEM", 99, 117], ["long molecules, stem-like structures", "PROBLEM", 148, 184], ["secondary", "OBSERVATION_MODIFIER", 4, 13], ["structure", "OBSERVATION_MODIFIER", 14, 23], ["NoV genomic RNA", "OBSERVATION", 31, 46], ["silico RNA folding", "OBSERVATION", 99, 117], ["long molecules", "OBSERVATION_MODIFIER", 148, 162], ["stem", "OBSERVATION_MODIFIER", 164, 168]]], ["However, the minimum free energy structure of the 266-base region encompassing VP1 nucleotides 38 to 303 predicted by the mfold algorithm (Zuker, 2003) did not show a stem-like structure.", [["nucleotides", "CHEMICAL", 83, 94], ["266-base region", "DNA", 50, 65], ["VP1 nucleotides 38 to 303", "DNA", 79, 104], ["VP1 nucleotides", "TEST", 79, 94], ["the mfold algorithm", "TEST", 118, 137], ["a stem-like structure", "PROBLEM", 165, 186], ["minimum", "OBSERVATION_MODIFIER", 13, 20], ["free", "OBSERVATION_MODIFIER", 21, 25], ["energy structure", "OBSERVATION", 26, 42], ["base", "ANATOMY_MODIFIER", 54, 58], ["region", "ANATOMY_MODIFIER", 59, 65], ["stem", "OBSERVATION", 167, 171]]], ["This suggests that ADAR acts on NoV double-stranded replicative intermediates.", [["ADAR", "GENE_OR_GENE_PRODUCT", 19, 23], ["ADAR", "PROTEIN", 19, 23], ["ADAR acts", "PROBLEM", 19, 28]]], ["ADAR 1 is ubiquitously expressed in human tissues (Kim et al., 1994) and, although HEK293 cells express relatively low ADAR 1 levels, this activity was shown to be sufficient to edit 5% of hepatitis delta virus RNA molecules (Sato et al., 2001).", [["tissues", "ANATOMY", 42, 49], ["HEK293 cells", "ANATOMY", 83, 95], ["ADAR 1", "GENE_OR_GENE_PRODUCT", 0, 6], ["human", "ORGANISM", 36, 41], ["tissues", "TISSUE", 42, 49], ["HEK293 cells", "CELL", 83, 95], ["ADAR 1", "GENE_OR_GENE_PRODUCT", 119, 125], ["hepatitis delta virus", "ORGANISM", 189, 210], ["ADAR 1", "PROTEIN", 0, 6], ["HEK293 cells", "CELL_LINE", 83, 95], ["ADAR 1", "PROTEIN", 119, 125], ["hepatitis delta virus RNA molecules", "PROTEIN", 189, 224], ["human", "SPECIES", 36, 41], ["hepatitis delta virus", "SPECIES", 189, 210], ["human", "SPECIES", 36, 41], ["hepatitis delta virus", "SPECIES", 189, 210], ["relatively low ADAR 1 levels", "PROBLEM", 104, 132], ["hepatitis delta virus RNA molecules", "PROBLEM", 189, 224], ["human tissues", "ANATOMY", 36, 49]]], ["In B lymphocytes, which are candidate cell targets for NoVs in vivo (Jones et al., 2014), ADAR1 and ADAR2 are more strongly expressed and have been shown to edit thousands of adenosines in cellular mRNA and long non-coding RNA (Wang et al., 2013).DiscussionA limitation of our study is that, whereas transfection assays were carried out using a cDNA clone belonging to genogroup I, viruses isolated from stool samples were all from genogroup II.", [["B lymphocytes", "ANATOMY", 3, 16], ["cell", "ANATOMY", 38, 42], ["cellular", "ANATOMY", 189, 197], ["stool samples", "ANATOMY", 404, 417], ["adenosines", "CHEMICAL", 175, 185], ["B lymphocytes", "CELL", 3, 16], ["cell", "CELL", 38, 42], ["NoVs", "GENE_OR_GENE_PRODUCT", 55, 59], ["ADAR1", "GENE_OR_GENE_PRODUCT", 90, 95], ["ADAR2", "GENE_OR_GENE_PRODUCT", 100, 105], ["adenosines", "GENE_OR_GENE_PRODUCT", 175, 185], ["cellular", "CELL", 189, 197], ["genogroup I", "ORGANISM", 369, 380], ["stool samples", "CANCER", 404, 417], ["B lymphocytes", "CELL_TYPE", 3, 16], ["NoVs", "PROTEIN", 55, 59], ["ADAR1", "PROTEIN", 90, 95], ["ADAR2", "PROTEIN", 100, 105], ["cellular mRNA", "RNA", 189, 202], ["long non-coding RNA", "RNA", 207, 226], ["cDNA clone", "DNA", 345, 355], ["genogroup I", "SPECIES", 369, 380], ["adenosines in cellular mRNA", "PROBLEM", 175, 202], ["long non-coding RNA", "PROBLEM", 207, 226], ["our study", "TEST", 273, 282], ["transfection assays", "TEST", 300, 319], ["a cDNA clone", "TREATMENT", 343, 355], ["viruses", "PROBLEM", 382, 389], ["stool samples", "TEST", 404, 417], ["B lymphocytes", "OBSERVATION", 3, 16], ["cellular mRNA", "OBSERVATION", 189, 202]]], ["However, the type of mutations produced and the neighbor base preferences were very similar in stool samples and in transfection assays.", [["stool samples", "ANATOMY", 95, 108], ["stool samples", "ORGANISM_SUBSTANCE", 95, 108], ["mutations", "PROBLEM", 21, 30], ["the neighbor base preferences", "PROBLEM", 44, 73], ["stool samples", "TEST", 95, 108], ["transfection assays", "TEST", 116, 135]]], ["Specifically, 82.9% of the 5\u2032 neighbors of U-to-C mutations and 72.3% of the 3\u2032 neighbors of A-to-G mutations were A or U in clinical samples.", [["samples", "ANATOMY", 134, 141], ["U-to-C", "GENE_OR_GENE_PRODUCT", 43, 49], ["A-to-G", "GENE_OR_GENE_PRODUCT", 93, 99], ["U", "GENE_OR_GENE_PRODUCT", 120, 121], ["samples", "CANCER", 134, 141], ["U", "TEST", 43, 44], ["U in clinical samples", "TEST", 120, 141]]], ["After correcting for base composition, the resulting 3\u2032 neighbor preferences for U-to-C mutations were A > U > G > C, whereas the 5\u2032 preferences for A-to-G mutations were U > A > G > C in clinical samples.", [["samples", "ANATOMY", 197, 204], ["U-to-C", "GENE_OR_GENE_PRODUCT", 81, 87], ["G > C", "GENE_OR_GENE_PRODUCT", 111, 116], ["A-to-G", "GENE_OR_GENE_PRODUCT", 149, 155], ["G > C", "SIMPLE_CHEMICAL", 179, 184], ["samples", "CANCER", 197, 204], ["U", "TEST", 81, 82], ["A-to-G mutations", "TEST", 149, 165], ["U", "TEST", 171, 172]]], ["The similarities between the results obtained in transfection assays and in vivo support a common underlying mechanism, despite the fact that different genogroups were used for these experiments.", [["transfection assays", "TEST", 49, 68], ["different genogroups", "PROBLEM", 142, 162]]], ["Still, hyper-mutation was 30-fold more abundant in the transfection assays than in clinical samples.", [["samples", "ANATOMY", 92, 99], ["hyper-mutation", "TEST", 7, 21], ["the transfection assays", "TEST", 51, 74]]], ["We attribute this difference to the fact that selection was mild or absent in transfection assays, whereas in stool samples (which should contain mainly free virions) we expect stronger selection against hyper-mutated genomes.", [["stool samples", "ANATOMY", 110, 123], ["stool samples", "ORGANISM_SUBSTANCE", 110, 123], ["hyper-mutated genomes", "DNA", 204, 225], ["transfection assays", "TEST", 78, 97], ["stool samples", "TEST", 110, 123], ["mainly free virions", "PROBLEM", 146, 165], ["hyper-mutated genomes", "PROBLEM", 204, 225], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["transfection assays", "OBSERVATION", 78, 97]]], ["Alternatively, it is possible that ADAR activity was lower in the NoV target cells in vivo than in HEK293 cells.", [["cells", "ANATOMY", 77, 82], ["HEK293 cells", "ANATOMY", 99, 111], ["ADAR", "GENE_OR_GENE_PRODUCT", 35, 39], ["NoV", "ORGANISM", 66, 69], ["cells", "CELL", 77, 82], ["HEK293 cells", "CELL", 99, 111], ["ADAR", "PROTEIN", 35, 39], ["NoV target cells", "CELL_TYPE", 66, 82], ["HEK293 cells", "CELL_LINE", 99, 111], ["ADAR activity", "PROBLEM", 35, 48], ["is possible", "UNCERTAINTY", 18, 29], ["ADAR activity", "OBSERVATION", 35, 48]]], ["However, B cells show extensive ADAR-mediated editing of cellular RNAs (Wang et al., 2013).", [["B cells", "ANATOMY", 9, 16], ["cellular", "ANATOMY", 57, 65], ["B cells", "CELL", 9, 16], ["ADAR", "GENE_OR_GENE_PRODUCT", 32, 36], ["cellular", "CELL", 57, 65], ["B cells", "CELL_TYPE", 9, 16], ["ADAR", "PROTEIN", 32, 36], ["cellular RNAs", "RNA", 57, 70], ["B cells", "TEST", 9, 16], ["extensive ADAR", "PROBLEM", 22, 36], ["cellular RNAs", "PROBLEM", 57, 70], ["extensive", "OBSERVATION_MODIFIER", 22, 31], ["ADAR", "OBSERVATION", 32, 36], ["cellular RNAs", "OBSERVATION", 57, 70]]], ["Work with HIV-1 has shown that the observed levels of hyper-mutation vary depending on whether intra-cellular or virion-associated sequences are analyzed (Russell et al., 2009).", [["intra-cellular", "ANATOMY", 95, 109], ["HIV-1", "ORGANISM", 10, 15], ["intra-cellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 109], ["virion", "CELLULAR_COMPONENT", 113, 119], ["HIV-1", "SPECIES", 10, 15], ["HIV-1", "SPECIES", 10, 15], ["hyper-mutation vary", "PROBLEM", 54, 73]]], ["APOBEC massively edits the retroviral cDNA, leading to a rate of G-to-A mutation of approximately 4 \u00d7 10\u2212 3 per base per cell, a value two orders of magnitude higher than HIV-1 reverse transcriptase errors (Cuevas et al., 2015).", [["cell", "ANATOMY", 121, 125], ["APOBEC", "GENE_OR_GENE_PRODUCT", 0, 6], ["retroviral", "ORGANISM", 27, 37], ["cell", "CELL", 121, 125], ["APOBEC", "PROTEIN", 0, 6], ["retroviral cDNA", "DNA", 27, 42], ["reverse transcriptase", "PROTEIN", 177, 198], ["HIV-1", "SPECIES", 171, 176], ["HIV-1", "SPECIES", 171, 176], ["APOBEC massively edits the retroviral cDNA", "PROBLEM", 0, 42], ["a rate", "TEST", 55, 61], ["G", "TEST", 65, 66], ["a value", "TEST", 127, 134], ["retroviral cDNA", "OBSERVATION", 27, 42]]], ["In contrast, the rate observed in plasma is 44 times lower, consistent with the notion that the vast majority of APOBEC-edited HIV-1 genomes is unviable and rapidly removed by selection (Ho et al., 2013).", [["plasma", "ANATOMY", 34, 40], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["APOBEC", "GENE_OR_GENE_PRODUCT", 113, 119], ["HIV-1", "ORGANISM", 127, 132], ["APOBEC-edited HIV-1 genomes", "DNA", 113, 140], ["HIV-1", "SPECIES", 127, 132], ["HIV-1", "SPECIES", 127, 132], ["the rate", "TEST", 13, 21], ["APOBEC", "TEST", 113, 119], ["consistent with", "UNCERTAINTY", 60, 75]]], ["In human hepatitis B virus, papilloma virus, herpes simplex virus 1 and Epstein\u2013Barr virus APOBEC-edited genomes are usually found at low frequencies and their identification required a modified PCR protocol in which the lower melting temperature of A/T-rich molecules is exploited for selective amplification of hyper-mutants (Susp\u00e8ne et al., 2011, Susp\u00e8ne et al., 2005, Vartanian et al., 2008).", [["hepatitis B", "DISEASE", 9, 20], ["papilloma virus", "DISEASE", 28, 43], ["herpes simplex", "DISEASE", 45, 59], ["human", "ORGANISM", 3, 8], ["hepatitis B virus, papilloma virus", "ORGANISM", 9, 43], ["herpes simplex virus 1", "ORGANISM", 45, 67], ["Epstein\u2013Barr virus", "ORGANISM", 72, 90], ["APOBEC", "ORGANISM", 91, 97], ["APOBEC-edited genomes", "DNA", 91, 112], ["human", "SPECIES", 3, 8], ["hepatitis B virus", "SPECIES", 9, 26], ["papilloma virus", "SPECIES", 28, 43], ["herpes simplex virus", "SPECIES", 45, 65], ["Barr virus APOBEC", "SPECIES", 80, 97], ["human hepatitis B virus", "SPECIES", 3, 26], ["herpes simplex virus 1", "SPECIES", 45, 67], ["Epstein\u2013Barr virus", "SPECIES", 72, 90], ["human hepatitis B virus", "PROBLEM", 3, 26], ["papilloma virus", "PROBLEM", 28, 43], ["herpes simplex virus", "PROBLEM", 45, 65], ["a modified PCR protocol", "TREATMENT", 184, 207], ["hyper-mutants", "PROBLEM", 313, 326], ["hepatitis", "OBSERVATION", 9, 18], ["papilloma virus", "OBSERVATION", 28, 43]]], ["A variant of this strategy has been devised for ADAR-edited sequences, which allowed detecting hyper-mutants in Rift Valley virus (Susp\u00e8ne et al., 2008).", [["ADAR", "GENE_OR_GENE_PRODUCT", 48, 52], ["Rift Valley virus", "ORGANISM", 112, 129], ["ADAR-edited sequences", "DNA", 48, 69], ["Rift Valley virus", "SPECIES", 112, 129], ["Rift Valley virus", "SPECIES", 112, 129]]], ["Therefore, probably with the exception of HIV-1, hyper-mutated sequences are generally rare.", [["HIV-1", "ORGANISM", 42, 47], ["hyper-mutated sequences", "DNA", 49, 72], ["HIV-1", "SPECIES", 42, 47], ["HIV-1", "SPECIES", 42, 47], ["HIV", "TEST", 42, 45], ["hyper-mutated sequences", "PROBLEM", 49, 72]]], ["Selective PCR amplification is valuable for detecting these sequences but does not allow an estimation of their population frequency.", [["Selective PCR amplification", "TEST", 0, 27], ["these sequences", "TEST", 54, 69]]], ["As a result, few studies have determined the abundance of viral hyper-mutants in an unbiased manner.", [["few studies", "TEST", 13, 24], ["viral hyper-mutants", "PROBLEM", 58, 77]]], ["Ultra-deep sequencing provides a powerful tool for achieving this goal.ConclusionsPrevious work has suggested that the high genetic diversity of RNA viruses originates mainly from the low replication fidelity of their polymerases.", [["polymerases", "PROTEIN", 218, 229], ["Ultra", "TEST", 0, 5], ["the high genetic diversity of RNA viruses", "PROBLEM", 115, 156], ["high", "OBSERVATION_MODIFIER", 119, 123], ["RNA viruses", "OBSERVATION", 145, 156], ["low replication", "OBSERVATION_MODIFIER", 184, 199]]], ["However, our in depth analysis of NoV spontaneous mutations in clinical samples and laboratory populations supports the notion that host-driven hyper-mutation is a source of diversity comparable to or even greater than polymerase infidelity.", [["samples", "ANATOMY", 72, 79], ["NoV", "ORGANISM", 34, 37], ["samples", "CANCER", 72, 79], ["our in depth analysis", "TEST", 9, 30], ["NoV spontaneous mutations", "PROBLEM", 34, 59], ["clinical samples", "TEST", 63, 79], ["laboratory populations", "TEST", 84, 106], ["hyper-mutation", "PROBLEM", 144, 158]]], ["Hyper-mutation is not necessarily an all-or-nothing process and the number of nucleotide substitutions per sequence varied extensively, suggesting that hyper-mutation may significantly contribute to NoV genetic diversity and evolution in nature.", [["Hyper-mutation", "DISEASE", 0, 14], ["nucleotide", "CHEMICAL", 78, 88], ["nucleotide", "CHEMICAL", 78, 88], ["NoV", "SPECIES", 199, 202], ["an all-or-nothing process", "PROBLEM", 34, 59], ["nucleotide substitutions", "PROBLEM", 78, 102], ["hyper-mutation", "PROBLEM", 152, 166], ["NoV genetic diversity", "PROBLEM", 199, 220], ["not necessarily", "UNCERTAINTY", 18, 33]]], ["Analysis of the types of mutations produced in longitudinal studies may help elucidate this contribution.", [["mutations", "PROBLEM", 25, 34], ["longitudinal studies", "TEST", 47, 67]]]], "PMC7088046": [["Executive SummaryThe escalating rates of infant, child, and maternal mortality in developing countries are a significant problem both for the developing world and for developed countries that are capable of initiating and sustaining cost-efficient interventions.", [["infant", "SPECIES", 41, 47], ["escalating", "OBSERVATION_MODIFIER", 21, 31]]], ["In 2000, the U.S. and 188 other countries committed to achieve 8 Millennium Development Goals which aim to reduce global infant, child, and maternal death rates by 2015.", [["death", "DISEASE", 149, 154], ["infant", "SPECIES", 121, 127], ["maternal death rates", "PROBLEM", 140, 160]]], ["More than 11 million children under the age of five die every year and an overwhelming majority of these cases arise from preventable or easily treatable conditions [2].", [["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29], ["easily treatable conditions", "PROBLEM", 137, 164]]], ["In fact, over 70% of global child deaths can be attributed to diarrhea, malaria, neonatal infection, pneumonia, preterm delivery, or lack of oxygen at birth.", [["deaths", "DISEASE", 34, 40], ["diarrhea", "DISEASE", 62, 70], ["malaria", "DISEASE", 72, 79], ["neonatal infection", "DISEASE", 81, 99], ["pneumonia", "DISEASE", 101, 110], ["preterm delivery", "DISEASE", 112, 128], ["oxygen", "CHEMICAL", 141, 147], ["oxygen", "CHEMICAL", 141, 147], ["oxygen", "SIMPLE_CHEMICAL", 141, 147], ["diarrhea", "PROBLEM", 62, 70], ["malaria", "PROBLEM", 72, 79], ["neonatal infection", "PROBLEM", 81, 99], ["pneumonia", "PROBLEM", 101, 110], ["preterm delivery", "TREATMENT", 112, 128], ["diarrhea", "OBSERVATION", 62, 70], ["malaria", "OBSERVATION", 72, 79], ["neonatal", "OBSERVATION_MODIFIER", 81, 89], ["infection", "OBSERVATION", 90, 99], ["pneumonia", "OBSERVATION", 101, 110]]], ["[3] Most child deaths occur in developing countries, which play host to contributing factors such as marginalization, conflict, HIV/AIDS, malnutrition, and lack of safe drinking water and sanitation.", [["deaths", "DISEASE", 15, 21], ["HIV/AIDS", "DISEASE", 128, 136], ["malnutrition", "DISEASE", 138, 150], ["child", "ORGANISM", 9, 14], ["HIV", "SPECIES", 128, 131], ["HIV", "SPECIES", 128, 131], ["HIV/AIDS", "PROBLEM", 128, 136], ["malnutrition", "PROBLEM", 138, 150]]], ["Children in the developing world are ten times more likely to die before age five as compared to their counterparts in developed countries [2].", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["In fact, in the ten countries with the highest child mortality rates, almost 1 of every 5 children dies before age five [2].Context of Child and Maternal HealthMaternal mortality is directly connected to neonatal mortality.", [["children", "ORGANISM", 90, 98], ["children", "SPECIES", 90, 98]]], ["About 20% of the disease burden in children under age 5 is tied to poor maternal health and nutrition, as well as the quality of care children receive in the first year of life [3].", [["children", "ORGANISM", 35, 43], ["children", "ORGANISM", 134, 142], ["children", "SPECIES", 35, 43], ["children", "SPECIES", 134, 142], ["the disease burden", "PROBLEM", 13, 31], ["disease", "OBSERVATION", 17, 24]]], ["Every year, 8 million babies die before or during delivery and during the newborn period, while others left motherless have a 10-fold risk of dying within 2 years of their mothers\u2019 death.", [["death", "DISEASE", 181, 186], ["babies", "ORGANISM", 22, 28], ["delivery", "TREATMENT", 50, 58]]], ["Maternal mortality is also at a critical level as nearly 550,000 women die each year from causes related to pregnancy and childbirth, including hemorrhage, infection, obstructed labor, hypertensive disorders, and unsafe abortion practices [4].", [["hemorrhage", "DISEASE", 144, 154], ["infection", "DISEASE", 156, 165], ["obstructed labor", "DISEASE", 167, 183], ["hypertensive disorders", "DISEASE", 185, 207], ["women", "ORGANISM", 65, 70], ["women", "SPECIES", 65, 70], ["Maternal mortality", "PROBLEM", 0, 18], ["pregnancy and childbirth", "PROBLEM", 108, 132], ["hemorrhage", "PROBLEM", 144, 154], ["infection", "PROBLEM", 156, 165], ["obstructed labor", "PROBLEM", 167, 183], ["hypertensive disorders", "PROBLEM", 185, 207], ["unsafe abortion practices", "TREATMENT", 213, 238], ["hemorrhage", "OBSERVATION", 144, 154], ["infection", "OBSERVATION", 156, 165], ["obstructed", "OBSERVATION_MODIFIER", 167, 177], ["labor", "OBSERVATION", 178, 183]]], ["The vast majority of these maternal deaths occur in the developing world.", [["deaths", "DISEASE", 36, 42], ["these maternal deaths", "PROBLEM", 21, 42], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17]]], ["Sadly, they are also due to preventable causes including pregnancy and childbirth at an early age, closely spaced births, infectious diseases, malnutrition, and complications during child birth [5].", [["infectious diseases", "DISEASE", 122, 141], ["malnutrition", "DISEASE", 143, 155], ["preventable causes", "PROBLEM", 28, 46], ["pregnancy and childbirth", "PROBLEM", 57, 81], ["infectious diseases", "PROBLEM", 122, 141], ["malnutrition", "PROBLEM", 143, 155], ["infectious", "OBSERVATION_MODIFIER", 122, 132]]], ["When it comes to the indicator of mortality risk, women in developing countries experience the largest disparity of any health indicator when contrasted to women in richer, developed countries.", [["women", "ORGANISM", 50, 55], ["women", "ORGANISM", 156, 161], ["women", "SPECIES", 50, 55], ["women", "SPECIES", 156, 161]]], ["Compared to a 1 in 4,000 risk of dying during pregnancy or childbirth in the developed world, a woman in sub-Saharan Africa, for example, faces a 1 in 16 chance of death [3].Context of Child and Maternal HealthThe issues of infant, child, and maternal death are pervasive and expected to grow without deliberate intervention.", [["death", "DISEASE", 164, 169], ["death", "DISEASE", 252, 257], ["woman", "ORGANISM", 96, 101], ["woman", "SPECIES", 96, 101], ["infant", "SPECIES", 224, 230], ["maternal death", "PROBLEM", 243, 257], ["deliberate intervention", "TREATMENT", 301, 324]]], ["In fact, research demonstrates that with the use of cost-effective, evidence-based healthcare interventions, 6 million child deaths can be prevented [3].", [["deaths", "DISEASE", 125, 131]]], ["Examples include immunization programs, antibiotics, insecticide-treated bed net distribution, micronutrient supplementation, and improved family care and breastfeeding practices [3].", [["immunization programs", "TREATMENT", 17, 38], ["antibiotics", "TREATMENT", 40, 51], ["insecticide", "TREATMENT", 53, 64], ["micronutrient supplementation", "TREATMENT", 95, 124]]], ["Legislating international strategy will mobilize stakeholders and appropriate funding in order to implement effective programs for sustainable change.", [["effective programs", "TREATMENT", 108, 126]]], ["This is precisely the task of Senate Bill 1966 (S. 1966) which seeks to improve the health of infants, children, and mothers in the world\u2019s poorest nations [6].Policy BackgroundWhile U.S. health policy pertaining specifically to global child and maternal health is a relatively recent development, several significant policies preceded S. 1966 in an attempt to create foreign assistance structures for the improvement of international health.", [["infants", "ORGANISM", 94, 101], ["children", "ORGANISM", 103, 111], ["infants", "SPECIES", 94, 101], ["children", "SPECIES", 103, 111], ["foreign assistance structures", "TREATMENT", 368, 397]]], ["After World War II, Europe\u2019s requests for assistance resulted in the international community\u2019s establishment of the International Monetary Fund and the International Bank for Reconstruction and Development in 1945.", [["Reconstruction", "TREATMENT", 175, 189]]], ["The U.S. responded in 1948 with the enactment of the Economic Cooperation Act and creation of the Marshall Plan which sought to stabilize Europe through temporary emergency assistance [7].", [["temporary emergency assistance", "TREATMENT", 153, 183]]], ["After the end of the Marshall Plan in 1951, Congress passed the first Mutual Security Act which paired military and economic programs with technical assistance as new foreign aid policy.", [["technical assistance", "TREATMENT", 139, 159]]], ["In 1953, the Foreign Operations Administration was established as an independent government agency to consolidate international assistance.", [["the Foreign Operations Administration", "TREATMENT", 9, 46]]], ["Congress approved a revised Mutual Security Act in 1957 and despite great development of foreign aid policy by this time, there remained a need for a long-term foreign development program.", [["a long-term foreign development program", "TREATMENT", 148, 187]]], ["This gap in policy contributed to the increasing dissatisfaction among the public and Congress with the U.S. foreign assistance structures already in place [7].Policy BackgroundCongress and the Eisenhower Administration were spurred to reorganize U.S. foreign assistance programs and focus U.S. aid on the developing world, which led to the enactment of the Foreign Assistance Act (FAA) of 1961 [8].", [["the increasing dissatisfaction", "PROBLEM", 34, 64], ["increasing", "OBSERVATION_MODIFIER", 38, 48], ["dissatisfaction", "OBSERVATION", 49, 64]]], ["The FAA separated military and non-military aid and mandated the creation of the U.S. Agency for International Development (USAID) to promote and administer long-term assistance programs for the economic and social growth of developing countries [7].", [["long-term assistance programs", "TREATMENT", 157, 186]]], ["The impact of current programs run by USAID is significant and has undoubtedly worked for the improvement of infant, child, and maternal health around the world.", [["infant", "SPECIES", 109, 115]]], ["While the FAA remains the prevailing and most effective foreign assistance legislation, disparities in child and maternal health in developing countries persist.Policy BackgroundTo continue combating the grave disparities faced by women and children in developing nations in the spirit of previous policy development, the U.S. joined 188 countries at the United Nations Millennium Summit in 2000 in committing to achieve 8 Millennium Development Goals (MDGs) [3].", [["women", "ORGANISM", 231, 236], ["children", "ORGANISM", 241, 249], ["women", "SPECIES", 231, 236], ["children", "SPECIES", 241, 249]]], ["The leaders declared that by 2015, the state of global health would be measurably improved with active progress by the international community towards the 8 key goals that are geared mainly towards children.", [["children", "ORGANISM", 198, 206], ["children", "SPECIES", 198, 206]]], ["Commitments to improving infant, child, and maternal health are reflected in MDG 4, to reduce child mortality by two thirds and MDG 5, to reduce maternal mortality by three quarters, between 1990 and 2015 [3].", [["infant", "SPECIES", 25, 31]]], ["This bill proposed various activities to improve the health of newborns, children, and mothers in developing countries but expired in the 109th session of Congress and never became law.", [["newborns", "ORGANISM", 63, 71], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81]]], ["Senate Bill 2765 (S. 2765) for the CHILD and Newborn Act of 2006 also died while under review in the 109th session of Congress [10].", [["CHILD", "DISEASE", 35, 40]]], ["First, it proposes to \u201cdevelop a strategy to reduce mortality and improve the health of newborns, children, and mothers, and authorize assistance for its implementation\u201d [13].", [["newborns", "ORGANISM", 88, 96], ["children", "ORGANISM", 98, 106], ["children", "SPECIES", 98, 106]]], ["This first component will be carried out by activities to improve essential newborn care and treatment, prevent childhood illness, improve maternal nutrition, and improve access to clean water and proper sanitation among many others.", [["illness", "DISEASE", 122, 129], ["essential newborn care", "TREATMENT", 66, 88], ["treatment", "TREATMENT", 93, 102], ["childhood illness", "PROBLEM", 112, 129], ["maternal nutrition", "TREATMENT", 139, 157], ["clean water", "TREATMENT", 181, 192], ["proper sanitation", "TREATMENT", 197, 214]]], ["Another component of this first goal calls for President Barack Obama to \u201cdevelop and implement a comprehensive strategy to reduce mortality and improve the health of newborns, children, and mothers in developing countries\u201d [5].", [["newborns", "ORGANISM", 167, 175], ["children", "ORGANISM", 177, 185], ["children", "SPECIES", 177, 185]]], ["This part of the bill would be accomplished by compiling mortality data, assessing causes of mortality, assessing necessary investments for programs, and describing specific goals and objectives for improving infant, child, and maternal health among many more activities.", [["infant", "SPECIES", 209, 215]]], ["S. 1966 has currently been read twice and referred to the Committee on Foreign Relations, the first step in the legislative process [13].Policy AnalysisGroups in favor of S. 1966 are practitioners including physicians and nurses, organizations working for child health, including the World Health Organization and United Nations Children\u2019s Fund, as well as the bill sponsors, Senators Dodd, Durbin, and Corker.", [["Children", "SPECIES", 329, 337]]], ["These bill supporters advocate for improvements in child and maternal health and for the use of low-cost interventions to reduce mortality.", [["low-cost interventions", "TREATMENT", 96, 118]]], ["The bill sponsors hold that the U.S. must follow through with its commitment to reduce infant, child, and maternal mortality and increase funding and delivery of cost-efficient interventions to ensure that MDG 4 is met [5].", [["cost-efficient interventions", "TREATMENT", 162, 190]]], ["Senators Dodd, Durbin, and Corker have gained support of S. 1966 by Save the Children, the U.S. Coalition for Child Survival, and the U.S. Fund for UNICEF [6].Policy AnalysisWhen examining S. 1966 alongside its previous version, S. 1418, it is evident that there are a few key differences.", [["Children", "SPECIES", 77, 85], ["few", "OBSERVATION_MODIFIER", 269, 272]]], ["While both of the bills sought \u201cto provide assistance to improve the health of newborns, children, and mothers in developing countries, and for other purposes,\u201d they differ in how they plan to provide assistance [5, 14].", [["newborns", "ORGANISM", 79, 87], ["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97]]], ["While S. 1418 does not focus at all on preventive care in order to improve health outcomes, S. 1966 details strategies to prevent childhood illness and disease, the onset of tropical diseases, as well as postpartum complications [5, 14].", [["illness", "DISEASE", 140, 147], ["preventive care", "TREATMENT", 39, 54], ["childhood illness", "PROBLEM", 130, 147], ["disease", "PROBLEM", 152, 159], ["tropical diseases", "PROBLEM", 174, 191], ["postpartum complications", "PROBLEM", 204, 228], ["tropical", "OBSERVATION_MODIFIER", 174, 182], ["diseases", "OBSERVATION", 183, 191]]], ["In essence, S. 1966 and S. 1418 are very similar.", [["S. 1418", "ORGANISM", 24, 31], ["very", "OBSERVATION_MODIFIER", 36, 40], ["similar", "OBSERVATION_MODIFIER", 41, 48]]], ["This bill mandated an increase in funding to expand child and maternal health interventions including $600 million for fiscal year 2008, $900 million for 2009, $1.2 billion for 2010, and $1.6 billion each for 2011 and 2012 [14, 15].", [["increase", "OBSERVATION_MODIFIER", 22, 30]]], ["The bill outlines sixteen broad categories of activities to help reduce mortality and improve health, in addition to the numerous components of the strategy and task force development sections of the bill.", [["the strategy", "TREATMENT", 144, 156]]], ["While there is no doubt that U.S leadership in improving maternal and child health in developing countries will eventually require a multi-faceted and complex approach, it is reasonable to expect that a bill that is too comprehensive may not appear feasible.", [["no doubt", "UNCERTAINTY", 15, 23]]], ["Taking smaller, more incremental steps that allow for experimentation and evaluation of results may be the only feasible approach to big problems such as global health disparities [16].", [["evaluation", "TEST", 74, 84], ["big problems", "PROBLEM", 133, 145]]], ["The current version of S. 1966, with its numerous activities, may very well be deliberated upon in committee for a long period of time and expire by the end of the current session of Congress just as its previous versions did.Policy CritiquesA third critique of S. 1966 is that there is no evidence provided for its potential benefit to the United States.", [["no evidence provided", "UNCERTAINTY", 287, 307]]], ["While plenty of evidence is given in the bill text for maternal and child mortality rates worldwide along with the potential impact of cost-efficient preventive strategies, there is no relationship drawn between improvements in global health and the health and well-being of Americans, which would present a strong argument in favor of the bill.", [["Americans", "ORGANISM", 275, 284], ["cost-efficient preventive strategies", "TREATMENT", 135, 171]]], ["Sponsors of S. 1966 should provide a broader funding context as well as articulate possible sources of funding in order to increase the bill\u2019s likelihood of passing into law.Policy RecommendationsIt is evident that if developing countries, which bear most of the total disease burden, are to reach the recognized health-related MDGs by 2015, they will need increased and sustained foreign assistance for health services from economically advanced countries [17].", [["the total disease burden", "PROBLEM", 259, 283]]], ["In order to increase U.S. commitment to improve global health, the Obama administration is investing $63 billion between 2009 and 2014 through the Global Health Initiative, a comprehensive whole-of-government approach to help partner countries in bolstering the health of women, newborns and children [18].", [["women", "ORGANISM", 272, 277], ["newborns", "ORGANISM", 279, 287], ["children", "ORGANISM", 292, 300], ["women", "SPECIES", 272, 277], ["children", "SPECIES", 292, 300]]], ["In a recent announcement, U.S. Secretary of State Hillary Clinton described the initiative as focused on \u201cmaternal and child health, family planning and programs to fight infectious diseases such as malaria, tuberculosis and HIV/AIDS\u201d [19].", [["infectious diseases", "DISEASE", 171, 190], ["malaria", "DISEASE", 199, 206], ["tuberculosis", "DISEASE", 208, 220], ["HIV/AIDS", "DISEASE", 225, 233], ["infectious diseases", "PROBLEM", 171, 190], ["malaria", "PROBLEM", 199, 206], ["tuberculosis", "PROBLEM", 208, 220]]], ["While $51 billion of the initiative\u2019s $63 billion budget will go to the President\u2019s Emergency Plan for AIDS Relief, the other $12 billion will be channeled into programming to fight tropical diseases and other health problems [20].", [["AIDS", "DISEASE", 103, 107], ["AIDS Relief", "TREATMENT", 103, 114], ["tropical diseases", "PROBLEM", 182, 199]]], ["We recommend that S. 1966 be financed through the Global Health Initiative because the goals of the bill correspond directly to those of the overarching strategy already in place.Policy RecommendationsWe also suggest that S. 1966 sponsors investigate other funding opportunities including raised funds through programs and organizations, both for-profit and non-profit, such as the March of Dimes, the Child Health Foundation, and the Boys & Girls Club of America.", [["the overarching strategy", "TREATMENT", 137, 161]]], ["We suggest that the bill be revised to focus on a few key areas to help reduce infant, child, and maternal mortality.", [["infant", "SPECIES", 79, 85]]], ["The areas of interest should be limited to breast feeding education initiatives, supplement distribution, and immunization programs.", [["breast", "ANATOMY", 43, 49], ["breast", "ORGANISM_SUBDIVISION", 43, 49], ["breast feeding education initiatives", "TREATMENT", 43, 79], ["immunization programs", "TREATMENT", 110, 131]]], ["Breast feeding education initiatives are imperative for expecting and new mothers.", [["Breast", "ANATOMY", 0, 6], ["mothers", "ORGANISM", 74, 81], ["Breast feeding education", "TREATMENT", 0, 24]]], ["In fact, the World Health Organization (WHO) states that \u201cif all babies and young children were breastfed exclusively for their first 6 months of life and then given nutritious complementary food with continued breastfeeding up to 2 years of age, the lives of an additional 1.5 million children under five would be saved every year\u201d [21].", [["babies", "ORGANISM", 65, 71], ["children", "ORGANISM", 82, 90], ["children", "ORGANISM", 286, 294], ["children", "SPECIES", 82, 90], ["children", "SPECIES", 286, 294]]], ["With regards to low-cost supplements, the Global Action for Children notes that \u201csupplements given two to three times per year can prevent blindness and lower the risk of death from diarrhea, malaria and measles\u201d [22].", [["blindness", "DISEASE", 139, 148], ["death", "DISEASE", 171, 176], ["diarrhea", "DISEASE", 182, 190], ["malaria", "DISEASE", 192, 199], ["measles", "DISEASE", 204, 211], ["Children", "SPECIES", 60, 68], ["low-cost supplements", "TREATMENT", 16, 36], ["supplements", "TREATMENT", 81, 92], ["blindness", "PROBLEM", 139, 148], ["death", "PROBLEM", 171, 176], ["diarrhea", "PROBLEM", 182, 190], ["malaria", "PROBLEM", 192, 199], ["diarrhea", "OBSERVATION", 182, 190]]], ["Although each capsule costs only two cents, an alarming 28 percent of children in developing countries are not receiving this preventive treatment [22].", [["capsule", "ANATOMY", 14, 21], ["capsule", "CANCER", 14, 21], ["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78], ["this preventive treatment", "TREATMENT", 121, 146]]], ["Immunization programs are also cost-efficient and can drastically improve the lives of infants, children, and mothers by protecting them from diseases such as measles, mumps, rubella, hepatitis, tetanus, and polio.", [["measles, mumps, rubella, hepatitis, tetanus", "DISEASE", 159, 202], ["polio", "DISEASE", 208, 213], ["infants", "ORGANISM", 87, 94], ["children", "ORGANISM", 96, 104], ["infants", "SPECIES", 87, 94], ["children", "SPECIES", 96, 104], ["Immunization programs", "TREATMENT", 0, 21], ["measles", "PROBLEM", 159, 166], ["mumps", "PROBLEM", 168, 173], ["rubella", "PROBLEM", 175, 182], ["hepatitis", "PROBLEM", 184, 193], ["tetanus", "PROBLEM", 195, 202], ["polio", "PROBLEM", 208, 213], ["hepatitis", "OBSERVATION", 184, 193]]], ["According to the WHO, \u201cmore widespread use of low-cost vaccines could prevent 1.6 million deaths a year among children under the age of five\u201d [23].", [["deaths", "DISEASE", 90, 96], ["children", "ORGANISM", 110, 118], ["children", "SPECIES", 110, 118], ["low-cost vaccines", "TREATMENT", 46, 63]]], ["By focusing the goals of S. 1966 on these three main components, it is more likely that it will progress through Congress successfully so that the U.S. can partner with developing countries to make significant improvements to health.Policy RecommendationsThe third recommendation is that some evidence be cited in support of the bill\u2019s anticipated benefits to the United States, an argument that would increase its likelihood of being passed into law.", [["more likely", "UNCERTAINTY", 71, 82]]], ["This is especially true when it comes to the spread of infectious diseases as demonstrated by the threat of recent outbreaks of SARS and H1N1 virus [24].", [["infectious diseases", "DISEASE", 55, 74], ["SARS", "DISEASE", 128, 132], ["H1N1 virus", "ORGANISM", 137, 147], ["H1N1 virus", "SPECIES", 137, 147], ["H1N1 virus", "SPECIES", 137, 147], ["infectious diseases", "PROBLEM", 55, 74], ["SARS", "PROBLEM", 128, 132], ["H1N1 virus", "PROBLEM", 137, 147], ["infectious", "OBSERVATION", 55, 65]]], ["The Global Health Council describes disease as being potentially broad and borderless, as increased travel and trade mean that people and goods are carrying endemic pathogens to new places and populations [25].", [["people", "ORGANISM", 127, 133], ["people", "SPECIES", 127, 133], ["disease", "PROBLEM", 36, 43], ["Global", "OBSERVATION_MODIFIER", 4, 10]]], ["Trade in agricultural products is just as high as international travel and has made foodborne illnesses and illnesses of animal origin more prevalent [25].", [["foodborne illnesses and illnesses of animal origin", "DISEASE", 84, 134]]], ["Stopping an outbreak when it emerges is more efficacious and cost-efficient than allowing it to become a global threat, and that requires stronger health services in developing countries where infectious disease is highest [24].", [["infectious disease", "DISEASE", 193, 211], ["infectious disease", "PROBLEM", 193, 211]]], ["By giving mothers and children in developing countries care and support through the activities of S. 1966, the United States will send a more powerful message about the country\u2019s values and commitment to the international community.Policy RecommendationsBy helping to reduce health disparities in infant, child, and maternal mortality through the actions of S. 1966, the U.S. will demonstrate sensitivity to other countries\u2019 needs in addition to those at home.", [["children", "ORGANISM", 22, 30], ["children", "SPECIES", 22, 30], ["infant", "SPECIES", 297, 303]]], ["The revisions suggested by the authors including clarity in funding options, a more narrowed focus, and evidence of local as well as global impact, will lead to S. 1966 being more likely to pass into law and leave a lasting legacy of collaboration and compassion.", [["The revisions", "TREATMENT", 0, 13], ["a more narrowed focus", "PROBLEM", 77, 98], ["revisions", "OBSERVATION", 4, 13], ["narrowed", "OBSERVATION_MODIFIER", 84, 92], ["focus", "OBSERVATION", 93, 98]]], ["Bob Corker, a member of the Senate Foreign Relations Committee, believes that \u201cWe have an opportunity through [S. 1966] to save the lives of more children and improve the health of mothers in developing nations\u201d [26].", [["children", "ORGANISM", 146, 154], ["children", "SPECIES", 146, 154]]], ["Corker also holds that \u201cMaintaining U.S. investment in proven, cost-effective programs to combat poverty and disease overseas helps bring stability to unstable and often dangerous regions of the world, ultimately supporting our security interests both at home and abroad\u201d [26].", [["poverty", "DISEASE", 97, 104], ["disease", "PROBLEM", 109, 116]]]], "PMC5325310": [["IntroductionNeutropenic fever is one of the most important complications in cancer patients.[1] It is critical to rapidly localize infections and identify the organism involved, especially for fungal infections, which need a specific treatment approach.", [["cancer", "ANATOMY", 76, 82], ["Neutropenic fever", "DISEASE", 12, 29], ["cancer", "DISEASE", 76, 82], ["infections", "DISEASE", 131, 141], ["fungal infections", "DISEASE", 193, 210], ["cancer", "CANCER", 76, 82], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["Neutropenic fever", "PROBLEM", 12, 29], ["infections", "PROBLEM", 131, 141], ["the organism", "PROBLEM", 155, 167], ["fungal infections", "PROBLEM", 193, 210], ["a specific treatment approach", "TREATMENT", 223, 252], ["one of the most important", "OBSERVATION_MODIFIER", 33, 58], ["complications", "OBSERVATION", 59, 72], ["cancer", "OBSERVATION", 76, 82], ["infections", "OBSERVATION", 131, 141]]], ["Despite a standard diagnostic workup including chest radiograph (CXR) and microbiological screening, no focus is identified in up to 44% of patients.[2] This can partly be explained by the low sensitivity of radiographs for diagnosing pulmonary infections in neutropenic patients.[3] Acquiring CXRs in respiratory asymptomatic patients with febrile neutropenia is therefore controversial.", [["pulmonary", "ANATOMY", 235, 244], ["pulmonary infections", "DISEASE", 235, 255], ["neutropenic", "DISEASE", 259, 270], ["febrile neutropenia", "DISEASE", 341, 360], ["patients", "ORGANISM", 140, 148], ["pulmonary", "ORGAN", 235, 244], ["patients", "ORGANISM", 271, 279], ["CXRs", "GENE_OR_GENE_PRODUCT", 294, 298], ["patients", "ORGANISM", 327, 335], ["patients", "SPECIES", 140, 148], ["patients", "SPECIES", 271, 279], ["patients", "SPECIES", 327, 335], ["a standard diagnostic workup", "TEST", 8, 36], ["chest radiograph", "TEST", 47, 63], ["CXR", "TEST", 65, 68], ["microbiological screening", "TEST", 74, 99], ["radiographs", "TEST", 208, 219], ["pulmonary infections", "PROBLEM", 235, 255], ["neutropenic patients", "TREATMENT", 259, 279], ["Acquiring CXRs", "TEST", 284, 298], ["febrile neutropenia", "PROBLEM", 341, 360], ["chest", "ANATOMY", 47, 52], ["pulmonary", "ANATOMY", 235, 244], ["infections", "OBSERVATION", 245, 255], ["respiratory", "ANATOMY", 302, 313]]], ["The ESMO guidelines recommend performance of a CXR in every neutropenic patient with fever, whereas the IDSA guidelines suggest its use only in patients with respiratory signs or symptoms.[1, 4]IntroductionIn febrile neutropenia a substantial part (~10%) of infections is caused by invasive fungal disease (IFD).[5] IFD usually presents as a pulmonary infection, which is rarely visible on CXR and is therefore often missed in the early phase of neutropenic fever.", [["respiratory", "ANATOMY", 158, 169], ["pulmonary", "ANATOMY", 342, 351], ["neutropenic", "DISEASE", 60, 71], ["fever", "DISEASE", 85, 90], ["respiratory signs", "DISEASE", 158, 175], ["febrile neutropenia", "DISEASE", 209, 228], ["infections", "DISEASE", 258, 268], ["invasive fungal disease", "DISEASE", 282, 305], ["IFD", "DISEASE", 307, 310], ["IFD", "DISEASE", 316, 319], ["pulmonary infection", "DISEASE", 342, 361], ["fever", "DISEASE", 458, 463], ["patient", "ORGANISM", 72, 79], ["patients", "ORGANISM", 144, 152], ["pulmonary", "ORGAN", 342, 351], ["patient", "SPECIES", 72, 79], ["patients", "SPECIES", 144, 152], ["a CXR", "TEST", 45, 50], ["fever", "PROBLEM", 85, 90], ["respiratory signs", "PROBLEM", 158, 175], ["symptoms", "PROBLEM", 179, 187], ["IntroductionIn febrile neutropenia", "PROBLEM", 194, 228], ["infections", "PROBLEM", 258, 268], ["invasive fungal disease", "PROBLEM", 282, 305], ["a pulmonary infection", "PROBLEM", 340, 361], ["CXR", "TEST", 390, 393], ["neutropenic fever", "PROBLEM", 446, 463], ["substantial", "OBSERVATION_MODIFIER", 231, 242], ["infections", "OBSERVATION", 258, 268], ["invasive", "OBSERVATION_MODIFIER", 282, 290], ["fungal disease", "OBSERVATION", 291, 305], ["pulmonary", "ANATOMY", 342, 351], ["infection", "OBSERVATION", 352, 361], ["neutropenic", "OBSERVATION", 446, 457]]], ["Notably, a delayed start of appropriate treatment has a negative impact on clinical outcome.[6]IntroductionIn order to improve the early detection of pulmonary infiltrates in febrile neutropenia, other imaging tools have been investigated as an alternative to CXR.", [["pulmonary infiltrates", "ANATOMY", 150, 171], ["pulmonary infiltrates", "DISEASE", 150, 171], ["febrile neutropenia", "DISEASE", 175, 194], ["pulmonary", "ORGAN", 150, 159], ["CXR", "PROTEIN", 260, 263], ["appropriate treatment", "TREATMENT", 28, 49], ["pulmonary infiltrates", "PROBLEM", 150, 171], ["febrile neutropenia", "PROBLEM", 175, 194], ["other imaging tools", "TEST", 196, 215], ["CXR", "TEST", 260, 263], ["pulmonary", "ANATOMY", 150, 159], ["infiltrates", "OBSERVATION", 160, 171], ["febrile neutropenia", "OBSERVATION", 175, 194]]], ["High-resolution computed tomography (HRCT) improved pulmonary focus detection: pulmonary abnormalities were found in 60% of the neutropenic patients with persistent fever (>48 hours) and a normal CXR.[7] Furthermore, direct initiation of effective antifungal treatment after the early detection of a halo sign on HRCT images, had a positive effect on treatment response and survival in case of IFD, emphasizing the importance of early diagnosis.[8] However, due to costs and high radiation doses of approximately 7 mSv average, HRCT scanning is usually not incorporated in the initial febrile neutropenia workup.[9]IntroductionAnother imaging modality that could be used for the evaluation of febrile neutropenia is low-dose CT scanning (LDCT).", [["pulmonary", "ANATOMY", 52, 61], ["pulmonary", "ANATOMY", 79, 88], ["pulmonary abnormalities", "DISEASE", 79, 102], ["neutropenic", "DISEASE", 128, 139], ["fever", "DISEASE", 165, 170], ["IFD", "DISEASE", 394, 397], ["neutropenia", "DISEASE", 593, 604], ["neutropenia", "DISEASE", 701, 712], ["pulmonary", "ORGAN", 52, 61], ["pulmonary", "ORGAN", 79, 88], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148], ["pulmonary abnormalities", "PROBLEM", 79, 102], ["persistent fever", "PROBLEM", 154, 170], ["effective antifungal treatment", "TREATMENT", 238, 268], ["a halo sign", "PROBLEM", 298, 309], ["HRCT images", "TEST", 313, 324], ["treatment response", "TREATMENT", 351, 369], ["survival", "TREATMENT", 374, 382], ["IFD", "PROBLEM", 394, 397], ["high radiation doses", "TREATMENT", 475, 495], ["HRCT scanning", "TEST", 528, 541], ["the initial febrile neutropenia workup", "TEST", 573, 611], ["Another imaging modality", "TEST", 627, 651], ["the evaluation", "TEST", 675, 689], ["febrile neutropenia", "PROBLEM", 693, 712], ["CT scanning", "TEST", 725, 736], ["LDCT", "TEST", 738, 742], ["pulmonary", "ANATOMY", 52, 61], ["pulmonary", "ANATOMY", 79, 88], ["abnormalities", "OBSERVATION", 89, 102], ["neutropenic", "OBSERVATION", 128, 139], ["persistent", "OBSERVATION_MODIFIER", 154, 164], ["fever", "OBSERVATION", 165, 170], ["positive effect", "OBSERVATION_MODIFIER", 332, 347]]], ["LDCT is performed with low mean radiation doses below 1.5 mSv and without the use of contrast.", [["LDCT", "TEST", 0, 4], ["low mean radiation doses", "TREATMENT", 23, 47]]], ["Two studies comparing LDCT to CXR in patients with persistent febrile neutropenia demonstrated an increased detection of pulmonary abnormalities.[10, 11] Therefore, we hypothesized that LDCT already acquired on day 1 of febrile neutropenia would improve detection of pulmonary infections.", [["pulmonary", "ANATOMY", 121, 130], ["pulmonary", "ANATOMY", 267, 276], ["febrile neutropenia", "DISEASE", 62, 81], ["pulmonary abnormalities", "DISEASE", 121, 144], ["febrile neutropenia", "DISEASE", 220, 239], ["pulmonary infections", "DISEASE", 267, 287], ["patients", "ORGANISM", 37, 45], ["pulmonary", "ORGAN", 121, 130], ["pulmonary", "ORGAN", 267, 276], ["CXR", "PROTEIN", 30, 33], ["patients", "SPECIES", 37, 45], ["Two studies", "TEST", 0, 11], ["LDCT", "TEST", 22, 26], ["CXR", "TEST", 30, 33], ["persistent febrile neutropenia", "PROBLEM", 51, 81], ["pulmonary abnormalities", "PROBLEM", 121, 144], ["LDCT", "TEST", 186, 190], ["febrile neutropenia", "PROBLEM", 220, 239], ["pulmonary infections", "PROBLEM", 267, 287], ["persistent", "OBSERVATION_MODIFIER", 51, 61], ["febrile", "OBSERVATION_MODIFIER", 62, 69], ["neutropenia", "OBSERVATION", 70, 81], ["increased", "OBSERVATION_MODIFIER", 98, 107], ["pulmonary", "ANATOMY", 121, 130], ["abnormalities", "OBSERVATION", 131, 144], ["pulmonary", "ANATOMY", 267, 276], ["infections", "OBSERVATION", 277, 287]]], ["The primary aim of our study was to compare the diagnostic performance of LDCT and 2-view CXR for early detection of pulmonary infiltrates.", [["pulmonary infiltrates", "ANATOMY", 117, 138], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 117, 138], ["our study", "TEST", 19, 28], ["LDCT", "TEST", 74, 78], ["2-view CXR", "TEST", 83, 93], ["pulmonary infiltrates", "PROBLEM", 117, 138], ["pulmonary", "ANATOMY", 117, 126], ["infiltrates", "OBSERVATION", 127, 138]]], ["The secondary aim was to explore its performance for early IFD detection.Subjects ::: Materials and methodsPatients with febrile neutropenia treated with intensive chemotherapy for haematological malignancies or receiving an autologous or myelo-ablative allogeneic stem cell transplant (SCT) were eligible for inclusion.", [["haematological malignancies", "ANATOMY", 181, 208], ["stem cell", "ANATOMY", 265, 274], ["febrile neutropenia", "DISEASE", 121, 140], ["haematological malignancies", "DISEASE", 181, 208], ["Patients", "ORGANISM", 107, 115], ["haematological malignancies", "CANCER", 181, 208], ["stem cell", "CELL", 265, 274], ["Patients", "SPECIES", 107, 115], ["early IFD detection", "TEST", 53, 72], ["febrile neutropenia", "PROBLEM", 121, 140], ["intensive chemotherapy", "TREATMENT", 154, 176], ["haematological malignancies", "PROBLEM", 181, 208], ["an autologous or myelo-ablative allogeneic stem cell transplant", "TREATMENT", 222, 285], ["allogeneic stem cell transplant", "OBSERVATION", 254, 285]]], ["Febrile neutropenia was defined as a single temperature measurement of \u226538.3\u00b0C or a temperature of \u226538\u00b0C for more than 1 hour, accompanied by an absolute neutrophil count of <0.5\u00d7109/L or a neutrophil count <1.0\u00d7109/L with a predicted decline to <0.5\u00d7109/L within 3 days.Subjects ::: Materials and methodsPatients were excluded in case of a known focus of infection unrelated to the lower respiratory tract at inclusion, active possible or probable fungal infection at inclusion, or concomitant participation in clinical research in which the subject was exposed to additional radiation.", [["neutrophil", "ANATOMY", 154, 164], ["neutrophil", "ANATOMY", 190, 200], ["lower respiratory tract", "ANATOMY", 383, 406], ["Febrile neutropenia", "DISEASE", 0, 19], ["infection", "DISEASE", 356, 365], ["fungal infection", "DISEASE", 449, 465], ["C", "SIMPLE_CHEMICAL", 103, 104], ["neutrophil", "CELL", 154, 164], ["neutrophil", "CELL", 190, 200], ["Patients", "ORGANISM", 305, 313], ["lower", "ORGANISM_SUBDIVISION", 383, 388], ["respiratory tract", "ORGANISM_SUBDIVISION", 389, 406], ["Patients", "SPECIES", 305, 313], ["Febrile neutropenia", "PROBLEM", 0, 19], ["a single temperature measurement", "TEST", 35, 67], ["a temperature", "TEST", 82, 95], ["an absolute neutrophil count", "TEST", 142, 170], ["a neutrophil count", "TEST", 188, 206], ["a predicted decline", "PROBLEM", 223, 242], ["infection", "PROBLEM", 356, 365], ["the lower respiratory tract", "PROBLEM", 379, 406], ["fungal infection", "PROBLEM", 449, 465], ["additional radiation", "TREATMENT", 566, 586], ["neutropenia", "OBSERVATION", 8, 19], ["neutrophil count", "OBSERVATION", 154, 170], ["infection", "OBSERVATION", 356, 365], ["lower", "ANATOMY_MODIFIER", 383, 388], ["respiratory tract", "ANATOMY", 389, 406], ["probable", "UNCERTAINTY", 440, 448], ["fungal", "OBSERVATION_MODIFIER", 449, 455], ["infection", "OBSERVATION", 456, 465]]], ["Patients could participate only once in case of multiple febrile episodes.Diagnostic workup for febrile neutropenia ::: Design ::: Materials and methodsThe diagnostic workup included a clinical examination, a 2-view CXR and microbiological screening.", [["febrile", "DISEASE", 57, 64], ["neutropenia", "DISEASE", 104, 115], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["multiple febrile episodes", "PROBLEM", 48, 73], ["Diagnostic workup", "TEST", 74, 91], ["febrile neutropenia", "PROBLEM", 96, 115], ["The diagnostic workup", "TEST", 152, 173], ["a clinical examination", "TEST", 183, 205], ["a 2-view CXR", "TEST", 207, 219], ["microbiological screening", "TEST", 224, 249], ["multiple", "OBSERVATION_MODIFIER", 48, 56], ["febrile", "OBSERVATION", 57, 64]]], ["Standard microbiological screening included evaluation of urine and blood cultures.[1, 4] A respiratory microbiological evaluation was performed in case of a suspected pulmonary infection (clinical symptoms of dyspnea or cough, sputum production, or an oxygen saturation level <93%).", [["urine", "ANATOMY", 58, 63], ["blood cultures", "ANATOMY", 68, 82], ["pulmonary", "ANATOMY", 168, 177], ["sputum", "ANATOMY", 228, 234], ["pulmonary infection", "DISEASE", 168, 187], ["dyspnea", "DISEASE", 210, 217], ["cough", "DISEASE", 221, 226], ["oxygen", "CHEMICAL", 253, 259], ["oxygen", "CHEMICAL", 253, 259], ["urine", "ORGANISM_SUBSTANCE", 58, 63], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["pulmonary", "ORGAN", 168, 177], ["oxygen", "SIMPLE_CHEMICAL", 253, 259], ["Standard microbiological screening", "TEST", 0, 34], ["evaluation of urine", "TEST", 44, 63], ["blood cultures", "TEST", 68, 82], ["A respiratory microbiological evaluation", "TEST", 90, 130], ["a suspected pulmonary infection", "PROBLEM", 156, 187], ["clinical symptoms", "PROBLEM", 189, 206], ["dyspnea", "PROBLEM", 210, 217], ["cough", "PROBLEM", 221, 226], ["sputum production", "PROBLEM", 228, 245], ["an oxygen saturation level", "TEST", 250, 276], ["pulmonary", "ANATOMY", 168, 177], ["infection", "OBSERVATION", 178, 187]]], ["For the respiratory evaluation a throat swab was taken and tested for viral pathogens with PCR pack 1 (influenza virus, respiratory syncytial virus (RSV), coronavirus, rhinovirus) and PCR pack 2 (adenovirus, human metapneumovirus (HMPV), parainfluenzavirus type 1\u20134, bocavirus and Mycoplasma pneumoniae).", [["respiratory", "ANATOMY", 8, 19], ["throat swab", "ANATOMY", 33, 44], ["influenza virus", "DISEASE", 103, 118], ["respiratory syncytial virus (RSV), coronavirus, rhinovirus", "DISEASE", 120, 178], ["Mycoplasma pneumoniae", "DISEASE", 281, 302], ["throat", "ORGANISM", 33, 39], ["swab", "ORGANISM_SUBSTANCE", 40, 44], ["influenza virus", "ORGANISM", 103, 118], ["respiratory syncytial virus", "ORGANISM", 120, 147], ["RSV", "ORGANISM", 149, 152], ["coronavirus", "ORGANISM", 155, 166], ["rhinovirus", "ORGANISM", 168, 178], ["adenovirus", "ORGANISM", 196, 206], ["human metapneumovirus", "ORGANISM", 208, 229], ["HMPV", "ORGANISM", 231, 235], ["parainfluenzavirus type 1\u20134", "ORGANISM", 238, 265], ["bocavirus", "ORGANISM", 267, 276], ["Mycoplasma pneumoniae", "ORGANISM", 281, 302], ["influenza virus", "SPECIES", 103, 118], ["respiratory syncytial virus (RSV", "SPECIES", 120, 152], ["coronavirus", "SPECIES", 155, 166], ["human", "SPECIES", 208, 213], ["metapneumovirus", "SPECIES", 214, 229], ["Mycoplasma pneumoniae", "SPECIES", 281, 302], ["respiratory syncytial virus", "SPECIES", 120, 147], ["RSV", "SPECIES", 149, 152], ["adenovirus", "SPECIES", 196, 206], ["human metapneumovirus", "SPECIES", 208, 229], ["HMPV", "SPECIES", 231, 235], ["parainfluenzavirus type 1\u20134", "SPECIES", 238, 265], ["Mycoplasma pneumoniae", "SPECIES", 281, 302], ["the respiratory evaluation", "TEST", 4, 30], ["a throat swab", "TEST", 31, 44], ["viral pathogens", "PROBLEM", 70, 85], ["PCR pack", "TEST", 91, 99], ["influenza virus", "PROBLEM", 103, 118], ["respiratory syncytial virus", "PROBLEM", 120, 147], ["RSV", "TEST", 149, 152], ["coronavirus", "PROBLEM", 155, 166], ["rhinovirus", "PROBLEM", 168, 178], ["PCR pack", "TREATMENT", 184, 192], ["adenovirus", "PROBLEM", 196, 206], ["human metapneumovirus", "PROBLEM", 208, 229], ["HMPV", "TEST", 231, 235], ["parainfluenzavirus type", "PROBLEM", 238, 261], ["bocavirus", "PROBLEM", 267, 276], ["Mycoplasma pneumoniae", "PROBLEM", 281, 302], ["respiratory syncytial", "ANATOMY", 120, 141], ["Mycoplasma pneumoniae", "OBSERVATION", 281, 302]]], ["In case of a possible atypical pneumonia the swab was additionally tested for atypical pathogens with PCR pack 3 (Legionella pneumoniae, Chlamydophila pneumoniae, Chlamydophila psitacci, Coxiella burnetti).", [["swab", "ANATOMY", 45, 49], ["pneumonia", "DISEASE", 31, 40], ["Legionella pneumoniae", "DISEASE", 114, 135], ["Chlamydophila pneumoniae", "DISEASE", 137, 161], ["Chlamydophila psitacci", "DISEASE", 163, 185], ["Legionella pneumoniae", "ORGANISM", 114, 135], ["Chlamydophila pneumoniae", "ORGANISM", 137, 161], ["Chlamydophila psitacci", "ORGANISM", 163, 185], ["Coxiella burnetti", "ORGANISM", 187, 204], ["Legionella pneumoniae", "SPECIES", 114, 135], ["Chlamydophila pneumoniae", "SPECIES", 137, 161], ["Chlamydophila psitacci", "SPECIES", 163, 185], ["Coxiella burnetti", "SPECIES", 187, 204], ["Legionella pneumoniae", "SPECIES", 114, 135], ["Chlamydophila pneumoniae", "SPECIES", 137, 161], ["Chlamydophila psitacci", "SPECIES", 163, 185], ["Coxiella burnetti", "SPECIES", 187, 204], ["atypical pneumonia", "PROBLEM", 22, 40], ["the swab", "TEST", 41, 49], ["atypical pathogens", "PROBLEM", 78, 96], ["PCR pack", "TEST", 102, 110], ["Legionella pneumoniae", "TEST", 114, 135], ["Chlamydophila pneumoniae", "PROBLEM", 137, 161], ["Chlamydophila", "PROBLEM", 163, 176], ["possible", "UNCERTAINTY", 13, 21], ["atypical", "OBSERVATION_MODIFIER", 22, 30], ["pneumonia", "OBSERVATION", 31, 40]]], ["If sputum was available this was tested for bacteria (gram stain, culture) and fungal pathogens (blancophore stain, culture).", [["sputum", "ANATOMY", 3, 9], ["sputum", "ORGANISM_SUBSTANCE", 3, 9], ["sputum", "TEST", 3, 9], ["bacteria", "PROBLEM", 44, 52], ["gram stain", "TEST", 54, 64], ["culture", "TEST", 66, 73], ["fungal pathogens", "TEST", 79, 95], ["blancophore stain", "TEST", 97, 114], ["culture", "TEST", 116, 123]]], ["Other microbiological testing was only performed if judged appropriate by the attending physician.", [["Other microbiological testing", "TEST", 0, 29]]], ["Furthermore, serum samples were taken twice weekly for galactomannan (GM) testing at the end of inclusion.Diagnostic workup for febrile neutropenia ::: Design ::: Materials and methodsIf fever persisted for 4 days, a routine HRCT scan was acquired to detect possible IFD.", [["serum samples", "ANATOMY", 13, 26], ["GM", "CHEMICAL", 70, 72], ["neutropenia", "DISEASE", 136, 147], ["fever", "DISEASE", 187, 192], ["IFD", "DISEASE", 267, 270], ["serum samples", "ORGANISM_SUBSTANCE", 13, 26], ["serum samples", "TEST", 13, 26], ["galactomannan (GM) testing", "TEST", 55, 81], ["Diagnostic workup", "TEST", 106, 123], ["febrile neutropenia", "PROBLEM", 128, 147], ["fever", "PROBLEM", 187, 192], ["a routine HRCT scan", "TEST", 215, 234], ["IFD", "PROBLEM", 267, 270]]], ["In case of abnormalities suspect for (fungal) pulmonary infection a broncho-alveolar lavage (BAL) was performed.", [["pulmonary", "ANATOMY", 46, 55], ["broncho-alveolar lavage", "ANATOMY", 68, 91], ["BAL", "ANATOMY", 93, 96], ["pulmonary infection", "DISEASE", 46, 65], ["pulmonary", "ORGAN", 46, 55], ["alveolar lavage", "PATHOLOGICAL_FORMATION", 76, 91], ["abnormalities", "PROBLEM", 11, 24], ["(fungal) pulmonary infection", "PROBLEM", 37, 65], ["a broncho-alveolar lavage (BAL)", "TEST", 66, 97], ["suspect for", "UNCERTAINTY", 25, 36], ["fungal", "OBSERVATION_MODIFIER", 38, 44], ["pulmonary", "ANATOMY", 46, 55], ["infection", "OBSERVATION", 56, 65], ["alveolar", "ANATOMY", 76, 84], ["lavage", "OBSERVATION", 85, 91]]], ["BAL fluid was routinely tested for bacteria (gram, stain, culture) including Haemophilus influenza, and fungal pathogens (blancophore stain, GM, microscopy and culture).", [["BAL fluid", "ANATOMY", 0, 9], ["Haemophilus influenza", "DISEASE", 77, 98], ["GM", "CHEMICAL", 141, 143], ["BAL fluid", "ORGANISM_SUBSTANCE", 0, 9], ["Haemophilus influenza", "ORGANISM", 77, 98], ["Haemophilus influenza", "SPECIES", 77, 98], ["Haemophilus influenza", "SPECIES", 77, 98], ["BAL fluid", "TEST", 0, 9], ["bacteria", "PROBLEM", 35, 43], ["gram", "TEST", 45, 49], ["stain", "TEST", 51, 56], ["culture", "TEST", 58, 65], ["Haemophilus influenza", "PROBLEM", 77, 98], ["fungal pathogens", "PROBLEM", 104, 120], ["blancophore stain", "TEST", 122, 139], ["GM", "TEST", 141, 143], ["microscopy", "TEST", 145, 155], ["culture", "TEST", 160, 167], ["fluid", "OBSERVATION", 4, 9]]], ["On indication BAL fluid was also tested for Nocardia (culture), Mycobacteria (culture, microscopy, PCR), Pneumocystis jiroveci pneumonia (PCR, microscopy) and viral pathogens: PCR pack 1,2 and 3.", [["BAL fluid", "ANATOMY", 14, 23], ["Pneumocystis jiroveci pneumonia", "DISEASE", 105, 136], ["BAL fluid", "ORGANISM_SUBSTANCE", 14, 23], ["Pneumocystis jiroveci", "SPECIES", 105, 126], ["Pneumocystis jiroveci", "SPECIES", 105, 126], ["BAL fluid", "TEST", 14, 23], ["Nocardia", "PROBLEM", 44, 52], ["culture", "TEST", 54, 61], ["Mycobacteria", "PROBLEM", 64, 76], ["culture", "TEST", 78, 85], ["microscopy", "TEST", 87, 97], ["PCR", "TEST", 99, 102], ["Pneumocystis jiroveci pneumonia", "PROBLEM", 105, 136], ["PCR", "TEST", 138, 141], ["microscopy", "TEST", 143, 153], ["viral pathogens", "PROBLEM", 159, 174], ["PCR pack", "TREATMENT", 176, 184], ["BAL fluid", "OBSERVATION", 14, 23], ["Pneumocystis jiroveci", "OBSERVATION", 105, 126]]], ["In case of IFD anti-fungal treatment was started and a HRCT was repeated after six weeks.Consensus diagnosis ::: Design ::: Materials and methodsThe consensus diagnosis of a fever episode was defined according to predefined categories as either pulmonary infection or non-pulmonary causes of fever such as line infection, mucositis, other infections (i.e. sinusitis), unknown focus of fever or any combination of the above.", [["pulmonary", "ANATOMY", 245, 254], ["non-pulmonary", "ANATOMY", 268, 281], ["IFD", "DISEASE", 11, 14], ["fever", "DISEASE", 174, 179], ["pulmonary infection", "DISEASE", 245, 264], ["fever", "DISEASE", 292, 297], ["infection", "DISEASE", 311, 320], ["mucositis", "DISEASE", 322, 331], ["infections", "DISEASE", 339, 349], ["sinusitis", "DISEASE", 356, 365], ["fever", "DISEASE", 385, 390], ["pulmonary", "ORGAN", 245, 254], ["IFD anti-fungal treatment", "TREATMENT", 11, 36], ["a HRCT", "TEST", 53, 59], ["a fever episode", "PROBLEM", 172, 187], ["pulmonary infection", "PROBLEM", 245, 264], ["non-pulmonary causes", "PROBLEM", 268, 288], ["fever", "PROBLEM", 292, 297], ["line infection", "PROBLEM", 306, 320], ["mucositis", "PROBLEM", 322, 331], ["other infections", "PROBLEM", 333, 349], ["sinusitis", "PROBLEM", 356, 365], ["fever", "PROBLEM", 385, 390], ["IFD", "OBSERVATION", 11, 14], ["anti-fungal treatment", "OBSERVATION", 15, 36], ["pulmonary", "ANATOMY", 245, 254], ["infection", "OBSERVATION", 255, 264], ["non-pulmonary", "ANATOMY", 268, 281], ["fever", "OBSERVATION", 292, 297], ["line", "OBSERVATION_MODIFIER", 306, 310], ["infection", "OBSERVATION", 311, 320], ["infections", "OBSERVATION", 339, 349], ["sinusitis", "OBSERVATION", 356, 365], ["fever", "OBSERVATION", 385, 390]]], ["The expert panel diagnosis was based on information obtained from the clinical charts, microbiology results and imaging results: the 2-view CXR and the HRCT.", [["imaging", "TEST", 112, 119], ["the 2-view CXR", "TEST", 129, 143], ["the HRCT", "TEST", 148, 156]]], ["HRCT was only available in case of persistent (4 days) fever, and LDCT results were not used for the consensus diagnosis.Consensus diagnosis ::: Design ::: Materials and methodsClinical criteria for a pulmonary infection included either one of the following symptoms: coughing, sputum production, dyspnea or an oxygen saturation level <93%.", [["pulmonary", "ANATOMY", 201, 210], ["sputum", "ANATOMY", 278, 284], ["fever", "DISEASE", 55, 60], ["pulmonary infection", "DISEASE", 201, 220], ["coughing", "DISEASE", 268, 276], ["dyspnea", "DISEASE", 297, 304], ["oxygen", "CHEMICAL", 311, 317], ["oxygen", "CHEMICAL", 311, 317], ["pulmonary", "ORGAN", 201, 210], ["oxygen", "SIMPLE_CHEMICAL", 311, 317], ["HRCT", "TEST", 0, 4], ["fever", "PROBLEM", 55, 60], ["LDCT", "TEST", 66, 70], ["a pulmonary infection", "PROBLEM", 199, 220], ["the following symptoms", "PROBLEM", 244, 266], ["coughing", "PROBLEM", 268, 276], ["sputum production", "PROBLEM", 278, 295], ["dyspnea", "PROBLEM", 297, 304], ["an oxygen saturation level", "TEST", 308, 334], ["persistent", "OBSERVATION_MODIFIER", 35, 45], ["pulmonary", "ANATOMY", 201, 210], ["infection", "OBSERVATION", 211, 220]]], ["Microbiological criteria were a positive culture or PCR for bacterial, viral and fungal pathogens known to cause pulmonary infections, or in case of invasive aspergillosis a positive GM in BAL (\u22650.8) or serum (\u22650.5).", [["pulmonary", "ANATOMY", 113, 122], ["invasive aspergillosis", "ANATOMY", 149, 171], ["BAL", "ANATOMY", 189, 192], ["serum", "ANATOMY", 203, 208], ["pulmonary infections", "DISEASE", 113, 133], ["aspergillosis", "DISEASE", 158, 171], ["GM", "CHEMICAL", 183, 185], ["pulmonary", "ORGAN", 113, 122], ["aspergillosis", "CANCER", 158, 171], ["BAL", "ORGANISM_SUBSTANCE", 189, 192], ["serum", "ORGANISM_SUBSTANCE", 203, 208], ["Microbiological criteria", "TEST", 0, 24], ["a positive culture", "PROBLEM", 30, 48], ["PCR", "TEST", 52, 55], ["bacterial, viral and fungal pathogens", "PROBLEM", 60, 97], ["pulmonary infections", "PROBLEM", 113, 133], ["invasive aspergillosis", "PROBLEM", 149, 171], ["a positive GM in BAL", "PROBLEM", 172, 192], ["serum", "TEST", 203, 208], ["pulmonary", "ANATOMY", 113, 122], ["infections", "OBSERVATION", 123, 133], ["invasive", "OBSERVATION_MODIFIER", 149, 157], ["aspergillosis", "OBSERVATION", 158, 171], ["positive GM", "OBSERVATION_MODIFIER", 174, 185]]], ["In case of abnormal imaging results without additional clinical or microbiological criteria these were considered false positive.", [["abnormal imaging results", "PROBLEM", 11, 35], ["microbiological criteria", "TEST", 67, 91], ["false positive", "PROBLEM", 114, 128]]], ["Fungal infections were classified as either possible, probable or proven in accordance with the revised European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria.[12] IFD was considered to be ruled out in all patients recovering from neutropenic fever within 3 days without ever receiving mould-active antifungal therapy, given the very low likelihood of spontaneous recovery during neutropenia, without appropriate treatment.Consensus diagnosis ::: Design ::: Materials and methodsCentral venous catheter infections were defined by criteria adapted from the Dutch surveillance network of nosocomial infections (PREZIES).[13]Consensus diagnosis ::: Design ::: Materials and methodsMucositis was diagnosed based on clinical and radiological (typhlitis) criteria.", [["venous", "ANATOMY", 532, 538], ["Fungal infections", "DISEASE", 0, 17], ["Cancer", "DISEASE", 156, 162], ["Mycosis", "DISEASE", 163, 170], ["fever", "DISEASE", 288, 293], ["neutropenia", "DISEASE", 425, 436], ["venous catheter infections", "DISEASE", 532, 558], ["nosocomial infections", "DISEASE", 631, 652], ["PREZIES", "DISEASE", 654, 661], ["Mucositis", "DISEASE", 723, 732], ["typhlitis", "DISEASE", 783, 792], ["[12] IFD", "SIMPLE_CHEMICAL", 204, 212], ["patients", "ORGANISM", 251, 259], ["venous", "MULTI-TISSUE_STRUCTURE", 532, 538], ["patients", "SPECIES", 251, 259], ["Fungal infections", "PROBLEM", 0, 17], ["Cancer", "PROBLEM", 156, 162], ["Mycosis Study", "TEST", 163, 176], ["IFD", "PROBLEM", 209, 212], ["neutropenic fever", "PROBLEM", 276, 293], ["mould-active antifungal therapy", "TREATMENT", 331, 362], ["spontaneous recovery", "PROBLEM", 397, 417], ["neutropenia", "PROBLEM", 425, 436], ["appropriate treatment", "TREATMENT", 446, 467], ["Central venous catheter infections", "PROBLEM", 524, 558], ["nosocomial infections", "PROBLEM", 631, 652], ["methodsMucositis", "PROBLEM", 716, 732], ["clinical and radiological (typhlitis) criteria", "PROBLEM", 756, 802], ["infections", "OBSERVATION", 7, 17], ["Cancer", "OBSERVATION", 156, 162], ["Mycosis", "OBSERVATION", 163, 170], ["neutropenic", "OBSERVATION", 276, 287], ["antifungal therapy", "OBSERVATION", 344, 362], ["neutropenia", "OBSERVATION", 425, 436], ["venous", "ANATOMY", 532, 538], ["catheter", "OBSERVATION", 539, 547], ["infections", "OBSERVATION", 548, 558], ["nosocomial infections", "OBSERVATION", 631, 652], ["typhlitis", "OBSERVATION", 783, 792]]], ["Clinical criteria included pain when swallowing, nausea, vomiting, abdominal pain/cramping and diarrhea, physical examination and the absence of a positive microbiological test.Consensus diagnosis ::: Design ::: Materials and methodsAny other focus of infection was mainly determined by the judgment of the attending physician combined with the results of the diagnostic workup.", [["abdominal", "ANATOMY", 67, 76], ["pain", "DISEASE", 27, 31], ["nausea", "DISEASE", 49, 55], ["vomiting", "DISEASE", 57, 65], ["abdominal pain", "DISEASE", 67, 81], ["cramping", "DISEASE", 82, 90], ["diarrhea", "DISEASE", 95, 103], ["infection", "DISEASE", 252, 261], ["abdominal", "ORGANISM_SUBDIVISION", 67, 76], ["pain", "PROBLEM", 27, 31], ["swallowing", "PROBLEM", 37, 47], ["nausea", "PROBLEM", 49, 55], ["vomiting", "PROBLEM", 57, 65], ["abdominal pain", "PROBLEM", 67, 81], ["cramping", "PROBLEM", 82, 90], ["diarrhea", "PROBLEM", 95, 103], ["physical examination", "TEST", 105, 125], ["a positive microbiological test", "PROBLEM", 145, 176], ["infection", "PROBLEM", 252, 261], ["the diagnostic workup", "TEST", 356, 377], ["abdominal", "ANATOMY", 67, 76], ["cramping", "OBSERVATION", 82, 90], ["focus", "OBSERVATION_MODIFIER", 243, 248], ["infection", "OBSERVATION", 252, 261]]], ["Fever of unknown origin was defined as fever without any focus or etiology identified by clinical, radiological or microbiological examination.Image acquisition and analysis ::: Materials and methodsThe LDCT scan was made during inspiration at the lowest achievable radiation dose.", [["Fever", "DISEASE", 0, 5], ["fever", "DISEASE", 39, 44], ["Fever", "PROBLEM", 0, 5], ["fever", "PROBLEM", 39, 44], ["microbiological examination", "TEST", 115, 142], ["Image acquisition", "TEST", 143, 160], ["The LDCT scan", "TEST", 199, 212], ["unknown origin", "OBSERVATION_MODIFIER", 9, 23]]], ["LDCT images were acquired at a tube potential of 80 kVp and a tube current-time product of 10 mAs or 20 mAs depending on patient\u2019s weight using a 256-slice CT system (iCT, Philips Healthcare, Best, The Netherlands), or at a tube current-time product of 15 mAs or 30 mAs with a 64-slice CT system (Brilliance 64, Philips Healthcare, Best, The Netherlands).", [["tube", "ANATOMY", 62, 66], ["tube", "TISSUE", 31, 35], ["tube", "TISSUE", 62, 66], ["patient", "ORGANISM", 121, 128], ["tube", "TISSUE", 224, 228], ["patient", "SPECIES", 121, 128], ["LDCT images", "TEST", 0, 11], ["a tube current-time product", "TREATMENT", 60, 87]]], ["At the end of the study, anonymized CXR and LDCT images were first independently evaluated by a board certified radiologist and a radiology resident who were not involved in the consensus diagnosis.", [["CXR", "DNA", 36, 39], ["the study", "TEST", 14, 23], ["anonymized CXR", "TEST", 25, 39], ["LDCT images", "TEST", 44, 55]]], ["The observers used a standard imaging scoring table (Table 1).", [["a standard imaging scoring table", "TEST", 19, 51]]], ["Second, CXR and LDCT images were re-analysed if one or two observers gave a positive score.", [["CXR", "DNA", 8, 11], ["CXR", "TEST", 8, 11], ["LDCT images", "TEST", 16, 27], ["a positive score", "PROBLEM", 74, 90]]], ["Re-evaluation was performed during consensus reading of the study exams, for which additional historical radiological images were available to prevent false-positives as a result of pre-existing abnormalities.Statistical analysis ::: Materials and methodsThe primary objective was to investigate whether LDCT is a better diagnostic tool than CXR for detection of pulmonary infections on the first day of neutropenic fever.", [["pulmonary", "ANATOMY", 363, 372], ["pulmonary infections", "DISEASE", 363, 383], ["fever", "DISEASE", 416, 421], ["pulmonary", "ORGAN", 363, 372], ["Re-evaluation", "TEST", 0, 13], ["the study exams", "TEST", 56, 71], ["additional historical radiological images", "TEST", 83, 124], ["false-positives", "PROBLEM", 151, 166], ["pre-existing abnormalities", "PROBLEM", 182, 208], ["LDCT", "TEST", 304, 308], ["CXR", "TEST", 342, 345], ["pulmonary infections", "PROBLEM", 363, 383], ["neutropenic fever", "PROBLEM", 404, 421], ["abnormalities", "OBSERVATION", 195, 208], ["pulmonary", "ANATOMY", 363, 372], ["infections", "OBSERVATION", 373, 383], ["neutropenic", "OBSERVATION", 404, 415]]], ["We hypothesized that LDCT could increase the detection rate of pulmonary infiltrates by 80%; from 15% with CXR (unpublished data from our institute) to 27%, considering an expected incidence of pulmonary focus of infection in febrile neutropenia of 30%.[14] We expected a proportion of discordant pairs of 15% with a two-sided test (alpha 0.05 and power 0.80).", [["pulmonary infiltrates", "ANATOMY", 63, 84], ["pulmonary", "ANATOMY", 194, 203], ["infection", "DISEASE", 213, 222], ["febrile neutropenia", "DISEASE", 226, 245], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 63, 84], ["pulmonary", "ORGAN", 194, 203], ["CXR", "PROTEIN", 107, 110], ["LDCT", "TEST", 21, 25], ["pulmonary infiltrates", "PROBLEM", 63, 84], ["CXR", "TEST", 107, 110], ["infection", "PROBLEM", 213, 222], ["febrile neutropenia", "PROBLEM", 226, 245], ["a two-sided test", "TEST", 315, 331], ["alpha", "TEST", 333, 338], ["pulmonary", "ANATOMY", 63, 72], ["infiltrates", "OBSERVATION", 73, 84], ["pulmonary", "ANATOMY", 194, 203], ["focus", "OBSERVATION", 204, 209], ["infection", "OBSERVATION", 213, 222], ["febrile", "OBSERVATION_MODIFIER", 226, 233]]], ["A sample size of 68 patients was esteemed sufficient according to a power calculation based on the McNemar test.Statistical analysis ::: Materials and methodsSensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of both tests were calculated using contingency tables, the consensus diagnosis served as reference standard.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["A sample size", "TEST", 0, 13], ["a power calculation", "TEST", 66, 85], ["the McNemar test", "TEST", 95, 111], ["methodsSensitivity", "TEST", 151, 169], ["specificity", "TEST", 171, 182], ["PPV", "TEST", 211, 214], ["NPV", "TEST", 247, 250], ["both tests", "TEST", 255, 265], ["size", "OBSERVATION_MODIFIER", 9, 13]]], ["An uncorrected McNemar test was applied to determine the differences between the two modalities.[15] A p-value of \u22640.05 was considered significant.", [["An uncorrected McNemar test", "TEST", 0, 27], ["A p-value", "TEST", 101, 110]]], ["Parametric data are presented as means \u00b1 standard deviation (SD) and non-parametric data as medians (range).", [["Parametric data", "TEST", 0, 15], ["standard deviation (SD)", "PROBLEM", 41, 64], ["non-parametric data", "TEST", 69, 88]]], ["Cohen\u2019s Kappa (\u03ba) was used to assess the inter observer agreement and defined as excellent with \u03ba > 0.80, good with \u03ba between 0.61 and 0.80, moderate with \u03ba between 0.41 and 0.60, and poor with \u03ba \u2264 0.40.", [["moderate", "OBSERVATION_MODIFIER", 141, 149]]], ["IBM SPSS statistics software version 22.0 (IBM, Somers, NY, USA) was used for statistical analyses.Statistical analysis ::: Materials and methodsThe secondary objective was to explore the performance of LDCT for detection of pulmonary lesions indicating IFD on day 1 of neutropenic fever.Imaging results ::: ResultsThe mean interval between CXR and LDCT was 3.1 \u00b1 6.3 hours.", [["pulmonary lesions", "ANATOMY", 225, 242], ["pulmonary lesions", "DISEASE", 225, 242], ["IFD", "DISEASE", 254, 257], ["neutropenic fever", "DISEASE", 270, 287], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 225, 242], ["statistical analyses", "TEST", 78, 98], ["LDCT", "TEST", 203, 207], ["pulmonary lesions", "PROBLEM", 225, 242], ["IFD", "PROBLEM", 254, 257], ["neutropenic fever", "PROBLEM", 270, 287], ["Imaging", "TEST", 288, 295], ["CXR", "TEST", 341, 344], ["LDCT", "TEST", 349, 353], ["pulmonary", "ANATOMY", 225, 234], ["lesions", "OBSERVATION", 235, 242], ["neutropenic", "OBSERVATION", 270, 281]]], ["The mean radiation dose for LDCT exams was 0.24 \u00b1 0.15 mSv, which is comparable to 2\u20133 chest radiographs (average dose posteroanterior and lateral chest radiograph: 0.1 mSv).[9] None of the patients experienced adverse events as a result of LDCT scanning or chest radiography.", [["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["The mean radiation dose", "TREATMENT", 0, 23], ["LDCT exams", "TEST", 28, 38], ["chest radiographs", "TEST", 87, 104], ["average dose posteroanterior and lateral chest radiograph", "TEST", 106, 163], ["adverse events", "PROBLEM", 211, 225], ["LDCT scanning", "TEST", 241, 254], ["chest radiography", "TEST", 258, 275], ["chest", "ANATOMY", 87, 92], ["chest", "ANATOMY", 147, 152], ["chest", "ANATOMY", 258, 263]]], ["Eight CXRs (11.9%) were indicative of pneumonia, 4 CXRs were false positive and 7 false negative as compared to the consensus diagnosis (Table 4).", [["pneumonia", "DISEASE", 38, 47], ["CXRs", "CANCER", 6, 10], ["Eight CXRs", "TEST", 0, 10], ["pneumonia", "PROBLEM", 38, 47], ["4 CXRs", "TEST", 49, 55], ["false positive", "PROBLEM", 61, 75], ["indicative of", "UNCERTAINTY", 24, 37], ["pneumonia", "OBSERVATION", 38, 47]]], ["This resulted in a sensitivity of 36%, a specificity of 93%, a PPV of 50% and a NPV of 88% for CXR.", [["CXR", "PROTEIN", 95, 98], ["a sensitivity", "TEST", 17, 30], ["a specificity", "TEST", 39, 52], ["a PPV", "TEST", 61, 66], ["a NPV", "TEST", 78, 83], ["CXR", "TEST", 95, 98]]], ["None of the CXRs were suspect for IFD.Imaging results ::: ResultsThirteen LDCT scans (19.4%) were suggestive of pneumonia.", [["IFD", "DISEASE", 34, 37], ["pneumonia", "DISEASE", 112, 121], ["CXRs", "CANCER", 12, 16], ["the CXRs", "TEST", 8, 16], ["IFD", "PROBLEM", 34, 37], ["Imaging", "TEST", 38, 45], ["ResultsThirteen LDCT scans", "TEST", 58, 84], ["pneumonia", "PROBLEM", 112, 121], ["suggestive of", "UNCERTAINTY", 98, 111], ["pneumonia", "OBSERVATION", 112, 121]]], ["Compared to the consensus diagnosis, 5 LDCT scans were false positive and 3 false negative.", [["LDCT", "CANCER", 39, 43], ["5 LDCT scans", "TEST", 37, 49]]], ["Sensitivity, specificity, PPV and NPV were 73%, 91%, 62% and 94% respectively.", [["Sensitivity", "TEST", 0, 11], ["specificity", "TEST", 13, 24], ["PPV", "TEST", 26, 29], ["NPV", "TEST", 34, 37]]], ["(Table 4)Imaging results ::: ResultsConsensus diagnosis of the 5 false positive LDCT scans were phlebitis and in 4 cases fever of unknown origin.", [["phlebitis", "DISEASE", 96, 105], ["fever", "DISEASE", 121, 126], ["the 5 false positive LDCT scans", "PROBLEM", 59, 90], ["phlebitis", "PROBLEM", 96, 105], ["fever", "PROBLEM", 121, 126], ["phlebitis", "OBSERVATION", 96, 105], ["unknown origin", "OBSERVATION_MODIFIER", 130, 144]]], ["No HRCT scans were made because in all 5 patients the fever subsided within 48 hours after receiving broad spectrum antibiotics, therefore CXR was the only available imaging tool for the consensus meeting.", [["fever", "DISEASE", 54, 59], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["HRCT scans", "TEST", 3, 13], ["the fever", "PROBLEM", 50, 59], ["broad spectrum antibiotics", "TREATMENT", 101, 127], ["CXR", "TEST", 139, 142], ["imaging tool", "TEST", 166, 178]]], ["Only one of the patients with a false positive LDCT had respiratory symptoms (cough), however a microbiological respiratory evaluation was negative.Imaging results ::: ResultsAn uncontrolled McNemar\u2019s test showed no statistically significant difference in the proportion of scans positive for pulmonary infection between CXR and LDCT (p = 0.197), which was our primary endpoint.", [["respiratory", "ANATOMY", 56, 67], ["respiratory", "ANATOMY", 112, 123], ["pulmonary", "ANATOMY", 293, 302], ["respiratory symptoms", "DISEASE", 56, 76], ["cough", "DISEASE", 78, 83], ["pulmonary infection", "DISEASE", 293, 312], ["patients", "ORGANISM", 16, 24], ["pulmonary", "ORGAN", 293, 302], ["patients", "SPECIES", 16, 24], ["a false positive LDCT", "PROBLEM", 30, 51], ["respiratory symptoms", "PROBLEM", 56, 76], ["cough", "PROBLEM", 78, 83], ["a microbiological respiratory evaluation", "TEST", 94, 134], ["Imaging", "TEST", 148, 155], ["McNemar\u2019s test", "TEST", 191, 205], ["scans", "TEST", 274, 279], ["pulmonary infection", "PROBLEM", 293, 312], ["CXR", "TEST", 321, 324], ["LDCT", "TEST", 329, 333], ["no", "UNCERTAINTY", 213, 215], ["significant", "OBSERVATION_MODIFIER", 230, 241], ["difference", "OBSERVATION", 242, 252], ["positive for", "UNCERTAINTY", 280, 292], ["pulmonary", "ANATOMY", 293, 302], ["infection", "OBSERVATION", 303, 312]]], ["Inter-observer agreement was moderate for both CXR and LDCT (\u03ba = 0.52 for CXR and \u03ba = 0.52 for LDCT, respectively).Imaging results ::: ResultsBased on the consensus diagnosis 5 patients in this cohort were classified as either probable (n = 3) or possible (n = 2) IFD.", [["IFD", "DISEASE", 264, 267], ["patients", "ORGANISM", 177, 185], ["CXR", "PROTEIN", 47, 50], ["CXR", "PROTEIN", 74, 77], ["patients", "SPECIES", 177, 185], ["both CXR", "TEST", 42, 50], ["LDCT", "TEST", 55, 59], ["CXR", "TEST", 74, 77], ["\u03ba", "TEST", 82, 83], ["LDCT", "TEST", 95, 99], ["Imaging", "TEST", 115, 122], ["IFD", "PROBLEM", 264, 267]]], ["The diagnosis of probable IFD was based on a positive BAL GM test in all cases and 2 out of 3 also had a positive serum GM test.", [["serum", "ANATOMY", 114, 119], ["IFD", "DISEASE", 26, 29], ["GM", "CHEMICAL", 58, 60], ["GM", "CHEMICAL", 120, 122], ["serum", "ORGANISM_SUBSTANCE", 114, 119], ["IFD", "PROBLEM", 26, 29], ["a positive BAL GM test", "PROBLEM", 43, 65], ["a positive serum GM test", "PROBLEM", 103, 127], ["probable", "UNCERTAINTY", 17, 25], ["IFD", "OBSERVATION", 26, 29]]], ["Only 1 patient had a positive BAL culture (A. Versicolor).", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["A. Versicolor", "SPECIES", 43, 56], ["a positive BAL culture", "PROBLEM", 19, 41]]], ["Four of the patients with IFD (3 probable, 1 possible) had a LDCT scan suspect for IFD on the first day of fever.", [["IFD", "DISEASE", 26, 29], ["IFD", "DISEASE", 83, 86], ["fever", "DISEASE", 107, 112], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["IFD", "PROBLEM", 26, 29], ["a LDCT scan", "TEST", 59, 70], ["IFD", "PROBLEM", 83, 86], ["fever", "PROBLEM", 107, 112], ["fever", "OBSERVATION", 107, 112]]], ["In all these patients the abnormalities were also seen on the HRCT performed as part of the diagnostic workup for persistent fever (mean 3.5 days later than LDCT).", [["fever", "DISEASE", 125, 130], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["the HRCT", "TEST", 58, 66], ["the diagnostic workup", "TEST", 88, 109], ["persistent fever", "PROBLEM", 114, 130], ["LDCT", "TEST", 157, 161], ["abnormalities", "OBSERVATION", 26, 39], ["persistent", "OBSERVATION_MODIFIER", 114, 124], ["fever", "OBSERVATION", 125, 130]]], ["(Fig 2) None of the patients diagnosed with pulmonary IFD had abnormalities on their CXR on the first day of fever, and only one had respiratory signs or symptoms.Imaging results ::: ResultsThe diagnosis of possible IFD in the patient with a negative LDCT scan was based on abnormalities on HRCT made on day 4 of fever.", [["pulmonary", "ANATOMY", 44, 53], ["respiratory", "ANATOMY", 133, 144], ["pulmonary IFD", "DISEASE", 44, 57], ["fever", "DISEASE", 109, 114], ["respiratory signs", "DISEASE", 133, 150], ["IFD", "DISEASE", 216, 219], ["fever", "DISEASE", 313, 318], ["patients", "ORGANISM", 20, 28], ["pulmonary", "ORGAN", 44, 53], ["patient", "ORGANISM", 227, 234], ["patients", "SPECIES", 20, 28], ["patient", "SPECIES", 227, 234], ["pulmonary IFD", "PROBLEM", 44, 57], ["abnormalities", "PROBLEM", 62, 75], ["their CXR", "TEST", 79, 88], ["fever", "PROBLEM", 109, 114], ["respiratory signs", "PROBLEM", 133, 150], ["symptoms", "PROBLEM", 154, 162], ["Imaging", "TEST", 163, 170], ["IFD", "PROBLEM", 216, 219], ["a negative LDCT scan", "TEST", 240, 260], ["abnormalities", "PROBLEM", 274, 287], ["HRCT", "TEST", 291, 295], ["fever", "PROBLEM", 313, 318], ["pulmonary", "ANATOMY", 44, 53], ["IFD", "OBSERVATION", 54, 57], ["possible", "UNCERTAINTY", 207, 215], ["IFD", "OBSERVATION", 216, 219]]], ["Serum GM values were negative and bronchoscopy was not performed because of severe thrombocytopenia.", [["Serum", "ANATOMY", 0, 5], ["GM", "CHEMICAL", 6, 8], ["thrombocytopenia", "DISEASE", 83, 99], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["GM", "GENE_OR_GENE_PRODUCT", 6, 8], ["Serum GM values", "TEST", 0, 15], ["bronchoscopy", "TEST", 34, 46], ["severe thrombocytopenia", "PROBLEM", 76, 99], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["thrombocytopenia", "OBSERVATION", 83, 99]]], ["Finally one LDCT scan with abnormalities suspect for IFD was considered false positive: the fever episode was classified as \u201cfever of unknown origin\u201d.DiscussionWe conducted a prospective study to evaluate whether pulmonary focus detection would improve using a LDCT scan instead of CXR on the first day of febrile neutropenia.", [["pulmonary", "ANATOMY", 213, 222], ["IFD", "DISEASE", 53, 56], ["fever", "DISEASE", 92, 97], ["fever", "DISEASE", 125, 130], ["febrile neutropenia", "DISEASE", 306, 325], ["LDCT", "CANCER", 12, 16], ["pulmonary", "ORGAN", 213, 222], ["CXR", "PROTEIN", 282, 285], ["one LDCT scan", "TEST", 8, 21], ["abnormalities", "TEST", 27, 40], ["IFD", "PROBLEM", 53, 56], ["false positive", "PROBLEM", 72, 86], ["the fever episode", "PROBLEM", 88, 105], ["fever", "PROBLEM", 125, 130], ["a prospective study", "TEST", 173, 192], ["pulmonary focus detection", "PROBLEM", 213, 238], ["a LDCT scan", "TEST", 259, 270], ["CXR", "TEST", 282, 285], ["febrile neutropenia", "PROBLEM", 306, 325], ["pulmonary", "ANATOMY", 213, 222]]], ["We established an improved detection rate from 11.9% of radiographs to 19.4% of the LDCT scans but our primary endpoint was not met.", [["radiographs", "TEST", 56, 67], ["the LDCT scans", "TEST", 80, 94], ["improved", "OBSERVATION_MODIFIER", 18, 26]]], ["As a result of the lower than expected incidence of pulmonary infections in this study, the study was underpowered.[14] Nevertheless, we demonstrated a clinically significant increased sensitivity of LDCT (73% versus CXR 36%) in detecting a pulmonary focus on day 1 of neutropenic fever.DiscussionThe limited value of CXR as a standard diagnostic procedure is in line with previous results.[3] In a retrospective study 1083 adult SCT patients were evaluated, but in none of the 242 CXRs performed in asymptomatic patients with febrile neutropenia pulmonary abnormalities indicative of infection were detected.", [["pulmonary", "ANATOMY", 52, 61], ["pulmonary", "ANATOMY", 241, 250], ["pulmonary", "ANATOMY", 547, 556], ["pulmonary infections", "DISEASE", 52, 72], ["neutropenic fever", "DISEASE", 269, 286], ["neutropenia", "DISEASE", 535, 546], ["infection", "DISEASE", 585, 594], ["pulmonary", "ORGAN", 52, 61], ["pulmonary", "ORGAN", 241, 250], ["patients", "ORGANISM", 434, 442], ["CXRs", "CANCER", 482, 486], ["patients", "ORGANISM", 513, 521], ["pulmonary", "ORGAN", 547, 556], ["CXR", "PROTEIN", 318, 321], ["patients", "SPECIES", 434, 442], ["patients", "SPECIES", 513, 521], ["pulmonary infections", "PROBLEM", 52, 72], ["this study", "TEST", 76, 86], ["the study", "TEST", 88, 97], ["LDCT", "TEST", 200, 204], ["CXR", "TEST", 217, 220], ["a pulmonary focus", "PROBLEM", 239, 256], ["neutropenic fever", "PROBLEM", 269, 286], ["CXR", "TEST", 318, 321], ["a standard diagnostic procedure", "TREATMENT", 325, 356], ["a retrospective study", "TEST", 397, 418], ["CXRs", "TEST", 482, 486], ["febrile neutropenia pulmonary abnormalities", "PROBLEM", 527, 570], ["infection", "PROBLEM", 585, 594], ["pulmonary", "ANATOMY", 52, 61], ["infections", "OBSERVATION", 62, 72], ["significant", "OBSERVATION_MODIFIER", 163, 174], ["increased", "OBSERVATION_MODIFIER", 175, 184], ["pulmonary", "ANATOMY", 241, 250], ["focus", "OBSERVATION", 251, 256], ["neutropenic", "OBSERVATION_MODIFIER", 269, 280], ["fever", "OBSERVATION", 281, 286], ["pulmonary", "ANATOMY", 547, 556], ["abnormalities", "OBSERVATION", 557, 570], ["indicative of", "UNCERTAINTY", 571, 584], ["infection", "OBSERVATION", 585, 594]]], ["In contrast, in 76 patients with respiratory symptoms 24 CXRs showed evidence of pneumonia.[3] In our study 4 patients had a true positive CXR; 1 of these patients had respiratory symptoms on the first day of fever.DiscussionTwo previous studies have compared the use of CXR with LDCT in febrile neutropenic patients.", [["respiratory", "ANATOMY", 33, 44], ["respiratory", "ANATOMY", 168, 179], ["respiratory symptoms", "DISEASE", 33, 53], ["pneumonia", "DISEASE", 81, 90], ["respiratory symptoms", "DISEASE", 168, 188], ["fever", "DISEASE", 209, 214], ["neutropenic", "DISEASE", 296, 307], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 155, 163], ["patients", "ORGANISM", 308, 316], ["CXR", "PROTEIN", 271, 274], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 155, 163], ["patients", "SPECIES", 308, 316], ["respiratory symptoms", "PROBLEM", 33, 53], ["CXRs", "TEST", 57, 61], ["pneumonia", "PROBLEM", 81, 90], ["our study", "TEST", 98, 107], ["a true positive CXR", "PROBLEM", 123, 142], ["respiratory symptoms", "PROBLEM", 168, 188], ["fever", "PROBLEM", 209, 214], ["CXR", "TEST", 271, 274], ["LDCT", "TEST", 280, 284], ["febrile neutropenic patients", "TREATMENT", 288, 316], ["respiratory", "ANATOMY", 33, 44], ["evidence of", "UNCERTAINTY", 69, 80], ["pneumonia", "OBSERVATION", 81, 90], ["fever", "OBSERVATION", 209, 214]]], ["In the present study a much lower mean radiation dose of 0.24 mSv was used compared to 0.6 mSv and 1.5 mSv in the other studies.[10, 11] Still, reconstructed images were of diagnostic quality in all patients.", [["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["a much lower mean radiation dose", "TREATMENT", 21, 53], ["the other studies", "TEST", 110, 127], ["reconstructed images", "TEST", 144, 164]]], ["The LDCT scans in the previous studies were acquired using older generation CT systems (4 slice CT scanner by Patsios et al.[10] and 16 slice CT scanner by Kim et al.[11].)", [["The LDCT scans", "TEST", 0, 14], ["the previous studies", "TEST", 18, 38], ["older generation CT systems", "TEST", 59, 86], ["16 slice CT scanner", "TEST", 133, 152]]], ["We used two newer generation CT systems (64 slices and 256 slices) with newer X-ray tubes, detectors and software, resulting in the potential to further reduce the radiation dose without compromising on image quality.DiscussionBoth previous studies demonstrated that LDCT increased the detection rate but they differ in several aspects from our study.", [["slices", "ANATOMY", 44, 50], ["slices", "ANATOMY", 59, 65], ["LDCT", "SIMPLE_CHEMICAL", 267, 271], ["two newer generation CT systems", "TEST", 8, 39], ["newer X-ray tubes", "TREATMENT", 72, 89], ["the radiation dose", "TREATMENT", 160, 178], ["previous studies", "TEST", 232, 248], ["LDCT", "TEST", 267, 271], ["the detection rate", "TEST", 282, 300], ["our study", "TEST", 341, 350], ["increased", "OBSERVATION_MODIFIER", 272, 281]]], ["Patsios et al.[10] compared CXR with LDCT in neutropenic AML patients with already clinically suspected pneumonia, and found abnormal imaging results in 31 of 40 CXRs, whereas 38 out of 40 patients had abnormalities on LDCT.", [["AML", "ANATOMY", 57, 60], ["CXRs", "ANATOMY", 162, 166], ["AML", "DISEASE", 57, 60], ["pneumonia", "DISEASE", 104, 113], ["AML", "CANCER", 57, 60], ["patients", "ORGANISM", 61, 69], ["CXRs", "CANCER", 162, 166], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 189, 197], ["CXR", "TEST", 28, 31], ["LDCT", "TEST", 37, 41], ["neutropenic AML", "PROBLEM", 45, 60], ["pneumonia", "PROBLEM", 104, 113], ["abnormal imaging", "PROBLEM", 125, 141], ["40 CXRs", "TEST", 159, 166], ["abnormalities", "PROBLEM", 202, 215], ["LDCT", "TEST", 219, 223], ["neutropenic AML", "OBSERVATION", 45, 60], ["pneumonia", "OBSERVATION", 104, 113]]], ["Instead of only focusing on pulmonary abnormalities suggestive of pulmonary infection, this study also included radiological signs of cardiac failure or fluid overload, which might explain the high number of patients with abnormalities in both CXR and LDCT.[10]DiscussionIn a prospective study Kim et al.[11] evaluated the use of LDCT in a selection of patients with persistent neutropenic fever (>48 hours) regardless of the presence of respiratory symptoms.", [["pulmonary", "ANATOMY", 28, 37], ["pulmonary", "ANATOMY", 66, 75], ["cardiac", "ANATOMY", 134, 141], ["fluid", "ANATOMY", 153, 158], ["respiratory", "ANATOMY", 438, 449], ["pulmonary abnormalities", "DISEASE", 28, 51], ["pulmonary infection", "DISEASE", 66, 85], ["cardiac failure", "DISEASE", 134, 149], ["fluid overload", "DISEASE", 153, 167], ["neutropenic fever", "DISEASE", 378, 395], ["respiratory symptoms", "DISEASE", 438, 458], ["pulmonary", "ORGAN", 28, 37], ["pulmonary", "ORGAN", 66, 75], ["cardiac", "ORGAN", 134, 141], ["fluid", "ORGANISM_SUBSTANCE", 153, 158], ["patients", "ORGANISM", 208, 216], ["LDCT", "SIMPLE_CHEMICAL", 330, 334], ["patients", "ORGANISM", 353, 361], ["patients", "SPECIES", 208, 216], ["patients", "SPECIES", 353, 361], ["pulmonary abnormalities", "PROBLEM", 28, 51], ["pulmonary infection", "PROBLEM", 66, 85], ["this study", "TEST", 87, 97], ["cardiac failure", "PROBLEM", 134, 149], ["fluid overload", "PROBLEM", 153, 167], ["abnormalities", "PROBLEM", 222, 235], ["both CXR", "TEST", 239, 247], ["LDCT", "TEST", 252, 256], ["a prospective study", "TEST", 274, 293], ["LDCT", "TREATMENT", 330, 334], ["persistent neutropenic fever", "PROBLEM", 367, 395], ["respiratory symptoms", "PROBLEM", 438, 458], ["pulmonary", "ANATOMY", 28, 37], ["abnormalities", "OBSERVATION", 38, 51], ["suggestive of", "UNCERTAINTY", 52, 65], ["pulmonary", "ANATOMY", 66, 75], ["infection", "OBSERVATION", 76, 85], ["cardiac", "ANATOMY", 134, 141], ["failure", "OBSERVATION", 142, 149], ["fluid overload", "OBSERVATION", 153, 167], ["high", "OBSERVATION_MODIFIER", 193, 197], ["number", "OBSERVATION_MODIFIER", 198, 204], ["persistent", "OBSERVATION_MODIFIER", 367, 377], ["neutropenic", "OBSERVATION", 378, 389], ["respiratory symptoms", "OBSERVATION", 438, 458]]], ["Of the 207 included patients 150 were diagnosed with pneumonia (72%).", [["pneumonia", "DISEASE", 53, 62], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["pneumonia", "PROBLEM", 53, 62], ["pneumonia", "OBSERVATION", 53, 62]]], ["Differences between sensitivity of CXR and LDCT for correctly diagnosing infectious pneumonia were a little less pronounced than in our study: CXR 39% and LDCT 63%.DiscussionTo our knowledge this is the first study to evaluate LDCT in all patients with febrile neutropenia on day 1 of fever.", [["pneumonia", "DISEASE", 84, 93], ["febrile neutropenia", "DISEASE", 253, 272], ["fever", "DISEASE", 285, 290], ["patients", "ORGANISM", 239, 247], ["CXR", "PROTEIN", 35, 38], ["patients", "SPECIES", 239, 247], ["CXR", "TEST", 35, 38], ["LDCT", "TEST", 43, 47], ["correctly diagnosing infectious pneumonia", "PROBLEM", 52, 93], ["our study", "TEST", 132, 141], ["CXR", "TEST", 143, 146], ["LDCT", "TEST", 155, 159], ["the first study", "TEST", 199, 214], ["LDCT", "TEST", 227, 231], ["febrile neutropenia", "PROBLEM", 253, 272], ["fever", "PROBLEM", 285, 290], ["infectious", "OBSERVATION_MODIFIER", 73, 83], ["pneumonia", "OBSERVATION", 84, 93], ["little less pronounced", "OBSERVATION_MODIFIER", 101, 123]]], ["We demonstrated an increase in sensitivity and an improved NPV when performing LDCT in the detection of a pulmonary infection in febrile neutropenia.", [["pulmonary", "ANATOMY", 106, 115], ["pulmonary infection", "DISEASE", 106, 125], ["febrile neutropenia", "DISEASE", 129, 148], ["pulmonary", "ORGAN", 106, 115], ["an increase in sensitivity", "PROBLEM", 16, 42], ["LDCT", "TEST", 79, 83], ["a pulmonary infection", "PROBLEM", 104, 125], ["febrile neutropenia", "PROBLEM", 129, 148], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["pulmonary", "ANATOMY", 106, 115], ["infection", "OBSERVATION", 116, 125], ["febrile neutropenia", "OBSERVATION", 129, 148]]], ["This is important because detection of a focus of infection in neutropenic fever is difficult and patients often undergo several diagnostic tests and uncertain treatments which can have negative side effects.", [["infection", "DISEASE", 50, 59], ["neutropenic fever", "DISEASE", 63, 80], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["infection", "PROBLEM", 50, 59], ["neutropenic fever", "PROBLEM", 63, 80], ["several diagnostic tests", "TEST", 121, 145], ["uncertain treatments", "TREATMENT", 150, 170], ["infection", "OBSERVATION", 50, 59], ["neutropenic", "OBSERVATION_MODIFIER", 63, 74]]], ["Therefore it can be expected that every improvement in the diagnostic workup will eventually lead to improved patient care.DiscussionA major advantage of our study is the completely independent assessment of both index and reference test (LDCT and CXR by independent radiologists) and the short time interval between CXR and LDCT (3.1 \u00b1 6.3 hours).", [["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["the diagnostic workup", "TEST", 55, 76], ["our study", "TEST", 154, 163], ["reference test", "TEST", 223, 237], ["LDCT", "TEST", 239, 243], ["CXR", "TEST", 248, 251], ["CXR", "TEST", 317, 320], ["LDCT", "TEST", 325, 329]]], ["However, the inter-observer agreement was moderate and should be improved when moving forward with the LDCT technique.", [["the LDCT technique", "TEST", 99, 117], ["moderate", "OBSERVATION_MODIFIER", 42, 50]]], ["This points out that evaluation of LDCT images in this neutropenic population at high-risk of developing pulmonary infections requires expert-thoracic radiologists, which may not yet be available in every hospital.DiscussionA limitation of the study is the use of the reference standard (consensus diagnosis) which may have contributed to the lower test performance of LDCT.", [["pulmonary", "ANATOMY", 105, 114], ["neutropenic", "DISEASE", 55, 66], ["pulmonary infections", "DISEASE", 105, 125], ["pulmonary", "ORGAN", 105, 114], ["evaluation", "TEST", 21, 31], ["LDCT images", "TEST", 35, 46], ["this neutropenic population", "PROBLEM", 50, 77], ["developing pulmonary infections", "PROBLEM", 94, 125], ["the study", "TEST", 240, 249], ["LDCT", "TEST", 369, 373], ["pulmonary", "ANATOMY", 105, 114], ["infections", "OBSERVATION", 115, 125], ["thoracic", "ANATOMY", 142, 150]]], ["In 38 of the 67 patients a CXR was the only imaging modality available for the consensus meeting, since HRCT was only performed in case of persistent fever.", [["fever", "DISEASE", 150, 155], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["a CXR", "TEST", 25, 30], ["imaging modality", "TEST", 44, 60], ["HRCT", "TEST", 104, 108], ["persistent fever", "PROBLEM", 139, 155], ["persistent", "OBSERVATION_MODIFIER", 139, 149], ["fever", "OBSERVATION", 150, 155]]], ["Considering the low sensitivity of CXR in this population, pulmonary abnormalities could have been missed, This may have led to an underestimation of the amount of patients with pneumonia, and LDCTs might have incorrectly be judged as false positives.DiscussionFurthermore clinical symptoms of cough, sputum production and dyspnea are not always evident in a (bedridden) neutropenic patient.[16] An extensive microbiological evaluation for respiratory causes of fever, which was only performed upon clinical indication, might therefore not have been performed in all patients that had abnormalities suspect for pulmonary infection on LDCT.", [["pulmonary", "ANATOMY", 59, 68], ["sputum", "ANATOMY", 301, 307], ["respiratory", "ANATOMY", 440, 451], ["pulmonary", "ANATOMY", 611, 620], ["pulmonary abnormalities", "DISEASE", 59, 82], ["pneumonia", "DISEASE", 178, 187], ["cough", "DISEASE", 294, 299], ["dyspnea", "DISEASE", 323, 330], ["neutropenic", "DISEASE", 371, 382], ["fever", "DISEASE", 462, 467], ["pulmonary infection", "DISEASE", 611, 630], ["pulmonary", "ORGAN", 59, 68], ["patients", "ORGANISM", 164, 172], ["sputum", "ORGANISM_SUBSTANCE", 301, 307], ["patient", "ORGANISM", 383, 390], ["patients", "ORGANISM", 567, 575], ["pulmonary", "ORGAN", 611, 620], ["CXR", "PROTEIN", 35, 38], ["patients", "SPECIES", 164, 172], ["patient", "SPECIES", 383, 390], ["patients", "SPECIES", 567, 575], ["CXR", "TEST", 35, 38], ["pulmonary abnormalities", "PROBLEM", 59, 82], ["pneumonia", "PROBLEM", 178, 187], ["LDCTs", "PROBLEM", 193, 198], ["false positives", "PROBLEM", 235, 250], ["clinical symptoms", "PROBLEM", 273, 290], ["cough", "PROBLEM", 294, 299], ["sputum production", "PROBLEM", 301, 318], ["dyspnea", "PROBLEM", 323, 330], ["neutropenic", "PROBLEM", 371, 382], ["An extensive microbiological evaluation", "TEST", 396, 435], ["respiratory causes", "PROBLEM", 440, 458], ["fever", "PROBLEM", 462, 467], ["pulmonary infection", "PROBLEM", 611, 630], ["LDCT", "TEST", 634, 638], ["low sensitivity", "OBSERVATION_MODIFIER", 16, 31], ["pulmonary", "ANATOMY", 59, 68], ["abnormalities", "OBSERVATION", 69, 82], ["amount", "OBSERVATION_MODIFIER", 154, 160], ["pneumonia", "OBSERVATION", 178, 187], ["cough", "OBSERVATION", 294, 299], ["fever", "OBSERVATION", 462, 467], ["suspect for", "UNCERTAINTY", 599, 610], ["pulmonary", "ANATOMY", 611, 620], ["infection", "OBSERVATION", 621, 630]]], ["Several studies report on the limited diagnostic yield of a respiratory microbiological evaluation in neutropenic patients.", [["neutropenic", "DISEASE", 102, 113], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["Several studies", "TEST", 0, 15], ["a respiratory microbiological evaluation", "TEST", 58, 98]]], ["In up to 70% of the lower airway infections a pathogen can not be identified.[17, 18] Sputum cultures (which are often not available) only reveal a possible pathogen in less than 50% of cases.[18] BAL seems to be the diagnostic procedure with the highest yield.", [["lower airway", "ANATOMY", 20, 32], ["airway infections", "DISEASE", 26, 43], ["airway", "MULTI-TISSUE_STRUCTURE", 26, 32], ["the lower airway infections", "PROBLEM", 16, 43], ["a pathogen", "PROBLEM", 44, 54], ["Sputum cultures", "TEST", 86, 101], ["pathogen", "PROBLEM", 157, 165], ["the diagnostic procedure", "TREATMENT", 213, 237], ["lower", "ANATOMY_MODIFIER", 20, 25], ["airway", "ANATOMY", 26, 32], ["infections", "OBSERVATION", 33, 43], ["pathogen", "OBSERVATION", 46, 54], ["possible", "UNCERTAINTY", 148, 156], ["pathogen", "OBSERVATION", 157, 165]]], ["Despite the low detection rates of a probable pathogen in approximately 50% of cases, it is the most sensitive procedure for detecting IFD.[19] However, since routinely performance of BAL in the initial assessment of fever is not performed due to its invasive nature, a consensus diagnosis as was used in our study is the best available option and complies with established guidelines.[1, 4]DiscussionWe were able to identify a probable pathogen in 36% of the patients with pneumonia (2 cases of possible IFD excluded), which is consistent with reports in literature.[17, 18] However we did not establish any case of bacterial pneumonia.", [["IFD", "DISEASE", 135, 138], ["fever", "DISEASE", 217, 222], ["pneumonia", "DISEASE", 474, 483], ["IFD", "DISEASE", 505, 508], ["pneumonia", "DISEASE", 627, 636], ["BAL", "MULTI-TISSUE_STRUCTURE", 184, 187], ["patients", "ORGANISM", 460, 468], ["patients", "SPECIES", 460, 468], ["pathogen", "PROBLEM", 46, 54], ["IFD", "PROBLEM", 135, 138], ["BAL", "TEST", 184, 187], ["the initial assessment", "TEST", 191, 213], ["fever", "PROBLEM", 217, 222], ["our study", "TEST", 305, 314], ["pathogen", "PROBLEM", 437, 445], ["pneumonia", "PROBLEM", 474, 483], ["IFD", "PROBLEM", 505, 508], ["bacterial pneumonia", "PROBLEM", 617, 636], ["probable", "UNCERTAINTY", 37, 45], ["pathogen", "OBSERVATION_MODIFIER", 46, 54], ["BAL", "OBSERVATION", 184, 187], ["pneumonia", "OBSERVATION", 474, 483], ["consistent with", "UNCERTAINTY", 529, 544], ["bacterial", "OBSERVATION_MODIFIER", 617, 626], ["pneumonia", "OBSERVATION", 627, 636]]], ["This may be explained by the low amount of patients with sputum available for culture (36%, all culture-negative), or a possible treatment response to broad spectrum antibiotics, resulting in defervescence within 3 days, in which case HRCT and BAL were not performed.DiscussionWe included a heterogenic population with patients with prolonged neutropenia as well as patients with shorter neutropenic episodes.", [["sputum", "ANATOMY", 57, 63], ["neutropenia", "DISEASE", 343, 354], ["neutropenic", "DISEASE", 388, 399], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 319, 327], ["patients", "ORGANISM", 366, 374], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 319, 327], ["patients", "SPECIES", 366, 374], ["sputum", "TEST", 57, 63], ["culture", "TEST", 78, 85], ["all culture", "TEST", 92, 103], ["broad spectrum antibiotics", "TREATMENT", 151, 177], ["HRCT and BAL", "TEST", 235, 247], ["prolonged neutropenia", "PROBLEM", 333, 354], ["shorter neutropenic episodes", "PROBLEM", 380, 408], ["may be explained", "UNCERTAINTY", 5, 21], ["low", "OBSERVATION_MODIFIER", 29, 32], ["amount", "OBSERVATION_MODIFIER", 33, 39], ["heterogenic", "OBSERVATION_MODIFIER", 291, 302], ["neutropenia", "OBSERVATION", 343, 354]]], ["This could have had an effect on the incidence of pulmonary infections, because the risk of developing pneumonia (especially IFD) increases in case of prolonged neutropenia.DiscussionThe use of LDCT scans for detection of pulmonary lesions indicating IFD at day 1 of neutropenic fever seems promising.", [["pulmonary", "ANATOMY", 50, 59], ["pulmonary lesions", "ANATOMY", 222, 239], ["pulmonary infections", "DISEASE", 50, 70], ["pneumonia", "DISEASE", 103, 112], ["IFD", "DISEASE", 125, 128], ["neutropenia", "DISEASE", 161, 172], ["pulmonary lesions", "DISEASE", 222, 239], ["IFD", "DISEASE", 251, 254], ["fever", "DISEASE", 279, 284], ["pulmonary", "ORGAN", 50, 59], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 222, 239], ["pulmonary infections", "PROBLEM", 50, 70], ["developing pneumonia", "PROBLEM", 92, 112], ["prolonged neutropenia", "PROBLEM", 151, 172], ["LDCT scans", "TEST", 194, 204], ["pulmonary lesions", "PROBLEM", 222, 239], ["IFD", "PROBLEM", 251, 254], ["neutropenic fever", "PROBLEM", 267, 284], ["pulmonary", "ANATOMY", 50, 59], ["infections", "OBSERVATION", 60, 70], ["developing", "OBSERVATION_MODIFIER", 92, 102], ["pneumonia", "OBSERVATION", 103, 112], ["prolonged", "OBSERVATION_MODIFIER", 151, 160], ["neutropenia", "OBSERVATION", 161, 172], ["pulmonary", "ANATOMY", 222, 231], ["lesions", "OBSERVATION", 232, 239]]], ["Out of 5 fever episodes classified as either possible or probable IFD, 4 patients already had abnormalities suspect for IFD on their LDCT whereas these where not seen on CXR.", [["fever", "DISEASE", 9, 14], ["IFD", "DISEASE", 66, 69], ["IFD", "DISEASE", 120, 123], ["patients", "ORGANISM", 73, 81], ["CXR", "PROTEIN", 170, 173], ["patients", "SPECIES", 73, 81], ["5 fever episodes", "PROBLEM", 7, 23], ["IFD", "PROBLEM", 66, 69], ["abnormalities", "PROBLEM", 94, 107], ["IFD", "PROBLEM", 120, 123], ["their LDCT", "TEST", 127, 137], ["CXR", "TEST", 170, 173]]], ["Importantly, only one of these patients had respiratory signs or symptoms and therefore we think that omitting chest imaging in patients without respiratory symptoms can lead to a delayed diagnosis of IFD.DiscussionIncorporation of LDCT in the diagnostic workup of all patients with neutropenic fever will increase costs when compared to CXR.", [["respiratory", "ANATOMY", 44, 55], ["chest", "ANATOMY", 111, 116], ["respiratory", "ANATOMY", 145, 156], ["respiratory symptoms", "DISEASE", 145, 165], ["IFD", "DISEASE", 201, 204], ["neutropenic fever", "DISEASE", 283, 300], ["patients", "ORGANISM", 31, 39], ["chest", "ORGANISM_SUBDIVISION", 111, 116], ["patients", "ORGANISM", 128, 136], ["patients", "ORGANISM", 269, 277], ["CXR", "PROTEIN", 338, 341], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 269, 277], ["respiratory signs", "PROBLEM", 44, 61], ["symptoms", "PROBLEM", 65, 73], ["omitting chest imaging", "TEST", 102, 124], ["respiratory symptoms", "PROBLEM", 145, 165], ["IFD", "PROBLEM", 201, 204], ["LDCT", "TEST", 232, 236], ["the diagnostic workup", "TEST", 240, 261], ["neutropenic fever", "PROBLEM", 283, 300], ["CXR", "TEST", 338, 341], ["chest", "ANATOMY", 111, 116]]], ["However, initiation of early and targeted treatment of IFD may reduce overall costs, for example by reducing length of hospital stay, intensive care unit admittance rates and the amount of diagnostic procedures required.", [["IFD", "DISEASE", 55, 58], ["IFD", "PROBLEM", 55, 58], ["diagnostic procedures", "TEST", 189, 210]]], ["Therefore the performance of LDCT in all patients with febrile neutropenia might still be cost-effective.", [["febrile neutropenia", "DISEASE", 55, 74], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["LDCT", "TEST", 29, 33], ["febrile neutropenia", "PROBLEM", 55, 74]]], ["This issue should be evaluated in future research.Conclusion and implicationPerformance of CXR in the initial assessment of febrile neutropenia is of limited value for detection of pulmonary abnormalities.", [["pulmonary", "ANATOMY", 181, 190], ["neutropenia", "DISEASE", 132, 143], ["pulmonary abnormalities", "DISEASE", 181, 204], ["pulmonary", "ORGAN", 181, 190], ["CXR", "PROTEIN", 91, 94], ["CXR", "TEST", 91, 94], ["the initial assessment", "TEST", 98, 120], ["febrile neutropenia", "PROBLEM", 124, 143], ["pulmonary abnormalities", "PROBLEM", 181, 204], ["pulmonary", "ANATOMY", 181, 190], ["abnormalities", "OBSERVATION", 191, 204]]], ["The introduction of LDCT improved the detection of pulmonary infiltrates and there was a clear signal that LDCT scanning is capable of detecting invasive fungal infections at a very early stage.", [["pulmonary infiltrates", "ANATOMY", 51, 72], ["fungal infections", "DISEASE", 154, 171], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 51, 72], ["LDCT", "TEST", 20, 24], ["pulmonary infiltrates", "PROBLEM", 51, 72], ["LDCT scanning", "TEST", 107, 120], ["invasive fungal infections", "PROBLEM", 145, 171], ["pulmonary", "ANATOMY", 51, 60], ["infiltrates", "OBSERVATION", 61, 72], ["invasive", "OBSERVATION_MODIFIER", 145, 153], ["fungal", "OBSERVATION_MODIFIER", 154, 160], ["infections", "OBSERVATION", 161, 171]]], ["Therefore, the use of LDCT in the initial assessment of febrile neutropenia is promising, and should be further evaluated in a larger study powered on IFD detection.", [["neutropenia", "DISEASE", 64, 75], ["LDCT", "TEST", 22, 26], ["the initial assessment", "TEST", 30, 52], ["febrile neutropenia", "PROBLEM", 56, 75], ["a larger study", "TEST", 125, 139], ["IFD detection", "TEST", 151, 164], ["febrile", "OBSERVATION_MODIFIER", 56, 63], ["neutropenia", "OBSERVATION", 64, 75]]], ["Furthermore it would be interesting to see whether LDCT could replace HRCT as imaging tool in patients with suspected IFD in order to decrease radiation exposure.", [["IFD", "DISEASE", 118, 121], ["LDCT", "SIMPLE_CHEMICAL", 51, 55], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["LDCT", "TEST", 51, 55], ["HRCT", "TEST", 70, 74], ["imaging tool", "TEST", 78, 90], ["suspected IFD", "PROBLEM", 108, 121], ["radiation exposure", "TREATMENT", 143, 161], ["radiation exposure", "OBSERVATION", 143, 161]]]], "990727242b1a009e030837971f811489f196fccc": [["22nd September 2020Contact-tracing is an essential tool in order to mitigate the impact of pandemic such as the COVID-19.", [["the COVID", "TEST", 108, 117]]], ["In order to achieve efficient and scalable contact-tracing in real time, digital devices can play an important role.", [["digital devices", "TREATMENT", 73, 88]]], ["While a lot of attention has been paid to analyzing the privacy and ethical risks of the associated mobile applications, so far much less research has been devoted to optimizing their performance and assessing their impact on the mitigation of the epidemic.22nd September 2020We develop Bayesian inference methods to estimate the risk that an individual is infected.", [["Bayesian inference methods", "TREATMENT", 287, 313], ["infected", "OBSERVATION", 357, 365]]], ["This inference is based on the list of his recent contacts and their own risk levels, as well as personal information such as results of tests or presence of syndromes.", [["tests", "TEST", 137, 142], ["syndromes", "PROBLEM", 158, 167]]], ["We propose to use probabilistic risk estimation in order to optimize testing and quarantining strategies for the control of an epidemic.", [["probabilistic risk estimation", "TEST", 18, 47], ["testing", "TEST", 69, 76], ["quarantining strategies", "TREATMENT", 81, 104], ["an epidemic", "PROBLEM", 124, 135]]], ["Our results show that in some range of epidemic spreading (typically when the manual tracing of all contacts of infected people becomes practically impossible, but before the fraction of infected people reaches the scale where a lock-down becomes unavoidable), this inference of individuals at risk could be an efficient way to mitigate the epidemic.", [["people", "ORGANISM", 121, 127], ["people", "ORGANISM", 196, 202], ["people", "SPECIES", 121, 127], ["people", "SPECIES", 196, 202], ["epidemic spreading", "PROBLEM", 39, 57], ["the manual tracing", "TEST", 74, 92], ["the epidemic", "PROBLEM", 337, 349], ["epidemic", "OBSERVATION_MODIFIER", 39, 47], ["spreading", "OBSERVATION_MODIFIER", 48, 57], ["infected", "OBSERVATION", 187, 195]]], ["Such communication may be encrypted and anonymized and thus compatible with privacy preserving standards.", [["privacy preserving standards", "TREATMENT", 76, 104]]], ["We conclude that probabilistic risk estimation is capable to enhance performance of digital contact tracing and should be considered in the currently developed mobile applications.22nd September 2020Motivation One of the main tools public health authorities use to mitigate the spread of a pandemic, such as COVID-19, is the trace-test-isolate strategy.", [["pandemic", "DISEASE", 290, 298], ["COVID-19", "CHEMICAL", 308, 316], ["probabilistic risk estimation", "TEST", 17, 46], ["digital contact tracing", "TEST", 84, 107], ["mobile applications", "TREATMENT", 160, 179], ["COVID", "TEST", 308, 313], ["main", "OBSERVATION_MODIFIER", 221, 225]]], ["Identifying, calling, testing, and if needed quarantining the recent contacts of an individual who has just been tested positive is the standard route for limiting the transmission of a highly contagious virus.", [["a highly contagious virus", "PROBLEM", 184, 209]]], ["This standard strategy proves its efficacy at early stages of the epidemic, when the number of newly infected individuals is small enough to be manageable by reasonable-scale manual contact tracing infrastructures.", [["newly infected individuals", "PROBLEM", 95, 121], ["newly", "OBSERVATION_MODIFIER", 95, 100], ["infected", "OBSERVATION", 101, 109], ["small", "OBSERVATION_MODIFIER", 125, 130]]], ["However, it cannot be applied as such when the epidemic starts to spread faster, because the average number of contacts of a typical individual in the few days before he is tested positive can be large, not all contacts are with people known to the individual, and manual tracing incurs delays during which infected contacts keep on spreading the virus.22nd September 2020For these reasons, and taking into account the properties and parameters of the COVID-19 epidemic, digital contact tracing was convincingly argued to be a viable route to mitigation of COVID-19 and other similar epidemics [1] .", [["people", "ORGANISM", 229, 235], ["people", "SPECIES", 229, 235], ["manual tracing", "TEST", 265, 279], ["spreading the virus", "PROBLEM", 333, 352], ["the COVID", "TEST", 448, 457], ["digital contact tracing", "TEST", 471, 494], ["COVID", "TEST", 557, 562]]], ["With currently developed mobile applications, the distance and duration of a contact between two individuals can be estimated.", [["mobile applications", "TREATMENT", 25, 44], ["mobile", "OBSERVATION_MODIFIER", 25, 31]]], ["Furthermore, contextual or health information about individuals can be included as well.", [["individuals", "ORGANISM", 52, 63]]], ["This tracing can be used while preserving the privacy of each individual's information, the level of privacy protection depending on the protocol.", [["This tracing", "TEST", 0, 12], ["privacy protection", "TREATMENT", 101, 119], ["the protocol", "TREATMENT", 133, 145]]], ["While many works have been devoted, justifiably, to the compatibility of privacy and tracing, see e.g. [2, 4, 6, 7, 8] , much less work is available concerning the assessment of the efficiency of tracing in mitigation of the pandemic.", [["tracing", "TEST", 85, 92], ["the assessment", "TEST", 160, 174], ["the pandemic", "PROBLEM", 221, 233]]], ["Most considered systems use the tracing data simply as a fast and scalable device to identify all recent contacts, in order to notify and perhaps isolate all of them.22nd September 2020In this paper we show that approximate Bayesian probabilistic inference techniques allow to use the data exchanged by the tracing applications in order to provide highly accurate estimates of the probability that any given individual is infected.", [["the tracing data", "TEST", 28, 44], ["a fast and scalable device", "PROBLEM", 55, 81], ["infected", "PROBLEM", 422, 430], ["infected", "OBSERVATION", 422, 430]]], ["This estimate can then be used in order to focus the tests and other interventions on the group of individuals who have the largest probabilities of being infected, even if they do not show symptoms.", [["individuals", "ORGANISM", 99, 110], ["the tests", "TEST", 49, 58], ["symptoms", "PROBLEM", 190, 198], ["infected", "OBSERVATION", 155, 163]]], ["The contact-tracing protocols that we propose require individuals that have been in contact in the recent past to be able to exchange messages about their risk level.", [["The contact-tracing protocols", "TREATMENT", 0, 29]]], ["Later on, these individuals exchange messages carrying information about their current status, e.g. an increased risk due to presence of syndromes associated with the illness or due to their history of past contacts.", [["illness", "DISEASE", 167, 174], ["an increased risk", "PROBLEM", 100, 117], ["syndromes", "PROBLEM", 137, 146], ["the illness", "PROBLEM", 163, 174]]], ["The latter requires smaller communication bandwidth between devices and could be potentially more privacy-friendly.", [["smaller communication bandwidth between devices", "TREATMENT", 20, 67], ["smaller", "OBSERVATION_MODIFIER", 20, 27], ["communication bandwidth", "OBSERVATION", 28, 51]]], ["For a given testing capacity we show, through extensive simulation on realistic models for COVID-19 diffusion, that both methods allow to significantly reduce the impact of an outbreak and eventually contain the epidemics in many cases where standard tracing protocols fail to do so.", [["a given testing capacity", "TEST", 4, 28], ["COVID", "TEST", 91, 96], ["the epidemics", "PROBLEM", 208, 221], ["standard tracing protocols", "TEST", 242, 268]]], ["We additionally evaluate robustness of the methods to presence of false negative tests as well as partial adoption of the contact-tracing mobile applications.22nd September 2020Related work While most considered systems use the tracing data simply as a fast and scalable device to identify all recent contacts, works aiming at estimating the risk of infection appeared recently.", [["infection", "DISEASE", 350, 359], ["false negative tests", "PROBLEM", 66, 86], ["the tracing data", "TEST", 224, 240], ["a fast and scalable device", "PROBLEM", 251, 277], ["infection", "PROBLEM", 350, 359], ["infection", "OBSERVATION", 350, 359]]], ["These include a machine learning based risk estimation proposed in [5] , that provides only limited validation of the approach even on data specific to the privacy preserving protocol, and is thus difficult to directly compare to our approach.", [["a machine learning", "TREATMENT", 14, 32]]], ["An approach similar to our MF algorithms was proposed by [19] using Monte Carlo sampling to estimate the corresponding probabilities.", [["Monte Carlo sampling", "TEST", 68, 88]]], ["This work does not provide validation of the approach involving the control of the epidemic.", [["the approach", "TREATMENT", 41, 53]]], ["Another recent work estimating the risks from the tracing data is [20] that is in the spirit similar to our work, it uses Monte Carlo sampling based estimations of the risks.", [["the tracing data", "TEST", 46, 62]]], ["As is common with Monte-Carlo schemes, convergence properties could significantly deteriorate with system size.", [["Monte-Carlo schemes", "TREATMENT", 18, 37], ["size", "OBSERVATION_MODIFIER", 106, 110]]], ["The lack of separation between the epidemic generating model and the inference procedure in the implementation of [20] makes it difficult for us to compare directly to our approach, and we thus leave it for future work.", [["the inference procedure", "TREATMENT", 65, 88], ["separation", "OBSERVATION_MODIFIER", 12, 22]]], ["In such models, at each time, a given individual is in a state that belongs to a finite set of possible states, like for instance susceptible, exposed, infected-asymptomatic, infected-asymptomatic, in ICU, recovered, or dead.", [["asymptomatic", "PROBLEM", 184, 196], ["infected", "OBSERVATION_MODIFIER", 175, 183]]], ["The most accurate mathematical descriptions of COVID-19 epidemic propagation are based on complex multi-state compartment models, in which infected individuals are not immediately contagious upon infection, may be asymptomatic or develop mild/severe symptoms with some delay, and the ages, households and workplaces are also taken into account.", [["infection", "DISEASE", 196, 205], ["individuals", "ORGANISM", 148, 159], ["COVID", "TEST", 47, 52], ["epidemic propagation", "PROBLEM", 56, 76], ["infected individuals", "PROBLEM", 139, 159], ["infection", "PROBLEM", 196, 205], ["asymptomatic", "PROBLEM", 214, 226], ["mild/severe symptoms", "PROBLEM", 238, 258], ["some delay", "PROBLEM", 264, 274], ["infected", "OBSERVATION", 139, 147], ["infection", "OBSERVATION", 196, 205], ["mild", "OBSERVATION_MODIFIER", 238, 242], ["severe", "OBSERVATION_MODIFIER", 243, 249]]], ["Even though the long-term effects of SARS-CoV-2 infection are still under study, it seems reasonable to assume that some level of immunity is developed with recovery, so that the individual progression through the epidemic compartments is not recurrent (a recovered person typically does not become infected again).", [["SARS", "DISEASE", 37, 41], ["infection", "DISEASE", 48, 57], ["SARS-CoV-2", "ORGANISM", 37, 47], ["person", "SPECIES", 266, 272], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "PROBLEM", 37, 41], ["CoV-2 infection", "PROBLEM", 42, 57], ["long-term", "OBSERVATION_MODIFIER", 16, 25], ["infection", "OBSERVATION", 48, 57]]], ["The observation of non-trivial distributions of incubation and recovery times as well as that of time-dependent viral transmission capacity [23, 24, 25, 26, 26] indicate that the most realistic models for SARS-CoV-2 infection clearly depart from the simplest, and largely adopted, Markovian epidemic models.", [["infection", "DISEASE", 216, 225], ["SARS-CoV-2", "ORGANISM", 205, 215], ["CoV-", "SPECIES", 210, 214], ["SARS-CoV", "SPECIES", 205, 213], ["dependent viral transmission capacity", "PROBLEM", 102, 139], ["SARS", "PROBLEM", 205, 209], ["CoV-2 infection", "PROBLEM", 210, 225], ["non-trivial", "OBSERVATION_MODIFIER", 19, 30], ["distributions", "OBSERVATION_MODIFIER", 31, 44]]], ["In addition, such models also provide representations of the time-varying contact network over which viral transmissions occur, some including real-world mobility data [27] or computer-generated synthetic surrogates [21, 28] .22nd September 2020In particular, the model in Ref.", [["contact network", "MULTI-TISSUE_STRUCTURE", 74, 89]]], ["[21] simulates the spread of COVID-19 in urban age-stratified populations with a multi-layer contact network (see also Supplemental Material A for details).Bayesian Epidemic TracingInformation regarding the status of tested or symptomatic individuals can be used in different ways within a contact tracing procedure.", [["COVID-19", "CHEMICAL", 29, 37], ["symptomatic individuals", "PROBLEM", 227, 250], ["a contact tracing procedure", "TREATMENT", 288, 315]]], ["In the simplest situation, the observation of an infected individual involves tracing (a fraction of) his recent contacts in order to prevent/contain further transmissions of the infection.", [["infection", "DISEASE", 179, 188], ["the infection", "PROBLEM", 175, 188], ["infected", "OBSERVATION", 49, 57], ["infection", "OBSERVATION", 179, 188]]], ["It is also possible to infer transmission chains and detect the parent cases which are the origin of the infection detected in an individual.", [["infection", "DISEASE", 105, 114], ["the infection", "PROBLEM", 101, 114], ["infection", "OBSERVATION", 105, 114]]], ["In a Bayesian approach, this is made possible assuming as a prior a particular probabilistic model of epidemic propagation and using it to define a likelihood function conditioned on the evidences coming from observational data, i.e. tests (PCR and/or serology) and self-reported symptoms from a fraction of the individuals.", [["observational data", "TEST", 209, 227], ["tests", "TEST", 234, 239], ["PCR", "TEST", 241, 244], ["serology", "TEST", 252, 260], ["self-reported symptoms", "PROBLEM", 266, 288]]], ["As we shall show, the adopted prior inferential model provides the mathematical framework for developing risk assessment, but it does not need to reflect the real epidemic spread in all its details in order to allow for valuable inference.", [["developing risk assessment", "TEST", 94, 120], ["the real epidemic spread", "PROBLEM", 154, 178]]], ["Indeed, for epidemic propagation generated with complex agent-based models along the lines described above, we show that the approximate computation of local probability marginals can be effectively obtained using as a prior much simpler inferential models.", [["epidemic propagation", "PROBLEM", 12, 32], ["complex agent", "TREATMENT", 48, 61]]], ["In practice in this paper we use a simple agent-based Susceptible-Infected-Recovered (SIR) model.", [["a simple agent", "TREATMENT", 33, 47]]], ["We emphasize that, depending on the approximate inference technique used for computing such probability marginals, some of the ingredients of realistic epidemic propagation can be reintroduced, such as non-Markovian evolution between states, time-dependent infectiousness or more compartments.Bayesian Epidemic TracingHere we propose two distributed algorithms for risk estimation from contact tracing data, which are both derived within a Bayesian framework and based on a message-passing principle: Mean-Field (MF) algorithm and Belief Propagation (BP) algorithm.", [["risk estimation", "TEST", 365, 380], ["contact tracing data", "TEST", 386, 406], ["Belief Propagation (BP) algorithm", "TEST", 531, 564]]], ["They both provide estimates of the time-dependent local probability marginals of being infected which can be used to estimate the risk level of each individual; this risk of being infected can in turn be used to implement a sanitary protocol, like suggesting higher risk individuals to be tested and/or quarantined.", [["a sanitary protocol", "TREATMENT", 222, 241], ["higher risk individuals", "PROBLEM", 259, 282], ["infected", "OBSERVATION", 180, 188]]], ["The main differences between these methods, which are presented in the next section, are in the accuracy of the approximation of the epidemic dynamics and in the way in which observational data are incorporated into the probabilistic model.MethodsWe use the Bayesian approach that is based on a prior description of the epidemic process, and a method to include the information from observations.", [["observational data", "TEST", 175, 193], ["main", "OBSERVATION_MODIFIER", 4, 8], ["differences", "OBSERVATION_MODIFIER", 9, 20]]], ["For the SIR model, this probability depends on the following parameters:Methods\u2022 the recovery rate \u00b5 i , defining the daily probability that the infected individual i moves to the recovered state 'R';Methods\u2022 the transmission rates {\u03bb k\u2192i (t)} k\u2208\u2202i(t) , which are the probability of infection from an infected k to a susceptible i on day t.Methods,...,N be a collective time-trajectory generated by the epidemic.", [["infection", "DISEASE", 283, 292], ["the transmission rates", "TEST", 209, 231], ["infection", "PROBLEM", 283, 292], ["infected", "OBSERVATION", 145, 153], ["infection", "OBSERVATION", 283, 292], ["infected", "OBSERVATION", 301, 309]]], ["Given a set O of observations O = {O r } r\u2208O , where each observation r provides some information on the state of an individual at a given time (as the result of tests, or of individual symptoms), and assuming that these observations are statistically independent, the posterior probability of the trajectory x can be expressed using Bayes theorem asMethodsFor the BP approach, we start from the posterior at (2) and remark that it can be written as:MethodsBelief Propagation [9] can then be used to estimate marginal posterior probabilities from (3).", [["O = {O r } r\u2208O", "CHEMICAL", 30, 44], ["tests", "TEST", 162, 167], ["individual symptoms", "PROBLEM", 175, 194], ["the BP approach", "TREATMENT", 361, 376], ["posterior", "ANATOMY_MODIFIER", 518, 527]]], ["However, a straightforward factor graph representation [29, 30] of (3) with {x i } as variable nodes and the compatibility functions {\u03c8 i (x i , x \u2202i )} as factor nodes, contains many short loops, so that the corresponding BP equations would not be exact even when the underlying contact network is acyclic.", [["BP", "PROTEIN", 223, 225], ["{x i } as variable nodes", "PROBLEM", 76, 100], ["the compatibility functions", "TEST", 105, 132], ["factor nodes", "PROBLEM", 156, 168], ["many short loops", "PROBLEM", 179, 195], ["the corresponding BP equations", "TEST", 205, 235], ["variable", "OBSERVATION_MODIFIER", 86, 94], ["nodes", "OBSERVATION", 95, 100], ["nodes", "OBSERVATION", 163, 168], ["many", "OBSERVATION_MODIFIER", 179, 183], ["short loops", "OBSERVATION_MODIFIER", 184, 195]]], ["We instead construct a factor graph representation that closely reflects the topological structure of the contact network by associating the individual trajectories of a pair of individuals in contact, and involves BP messages m ij (x i , x j ) for pairs of trajectories.", [["contact network", "MULTI-TISSUE_STRUCTURE", 106, 121], ["BP", "PROTEIN", 215, 217], ["a factor graph representation", "PROBLEM", 21, 50], ["ij", "ANATOMY", 229, 231]]], ["The corresponding BP fixed-point system for {m ij (x i , x j )} (ij)\u2208E is solved by iteration.", [["BP", "PROTEIN", 18, 20], ["The corresponding BP fixed", "TEST", 0, 26], ["ij", "ANATOMY", 65, 67]]], ["This formalism has been employed for large-deviation analyses of a class of dynamical processes including applications to epidemics [12, 13, 15, 31, 32] , in particular regarding the patient zero problem and the inference of causality chains of infection.", [["infection", "DISEASE", 245, 254], ["patient", "ORGANISM", 183, 190], ["patient", "SPECIES", 183, 190], ["epidemics", "PROBLEM", 122, 131], ["the patient zero problem", "PROBLEM", 179, 203], ["infection", "PROBLEM", 245, 254], ["infection", "OBSERVATION", 245, 254]]], ["We extended here previous works to deal with non-Markovian processes and to make it computationally efficient through a limited time-window approximation (see Supplemental Material).", [["non-Markovian processes", "PROBLEM", 45, 68], ["a limited time-window approximation", "TREATMENT", 118, 153]]], ["The algorithm propagates the information on the population from t M F days before the current time and it simply takes into account the following facts:Methods\u2022 If an individual is tested 'S' at time t obs , it has been 'S' at all previous timesMethods\u2022 If an individual is tested 'R' at time t obs , it will be 'R' at all following timesMethods\u2022 If an individual is tested 'I' at time t obs , we assume that he has been 'I' at times [t obs \u2212\u03c4, t obs ], where \u03c4 , the typical time between infection and observation, is a parameter of the algorithm.ResultsWe test the inference of risk on two types of epidemic spreading and contact networks.Results\u2022 SIR spreading model on proximity-based random network: This is a simple SIR-modelbased propagation in a population of N individuals, where the graph of contact is updated dynamically at each step as follows.", [["infection", "DISEASE", 489, 498], ["infection", "PROBLEM", 489, 498], ["ResultsWe test", "TEST", 548, 562], ["epidemic spreading", "PROBLEM", 601, 619], ["infection", "OBSERVATION", 489, 498]]], ["The individuals are distributed uniformly in a square of side \u221a N , and at each time step a contact can be established between two individuals i and j with a probability e \u2212d ij / , where d ij is the Euclidean distance between the points and is a parameter that controls the density of the contact graph.", [["distributed", "OBSERVATION_MODIFIER", 20, 31], ["uniformly", "OBSERVATION_MODIFIER", 32, 41], ["ij", "ANATOMY", 175, 177], ["ij", "ANATOMY", 190, 192]]], ["We shall call this the geometric contact model.Results\u2022 Oxford OpenABM model: The second model is a much more realistic epidemic spread model [1] , which is aimed at capturing essential features of the contacts in real populations as well as the real epidemiology of COVID-19, we call it the OpenABM model.", [["COVID", "TEST", 267, 272]]], ["In the absence of sufficiently detailed real world data, we view the data from the OpenABM model as realistic and our main point is to demonstrate that even though the proposed inference procedures do not capture most of the details and complexity of this model, they still work and provide large improvement over competing current contact tracing methods.ResultsFor the OpenABM model, we use in MF inference an extremely simplified hypothesis of equal recovery rates, \u00b5 i = \u00b5, and transmission probabilities only divided into two classes (interhousehold contacts, with \u03bb k\u2192i (t) = \u03bb and intra-household contacts, with \u03bb k\u2192i (t) = 2\u03bb).", [["\u03bb", "PROTEIN", 619, 620], ["the data", "TEST", 65, 73], ["large", "OBSERVATION_MODIFIER", 291, 296], ["improvement", "OBSERVATION_MODIFIER", 297, 308]]], ["The values of parameters \u00b5 and \u03bb are chosen on the basis of population averages; they could also be inferred from data.", [["The values", "TEST", 0, 10]]], ["Note that arbitrarily heterogeneous parameters can be used if more information is available, such as the duration of a contact.", [["heterogeneous", "OBSERVATION", 22, 35]]], ["It is important to notice that the MF algorithms that we derive from this simple model turn out to be very efficient at predicting the risk of an individual to be infected, even in sophisticated propagation models that involve individual and time-dependent rates \u00b5 i and \u03bb k\u2192i (t).", [["infected", "PROBLEM", 163, 171], ["infected", "OBSERVATION", 163, 171]]], ["The BP inference model is slightly more complex (see Section C.4 for details), although still much simpler than the original OpenABM propagation model.ResultsIn both models, we start the simulation at time 0 with everybody in the susceptible state S except a small number of infected individuals.", [["BP", "PROTEIN", 4, 6], ["The BP inference model", "TEST", 0, 22], ["slightly more complex", "PROBLEM", 26, 47], ["infected individuals", "PROBLEM", 275, 295], ["slightly", "OBSERVATION_MODIFIER", 26, 34], ["more complex", "OBSERVATION_MODIFIER", 35, 47], ["small", "OBSERVATION_MODIFIER", 259, 264], ["number", "OBSERVATION_MODIFIER", 265, 271], ["infected", "OBSERVATION", 275, 283]]], ["The number of these \"patients-zero\" will be specified in the following for each case.ResultsWe apply the following testing protocol.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["testing protocol", "TEST", 115, 131]]], ["We observe a fraction of symptomatic individuals at the day of symptoms.", [["symptomatic individuals", "PROBLEM", 25, 48], ["symptoms", "PROBLEM", 63, 71]]], ["After a fixed number of days (t start ) the interventions start.", [["the interventions", "TREATMENT", 40, 57]]], ["Every day, we perform a fixed amount n r of tests to the top individuals ranked as having the largest probabilities of being infected, according to the different risk estimation strategies.", [["a fixed amount n r of tests", "TREATMENT", 22, 49], ["largest", "OBSERVATION_MODIFIER", 94, 101], ["infected", "OBSERVATION", 125, 133]]], ["We assume that the result of the test is available on the same time step (day) and is included in the observations used to adjust the probabilities of risk on the next time step (day).ResultsBesides BP and MF risk estimation, the ranking strategies considered for comparison are:Results\u2022 Random Guessing (RG): The n r individuals on which the tests are performed are randomly chosen among the individuals that were not previously tested positive.Results\u2022 Contact Tracing (CT): One ranks the individuals who have not been tested positive previously according to the number of contacts with confirmed positive individuals during the time interval [t \u2212 \u03c4, t[, and tests the n r individuals with the largest number of contacts.", [["the test", "TEST", 29, 37], ["BP", "TEST", 199, 201], ["the tests", "TEST", 339, 348], ["Contact Tracing (CT", "TEST", 455, 474], ["largest", "OBSERVATION_MODIFIER", 696, 703]]], ["This is what would be possible to implement with the currently deployed mobile applications.ResultsFor BP and MF inference, the ranking is done as follows:Results\u2022 Belief Propagation (BP) and Mean-Field (MF): One uses the algorithm (BP or MF) in order to estimate the probabilities q t i = p(x t i = I) of being infected at time t.", [["mobile applications", "TREATMENT", 72, 91], ["BP", "TEST", 103, 105], ["Propagation", "TEST", 171, 182], ["BP", "TEST", 184, 186], ["the algorithm", "TEST", 218, 231], ["BP", "TEST", 233, 235], ["infected", "OBSERVATION", 312, 320]]], ["For BP, the rank is computed as the probability of infection in the last \u03b4 rank days.", [["infection", "DISEASE", 51, 60], ["BP", "PROTEIN", 4, 6], ["BP", "TEST", 4, 6], ["infection", "PROBLEM", 51, 60], ["infection", "OBSERVATION", 51, 60]]], ["Prioritizing recent infections can be more effective as it helps containing the \"boundary\" of an ongoing outbreak.ResultsWe compare test-guided containment strategies based on MF, BP, RG and CT in a scenario where quarantines are put in place when tested individuals result infected.", [["infections", "DISEASE", 20, 30], ["Prioritizing recent infections", "PROBLEM", 0, 30], ["an ongoing outbreak", "PROBLEM", 94, 113], ["test", "TEST", 132, 136], ["containment strategies", "TREATMENT", 144, 166], ["MF", "TEST", 176, 178], ["BP", "TEST", 180, 182], ["CT", "TEST", 191, 193], ["quarantines", "TREATMENT", 214, 225], ["infected", "PROBLEM", 274, 282], ["infections", "OBSERVATION", 20, 30], ["infected", "OBSERVATION", 274, 282]]], ["We show that BP and MF-based methods are able to predict infections and control the epidemic considerably more successfully than the classic contact tracing strategy.", [["infections", "DISEASE", 57, 67], ["BP", "SIMPLE_CHEMICAL", 13, 15], ["BP", "TEST", 13, 15], ["infections", "PROBLEM", 57, 67]]], ["Implementation of the MF and BP risk estimation algorithms and all the tests that follow can be found at [22] .ResultsWe evaluate the proposed framework in a pessimistic regime with 200 simultaneous independent outbreaks that are discovered after ten days.", [["BP risk estimation algorithms", "TEST", 29, 58], ["all the tests", "TEST", 63, 76], ["a pessimistic regime", "TREATMENT", 156, 176]]], ["Figure 1 shows the development of the epidemic over three months in a population of 500 000 individuals, starting from 200 patients-zero, and performing n r = 1500 tests per day.", [["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["epidemic", "OBSERVATION_MODIFIER", 38, 46]]], ["In spite of rather large fluctuations from run to run, one sees a very clear signal indicating that the proposed inference methods, MF and BP, largely improve upon the usual CT, which is itself better than RG.", [["rather large fluctuations", "PROBLEM", 12, 37], ["BP", "TEST", 139, 141], ["the usual CT", "TEST", 164, 176], ["large", "OBSERVATION_MODIFIER", 19, 24], ["fluctuations", "OBSERVATION", 25, 37]]], ["The best inference method is clearly BP, but the simpler MF, which is less demanding in terms of the amount of information exchanged between individuals, and therefore easier to protect for better privacy, is also quite successful.", [["BP", "TEST", 37, 39], ["less", "OBSERVATION_MODIFIER", 70, 74]]], ["Even in this pessimistic regime both risk inference methods allow to slow down the epidemic spread by more than a month compared to classic contact tracing.ResultsIn this first test we assumed that the model used for BP and MF inference coincides exactly with underlying epidemic propagation model (SIR), which is overly optimistic.", [["BP", "PROTEIN", 217, 219], ["this pessimistic regime", "TREATMENT", 8, 31], ["classic contact tracing", "TEST", 132, 155], ["BP", "TEST", 217, 219]]], ["A much more stringent test has been performed on the more realistic OpenABM COVID-19 model.", [["A much more stringent test", "TEST", 0, 26]]], ["In this framework, each infected individual can either be asymptomatic or show symptoms of various degree (mild or severe).", [["symptoms of various degree (mild or severe)", "PROBLEM", 79, 122], ["infected", "OBSERVATION", 24, 32], ["various degree", "OBSERVATION_MODIFIER", 91, 105], ["mild", "OBSERVATION_MODIFIER", 107, 111], ["severe", "OBSERVATION_MODIFIER", 115, 121]]], ["As in a realistic setting, we will consider an additional source of information: individuals that show severe symptoms are immediately quarantined when symptoms emerge (typically 5 days after infection) or hospitalized.", [["infection", "DISEASE", 192, 201], ["severe symptoms", "PROBLEM", 103, 118], ["symptoms", "PROBLEM", 152, 160], ["infection", "PROBLEM", 192, 201], ["severe", "OBSERVATION_MODIFIER", 103, 109]]], ["In addition, half of the mildly symptomatic individuals is assumed to self-report and self-isolate as well.", [["the mildly symptomatic individuals", "PROBLEM", 21, 55], ["mildly", "OBSERVATION_MODIFIER", 25, 31], ["symptomatic", "OBSERVATION", 32, 43]]], ["No direct information is available on asymptomatic (or pre-symptomatic) infected individuals, their detection is possible only through contact tracing.", [["asymptomatic (or pre-symptomatic) infected individuals", "PROBLEM", 38, 92]]], ["We mimic a post lock-down scenario where only a small fraction of individuals is initially infected, i.e. few tens of patients zero in a population of 500 thousand individuals that all employ a contact-tracing application.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["a post lock-down scenario", "TREATMENT", 9, 34], ["a small fraction of individuals", "PROBLEM", 46, 77], ["small", "OBSERVATION_MODIFIER", 48, 53], ["fraction", "OBSERVATION", 54, 62], ["infected", "OBSERVATION", 91, 99], ["few", "OBSERVATION_MODIFIER", 106, 109], ["tens", "OBSERVATION_MODIFIER", 110, 114]]], ["The epidemic dynamics freely evolves according to the OpenABM model [21] for ten days and then a number of individuals with the highest infection risk, assessed by RG, CT, MF, or BP, is tested on a daily basis.", [["infection", "DISEASE", 136, 145], ["the highest infection risk", "PROBLEM", 124, 150], ["CT", "TEST", 168, 170], ["BP", "TEST", 179, 181], ["infection", "OBSERVATION", 136, 145]]], ["The MF algorithm assumes a Markovian SIR spreading with parameters \u03bb = 0.02 and \u00b5 = 1/12, and has parameters \u03c4 = 5 and t MF = 10.", [["parameters", "TEST", 98, 108]]], ["See Section C.4 for details on the BP parameters.", [["BP", "PROTEIN", 35, 37], ["the BP parameters", "TEST", 31, 48]]], ["In these simulations, the result of the medical tests is assumed to be exact; errors in tests will be addressed below.", [["the medical tests", "TEST", 36, 53], ["errors in tests", "PROBLEM", 78, 93]]], ["The number of medical tests associated with the individuals detected by the mobile application is fixed while there is no limitation on those performed to the fraction of symptomatic people presented above.", [["people", "ORGANISM", 183, 189], ["people", "SPECIES", 183, 189], ["medical tests", "TEST", 14, 27], ["no", "UNCERTAINTY", 119, 121]]], ["The original contact dynamics is then modified in agreement to two alternative strategies: tested positive are confined and can have contacts only with their cohabitants or, whenever one person results positive to the medical test, all the households are quarantined without being tested.", [["person", "SPECIES", 187, 193], ["the medical test", "TEST", 214, 230]]], ["Figure 2 shows the number of infected individuals in a time interval of 100 days when the number of initial infections is 50 and the intervention starts after 10 days.", [["infections", "DISEASE", 108, 118], ["infected individuals", "PROBLEM", 29, 49], ["initial infections", "PROBLEM", 100, 118], ["the intervention", "TREATMENT", 129, 145], ["number", "OBSERVATION_MODIFIER", 19, 25], ["infected", "OBSERVATION", 29, 37], ["infections", "OBSERVATION", 108, 118]]], ["In the top panels, we show the results for three independent realizations of the epidemics in the case where tested positive individuals only are quarantined, while in the bottom panels we show the results for a more restrictive intervention scenario in which all the households are confined.", [["a more restrictive intervention scenario", "TREATMENT", 210, 250]]], ["The number of available tests per day increases from 625 to 5000 (from left to the right panels).", [["right", "ANATOMY_MODIFIER", 83, 88]]], ["The lines are colored according to the adopted ranking strategy and the thick lines show the mean number of infected individuals mediated on the three instances.", [["lines", "ANATOMY", 4, 9], ["lines", "CELL", 4, 9], ["thick lines", "CELL", 72, 83], ["thick lines", "CELL_LINE", 72, 83], ["The lines", "TREATMENT", 0, 9], ["the thick lines", "TREATMENT", 68, 83], ["lines", "OBSERVATION", 4, 9], ["infected", "OBSERVATION", 108, 116]]], ["The results suggest that for both the inference strategies the size of the epidemics is significantly reduced if compared to the random testing and also to the classic contact tracing, even when few tests are available.", [["the epidemics", "PROBLEM", 71, 84], ["the random testing", "TEST", 125, 143], ["the classic contact tracing", "TEST", 156, 183], ["size", "OBSERVATION_MODIFIER", 63, 67], ["epidemics", "OBSERVATION", 75, 84], ["significantly", "OBSERVATION_MODIFIER", 88, 101], ["reduced", "OBSERVATION_MODIFIER", 102, 109]]], ["We remark the behavior of the BP-based strategy when 1000 (1250 when the confinement is not extended to the households) daily medical tests are performed: the confinement of the people inferred by this method suffices to stop the epidemic after 75 days.", [["people", "ORGANISM", 178, 184], ["people", "SPECIES", 178, 184], ["medical tests", "TEST", 126, 139]]], ["The MF-based strategy performs notably better than CT and it achieves similar performances to BP when the number of daily observations is large.ResultsIn Figure 5 of the Supplemental Material we show the number of infected individuals for a time window of 100 days in, to some extent, a different scenario, that is when the containment measures are applied earlier in time, after a week from the beginning of the epidemics, and the size of the epidemics at initial time is smaller than that examined in Figure 2 .ResultsRobustness of the inference In the previous section we investigated how several intervention protocols (differing in the treatment of the households and the number of available tests) control realistic epidemics when paired to the considered risk assessment strategies (RG, CT, MF and BP).", [["BP", "PROTEIN", 94, 96], ["CT", "TEST", 51, 53], ["BP", "TEST", 94, 96], ["the Supplemental Material", "TREATMENT", 166, 191], ["several intervention protocols", "TREATMENT", 592, 622], ["available tests", "TEST", 687, 702], ["risk assessment", "TEST", 762, 777], ["CT", "TEST", 794, 796], ["BP", "TEST", 805, 807], ["large", "OBSERVATION_MODIFIER", 138, 143], ["infected", "OBSERVATION", 214, 222], ["some extent", "OBSERVATION_MODIFIER", 272, 283], ["different", "OBSERVATION_MODIFIER", 287, 296], ["scenario", "OBSERVATION", 297, 305], ["size", "OBSERVATION_MODIFIER", 432, 436], ["epidemics", "OBSERVATION", 444, 453], ["smaller", "OBSERVATION_MODIFIER", 473, 480]]], ["In reality, the sensitivity of medical tests is not 100% and it is to be expected that only a fraction of the population will adopt the app, so that not all contacts are detectable.", [["medical tests", "TEST", 31, 44]]], ["In this section, we shall address these two issues, focusing on the more realistic OpenABM model.ResultsWe first consider the case in which the results of the medical tests are inaccurate and therefore there exists a fraction of the tested individuals incorrectly identified as uninfected or infected.", [["these two issues", "PROBLEM", 34, 50], ["the medical tests", "TEST", 155, 172], ["infected", "PROBLEM", 292, 300], ["infected", "OBSERVATION_MODIFIER", 292, 300]]], ["Concerning the fraction of false positive tests this simply puts a small additional fraction of individual in isolation, but does not lead to deterioration of the epidemic control.", [["false positive tests", "PROBLEM", 27, 47], ["a small additional fraction", "PROBLEM", 65, 92], ["the epidemic control", "PROBLEM", 159, 179], ["false positive", "OBSERVATION", 27, 41], ["small", "OBSERVATION_MODIFIER", 67, 72]]], ["We hence focus on the influence of false negatives and test how the performance depends on the false negative rate (FNR) of the medical tests.", [["false negatives", "TEST", 35, 50], ["the medical tests", "TEST", 124, 141]]], ["We remark that within the Bayesian framework it is possible to correctly include this information in a straight-forward way and we do so for the BP algorithm, but not for the MF as we want to keep it as simple as possible and test its robustness.", [["the BP algorithm", "TEST", 141, 157]]], ["In Figure 3 we show the results of several simulations (three different realizations of the dynamics), starting from the setting in Figure 2 with 2500 medical tests and the quarantine of the entire households, when the FNR spans the range [0.09, 0.40].", [["FNR", "PROTEIN", 219, 222], ["medical tests", "TEST", 151, 164], ["the FNR", "TEST", 215, 222]]], ["We see that all the control strategies present good robustness with respect to the false negative tests.", [["the false negative tests", "TEST", 79, 103]]], ["The CT controls the spreading up to FNR 0.19, MF is robustly better than CT up about FNR 0.25.", [["FNR", "PROTEIN", 36, 39], ["FNR", "PROTEIN", 85, 88], ["The CT controls", "TEST", 0, 15], ["FNR", "TEST", 36, 39], ["CT", "TEST", 73, 75], ["FNR", "TEST", 85, 88]]], ["Remarkably the intervention based of BP predictions not only limits the number of the infected individuals in time, but its performance remains almost unchanged with respect to the noiseless case as it completely stops the epidemic spreading even for large values of the FNR, up to 0.31.", [["BP", "PROTEIN", 37, 39], ["FNR", "PROTEIN", 271, 274], ["the intervention", "TREATMENT", 11, 27], ["BP predictions", "TEST", 37, 51], ["the FNR", "TEST", 267, 274], ["infected", "OBSERVATION", 86, 94]]], ["Figure 6 of the Supplemental Material displays the results of the same experiment but starting from the initial setting of Figure 5 using 1000 medical tests, bottom panel.", [["medical tests", "TEST", 143, 156], ["bottom panel", "TEST", 158, 170]]], ["These results confirm the effectiveness of inference-based ranking and reveal the robustness in a realistic scenario of a fully Bayesian approach such as the proposed Belief Propagation in which the probabilistic evidence of tests can be consistently included as priors.", [["tests", "TEST", 225, 230]]], ["We now turn to the study of partial adoption of the mobile application.", [["the study", "TEST", 15, 24], ["the mobile application", "TREATMENT", 48, 70]]], ["Figure 4 shows the result of mitigation, in the OpenABM model, with AF (the fraction of individuals who have adopted the app) ranging between 0.6 and 0.9.", [["AF", "DISEASE", 68, 70], ["AF", "PROBLEM", 68, 70]]], ["Although performance is severely affected, one observes that even at AF equal to 0.6 the use of inference algorithms allows to delay the spreading of the epidemic and to flatten the peak of infected individuals, way more efficiently than the classical contact tracing strategy.", [["severely affected", "PROBLEM", 24, 41], ["inference algorithms", "PROBLEM", 96, 116], ["the epidemic", "PROBLEM", 150, 162], ["infected individuals", "PROBLEM", 190, 210], ["severely", "OBSERVATION_MODIFIER", 24, 32], ["affected", "OBSERVATION", 33, 41], ["peak", "OBSERVATION_MODIFIER", 182, 186], ["infected", "OBSERVATION", 190, 198]]], ["Including more detailed information about mobile application utilization e.g. in population age classes may greatly reduce the impact of low adoption.", [["mobile application utilization", "TREATMENT", 42, 72]]], ["Similar results are presented in the Supplemental Material, Figure 7 for a smaller number of daily observations.", [["smaller", "OBSERVATION_MODIFIER", 75, 82]]], ["Figure 4 : Effect of a poor adoption fraction of the mobile application to the number of infected individuals.", [["infected individuals", "PROBLEM", 89, 109], ["infected", "OBSERVATION", 89, 97]]], ["We simulate the same intervention protocol as Figure 2 for 5000 daily observations.", [["the same intervention protocol", "TREATMENT", 12, 42]]], ["We assume here that only a fraction of the population, from 90 % to 60%, uses the mobile application for contact tracing.ConclusionThe above results show that, in the regime where the epidemic is growing and exhaustive testing of all contacts is unfeasible, inference methods allow to contain the epidemics more efficiently than the classical tracing of contacts, which itself is better than random testing.", [["contact tracing", "TEST", 105, 120], ["exhaustive testing", "TEST", 208, 226], ["the epidemics", "PROBLEM", 293, 306], ["random testing", "TEST", 392, 406], ["population", "OBSERVATION_MODIFIER", 43, 53], ["growing", "OBSERVATION_MODIFIER", 196, 203]]], ["Additionally, numerical tests show that the approach is robust to false negatives in the test results as well as to partial adoption of the mobile tracing applications, although the adoption rate required for efficient control of the epidemic with the number of daily tests considered is large relative to the one of the currently deployed applications.", [["numerical tests", "TEST", 14, 29], ["the adoption rate", "TEST", 178, 195], ["daily tests", "TEST", 262, 273], ["false negatives", "OBSERVATION", 66, 81], ["large", "OBSERVATION_MODIFIER", 288, 293]]], ["The volume of daily exchanged messages per pair of individuals in the two proposed methods is constant with respect to both the population size and time (a total of about 1kB for MF, 1MB for BP per individual assuming \u223c 10 daily contacts).", [["BP", "PROTEIN", 191, 193], ["BP", "TEST", 191, 193], ["volume", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 139, 143]]], ["This volume is negligible when compared with normal data usage.", [["This volume", "TEST", 0, 11], ["negligible", "OBSERVATION_MODIFIER", 15, 25]]], ["A privacy-preserving implementation will require an additional overload, but the computational burden on the phone's CPU will remain negligible.ConclusionHaving access to the estimated posterior probability of being infected in time, a series of threshold values could be put in place so as to suggest actions on individuals, including reduction of contacts, self-isolation and testing.ConclusionWith regard to privacy, it is worth emphasizing that the proposed inference methods are in principle more protective than the usual (manual) tracing.", [["an additional overload", "PROBLEM", 49, 71], ["threshold values", "TEST", 246, 262], ["self-isolation", "TREATMENT", 359, 373], ["testing", "TEST", 378, 385], ["manual) tracing", "TEST", 529, 544], ["overload", "OBSERVATION", 63, 71], ["posterior", "OBSERVATION_MODIFIER", 185, 194], ["infected", "OBSERVATION", 216, 224]]], ["On the one hand, both can be implemented in a fully distributed way using point to point cryptography without fully centralized processing and storage of information on infections or contacts.", [["infections", "DISEASE", 169, 179], ["infections", "PROBLEM", 169, 179]]], ["On the other hand, by identifying individuals who have the largest probability of being infected through a cumulative process by which information is integrated, the direct attribution of potential infection events to a given individual is made much harder.", [["infection", "DISEASE", 198, 207], ["potential infection events", "PROBLEM", 188, 214], ["infected", "OBSERVATION", 88, 96], ["infection", "OBSERVATION", 198, 207]]], ["Details of such fully privacy preserving implementation, along the lines of [4] , are left for future work.A. Brief description of the OpenABM modelThe OpenABM computational model by R. Hinch et al. [21] involves simulating epidemic propagation in an age-stratified population based on the UK national census data (see Table 1 in [21] ).", [["left", "ANATOMY_MODIFIER", 86, 90]]], ["Each individual is represented by a node of a multi-layered network and takes part in three different subnets describing different social contexts: two static subnets represent households and workplaces while a degree-heterogeneous random network, different every day, represents the occasional interactions which individuals have on a daily basis.", [["random network", "MULTI-TISSUE_STRUCTURE", 232, 246], ["node", "OBSERVATION", 36, 40]]], ["Age stratification influences both the composition of households (the elderly tend to live with other elderly, children preferably live with young adults) and the social activity level of individuals (e.g. participation in the workplace network, average number of random daily interactions).", [["children", "ORGANISM", 111, 119], ["children", "SPECIES", 111, 119]]], ["The epidemic states considered by the model are those discussed above, apart from the exposed state, which is not explicitly modeled.", [["not explicitly", "UNCERTAINTY", 110, 124]]], ["Hospitalization and/or death is possible only for severely symptomatic patients, while the resistant state is eventually reached in case of no or mild symptoms.", [["death", "DISEASE", 23, 28], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["death", "PROBLEM", 23, 28], ["severely symptomatic patients", "PROBLEM", 50, 79], ["mild symptoms", "PROBLEM", 146, 159], ["mild", "OBSERVATION_MODIFIER", 146, 150], ["symptoms", "OBSERVATION", 151, 159]]], ["The epidemic dynamics is modeled as a discrete-time stochastic process, with a temporal resolution of one day, in which infected individuals can transmit the disease with a (daily) infection rate which depends mainly on the symptomatic state of the potential infector, the age of the potential infected and the time passed since the potential infector became infected.", [["infection", "DISEASE", 181, 190], ["individuals", "ORGANISM", 129, 140], ["the disease", "PROBLEM", 154, 165], ["a (daily) infection rate", "PROBLEM", 171, 195], ["the potential infector", "PROBLEM", 329, 351], ["infected", "PROBLEM", 359, 367], ["temporal", "OBSERVATION_MODIFIER", 79, 87], ["resolution", "OBSERVATION_MODIFIER", 88, 98], ["infected", "OBSERVATION", 120, 128], ["infection", "OBSERVATION", 181, 190], ["infected", "OBSERVATION", 294, 302], ["infected", "OBSERVATION", 359, 367]]], ["The latter dependence, modeled through a Gamma distribution, is an attempt to describe the temporal variation of the infectiousness level of SARS-CoV-2.", [["SARS", "DISEASE", 141, 145], ["SARS-CoV", "SPECIES", 141, 149], ["The latter dependence", "PROBLEM", 0, 21], ["latter", "OBSERVATION_MODIFIER", 4, 10], ["dependence", "OBSERVATION_MODIFIER", 11, 21], ["Gamma distribution", "OBSERVATION", 41, 59]]], ["In particular, the incubation period (usually represented by the E state), is here implicitly taken into account by assuming an infectiousness level which does not immediately grow from zero.", [["an infectiousness level", "TEST", 125, 148]]], ["Finally, the infection rate depends on an intrinsic infectiousness level of the virus and on the type of network on which the contact occurs.", [["infection", "DISEASE", 13, 22], ["the infection rate", "PROBLEM", 9, 27], ["the virus", "PROBLEM", 76, 85], ["infection", "OBSERVATION", 13, 22]]], ["Although the notion of duration of contacts is not present, the infectiousness rate associated with contacts inside households is larger than for the other environments, to account for the typically longer duration of domestic interactions.", [["the infectiousness rate", "PROBLEM", 60, 83], ["larger", "OBSERVATION_MODIFIER", 130, 136]]], ["With the exception of the viral transmission process just described, all other possible transitions between individual epidemic states (e.g. transition from mild symptomatic infected state to the resistant state) are independent of the state of the other individuals.", [["the viral transmission process", "PROBLEM", 22, 52], ["individual epidemic states", "PROBLEM", 108, 134], ["mild symptomatic infected state", "PROBLEM", 157, 188], ["viral transmission", "OBSERVATION", 26, 44], ["mild", "OBSERVATION_MODIFIER", 157, 161], ["symptomatic", "OBSERVATION_MODIFIER", 162, 173], ["infected", "OBSERVATION", 174, 182]]], ["These events are characterized by a (discrete) waiting time, also distributed according to a Gamma distribution or, in case of dichotomous support, according to a shifted Bernoulli distribution.", [["dichotomous support", "TREATMENT", 127, 146], ["Bernoulli distribution", "OBSERVATION", 171, 193]]], ["The parameters of these distributions have been extracted from recent SARS-CoV-2 literature and are summarized in Tables 5-6-7 of Hinch et al. [21] .A. Brief description of the OpenABM modelThe model provides the possibility of intervention in order to slow down and, if possible, contain the epidemic outbreak.", [["intervention", "TREATMENT", 228, 240], ["the epidemic outbreak", "PROBLEM", 289, 310], ["epidemic", "OBSERVATION_MODIFIER", 293, 301]]], ["In particular, it is possible to introduce interventions of increasing severity, from case-based measures (e.g. quarantine for individuals which are positive to swab tests and their housemates) to mobility restrictions for some categories of individuals and lockdown scenarios.", [["increasing severity", "PROBLEM", 60, 79], ["individuals", "PROBLEM", 127, 138], ["swab tests", "TEST", 161, 171]]], ["In this respect, the OpenABM model is very appropriate for the implementation of contact tracing strategies.", [["contact tracing strategies", "TREATMENT", 81, 107]]], ["Finally, the OpenABM model also provides for the possibility of varying the adoption fraction of the contact tracing app within the population, possibly introducing different percentages of adoption in different age groups of individuals.B. Mean-Field Inference of RiskThe mean field inference is based on a prior epidemic model which is an agent-based SIR model.", [["mean", "OBSERVATION_MODIFIER", 273, 277], ["field", "OBSERVATION_MODIFIER", 278, 283]]], ["At each time, an individual i is in either one of the three states: Susceptible, Infected, Removed, x i (t) \u2208 {S, I, R} (where the \"Removed\" state means either dead, or recovered and having acquired immunity).B. Mean-Field Inference of RiskWhen going from time t to time t + 1, the following events can take place:B. Mean-Field Inference of Risk\u2022 If x i (t) = R: x i (t + 1) = R.B. Mean-Field Inference of Risk\u2022 If x i (t) = I: we call \u00b5 i the probability that an infected individual i recovers:B. Mean-Field Inference of Riskx i (t + 1) = I with probability 1 \u2212 \u00b5 i x i (t + 1) = R with probability \u00b5 iB.", [["Riskx", "TEST", 522, 527], ["probability", "TEST", 547, 558], ["Infected", "OBSERVATION", 81, 89], ["infected", "OBSERVATION", 464, 472], ["iB", "OBSERVATION", 602, 604]]], ["Mean-Field Inference of Risk\u2022 If x i (t) = S: One looks at all the individuals j which are infected and have been in contact with i at time t (in practice this means between day t and day t + 1).", [["Mean", "TEST", 0, 4], ["infected", "OBSERVATION", 91, 99]]], ["More precisely:B. Mean-Field Inference of RiskTo resume, the parameters of the model are:B. Mean-Field Inference of Risk\u2022 \u00b5 i : The probability of removal of the infectious patient i.B. Mean-Field Inference of Risk\u2022 \u03bb i\u2192j (t): The transmission probability given that there was a contact between an infected i and susceptible j at time t.", [["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["removal", "TREATMENT", 147, 154], ["Mean", "TEST", 186, 190], ["infectious", "OBSERVATION", 162, 172], ["infected", "OBSERVATION", 298, 306]]], ["These marginal probabilities are in general difficult to evaluate.", [["marginal", "OBSERVATION_MODIFIER", 6, 14], ["probabilities", "OBSERVATION", 15, 28]]], ["A straightforward strategy for this evaluation is to simulate a large number of instances of the propagation, and estimate P j S (t) as the fraction of instances where individual j is in state S at time t.", [["this evaluation", "TEST", 31, 46], ["large", "OBSERVATION_MODIFIER", 64, 69]]], ["However this requires a centralized system, and a large computing power.", [["a centralized system", "TREATMENT", 22, 42], ["large", "OBSERVATION_MODIFIER", 50, 55]]], ["Here, instead, we use some approximate techniques from statistical physics, that allow for a good estimate of P j S (t) through a fully distributed method, using only simple exchange of information at each contact.B. Mean-Field Inference of RiskThe Mean-Field (MF) method computes the marginal probabilities of (1) through an iterative process.", [["marginal", "OBSERVATION_MODIFIER", 285, 293]]], ["The probability of individual j receiving the infection from her contact k at time t depends on their contact transmission \u03bb k\u2192j (t) and on the joint probability of j being S and k being I at time t.", [["infection", "DISEASE", 46, 55], ["the infection", "PROBLEM", 42, 55], ["infection", "OBSERVATION", 46, 55], ["joint", "ANATOMY", 144, 149]]], ["The mean field approximation estimates this joint probability by the product P j S (t)P k I (t).", [["joint", "ANATOMY", 44, 49]]], ["Mean-Field Inference of RiskThe probability of being recovered isB.", [["isB", "PROTEIN", 63, 66], ["Mean", "TEST", 0, 4]]], ["Mean-Field Inference of Riskand the probability of being infected is obtained using the fact that P S + P R + P I = 1.", [["P S", "DNA", 98, 101], ["P R", "DNA", 104, 107], ["Mean", "TEST", 0, 4], ["P S", "TEST", 98, 101], ["infected", "OBSERVATION", 57, 65]]], ["In practice, considering that the probability of transmission is small, our MF algorithm is based on the following linearized form for P S (and we have checked that this linearization is fine in the regimes of epidemic propagation that we explore):B. Mean-Field Inference of RiskP j R (t + 1) = P j R (t) + \u00b5 j P j I (t), P j I (t + 1) = P j I (t) + P j S (t)B. Mean-Field Inference of RiskThe mean-field equations have an intuitive content which is easy to understand.", [["P S", "DNA", 135, 138], ["j S", "TEST", 352, 355], ["small", "OBSERVATION_MODIFIER", 65, 70], ["mean", "OBSERVATION_MODIFIER", 394, 398], ["intuitive content", "OBSERVATION", 423, 440]]], ["They basically reproduce in an agent-dependent model the equations used for the global monitoring of the proportions of S,I,R states in a population.", [["an agent-dependent model the equations", "TREATMENT", 28, 66]]], ["They can also be derived as a limiting case of the dynamical message passing equations from [10] , when the transmission probabilities are small.", [["small", "OBSERVATION_MODIFIER", 139, 144]]], ["Every individual j can estimate her probabilities P j S (t), P j I (t), P j R (t) every day, by updating the equations (7).", [["her probabilities", "TEST", 32, 49]]], ["For the update, individual j needs to receive, during the contact with k, the information on \u03bb k\u2192j (t) and the information from k about his estimates of P k S (t), P k I (t), P k R (t).", [["his estimates", "TEST", 136, 149]]], ["The value of \u03bb k\u2192j (t) is the standard contact-tracing information, which estimates the encounter duration within a certain distance, as used in all contact tracing applications that are being developed, for instance based on bluetooth signals between the phones of j and k.", [["The value", "TEST", 0, 9]]], ["On top of this, the phone of individual k should send the values of P k S (t) and P k I (t) to individual j during the contact, and reciprocally.", [["P k S", "TEST", 68, 73]]], ["The information is fully distributed, there is no need for a central system that stores the full information, and the data exchange can be encrypted.B. Mean-Field Inference of RiskWe suppose that, at time t obs an individual i is tested or presents illness-associated syndromes.", [["illness", "DISEASE", 249, 256], ["illness", "PROBLEM", 249, 256], ["associated syndromes", "PROBLEM", 257, 277], ["no need for", "UNCERTAINTY", 47, 58]]], ["In case of syndromes at time t obs the probability P i q (t obs ) is updated on the basis of external medical data, namely the probability to be infected among all people presenting the same set of syndromes.B. Mean-Field Inference of RiskA simple inference method that turns out to be quite efficient consists in adapting the mean-field equations (7) in order to take into account the results of tests and symptoms.", [["people", "ORGANISM", 164, 170], ["P", "DNA", 51, 52], ["people", "SPECIES", 164, 170], ["syndromes", "PROBLEM", 11, 20], ["external medical data", "TEST", 93, 114], ["syndromes", "PROBLEM", 198, 207], ["tests", "TEST", 397, 402], ["symptoms", "PROBLEM", 407, 415], ["infected", "OBSERVATION", 145, 153]]], ["The information about tests and syndroms must be propagated back in time and be used to update the risk levels of the contacts of person i in recent times.", [["person", "SPECIES", 130, 136], ["tests", "TEST", 22, 27], ["syndroms", "TREATMENT", 32, 40]]], ["We run the mean-field equations (7) starting at time t \u2212 t M F with the whole population S, and imposing the constraints due to the tests done in the interval [t \u2212 t M F , t] as follows.", [["the tests", "TEST", 128, 137]]], ["If j is tested at a time t obs in this interval, then:B. Mean-Field Inference of Riskif x j (t obs ) = I : P j I (t ) = 1 for t obs \u2212 \u03c4 \u2264 t \u2264 t obs (9) if x j (t obs ) = R : P j R (t ) = 1 for t \u2265 t obsB.", [["Mean", "TEST", 57, 61], ["Riskif", "TEST", 81, 87], ["t obs", "TEST", 126, 131], ["obs", "TEST", 144, 147], ["j", "TEST", 157, 158], ["obs", "TEST", 162, 165], ["t \u2265 t obsB", "PROBLEM", 193, 203], ["obsB", "ANATOMY", 199, 203]]], ["Mean-Field Inference of RiskOur inference procedure depends on two parameters: \u03c4 is the typical time between the infection and the testing consecutive to the apparition of syndroms, and t M F is the integration time of the mean-field procedure.C.1.", [["infection", "DISEASE", 113, 122], ["C", "GENE_OR_GENE_PRODUCT", 244, 245], ["Mean", "TEST", 0, 4], ["RiskOur inference procedure", "TREATMENT", 24, 51], ["the infection", "PROBLEM", 109, 122], ["the testing", "TEST", 127, 138], ["syndroms", "PROBLEM", 172, 180], ["the mean-field procedure", "TREATMENT", 219, 243], ["infection", "OBSERVATION", 113, 122]]], ["For reasons that will become clear in the following, we will always assume \u221e \u2208 X ij .", [["clear", "OBSERVATION", 29, 34], ["ij", "ANATOMY", 81, 83]]], ["As time advances, instantaneous contagion will happen with probability \u03bb at time s ij \u2208 X ij if i is infected and j is susceptible.", [["ij \u2208 X ij", "TREATMENT", 83, 92], ["ij", "ANATOMY", 83, 85], ["ij", "ANATOMY", 90, 92], ["infected", "OBSERVATION", 101, 109]]], ["We will assume \u03bb = \u03bbC.1.", [["C.1", "PROTEIN", 20, 23]]], ["Graphical model settingto possibly depend both on the specific (absolute) contact time s ij , on the direction of the contact and on the time t i of infection of individual i.", [["infection", "DISEASE", 149, 158], ["infection", "PROBLEM", 149, 158], ["infection", "OBSERVATION", 149, 158]]], ["Individual i can thus become infected in one instant in the set X i = \u222a j\u2208\u2202i X ij .", [["infected", "PROBLEM", 29, 37], ["infected", "OBSERVATION", 29, 37], ["ij", "ANATOMY", 79, 81]]], ["We will denote by t i \u2208 X i , r i \u2208 R respectively the times of infection and recovery of individual i, with t i = \u221e (resp. r i = \u221e) if the individual did not become infected (resp. recovered) within the time-frame.C.1.", [["infection", "DISEASE", 64, 73], ["C", "GENE_OR_GENE_PRODUCT", 215, 216], ["infection", "PROBLEM", 64, 73], ["infection", "OBSERVATION", 64, 73], ["infected", "OBSERVATION", 166, 174]]], ["Graphical model settingWe will assume the recovery delay r i \u2212 t i of node i to be distributed with a continuous distribution with pdf p R,i (r i \u2212 t i ).", [["node", "OBSERVATION", 70, 74]]], ["We will assume a set of factorized, site-dependent observations p O,i (O i |t i , r i ).", [["p O", "CHEMICAL", 64, 67]]], ["Model parameters will be hidden for the moment inside functions p R,i , \u03bb s,t ij , and p O,i and we will include them only later to avoid cluttering the notation.", [["ij", "ANATOMY", 78, 80]]], ["The standard SIR model can be obtained by setting p R,i (r i \u2212 t i ) = \u00b5e \u2212\u00b5(r i \u2212t i ) , \u03bb s,t ij \u2261 \u03bb.", [["\u03bb s", "TEST", 90, 93], ["ij", "ANATOMY", 96, 98]]], ["In this setup, the model is memory-less (Markov) on the state of infection variables x t i \u2208 {S, I, R}.", [["infection", "DISEASE", 65, 74], ["infection variables", "PROBLEM", 65, 84], ["memory", "OBSERVATION", 28, 34], ["infection", "OBSERVATION", 65, 74]]], ["In the following we will always assume that t i \u2208 X i and s ij , s ji \u2208 X ij .", [["ij", "ANATOMY", 60, 62], ["ij", "ANATOMY", 74, 76]]], ["Given the times of infection and recovery t i and r i , the transmission delay s ij has \"truncated\" generalized geometric distributionC.1.", [["infection", "DISEASE", 19, 28], ["infection", "PROBLEM", 19, 28], ["generalized geometric distributionC", "PROBLEM", 100, 135], ["infection", "OBSERVATION", 19, 28], ["ij", "ANATOMY", 81, 83], ["generalized", "OBSERVATION_MODIFIER", 100, 111], ["geometric distributionC", "OBSERVATION", 112, 135]]], ["Graphical model settingbecause i will be infectious in the open time interval (t i , r i ) and will possibly (i.e. if j is susceptible at the time) transmit the disease at some time s ij in that interval if he did not transmit it before.", [["infectious", "PROBLEM", 41, 51], ["the disease", "PROBLEM", 157, 168], ["ij", "TREATMENT", 184, 186], ["infectious", "OBSERVATION_MODIFIER", 41, 51], ["disease", "OBSERVATION", 161, 168], ["ij", "ANATOMY", 184, 186]]], ["If time r i arrives and he did not transmit the disease, the individual will recover and never transmit the disease through that link; then transmission time on that link will be nominally s ij = \u221e.", [["the disease", "PROBLEM", 44, 55], ["the disease", "PROBLEM", 104, 115], ["disease", "OBSERVATION", 48, 55]]], ["Special attention must be taken for auto-infections (otherwise, no infection can enter into the closed system).", [["auto-infections", "DISEASE", 36, 51], ["infection", "DISEASE", 67, 76], ["auto-infections", "PROBLEM", 36, 51], ["infection", "PROBLEM", 67, 76]]], ["By adding a contact with an additional extra always-infected virtual neighbor i t * to node i at time instant t \u2208 X i with probability p t (s i t * i = t) = \u03b3 t i (typically small),C.1.", [["C.1", "DNA", 181, 184], ["node", "ANATOMY", 87, 91]]], ["Graphical model settingWe can now write the joint pdf of discrete variables t, s and continuous variables r asC.1.", [["asC", "PROTEIN", 108, 111], ["joint", "ANATOMY", 44, 49], ["asC", "OBSERVATION", 108, 111]]], ["Graphical model settingso then as p (t, r, s|O) \u221d p (O|t, r) p (t, r, s), we getC.1.", [["p (t, r, s|O) \u221d p (O|t, r) p", "CHEMICAL", 34, 62], ["Graphical model settingso", "TEST", 0, 25], ["O|t", "TEST", 53, 56], ["we getC", "TEST", 74, 81]]], ["We will exploit this fact and write r i =r i + u i , wher\u00ea r i = max {r \u2208 X i : r < r i }.", [["this fact", "TEST", 16, 25]]], ["Integrating away the u i variables in (14) , we obtain an all-discrete model for variables t, s,r, with an identical expression to (14) but in which r i has been replaced byr i andC.1.", [["byr i andC", "GENE_OR_GENE_PRODUCT", 171, 181], ["andC", "PROTEIN", 177, 181]]], ["Graphical model settingdu.", [["model settingdu", "OBSERVATION", 10, 25]]], ["For simplicity of notation, we will drop the\u02c6symbols in the following.C.2.", [["C.2", "DNA", 70, 73]]], ["For example, pairs (t i , s ji ) , (t i , s ij ) , (t j , s ij ) , (t j , s ji ) share respectively factors with indices i, (ij) , j, (ji) , effectively forming a small cycle.", [["ij", "ANATOMY", 44, 46], ["ij", "ANATOMY", 60, 62], ["ij", "ANATOMY", 125, 127], ["small cycle", "OBSERVATION", 163, 174]]], ["A simple solution consists in regrouping factors as in (15) and considering (s ij , s ji ) as a single variable:C.2.", [["regrouping factors", "PROTEIN", 30, 48], ["C.2", "PROTEIN", 112, 115], ["A simple solution", "TREATMENT", 0, 17], ["regrouping factors", "PROBLEM", 30, 48], ["ij", "ANATOMY", 79, 81]]], ["Belief propagation equations1 A particularly interesting case is with \u03b3 0 i = \u03b3 \u2192 0 and \u03b3 t i = 0 for t > 0: in this case individuals can be self-infected only at time 0, representing a closed system with a single unknown seed at time t = 0. which results in a factor graph for (14) in which variables (s ij , s ji ) have degree two and live in the middle of the original edges, and vars t i , r i have degree 1, i.e. a topology that closely follows the one of the original contact network:C.2.", [["C.2", "PROTEIN", 490, 493], ["a closed system", "TREATMENT", 184, 199], ["a factor graph", "TEST", 259, 273], ["infected", "OBSERVATION", 146, 154], ["closed", "OBSERVATION", 186, 192], ["ij", "ANATOMY", 305, 307], ["middle", "ANATOMY_MODIFIER", 349, 355]]], ["Belief propagation equationsThe corresponding BP equations for \u03a8 i areC.2.", [["\u03a8 i areC", "GENE_OR_GENE_PRODUCT", 63, 71], ["areC", "PROTEIN", 67, 71], ["The corresponding BP equations", "TEST", 28, 58], ["propagation equations", "OBSERVATION", 7, 28]]], ["Belief propagation equationsand marginals for t i areC.2.", [["areC", "DNA", 50, 54]]], ["A more efficient computation of the equations can be achieved by defining:C.2.", [["C.2", "PROTEIN", 74, 77]]], ["Belief propagation equationsNote that products k\u2208\u2202iG k can be computed simultaneously for j \u2208 \u2202i in time O (|\u2202i|)C.2.", [["O (|\u2202i|)C.2", "CHEMICAL", 105, 116], ["C.2", "PROTEIN", 113, 116], ["propagation equations", "OBSERVATION", 7, 28]]], ["Belief propagation equations(either by computing it as the fraction G \u22121 j k\u2208\u2202i G k , or by first recursively computing =1 G k and |\u2202i| = G k for = 1, . . . , |\u2202i| and then = G k = \u22121 =1 G k |\u2202i| = +1 G k , a method that does not involve divisions and is thus numerically more stable).", [["G k", "GENE_OR_GENE_PRODUCT", 201, 204], ["the fraction G", "TEST", 55, 69], ["k", "TEST", 82, 83], ["k", "TEST", 125, 126], ["\u2202i", "TEST", 132, 134], ["k", "TEST", 140, 141], ["|\u2202i|", "TEST", 159, 163], ["k", "TEST", 177, 178], ["\u2212", "TEST", 181, 182], ["k", "TEST", 189, 190]]], ["The resulting implementation of the update of all messages in factor \u03a8 i has complexity O |X i | j\u2208\u2202i |X i | + |X ij | 2 .C.3.", [[".C.3", "DNA", 121, 125], ["j\u2208\u2202i", "TEST", 97, 101], ["ij", "TEST", 114, 116]]], ["Finite-window approximationIn the BP-based epidemic tracing scheme, exchanged messages between two individuals grow quadratically with the number of temporal contacts occurred between them.", [["BP", "PROTEIN", 34, 36], ["the BP", "TEST", 30, 36]]], ["For better accuracy, information about contacts and observations at the dropped times is included approximately as simple factorized priors applied at the start of the window.", [["simple factorized priors", "TREATMENT", 115, 139]]], ["This prior contains the posterior probability at the first non-dropped time computed only using contacts and observations at the dropped time (and the prior computed in the previous step).", [["the posterior probability", "PROBLEM", 20, 45], ["posterior", "ANATOMY_MODIFIER", 24, 33]]], ["All simulations have been performed using a 21 days time window.C.4.", [["C.4", "DNA", 64, 67]]], ["Algorithm ParametersFor the OpenABM model, we chose to use Gamma distributions for the recovery density p R.i = p R and a rescaled Gamma for the infection transmissivity \u03bb s ij ,t i ij = p I (s ij \u2212 t i ).", [["infection", "DISEASE", 145, 154], ["the OpenABM model", "TREATMENT", 24, 41], ["Gamma distributions", "TREATMENT", 59, 78], ["a rescaled Gamma", "TREATMENT", 120, 136], ["the infection transmissivity", "PROBLEM", 141, 169], ["infection", "OBSERVATION", 145, 154], ["ij", "ANATOMY", 174, 176], ["ij", "ANATOMY", 182, 184], ["ij", "ANATOMY", 194, 196]]], ["The five parameters were fitted from experimental data produced by the model (parameters could in principle be also learned or adjusted online during the process through an approximate maximum likelihood procedure [13] , but we leave this for future work).", [["experimental data", "TEST", 37, 54], ["an approximate maximum likelihood procedure", "TREATMENT", 170, 213]]], ["Note that the model used for inference with BP is still much simplified with respect to OpenABM itself, in particular having only three states (against 11 in OpenABM).", [["BP", "PROTEIN", 44, 46], ["OpenABM", "PROTEIN", 158, 165], ["BP", "TEST", 44, 46]]], ["The used values were Gamma(k = 10, \u00b5 = 0.57) for p R and Gamma(k=5.76, \u00b5 = 0.96), with a scale of 0.25 (multiplied by 2 for intra-household contacts as with MF inference) for \u03bb.", [["The used values", "TEST", 0, 15], ["Gamma", "TEST", 21, 26], ["k", "TEST", 27, 28], ["\u00b5", "TEST", 35, 36], ["Gamma", "TEST", 57, 62], ["k", "TEST", 63, 64], ["\u00b5", "TEST", 71, 72], ["a scale", "TEST", 87, 94], ["Gamma", "ANATOMY", 57, 62]]], ["The self-infection probability was chosen to be p seed = 1/N at time t = 0 (k/N where k is the number of patient zeros would bring slightly better results, but would use inaccessible information) and 0 for t > 0 except for the case with partial adoption, in which we allowed a small probability of self-infections at times t > 0 to avoid plain incompatibility between the inference model and observations due to undetected transmissions).", [["infection", "DISEASE", 9, 18], ["infections", "DISEASE", 303, 313], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["The self-infection probability", "PROBLEM", 0, 30], ["self-infections", "PROBLEM", 298, 313], ["undetected transmissions)", "PROBLEM", 412, 437], ["infection", "OBSERVATION", 9, 18]]], ["The parameter \u03b4 rank for the computation of the ranking was chosen to be 10 days.D. Additional ResultsIn this section, we present additional results to stress how the containment measures associated with the inference-based methods proposed in the main text, are effective in limiting the epidemics.", [["main text", "ANATOMY", 248, 257]]], ["We consider a realistic spreading dynamics given by the OpenABM model [21] and, unlike the setting illustrated in the main text, we study the case in which the restrictions are applied earlier in time (i.e. after a week from the beginning of the epidemics) and the size of the epidemics at the initial time is smaller (the number of patients zero here is 20), being also consistent with an earlier intervention scenario.", [["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 333, 341], ["the epidemics", "PROBLEM", 273, 286], ["an earlier intervention scenario", "TREATMENT", 387, 419], ["size", "OBSERVATION_MODIFIER", 265, 269], ["epidemics", "OBSERVATION", 277, 286], ["smaller", "OBSERVATION_MODIFIER", 310, 317], ["consistent with", "UNCERTAINTY", 371, 386]]], ["In Figure 5 , we display the behavior of the number of infected individuals as a function of time, similarly to Figure 2 of the main text.", [["infected", "OBSERVATION", 55, 63], ["main", "OBSERVATION_MODIFIER", 128, 132]]], ["Qualitatively, we retrieve the same behavior we have observed in Figure 2 : inference-based ranking allows for a more effective intervention resulting in a remarkable decrease of the number of infected individuals, and when the number of tests is sufficiently large, the epidemics are stopped in slightly more than two months.", [["a more effective intervention", "TREATMENT", 111, 140], ["infected individuals", "PROBLEM", 193, 213], ["tests", "TEST", 238, 243], ["the epidemics", "PROBLEM", 267, 280], ["remarkable", "OBSERVATION_MODIFIER", 156, 166], ["decrease", "OBSERVATION_MODIFIER", 167, 175], ["infected", "OBSERVATION", 193, 201], ["large", "OBSERVATION_MODIFIER", 260, 265]]], ["Quantitatively, we notice that to control the spreading a reduced number of daily medical tests are needed (about ten times less than those used for the results in Figure 2 ), suggesting that early intervention is equally effective with a more parsimonious usage of testing resources.", [["daily medical tests", "TEST", 76, 95], ["early intervention", "TREATMENT", 192, 210], ["testing resources", "TREATMENT", 266, 283]]], ["Figure 6 suggests how robust the containment measures are when the medical tests are Figure 6 : Effect of tests inaccuracy to the evolution of the controlled epidemics.", [["the medical tests", "TEST", 63, 80], ["tests inaccuracy", "PROBLEM", 106, 122], ["the controlled epidemics", "PROBLEM", 143, 167]]], ["We simulate the same intervention protocol as Figure 5 for 1000 daily observations (bottom panel).", [["the same intervention protocol", "TREATMENT", 12, 42], ["bottom panel", "TEST", 84, 96]]], ["We consider here the effects of an additional source of noise, that is a non negligible false negative rate (FNR) of the results of the medical tests, from 0.09 to 0.40.", [["FNR", "PROTEIN", 109, 112], ["the medical tests", "TEST", 132, 149]]], ["Figure 7 : Effect of a poor adoption fraction of the app to the number of infected individuals.", [["a poor adoption fraction", "PROBLEM", 21, 45], ["infected individuals", "PROBLEM", 74, 94], ["infected", "OBSERVATION", 74, 82]]], ["We simulate the same intervention protocol as Figure 5 for 1000 daily observations.", [["the same intervention protocol", "TREATMENT", 12, 42]]], ["We assume here that only a fraction of the population, from 90 % to 60%, uses the app for contact tracing.D. Additional Resultsinaccurate.", [["contact tracing", "TEST", 90, 105]]], ["We quantify their sensitivity through a false-negative rate (FNR) of the medical tests (similar results are discussed in the main text, see Figure 3 ).", [["the medical tests", "TEST", 69, 86]]], ["The setting is the same as in Figure 5 when 1000 medical tests are performed to the individuals who present the higher risk to be infected, according to RG, CT, MF, and BP.", [["medical tests", "TEST", 49, 62], ["CT", "TEST", 157, 159], ["MF", "TEST", 161, 163], ["BP", "TEST", 169, 171], ["infected", "OBSERVATION", 130, 138]]], ["These curves support the conclusion of the main text: inference-based methods successfully contain an epidemic in a realistic setting with non-zero FNR.", [["FNR", "GENE_OR_GENE_PRODUCT", 148, 151], ["FNR", "PROTEIN", 148, 151], ["non-zero FNR", "PROBLEM", 139, 151], ["epidemic", "OBSERVATION", 102, 110]]], ["Indeed, CT and MF are able to contain the epidemics up to FNR equal to 0.09 and 0.25, respectively.", [["FNR", "PROTEIN", 58, 61], ["CT", "TEST", 8, 10], ["the epidemics", "PROBLEM", 38, 51], ["FNR", "TEST", 58, 61]]], ["BP shows the most robust performance as it is able to stop the epidemics even for larger values of the FNR, up to 0.31.", [["BP", "PROTEIN", 0, 2], ["FNR", "PROTEIN", 103, 106], ["BP", "TEST", 0, 2], ["the FNR", "TEST", 99, 106]]], ["Finally, we show the average epidemic size as a function of the time in Figure 7 when only a fraction of the population uses the app for contact tracing and, therefore, only partial information on potentially infectious contacts is available to the risk assessment methods.", [["contact tracing", "TEST", 137, 152], ["the risk assessment", "TEST", 245, 264], ["average", "OBSERVATION_MODIFIER", 21, 28], ["epidemic", "OBSERVATION_MODIFIER", 29, 37], ["size", "OBSERVATION_MODIFIER", 38, 42]]], ["Up to an adoption fraction of 0.7, inference-based methods (MF and BP) allows for a significantly slowing down of the epidemic spreading compared to both the random and CT-based testing.", [["an adoption fraction", "TEST", 6, 26], ["BP", "TEST", 67, 69], ["a significantly slowing down", "PROBLEM", 82, 110], ["the epidemic spreading", "PROBLEM", 114, 136], ["CT-based testing", "TEST", 169, 185]]]], "2841462a4f0639168831b839a6c4dc1f3b082bdd": [["CorrespondenceIn Brief Thiele et al. show that importin-a3 is one of the major nuclear transporters of NF-kB in the mammalian lung.", [["nuclear", "ANATOMY", 79, 86], ["lung", "ANATOMY", 126, 130], ["importin-a3", "GENE_OR_GENE_PRODUCT", 47, 58], ["NF-kB", "GENE_OR_GENE_PRODUCT", 103, 108], ["lung", "ORGAN", 126, 130], ["importin-a3", "PROTEIN", 47, 58], ["NF-kB", "PROTEIN", 103, 108], ["mammalian", "ANATOMY_MODIFIER", 116, 125], ["lung", "ANATOMY", 126, 130]]], ["High-level TNF-a-inducing HPAIVs inhibit importin-a3 mRNA transcription by interfering with its promoter activity.", [["TNF", "GENE_OR_GENE_PRODUCT", 11, 14], ["HPAIVs", "GENE_OR_GENE_PRODUCT", 26, 32], ["importin-a3", "GENE_OR_GENE_PRODUCT", 41, 52], ["TNF", "PROTEIN", 11, 14], ["importin", "PROTEIN", 41, 49], ["a3 mRNA transcription", "TREATMENT", 50, 71]]], ["Thus, HPAIVs may evade antiviral immunity in the respiratory tract by generating a bottleneck in importin-a3 availability.", [["respiratory tract", "ANATOMY", 49, 66], ["HPAIVs", "CHEMICAL", 6, 12], ["HPAIVs", "GENE_OR_GENE_PRODUCT", 6, 12], ["respiratory tract", "ORGANISM_SUBDIVISION", 49, 66], ["importin-a3", "GENE_OR_GENE_PRODUCT", 97, 108], ["importin", "PROTEIN", 97, 105], ["a3", "PROTEIN", 106, 108], ["HPAIVs", "TREATMENT", 6, 12], ["antiviral immunity in the respiratory tract", "PROBLEM", 23, 66], ["antiviral immunity", "OBSERVATION", 23, 41], ["respiratory tract", "ANATOMY", 49, 66]]], ["INTRODUCTION Molecular trafficking of proteins between the cytoplasm and the nucleus is a fundamental process that is essential to maintain cellular homeostasis (G\u00f6 rlich and Mattaj, 1996; Imamoto et al., 1995) .", [["cytoplasm", "ANATOMY", 59, 68], ["nucleus", "ANATOMY", 77, 84], ["cellular", "ANATOMY", 140, 148], ["cytoplasm", "ORGANISM_SUBSTANCE", 59, 68], ["nucleus", "CELLULAR_COMPONENT", 77, 84], ["cellular", "CELL", 140, 148], ["a fundamental process", "PROBLEM", 88, 109], ["nucleus", "ANATOMY", 77, 84], ["fundamental process", "OBSERVATION", 90, 109], ["cellular homeostasis", "OBSERVATION", 140, 160]]], ["Disturbances in these highly sensitive regulatory processes may result in the disequilibrium of cellular and nuclear proteins and eventually cause diseases.", [["cellular", "ANATOMY", 96, 104], ["nuclear", "ANATOMY", 109, 116], ["cellular", "CELL", 96, 104], ["nuclear", "CELLULAR_COMPONENT", 109, 116], ["cellular and nuclear proteins", "PROTEIN", 96, 125], ["Disturbances in these highly sensitive regulatory processes", "PROBLEM", 0, 59], ["the disequilibrium of cellular and nuclear proteins", "PROBLEM", 74, 125], ["diseases", "PROBLEM", 147, 155]]], ["Importin-a proteins belong to the major nuclear transport factors in the cell shuttling various cargo proteins containing a nuclear localization signal (NLS) from the cytoplasm to the nucleus (Goldfarb et al., 2004) .", [["nuclear", "ANATOMY", 40, 47], ["cell", "ANATOMY", 73, 77], ["nuclear", "ANATOMY", 124, 131], ["cytoplasm", "ANATOMY", 167, 176], ["nucleus", "ANATOMY", 184, 191], ["Importin-a proteins", "GENE_OR_GENE_PRODUCT", 0, 19], ["cell", "CELL", 73, 77], ["nuclear", "CELLULAR_COMPONENT", 124, 131], ["NLS", "CELLULAR_COMPONENT", 153, 156], ["cytoplasm", "ORGANISM_SUBSTANCE", 167, 176], ["nucleus", "CELLULAR_COMPONENT", 184, 191], ["Importin", "PROTEIN", 0, 8], ["major nuclear transport factors", "PROTEIN", 34, 65], ["cargo proteins", "PROTEIN", 96, 110], ["nuclear localization signal", "PROTEIN", 124, 151], ["NLS", "PROTEIN", 153, 156], ["a nuclear localization signal", "TEST", 122, 151], ["cargo proteins", "OBSERVATION", 96, 110], ["nucleus", "ANATOMY", 184, 191]]], ["Importin-a proteins are acidophilic proteins that bind as adaptors to cargo proteins containing a basic stretch of mono-or bipartite NLS motifs.", [["Importin", "PROTEIN", 0, 8], ["acidophilic proteins", "PROTEIN", 24, 44], ["cargo proteins", "PROTEIN", 70, 84], ["mono-or bipartite NLS motifs", "PROTEIN", 115, 143], ["acidophilic proteins", "PROBLEM", 24, 44], ["cargo proteins", "PROBLEM", 70, 84], ["a basic stretch of mono", "TREATMENT", 96, 119], ["bipartite NLS motifs", "PROBLEM", 123, 143]]], ["This importin-a/cargo complex forms a trimeric complex with the receptor protein importin-b 1 , which finally translocates through the nuclear pore by the interaction of importin-b 1 with nucleoporins (Hu et al., 1996; Radu et al., 1995; Rexach and Blobel, 1995) .", [["nuclear pore", "ANATOMY", 135, 147], ["importin", "GENE_OR_GENE_PRODUCT", 5, 13], ["importin-b 1", "GENE_OR_GENE_PRODUCT", 81, 93], ["nuclear pore", "CELLULAR_COMPONENT", 135, 147], ["importin-b 1", "GENE_OR_GENE_PRODUCT", 170, 182], ["importin", "PROTEIN", 5, 13], ["cargo complex", "PROTEIN", 16, 29], ["trimeric complex", "PROTEIN", 38, 54], ["receptor protein importin-b 1", "PROTEIN", 64, 93], ["importin-b 1", "PROTEIN", 170, 182], ["nucleoporins", "PROTEIN", 188, 200], ["the receptor protein importin", "TREATMENT", 60, 89]]], ["In the nucleus, the guanosine triphosphate (GTP)-bound form of Ran binds to importin-b 1 and mediates the dissociation and release of the cargo protein into the nucleus (Lee et al., 2005; Matsuura and Stewart, 2005) .", [["nucleus", "ANATOMY", 7, 14], ["nucleus", "ANATOMY", 161, 168], ["guanosine triphosphate", "CHEMICAL", 20, 42], ["GTP", "CHEMICAL", 44, 47], ["guanosine triphosphate", "CHEMICAL", 20, 42], ["GTP", "CHEMICAL", 44, 47], ["nucleus", "CELLULAR_COMPONENT", 7, 14], ["guanosine triphosphate", "SIMPLE_CHEMICAL", 20, 42], ["GTP", "SIMPLE_CHEMICAL", 44, 47], ["Ran", "GENE_OR_GENE_PRODUCT", 63, 66], ["importin-b 1", "GENE_OR_GENE_PRODUCT", 76, 88], ["nucleus", "CELLULAR_COMPONENT", 161, 168], ["guanosine triphosphate (GTP)-bound form", "PROTEIN", 20, 59], ["Ran", "PROTEIN", 63, 66], ["importin-b 1", "PROTEIN", 76, 88], ["cargo protein", "PROTEIN", 138, 151], ["the guanosine triphosphate (GTP", "TREATMENT", 16, 47], ["the dissociation", "PROBLEM", 102, 118], ["nucleus", "ANATOMY", 7, 14], ["cargo protein", "OBSERVATION", 138, 151], ["nucleus", "ANATOMY", 161, 168]]], ["After successful nuclear import, importin-a binds to the recycling factor cellular apoptosis susceptibility protein (CAS) that, in conjunction with RanGTP, transports the complex back into the cytoplasm where importin-a is again available for the nuclear import of other cargo proteins (Kutay et al., 1997) .", [["nuclear", "ANATOMY", 17, 24], ["cellular", "ANATOMY", 74, 82], ["cytoplasm", "ANATOMY", 193, 202], ["nuclear", "ANATOMY", 247, 254], ["nuclear", "CELLULAR_COMPONENT", 17, 24], ["importin", "GENE_OR_GENE_PRODUCT", 33, 41], ["cellular apoptosis susceptibility protein", "GENE_OR_GENE_PRODUCT", 74, 115], ["CAS", "GENE_OR_GENE_PRODUCT", 117, 120], ["RanGTP", "GENE_OR_GENE_PRODUCT", 148, 154], ["cytoplasm", "ORGANISM_SUBSTANCE", 193, 202], ["importin", "GENE_OR_GENE_PRODUCT", 209, 217], ["nuclear", "CELLULAR_COMPONENT", 247, 254], ["importin", "PROTEIN", 33, 41], ["recycling factor cellular apoptosis susceptibility protein", "PROTEIN", 57, 115], ["CAS", "PROTEIN", 117, 120], ["RanGTP", "PROTEIN", 148, 154], ["importin", "PROTEIN", 209, 217], ["cargo proteins", "PROTEIN", 271, 285]]], ["Importina proteins are highly conserved throughout evolution (Goldfarb et al., 2004) .", [["Importina", "GENE_OR_GENE_PRODUCT", 0, 9], ["Importina proteins", "PROTEIN", 0, 18], ["Importina proteins", "PROBLEM", 0, 18]]], ["In eukaryotes, seven importin-a isoforms were described, whereas the budding yeast encodes one importina, and flies and nematodes encode for three importin-a isoforms.", [["importin", "GENE_OR_GENE_PRODUCT", 21, 29], ["budding yeast", "ORGANISM", 69, 82], ["importina", "GENE_OR_GENE_PRODUCT", 95, 104], ["importin", "GENE_OR_GENE_PRODUCT", 147, 155], ["importin", "PROTEIN", 21, 29], ["isoforms", "PROTEIN", 32, 40], ["importina", "PROTEIN", 95, 104], ["importin", "PROTEIN", 147, 155], ["isoforms", "PROTEIN", 158, 166], ["yeast", "SPECIES", 77, 82], ["yeast", "SPECIES", 77, 82]]], ["However, all of these organisms encode for only one importin-b 1 receptor protein.", [["importin-b 1 receptor", "GENE_OR_GENE_PRODUCT", 52, 73], ["importin-b 1 receptor protein", "PROTEIN", 52, 81]]], ["The specificity of importin-a isoforms to cargo proteins is determined by the complexity and the three-dimensional context (Friedrich et al., 2006; Goldfarb et al., 2004; Sankhala et al., 2017) .", [["importin", "GENE_OR_GENE_PRODUCT", 19, 27], ["importin", "PROTEIN", 19, 27], ["cargo proteins", "PROTEIN", 42, 56]]], ["Moreover, importin-a proteins play a key role in cellular differentiation by regulating the transport of transcription factors through lineage-specific expression profiles in cells (Yasuhara et al., 2007) .", [["cellular", "ANATOMY", 49, 57], ["cells", "ANATOMY", 175, 180], ["importin-a proteins", "GENE_OR_GENE_PRODUCT", 10, 29], ["cellular", "CELL", 49, 57], ["cells", "CELL", 175, 180], ["importin", "PROTEIN", 10, 18], ["transcription factors", "PROTEIN", 105, 126]]], ["However, little is known about the expression profiles of importin-a isoforms in organs that could give important insights into molecular mechanisms in health and disease.", [["organs", "ANATOMY", 81, 87], ["importin-a isoforms", "GENE_OR_GENE_PRODUCT", 58, 77], ["organs", "ORGAN", 81, 87], ["importin", "PROTEIN", 58, 66]]], ["There is accumulating evidence that under cellular stress, such as oxidative stress, heat shock, or ultraviolet irradiation, importin-a proteins may accumulate in the nucleus and disrupt cellular homeostasis (Furuta et al., 2004; Kodiha et al., 2004; Yasuda et al., 2012) .", [["cellular", "ANATOMY", 42, 50], ["nucleus", "ANATOMY", 167, 174], ["cellular", "ANATOMY", 187, 195], ["shock", "DISEASE", 90, 95], ["cellular", "CELL", 42, 50], ["importin-a proteins", "GENE_OR_GENE_PRODUCT", 125, 144], ["nucleus", "CELLULAR_COMPONENT", 167, 174], ["cellular", "CELL", 187, 195], ["importin", "PROTEIN", 125, 133], ["under cellular stress", "PROBLEM", 36, 57], ["oxidative stress", "PROBLEM", 67, 83], ["heat shock", "PROBLEM", 85, 95], ["ultraviolet irradiation", "TREATMENT", 100, 123], ["a proteins", "PROBLEM", 134, 144], ["cellular stress", "OBSERVATION", 42, 57], ["nucleus", "ANATOMY", 167, 174], ["cellular homeostasis", "OBSERVATION", 187, 207]]], ["In the last decade, a growing amount of evidence suggests that importin-a proteins are utilized by various viruses (e.g., influenza, Ebola, dengue, hepatitis C, and coronaviruses) to circumvent host defense mechanisms (Basler and Amarasinghe, 2009; Canton et al., 2018; Fraser et al., 2014; Frieman et al., 2007; Gabriel et al., 2011; Hudjetz and Gabriel, 2012; Kopecky-Bromberg et al., 2007; Neufeldt et al., 2013; Pryor et al., 2007) .", [["influenza, Ebola, dengue, hepatitis C, and coronaviruses", "DISEASE", 122, 178], ["importin-a proteins", "GENE_OR_GENE_PRODUCT", 63, 82], ["Ebola", "ORGANISM", 133, 138], ["hepatitis C", "ORGANISM", 148, 159], ["coronaviruses", "ORGANISM", 165, 178], ["importin", "PROTEIN", 63, 71], ["a proteins", "PROBLEM", 72, 82], ["various viruses", "PROBLEM", 99, 114], ["influenza", "PROBLEM", 122, 131], ["Ebola", "PROBLEM", 133, 138], ["dengue", "PROBLEM", 140, 146], ["hepatitis C", "PROBLEM", 148, 159], ["coronaviruses", "PROBLEM", 165, 178], ["evidence suggests", "UNCERTAINTY", 40, 57], ["viruses", "OBSERVATION", 107, 114]]], ["Little evidence is available on their mode of action in specific organs under inflammatory conditions such as virus infections.", [["organs", "ANATOMY", 65, 71], ["infections", "DISEASE", 116, 126], ["organs", "ORGAN", 65, 71], ["inflammatory conditions", "PROBLEM", 78, 101], ["virus infections", "PROBLEM", 110, 126], ["inflammatory", "OBSERVATION", 78, 90]]], ["In this study, we identified the anatomic expression profile of importin-a isoforms in the mammalian lung and studied their transcriptional regulation and impact on influenza-virusinduced pneumonia using cell culture models, genome-wide transcription analyses, and transgenic mouse models.Importin-a3 Is the Most Abundantly Expressed Importina Isoform in the Mammalian Respiratory TractIn order to analyze the expression pattern of major importin-a isoforms throughout the mammalian respiratory tract (RT), we anatomically dissected the human and murine RT into an upper part defined by respiratory cells of the nasal concha (URT) and a lower part defined by bronchi and alveoli (LRT).", [["lung", "ANATOMY", 101, 105], ["cell culture", "ANATOMY", 204, 216], ["respiratory tract", "ANATOMY", 483, 500], ["respiratory cells", "ANATOMY", 587, 604], ["nasal concha", "ANATOMY", 612, 624], ["URT", "ANATOMY", 626, 629], ["bronchi", "ANATOMY", 659, 666], ["alveoli", "ANATOMY", 671, 678], ["pneumonia", "DISEASE", 188, 197], ["importin-a", "GENE_OR_GENE_PRODUCT", 64, 74], ["lung", "ORGAN", 101, 105], ["cell culture", "CELL", 204, 216], ["mouse", "ORGANISM", 276, 281], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 289, 300], ["Importina Isoform", "GENE_OR_GENE_PRODUCT", 334, 351], ["importin", "GENE_OR_GENE_PRODUCT", 438, 446], ["mammalian", "ORGANISM", 473, 482], ["respiratory tract", "ORGAN", 483, 500], ["human", "ORGANISM", 537, 542], ["murine", "ORGANISM", 547, 553], ["respiratory cells", "CELL", 587, 604], ["nasal concha", "MULTI-TISSUE_STRUCTURE", 612, 624], ["bronchi", "MULTI-TISSUE_STRUCTURE", 659, 666], ["alveoli", "MULTI-TISSUE_STRUCTURE", 671, 678], ["importin", "PROTEIN", 64, 72], ["Importin", "PROTEIN", 289, 297], ["Most Abundantly Expressed Importina Isoform", "PROTEIN", 308, 351], ["importin", "PROTEIN", 438, 446], ["respiratory cells", "CELL_TYPE", 587, 604], ["mouse", "SPECIES", 276, 281], ["human", "SPECIES", 537, 542], ["murine", "SPECIES", 547, 553], ["mouse", "SPECIES", 276, 281], ["human", "SPECIES", 537, 542], ["this study", "TEST", 3, 13], ["influenza", "PROBLEM", 165, 174], ["virusinduced pneumonia", "PROBLEM", 175, 197], ["cell culture models", "TEST", 204, 223], ["wide transcription analyses", "TEST", 232, 259], ["lung", "ANATOMY", 101, 105], ["pneumonia", "OBSERVATION", 188, 197], ["Respiratory TractIn", "OBSERVATION", 369, 388], ["respiratory tract", "ANATOMY", 483, 500], ["upper", "ANATOMY_MODIFIER", 565, 570], ["respiratory cells", "OBSERVATION", 587, 604], ["nasal concha", "ANATOMY", 612, 624], ["URT", "ANATOMY", 626, 629], ["lower", "ANATOMY_MODIFIER", 637, 642], ["bronchi", "ANATOMY", 659, 666], ["alveoli", "ANATOMY_MODIFIER", 671, 678]]], ["Importin-a1, -a3, and -a5/7 isoforms (Kpna2, Kpna4, and Kpna1/6, respectively) were abundantly expressed in epithelial cells, glands, and macrophages of the human ( Figure 1A ) as well as the murine URT and LRT ( Figure 1B ).", [["epithelial cells", "ANATOMY", 108, 124], ["glands", "ANATOMY", 126, 132], ["macrophages", "ANATOMY", 138, 149], ["Importin-a1", "GENE_OR_GENE_PRODUCT", 0, 11], ["-a3", "GENE_OR_GENE_PRODUCT", 13, 16], ["a5/7", "GENE_OR_GENE_PRODUCT", 23, 27], ["Kpna2", "GENE_OR_GENE_PRODUCT", 38, 43], ["Kpna4", "GENE_OR_GENE_PRODUCT", 45, 50], ["Kpna1/6", "GENE_OR_GENE_PRODUCT", 56, 63], ["epithelial cells", "CELL", 108, 124], ["glands", "ORGAN", 126, 132], ["macrophages", "CELL", 138, 149], ["human", "ORGANISM", 157, 162], ["murine", "ORGANISM", 192, 198], ["URT", "CANCER", 199, 202], ["Importin", "PROTEIN", 0, 8], ["a1", "PROTEIN", 9, 11], ["a3", "PROTEIN", 14, 16], ["a5/7 isoforms", "PROTEIN", 23, 36], ["Kpna2", "PROTEIN", 38, 43], ["Kpna4", "PROTEIN", 45, 50], ["Kpna1", "PROTEIN", 56, 61], ["6", "PROTEIN", 62, 63], ["epithelial cells", "CELL_TYPE", 108, 124], ["macrophages", "CELL_TYPE", 138, 149], ["murine URT", "PROTEIN", 192, 202], ["human", "SPECIES", 157, 162], ["murine", "SPECIES", 192, 198], ["human", "SPECIES", 157, 162], ["Importin", "TEST", 0, 8], ["Kpna2", "TEST", 38, 43], ["Kpna4", "TEST", 45, 50], ["Kpna1", "TEST", 56, 61], ["the murine URT", "TEST", 188, 202], ["epithelial cells", "OBSERVATION", 108, 124], ["glands", "ANATOMY", 126, 132]]], ["We then measured the relative mRNA expression levels of importin-a isoforms along the mammalian RT.", [["importin", "GENE_OR_GENE_PRODUCT", 56, 64], ["importin", "PROTEIN", 56, 64], ["the mammalian RT", "TREATMENT", 82, 98]]], ["In the human URT and LRT, importin-a3 was by far the most abundantly expressed isoform, with 4-5 times increased mRNA levels compared to importin-a1.", [["human", "ORGANISM", 7, 12], ["URT", "CANCER", 13, 16], ["importin-a3", "GENE_OR_GENE_PRODUCT", 26, 37], ["importin-a1", "GENE_OR_GENE_PRODUCT", 137, 148], ["human URT", "PROTEIN", 7, 16], ["LRT", "PROTEIN", 21, 24], ["importin", "PROTEIN", 26, 34], ["a3", "PROTEIN", 35, 37], ["importin-a1", "PROTEIN", 137, 148], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["increased mRNA levels", "PROBLEM", 103, 124], ["human URT", "ANATOMY", 7, 16]]], ["Average expression levels of other isoforms were similar to those of importin-a1, except for importin-a7, which was the second-most abundant isoform (Figure 1C) .", [["importin-a1", "GENE_OR_GENE_PRODUCT", 69, 80], ["importin-a7", "GENE_OR_GENE_PRODUCT", 93, 104], ["importin-a1", "PROTEIN", 69, 80], ["importin", "PROTEIN", 93, 101], ["a7", "PROTEIN", 102, 104], ["Figure 1C", "PROTEIN", 150, 159], ["Average expression levels", "TEST", 0, 25]]], ["Similarly, importin-a3 was also the highest-expressed isoform, followed by importin-a7 in the murine URT and LRT.", [["importin-a3", "GENE_OR_GENE_PRODUCT", 11, 22], ["importin-a7", "GENE_OR_GENE_PRODUCT", 75, 86], ["murine", "ORGANISM", 94, 100], ["URT", "CANCER", 101, 104], ["importin", "PROTEIN", 11, 19], ["a3", "PROTEIN", 20, 22], ["importin", "PROTEIN", 75, 83], ["a7", "PROTEIN", 84, 86], ["murine URT", "PROTEIN", 94, 104], ["LRT", "PROTEIN", 109, 112], ["murine", "SPECIES", 94, 100]]], ["Laser-based microdissection of epithelial cells was used to ensure homogeneous cell populations ( Figure 1D ).", [["epithelial cells", "ANATOMY", 31, 47], ["cell", "ANATOMY", 79, 83], ["epithelial cells", "CELL", 31, 47], ["cell populations", "CELL", 79, 95], ["epithelial cells", "CELL_TYPE", 31, 47], ["Laser-based microdissection of", "TREATMENT", 0, 30], ["epithelial cells", "PROBLEM", 31, 47], ["microdissection", "OBSERVATION", 12, 27], ["epithelial cells", "OBSERVATION", 31, 47], ["homogeneous", "OBSERVATION_MODIFIER", 67, 78], ["cell populations", "OBSERVATION", 79, 95]]], ["We further confirmed the exclusive abundance of importin-a3 in the murine lung, followed by importin-a7 as the second-most abundant isoform also on the protein level, using whole-organ homogenates (Figures 1E and 1F) .", [["lung", "ANATOMY", 74, 78], ["organ homogenates", "ANATOMY", 179, 196], ["importin-a3", "GENE_OR_GENE_PRODUCT", 48, 59], ["murine", "ORGANISM", 67, 73], ["lung", "ORGAN", 74, 78], ["importin-a7", "GENE_OR_GENE_PRODUCT", 92, 103], ["importin-a3", "PROTEIN", 48, 59], ["importin", "PROTEIN", 92, 100], ["a7", "PROTEIN", 101, 103], ["murine", "SPECIES", 67, 73], ["the protein level", "TEST", 148, 165], ["lung", "ANATOMY", 74, 78]]], ["Notably, in immortalized cells (Figures S1A-S1D) and unlike in primary cells, importin-a1 is the most abundant isoform and is therefore used as a prognostic cancer marker (Christiansen and Dyrskj\u00f8t, 2013; Dahl et al., 2006; Kau et al., 2004) .", [["cells", "ANATOMY", 25, 30], ["primary cells", "ANATOMY", 63, 76], ["cancer", "ANATOMY", 157, 163], ["cancer", "DISEASE", 157, 163], ["cells", "CELL", 25, 30], ["Figures S1A-S1D", "GENE_OR_GENE_PRODUCT", 32, 47], ["cells", "CELL", 71, 76], ["importin-a1", "GENE_OR_GENE_PRODUCT", 78, 89], ["cancer", "CANCER", 157, 163], ["immortalized cells", "CELL_LINE", 12, 30], ["S1A", "PROTEIN", 40, 43], ["S1D", "PROTEIN", 44, 47], ["primary cells", "CELL_TYPE", 63, 76], ["importin-a1", "PROTEIN", 78, 89], ["immortalized cells", "OBSERVATION", 12, 30]]], ["Thus, it is particularly important to investigate the role of importin-a isoforms either in primary cells or in an in vivo animal model.", [["primary cells", "ANATOMY", 92, 105], ["importin", "GENE_OR_GENE_PRODUCT", 62, 70], ["cells", "CELL", 100, 105], ["importin", "PROTEIN", 62, 70], ["primary cells", "CELL_TYPE", 92, 105]]], ["We then determined the expression of importin-a isoforms in various murine organs on the mRNA and protein levels and confirmed that the lung ( Figure S1E ) is unique in exhib-iting exclusively high importin-a3 levels, compared to other solid organs (Figures S1F-S1K).", [["organs", "ANATOMY", 75, 81], ["lung", "ANATOMY", 136, 140], ["solid organs", "ANATOMY", 236, 248], ["importin-a", "GENE_OR_GENE_PRODUCT", 37, 47], ["murine", "ORGANISM", 68, 74], ["organs", "ORGAN", 75, 81], ["lung", "ORGAN", 136, 140], ["S1E", "GENE_OR_GENE_PRODUCT", 150, 153], ["importin-a3", "GENE_OR_GENE_PRODUCT", 198, 209], ["organs", "ORGAN", 242, 248], ["S1F-S1K", "GENE_OR_GENE_PRODUCT", 258, 265], ["importin", "PROTEIN", 37, 45], ["importin", "PROTEIN", 198, 206], ["a3", "PROTEIN", 207, 209], ["murine", "SPECIES", 68, 74], ["the mRNA and protein levels", "TEST", 85, 112], ["lung", "ANATOMY", 136, 140]]], ["Moreover, comparable distribution and expression levels of importin-a isoforms within the human and murine RT suggest that the mouse model may be considered adequate to study the impact and mode-of-action of these cellular factors in health and disease.", [["cellular", "ANATOMY", 214, 222], ["importin-a isoforms", "GENE_OR_GENE_PRODUCT", 59, 78], ["human", "ORGANISM", 90, 95], ["murine", "ORGANISM", 100, 106], ["RT", "ORGANISM", 107, 109], ["mouse", "ORGANISM", 127, 132], ["cellular", "CELL", 214, 222], ["importin", "PROTEIN", 59, 67], ["cellular factors", "PROTEIN", 214, 230], ["human", "SPECIES", 90, 95], ["murine", "SPECIES", 100, 106], ["mouse", "SPECIES", 127, 132], ["human", "SPECIES", 90, 95], ["mouse", "SPECIES", 127, 132], ["these cellular factors", "PROBLEM", 208, 230], ["disease", "PROBLEM", 245, 252], ["cellular factors", "OBSERVATION", 214, 230]]], ["Next, we directly compared relative importin-a amounts in laser-microdissected epithelial samples of the URT versus the LRT (Figures 1G-1K ).", [["epithelial samples", "ANATOMY", 79, 97], ["URT", "ANATOMY", 105, 108], ["importin", "GENE_OR_GENE_PRODUCT", 36, 44], ["epithelial samples", "TISSUE", 79, 97], ["importin", "PROTEIN", 36, 44], ["the LRT", "TEST", 116, 123], ["Figures", "TEST", 125, 132], ["epithelial", "ANATOMY_MODIFIER", 79, 89], ["URT", "ANATOMY", 105, 108]]], ["For all importin-a isoforms, mRNA levels were highest in the alveolar tissue (LRT (A), up to 6 times) followed by epithelial cells of the bronchi and bronchioles (LRT [bronchiolar epithelium, BE]).", [["alveolar tissue", "ANATOMY", 61, 76], ["epithelial cells", "ANATOMY", 114, 130], ["bronchi", "ANATOMY", 138, 145], ["bronchioles", "ANATOMY", 150, 161], ["LRT [bronchiolar epithelium", "ANATOMY", 163, 190], ["BE", "ANATOMY", 192, 194], ["importin-a isoforms", "GENE_OR_GENE_PRODUCT", 8, 27], ["alveolar tissue", "TISSUE", 61, 76], ["epithelial cells", "CELL", 114, 130], ["bronchi", "MULTI-TISSUE_STRUCTURE", 138, 145], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 150, 161], ["bronchiolar epithelium", "TISSUE", 168, 190], ["importin", "PROTEIN", 8, 16], ["epithelial cells", "CELL_TYPE", 114, 130], ["mRNA levels", "TEST", 29, 40], ["highest", "OBSERVATION_MODIFIER", 46, 53], ["alveolar tissue", "ANATOMY", 61, 76], ["epithelial cells", "OBSERVATION", 114, 130], ["bronchi", "ANATOMY", 138, 145], ["bronchioles", "ANATOMY", 150, 161], ["bronchiolar epithelium", "ANATOMY", 168, 190]]], ["The lowest mRNA levels were detected in epithelial cells of the nasal concha (URT).", [["epithelial cells", "ANATOMY", 40, 56], ["nasal concha", "ANATOMY", 64, 76], ["URT", "ANATOMY", 78, 81], ["epithelial cells", "CELL", 40, 56], ["nasal concha", "MULTI-TISSUE_STRUCTURE", 64, 76], ["epithelial cells", "CELL_TYPE", 40, 56], ["The lowest mRNA levels", "TEST", 0, 22], ["epithelial cells", "OBSERVATION", 40, 56], ["nasal concha", "ANATOMY", 64, 76], ["URT", "ANATOMY", 78, 81]]], ["Thus, importin-a isoforms are expressed as a gradient in the RT with gradually increasing mRNA levels from the URT toward the LRT ( Figure 1L ).", [["importin-a isoforms", "GENE_OR_GENE_PRODUCT", 6, 25], ["importin", "PROTEIN", 6, 14], ["LRT", "DNA", 126, 129], ["a gradient in the RT", "PROBLEM", 43, 63], ["gradually increasing mRNA levels", "PROBLEM", 69, 101]]], ["However, importin-a3 is the most abundantly expressed importin-a isoform in the mammalian RT, unlike in other solid organs.Importin-a3 Is the Most Abundantly Expressed Importina Isoform in the Mammalian Respiratory TractImportin-a3 Mediates Nuclear Translocation of TNFa-Activated NF-kB NF-kB subunits (p50, p65) are translocated into the nucleus in an importin-a-mediated manner.", [["solid organs", "ANATOMY", 110, 122], ["nucleus", "ANATOMY", 339, 346], ["importin-a3", "GENE_OR_GENE_PRODUCT", 9, 20], ["importin", "GENE_OR_GENE_PRODUCT", 54, 62], ["solid organs", "MULTI-TISSUE_STRUCTURE", 110, 122], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 123, 134], ["Importina Isoform", "GENE_OR_GENE_PRODUCT", 168, 185], ["TractImportin-a3", "GENE_OR_GENE_PRODUCT", 215, 231], ["TNFa", "GENE_OR_GENE_PRODUCT", 266, 270], ["NF-kB NF-kB", "GENE_OR_GENE_PRODUCT", 281, 292], ["p50", "GENE_OR_GENE_PRODUCT", 303, 306], ["p65", "GENE_OR_GENE_PRODUCT", 308, 311], ["nucleus", "CELLULAR_COMPONENT", 339, 346], ["importin", "GENE_OR_GENE_PRODUCT", 353, 361], ["a-", "GENE_OR_GENE_PRODUCT", 362, 364], ["importin", "PROTEIN", 9, 17], ["a3", "PROTEIN", 18, 20], ["importin", "PROTEIN", 54, 62], ["Importin", "PROTEIN", 123, 131], ["Most Abundantly Expressed Importina Isoform", "PROTEIN", 142, 185], ["Mammalian Respiratory TractImportin-a3", "PROTEIN", 193, 231], ["TNFa", "PROTEIN", 266, 270], ["Activated NF-kB NF-kB subunits", "PROTEIN", 271, 301], ["p50", "PROTEIN", 303, 306], ["p65", "PROTEIN", 308, 311], ["importin", "PROTEIN", 353, 361], ["the mammalian RT", "TREATMENT", 76, 92], ["TNFa", "TEST", 266, 270], ["Activated NF", "TREATMENT", 271, 283], ["nucleus", "ANATOMY", 339, 346]]], ["Herein, particularly importin-a3 and its close relative, importin-a4, were shown to act as one of the main isoforms that imports tumor necrosis factor alpha (TNF-a)-activated p50/p65 heterodimers into the nucleus via direct interaction (Fagerlund et al., 2005) .", [["nucleus", "ANATOMY", 205, 212], ["tumor", "DISEASE", 129, 134], ["importin-a3", "GENE_OR_GENE_PRODUCT", 21, 32], ["importin-a4", "GENE_OR_GENE_PRODUCT", 57, 68], ["tumor necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 129, 156], ["TNF-a", "GENE_OR_GENE_PRODUCT", 158, 163], ["p50", "GENE_OR_GENE_PRODUCT", 175, 178], ["p65", "GENE_OR_GENE_PRODUCT", 179, 182], ["nucleus", "CELLULAR_COMPONENT", 205, 212], ["importin", "PROTEIN", 21, 29], ["a3", "PROTEIN", 30, 32], ["importin", "PROTEIN", 57, 65], ["a4", "PROTEIN", 66, 68], ["tumor necrosis factor alpha", "PROTEIN", 129, 156], ["TNF", "PROTEIN", 158, 161], ["p50", "PROTEIN", 175, 178], ["p65 heterodimers", "PROTEIN", 179, 195], ["tumor necrosis factor alpha", "PROBLEM", 129, 156], ["TNF", "TEST", 158, 161], ["activated p50/p65 heterodimers", "TREATMENT", 165, 195], ["tumor", "OBSERVATION_MODIFIER", 129, 134], ["necrosis", "OBSERVATION", 135, 143], ["nucleus", "ANATOMY", 205, 212]]], ["Since the mammalian lung most abundantly expresses the importin-a3 isoform, we continued to dissect the physical and functional interaction between importin-a3 and NF-kB.", [["lung", "ANATOMY", 20, 24], ["lung", "ORGAN", 20, 24], ["importin-a3", "GENE_OR_GENE_PRODUCT", 55, 66], ["importin-a3", "GENE_OR_GENE_PRODUCT", 148, 159], ["NF-kB.", "GENE_OR_GENE_PRODUCT", 164, 170], ["importin-a3 isoform", "PROTEIN", 55, 74], ["importin", "PROTEIN", 148, 156], ["a3", "PROTEIN", 157, 159], ["NF", "PROTEIN", 164, 166], ["lung", "ANATOMY", 20, 24]]], ["We could confirm that purified human importin-a3 protein directly interacts with NF-kB p50 and p65 subunits as well as with its precursor p105 protein upon activation with TNF-a unlike importin-a1 that was used as a negative control (Figures 2A and 2B) .", [["human", "ORGANISM", 31, 36], ["importin-a3", "GENE_OR_GENE_PRODUCT", 37, 48], ["NF-kB p50", "GENE_OR_GENE_PRODUCT", 81, 90], ["p65", "GENE_OR_GENE_PRODUCT", 95, 98], ["p105", "GENE_OR_GENE_PRODUCT", 138, 142], ["TNF", "GENE_OR_GENE_PRODUCT", 172, 175], ["importin-a1", "GENE_OR_GENE_PRODUCT", 185, 196], ["purified human importin-a3 protein", "PROTEIN", 22, 56], ["NF-kB p50", "PROTEIN", 81, 90], ["p65 subunits", "PROTEIN", 95, 107], ["p105 protein", "PROTEIN", 138, 150], ["TNF", "PROTEIN", 172, 175], ["importin-a1", "PROTEIN", 185, 196], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["purified human importin", "TREATMENT", 22, 45], ["NF-kB p50", "TREATMENT", 81, 90], ["p65 subunits", "TREATMENT", 95, 107], ["TNF", "TREATMENT", 172, 175]]], ["Consistently, treatment of murine fibroblasts with TNF-a most significantly increased NF-kB levels in nuclear cell fractions along with importin-a3 ( Figure 2C ).", [["fibroblasts", "ANATOMY", 34, 45], ["nuclear cell fractions", "ANATOMY", 102, 124], ["murine", "ORGANISM", 27, 33], ["fibroblasts", "CELL", 34, 45], ["TNF", "GENE_OR_GENE_PRODUCT", 51, 54], ["NF-kB", "GENE_OR_GENE_PRODUCT", 86, 91], ["nuclear cell", "CELL", 102, 114], ["importin-a3", "GENE_OR_GENE_PRODUCT", 136, 147], ["Figure 2C", "GENE_OR_GENE_PRODUCT", 150, 159], ["murine fibroblasts", "CELL_TYPE", 27, 45], ["TNF", "PROTEIN", 51, 54], ["NF-kB", "PROTEIN", 86, 91], ["importin", "PROTEIN", 136, 144], ["a3", "PROTEIN", 145, 147], ["Figure 2C", "PROTEIN", 150, 159], ["murine", "SPECIES", 27, 33], ["murine fibroblasts", "PROBLEM", 27, 45], ["TNF", "TEST", 51, 54], ["a most significantly increased NF", "PROBLEM", 55, 88], ["kB levels", "TEST", 89, 98], ["murine fibroblasts", "OBSERVATION", 27, 45], ["nuclear cell fractions", "OBSERVATION", 102, 124]]], ["In order to confirm that importin-a3 is required for the nuclear import of NF-kB, we generated murine embryo fibroblasts (MEFs) with a deleted importin-a3 gene (a3 \u00c0/\u00c0 ).", [["nuclear", "ANATOMY", 57, 64], ["embryo fibroblasts", "ANATOMY", 102, 120], ["MEFs", "ANATOMY", 122, 126], ["importin-a3", "GENE_OR_GENE_PRODUCT", 25, 36], ["nuclear", "CELLULAR_COMPONENT", 57, 64], ["NF-kB", "GENE_OR_GENE_PRODUCT", 75, 80], ["murine", "ORGANISM", 95, 101], ["embryo fibroblasts", "CELL", 102, 120], ["MEFs", "CELL", 122, 126], ["importin-a3", "GENE_OR_GENE_PRODUCT", 143, 154], ["importin-a3", "PROTEIN", 25, 36], ["NF-kB", "PROTEIN", 75, 80], ["murine embryo fibroblasts", "CELL_TYPE", 95, 120], ["MEFs", "CELL_TYPE", 122, 126], ["importin-a3 gene", "DNA", 143, 159], ["a3 \u00c0", "DNA", 161, 165], ["\u00c0", "DNA", 166, 167], ["murine", "SPECIES", 95, 101], ["murine embryo fibroblasts (MEFs", "TREATMENT", 95, 126]]], ["Nuclear fractionation analysis in TNF-a-treated a3 \u00c0/\u00c0 MEFs showed significantly reduced nuclear translocation of the NF-kB subunit p65 compared to wild-type (WT) control (a3 +/+ ) MEFs ( Figure 2D ).", [["MEFs", "ANATOMY", 55, 59], ["nuclear", "ANATOMY", 89, 96], ["a3 +/+ ) MEFs", "ANATOMY", 172, 185], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["TNF-a-", "GENE_OR_GENE_PRODUCT", 34, 40], ["MEFs", "CELL", 55, 59], ["nuclear", "CELLULAR_COMPONENT", 89, 96], ["NF-kB", "GENE_OR_GENE_PRODUCT", 118, 123], ["p65", "GENE_OR_GENE_PRODUCT", 132, 135], ["TNF-a-treated a3 \u00c0/\u00c0 MEFs", "CELL_LINE", 34, 59], ["NF-kB subunit p65", "PROTEIN", 118, 135], ["Nuclear fractionation analysis", "TEST", 0, 30], ["TNF", "TEST", 34, 37], ["MEFs", "TEST", 55, 59], ["significantly reduced nuclear translocation of the NF", "PROBLEM", 67, 120], ["MEFs", "PROBLEM", 181, 185], ["fractionation", "OBSERVATION", 8, 21]]], ["Immunofluorescence analysis further confirmed that nuclear localization of NF-kB p65 was also reduced in a3 \u00c0/\u00c0 MEFs compared to a3 +/+ MEFs ( Figure 2E ).", [["nuclear", "ANATOMY", 51, 58], ["a3 \u00c0/\u00c0 MEFs", "ANATOMY", 105, 116], ["a3 +/+ MEFs", "ANATOMY", 129, 140], ["nuclear", "CELLULAR_COMPONENT", 51, 58], ["NF-kB p65", "GENE_OR_GENE_PRODUCT", 75, 84], ["a3 \u00c0/\u00c0 MEFs", "CELL", 105, 116], ["a3", "GENE_OR_GENE_PRODUCT", 129, 131], ["NF-kB p65", "PROTEIN", 75, 84], ["a3 \u00c0/\u00c0 MEFs", "CELL_LINE", 105, 116], ["a3 +/+ MEFs", "CELL_LINE", 129, 140], ["Immunofluorescence analysis", "TEST", 0, 27], ["nuclear localization of NF-kB p65", "TEST", 51, 84], ["MEFs", "TEST", 112, 116], ["a3", "TEST", 129, 131]]], ["Conversely, NF-kB p65 accumulated in the cytoplasm of a3 \u00c0/\u00c0 MEFs, albeit slightly, likely due to the degradation of inefficiently transported cargo proteins ( Figure 2E ).", [["cytoplasm", "ANATOMY", 41, 50], ["a3 \u00c0/\u00c0 MEFs", "ANATOMY", 54, 65], ["NF-kB p65", "GENE_OR_GENE_PRODUCT", 12, 21], ["cytoplasm", "ORGANISM_SUBSTANCE", 41, 50], ["a3", "GENE_OR_GENE_PRODUCT", 54, 56], ["NF-kB p65", "PROTEIN", 12, 21], ["a3 \u00c0/\u00c0 MEFs", "CELL_LINE", 54, 65], ["cargo proteins", "PROTEIN", 143, 157], ["Figure 2E", "PROTEIN", 160, 169], ["NF-kB p65", "TEST", 12, 21], ["cytoplasm", "ANATOMY_MODIFIER", 41, 50]]], ["The extent of reduced nuclear localization of importin-a3 was dependent on the method used, albeit the absence of importin-a3 consistently impaired efficient nuclear localization of TNF-a-induced NF-kB subunit p65.", [["nuclear", "ANATOMY", 22, 29], ["nuclear", "ANATOMY", 158, 165], ["nuclear", "CELLULAR_COMPONENT", 22, 29], ["importin-a3", "GENE_OR_GENE_PRODUCT", 46, 57], ["importin-a3", "GENE_OR_GENE_PRODUCT", 114, 125], ["nuclear", "CELLULAR_COMPONENT", 158, 165], ["TNF", "GENE_OR_GENE_PRODUCT", 182, 185], ["NF-kB", "GENE_OR_GENE_PRODUCT", 196, 201], ["p65", "GENE_OR_GENE_PRODUCT", 210, 213], ["importin-a3", "PROTEIN", 46, 57], ["importin-a3", "PROTEIN", 114, 125], ["TNF", "PROTEIN", 182, 185], ["NF-kB subunit p65", "PROTEIN", 196, 213], ["a-induced NF", "TREATMENT", 186, 198], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["reduced", "OBSERVATION_MODIFIER", 14, 21], ["nuclear localization", "OBSERVATION", 22, 42]]], ["These data clearly show that importin-a3 acts as a nuclear translocator of TNF-a-activated NF-kB.Importin-a3 Is the Most Abundantly Expressed Importina Isoform in the Mammalian Respiratory TractImportin-a3 Promoter Activity Is Regulated by TNF-a-Activated NF-kB We further observed an increase in general importin-a3 protein levels upon TNF-a treatment in total cell lysates, including nuclear and cytoplasmic cell fractions of murine as well as primary (A and B) Importin-a1, -a3, or -a5/7 proteins were stained (red) in human (A) or murine (B) upper (URT, nasal epithelial cells) and lower respiratory tract (LRT, bronchi and alveoli) sections by IHC-P (immunohistochemistry-paraffin protocol) and counterstained with hematoxylin.", [["nuclear", "ANATOMY", 51, 58], ["cell lysates", "ANATOMY", 362, 374], ["nuclear", "ANATOMY", 386, 393], ["cytoplasmic cell fractions", "ANATOMY", 398, 424], ["B", "ANATOMY", 543, 544], ["URT", "ANATOMY", 553, 556], ["nasal epithelial cells", "ANATOMY", 558, 580], ["lower respiratory tract", "ANATOMY", 586, 609], ["LRT", "ANATOMY", 611, 614], ["bronchi", "ANATOMY", 616, 623], ["alveoli", "ANATOMY", 628, 635], ["sections", "ANATOMY", 637, 645], ["hematoxylin", "CHEMICAL", 720, 731], ["importin-a3", "GENE_OR_GENE_PRODUCT", 29, 40], ["nuclear", "CELLULAR_COMPONENT", 51, 58], ["TNF", "GENE_OR_GENE_PRODUCT", 75, 78], ["NF-kB.Importin-a3", "GENE_OR_GENE_PRODUCT", 91, 108], ["Importina Isoform", "GENE_OR_GENE_PRODUCT", 142, 159], ["TractImportin-a3", "GENE_OR_GENE_PRODUCT", 189, 205], ["TNF-a-", "GENE_OR_GENE_PRODUCT", 240, 246], ["NF-kB", "GENE_OR_GENE_PRODUCT", 256, 261], ["importin-a3", "GENE_OR_GENE_PRODUCT", 305, 316], ["TNF", "GENE_OR_GENE_PRODUCT", 337, 340], ["cell lysates", "ORGANISM_SUBSTANCE", 362, 374], ["nuclear", "CELLULAR_COMPONENT", 386, 393], ["cytoplasmic cell", "ORGANISM_SUBSTANCE", 398, 414], ["murine", "ORGANISM", 428, 434], ["Importin-a1", "GENE_OR_GENE_PRODUCT", 464, 475], ["-a3", "GENE_OR_GENE_PRODUCT", 477, 480], ["a5/7", "GENE_OR_GENE_PRODUCT", 486, 490], ["human", "ORGANISM", 522, 527], ["A", "CANCER", 529, 530], ["murine", "ORGANISM", 535, 541], ["B) upper", "CELL", 543, 551], ["URT", "CELL", 553, 556], ["nasal epithelial cells", "CELL", 558, 580], ["tract", "ORGANISM_SUBDIVISION", 604, 609], ["bronchi", "MULTI-TISSUE_STRUCTURE", 616, 623], ["alveoli", "MULTI-TISSUE_STRUCTURE", 628, 635], ["hematoxylin", "SIMPLE_CHEMICAL", 720, 731], ["importin-a3", "PROTEIN", 29, 40], ["TNF", "PROTEIN", 75, 78], ["a-activated NF-kB.Importin-a3 Is the Most Abundantly Expressed Importina Isoform", "PROTEIN", 79, 159], ["Mammalian Respiratory TractImportin", "PROTEIN", 167, 202], ["TNF", "PROTEIN", 240, 243], ["NF-kB", "PROTEIN", 256, 261], ["importin", "PROTEIN", 305, 313], ["TNF", "PROTEIN", 337, 340], ["Importin", "PROTEIN", 464, 472], ["a1", "PROTEIN", 473, 475], ["a3", "PROTEIN", 478, 480], ["a5/7 proteins", "PROTEIN", 486, 499], ["murine (B) upper (URT, nasal epithelial cells", "CELL_TYPE", 535, 580], ["murine", "SPECIES", 428, 434], ["human", "SPECIES", 522, 527], ["murine", "SPECIES", 535, 541], ["human", "SPECIES", 522, 527], ["Mammalian Respiratory TractImportin", "TREATMENT", 167, 202], ["TNF", "TEST", 337, 340], ["a treatment", "TREATMENT", 341, 352], ["total cell lysates", "TREATMENT", 356, 374], ["nuclear and cytoplasmic cell fractions", "TEST", 386, 424], ["murine (B) upper (URT, nasal epithelial cells", "TEST", 535, 580], ["lower respiratory tract", "PROBLEM", 586, 609], ["IHC", "TEST", 649, 652], ["immunohistochemistry", "TEST", 656, 676], ["-paraffin protocol", "TREATMENT", 676, 694], ["hematoxylin", "TREATMENT", 720, 731], ["increase", "OBSERVATION_MODIFIER", 285, 293], ["cytoplasmic cell fractions", "OBSERVATION", 398, 424], ["upper", "ANATOMY_MODIFIER", 546, 551], ["URT", "ANATOMY", 553, 556], ["nasal epithelial", "ANATOMY", 558, 574], ["lower", "ANATOMY_MODIFIER", 586, 591], ["respiratory tract", "ANATOMY", 592, 609], ["bronchi", "ANATOMY", 616, 623], ["alveoli", "ANATOMY", 628, 635]]], ["The importin-a7 antibody cross-reacts with importin-a5.", [["importin-a7", "GENE_OR_GENE_PRODUCT", 4, 15], ["importin-a5", "GENE_OR_GENE_PRODUCT", 43, 54], ["importin", "PROTEIN", 4, 12], ["a7 antibody", "PROTEIN", 13, 24], ["importin", "PROTEIN", 43, 51], ["a5", "PROTEIN", 52, 54], ["The importin", "TREATMENT", 0, 12]]], ["4003 (URT and bronchi in A) or 10003 (alveoli in A and B) original magnification.", [["bronchi", "ANATOMY", 14, 21], ["alveoli", "ANATOMY", 38, 45], ["bronchi", "MULTI-TISSUE_STRUCTURE", 14, 21], ["alveoli", "MULTI-TISSUE_STRUCTURE", 38, 45], ["bronchi", "ANATOMY", 14, 21]]], ["Scale bar, 10 mm.Importin-a3 Is the Most Abundantly Expressed Importina Isoform in the Mammalian Respiratory Tract(C and D) Importin-a mRNA levels in the human (C) and murine (D) URT and LRT determined by qRT-PCR.", [["Importin-a3", "GENE_OR_GENE_PRODUCT", 17, 28], ["Importina Isoform", "GENE_OR_GENE_PRODUCT", 62, 79], ["C", "MULTI-TISSUE_STRUCTURE", 115, 116], ["Importin-a", "GENE_OR_GENE_PRODUCT", 124, 134], ["human", "ORGANISM", 154, 159], ["C", "CELL", 161, 162], ["murine", "ORGANISM", 168, 174], ["(D) URT", "GENE_OR_GENE_PRODUCT", 175, 182], ["Importin", "PROTEIN", 17, 25], ["Importina Isoform", "PROTEIN", 62, 79], ["human", "SPECIES", 154, 159], ["murine", "SPECIES", 168, 174], ["human", "SPECIES", 154, 159], ["C and D) Importin", "TREATMENT", 115, 132], ["a mRNA levels", "TEST", 133, 146], ["LRT", "TEST", 187, 190], ["PCR", "TEST", 209, 212], ["10 mm", "OBSERVATION_MODIFIER", 11, 16], ["Respiratory Tract", "ANATOMY", 97, 114]]], ["Relative importin-a1 expression values were set to 1 after normalization against GAPDH (Glycerinaldehyd-3-phosphat-dehydrogenase).", [["Glycerinaldehyd-3-phosphat", "CHEMICAL", 88, 114], ["Glycerinaldehyd-3-phosphat", "CHEMICAL", 88, 114], ["importin-a1", "GENE_OR_GENE_PRODUCT", 9, 20], ["GAPDH", "GENE_OR_GENE_PRODUCT", 81, 86], ["Glycerinaldehyd-3-phosphat-dehydrogenase", "GENE_OR_GENE_PRODUCT", 88, 128], ["importin", "PROTEIN", 9, 17], ["GAPDH", "PROTEIN", 81, 86], ["Glycerinaldehyd-3-phosphat-dehydrogenase", "PROTEIN", 88, 128], ["GAPDH", "TEST", 81, 86], ["Glycerinaldehyd", "TEST", 88, 103], ["phosphat", "TREATMENT", 106, 114]]], ["Each data point represents an individual sample (n = 6-12).Importin-a3 Is the Most Abundantly Expressed Importina Isoform in the Mammalian Respiratory Tract(E and F) Importin-a protein amounts in murine LRT.", [["Importin-a3", "GENE_OR_GENE_PRODUCT", 59, 70], ["Importina Isoform", "GENE_OR_GENE_PRODUCT", 104, 121], ["murine", "ORGANISM", 196, 202], ["Importin", "PROTEIN", 59, 67], ["Most Abundantly Expressed Importina Isoform", "PROTEIN", 78, 121], ["Importin", "PROTEIN", 166, 174], ["murine", "SPECIES", 196, 202], ["an individual sample", "TEST", 27, 47], ["a protein amounts in murine LRT", "TREATMENT", 175, 206], ["Respiratory Tract", "ANATOMY", 139, 156]]], ["Western blot analyses using importin-a isoform-specific antibodies and GAPDH adjustment were performed to determine endogenous importin-a protein amounts (a1, a3, a5, a7) in murine organs.", [["organs", "ANATOMY", 181, 187], ["importin", "GENE_OR_GENE_PRODUCT", 28, 36], ["GAPDH", "GENE_OR_GENE_PRODUCT", 71, 76], ["importin", "GENE_OR_GENE_PRODUCT", 127, 135], ["a1", "GENE_OR_GENE_PRODUCT", 155, 157], ["a3", "GENE_OR_GENE_PRODUCT", 159, 161], ["a5", "GENE_OR_GENE_PRODUCT", 163, 165], ["a7", "GENE_OR_GENE_PRODUCT", 167, 169], ["murine", "ORGANISM", 174, 180], ["organs", "ORGAN", 181, 187], ["importin", "PROTEIN", 28, 36], ["importin", "PROTEIN", 127, 135], ["a1", "PROTEIN", 155, 157], ["a3", "PROTEIN", 159, 161], ["a5", "PROTEIN", 163, 165], ["a7", "PROTEIN", 167, 169], ["murine", "SPECIES", 174, 180], ["GAPDH adjustment", "TEST", 71, 87], ["organs", "ANATOMY", 181, 187]]], ["For relative quantification (E), standard curves of affinity-purified, FLAGtagged importin-a proteins were used.", [["importin", "GENE_OR_GENE_PRODUCT", 82, 90], ["FLAGtagged importin", "PROTEIN", 71, 90], ["standard curves of affinity", "TEST", 33, 60], ["FLAGtagged importin", "TREATMENT", 71, 90], ["a proteins", "TREATMENT", 91, 101]]], ["Relative importin-a1 protein amount in murine LRT was set to 1.", [["importin-a1", "GENE_OR_GENE_PRODUCT", 9, 20], ["murine", "ORGANISM", 39, 45], ["importin", "PROTEIN", 9, 17], ["a1 protein", "PROTEIN", 18, 28], ["murine", "SPECIES", 39, 45], ["murine LRT", "TEST", 39, 49], ["a1 protein", "OBSERVATION_MODIFIER", 18, 28], ["amount", "OBSERVATION_MODIFIER", 29, 35]]], ["Data shown represent means \u00b1 SD (n = 3 biological replicates; technical replicates: n = 1-2 per organ, n = 1-2 western blot analyses).", [["organ", "ANATOMY", 96, 101], ["organ", "ORGAN", 96, 101], ["blot analyses", "TEST", 119, 132]]], ["Representative western blots for the endogenous importin-a isoforms and the standard curves are shown in (F).", [["importin", "GENE_OR_GENE_PRODUCT", 48, 56], ["importin", "PROTEIN", 48, 56]]], ["The gaps in (F) depict cropping of the relevant bands run on the same gel.Importin-a3 Is the Most Abundantly Expressed Importina Isoform in the Mammalian Respiratory Tract(G-K) Comparison of importin-a mRNA expression levels between murine URT and LRT: a1 (G), a3 (H), a4 (I), a5 (J), or a7 (K).", [["Importin-a3", "GENE_OR_GENE_PRODUCT", 74, 85], ["Importina Isoform", "GENE_OR_GENE_PRODUCT", 119, 136], ["G-K", "GENE_OR_GENE_PRODUCT", 172, 175], ["importin-a", "GENE_OR_GENE_PRODUCT", 191, 201], ["murine", "ORGANISM", 233, 239], ["URT", "GENE_OR_GENE_PRODUCT", 240, 243], ["a1 (G)", "GENE_OR_GENE_PRODUCT", 253, 259], ["a3 (H)", "GENE_OR_GENE_PRODUCT", 261, 267], ["a4 (I)", "GENE_OR_GENE_PRODUCT", 269, 275], ["a7 (K)", "GENE_OR_GENE_PRODUCT", 288, 294], ["Importin", "PROTEIN", 74, 82], ["Most Abundantly Expressed Importina Isoform", "PROTEIN", 93, 136], ["importin", "PROTEIN", 191, 199], ["murine URT", "PROTEIN", 233, 243], ["murine", "SPECIES", 233, 239], ["the relevant bands", "PROBLEM", 35, 53], ["gaps", "OBSERVATION_MODIFIER", 4, 8], ["Respiratory Tract", "ANATOMY", 154, 171], ["a7", "ANATOMY", 288, 290]]], ["A, alveoli; BE, bronchiolar epithelium; n = 8-12.Importin-a3 Is the Most Abundantly Expressed Importina Isoform in the Mammalian Respiratory Tract(L) Schematic partition of the RT with increasing importin-a mRNA levels from URT to LRT. p < 0.001. airway epithelial cells ( Figures 2F and 2G ).", [["alveoli", "ANATOMY", 3, 10], ["BE", "ANATOMY", 12, 14], ["bronchiolar epithelium", "ANATOMY", 16, 38], ["airway epithelial cells", "ANATOMY", 247, 270], ["BE", "CHEMICAL", 12, 14], ["alveoli", "TISSUE", 3, 10], ["BE", "TISSUE", 12, 14], ["bronchiolar epithelium", "TISSUE", 16, 38], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 49, 60], ["Importina Isoform", "GENE_OR_GENE_PRODUCT", 94, 111], ["importin", "GENE_OR_GENE_PRODUCT", 196, 204], ["airway epithelial cells", "CELL", 247, 270], ["Importin", "PROTEIN", 49, 57], ["Most Abundantly Expressed Importina Isoform", "PROTEIN", 68, 111], ["importin", "PROTEIN", 196, 204], ["airway epithelial cells", "CELL_TYPE", 247, 270], ["the RT", "TREATMENT", 173, 179], ["increasing importin", "TREATMENT", 185, 204], ["a mRNA levels", "TEST", 205, 218], ["airway epithelial cells", "PROBLEM", 247, 270], ["alveoli", "ANATOMY", 3, 10], ["bronchiolar epithelium", "ANATOMY", 16, 38], ["Respiratory Tract", "ANATOMY", 129, 146], ["epithelial cells", "OBSERVATION", 254, 270]]], ["These findings might suggest that importin-a3 gene expression itself could also be affected by TNF-a treatment.", [["importin-a3", "GENE_OR_GENE_PRODUCT", 34, 45], ["TNF", "GENE_OR_GENE_PRODUCT", 95, 98], ["importin", "PROTEIN", 34, 42], ["TNF", "PROTEIN", 95, 98], ["a treatment", "TREATMENT", 99, 110]]], ["In order to understand how importin-a3 gene transcription is regulated, we screened the promoter region of the importin-a3 gene for the presence of potential transcription factor binding sites.", [["importin-a3", "GENE_OR_GENE_PRODUCT", 27, 38], ["importin-a3", "GENE_OR_GENE_PRODUCT", 111, 122], ["importin", "PROTEIN", 27, 35], ["promoter region", "DNA", 88, 103], ["importin-a3 gene", "DNA", 111, 127], ["transcription factor binding sites", "DNA", 158, 192], ["potential transcription factor binding sites", "PROBLEM", 148, 192]]], ["We found that the promoter region of the importin-a3 gene contains a binding site for NF-kB, as shown by earlier chromatin immunoprecipitation studies (Raskatov et al., 2012) ( Figure 2H ).", [["chromatin", "ANATOMY", 113, 122], ["importin-a3", "GENE_OR_GENE_PRODUCT", 41, 52], ["NF-kB", "GENE_OR_GENE_PRODUCT", 86, 91], ["chromatin", "CELLULAR_COMPONENT", 113, 122], ["promoter region", "DNA", 18, 33], ["importin-a3 gene", "DNA", 41, 57], ["binding site", "DNA", 69, 81], ["NF-kB", "PROTEIN", 86, 91], ["chromatin", "DNA", 113, 122], ["a binding site", "PROBLEM", 67, 81]]], ["Consistently, using a reporter construct encoding for renilla luciferase under the control of the importin-a3 promoter, we could show that importin-a3 gene expression is differentially affected upon TNF-a treatment in a cell-type-and dose-dependent manner ( Figures 2I-2K ).", [["cell", "ANATOMY", 220, 224], ["renilla", "GENE_OR_GENE_PRODUCT", 54, 61], ["luciferase", "GENE_OR_GENE_PRODUCT", 62, 72], ["importin-a3", "GENE_OR_GENE_PRODUCT", 98, 109], ["importin-a3", "GENE_OR_GENE_PRODUCT", 139, 150], ["TNF", "GENE_OR_GENE_PRODUCT", 199, 202], ["cell", "CELL", 220, 224], ["renilla luciferase", "DNA", 54, 72], ["importin-a3 promoter", "DNA", 98, 118], ["importin", "PROTEIN", 139, 147], ["TNF", "PROTEIN", 199, 202], ["a reporter construct", "TREATMENT", 20, 40], ["renilla luciferase", "TREATMENT", 54, 72], ["a treatment", "TREATMENT", 203, 214]]], ["In clinically relevant primary human airway epithelial cells as well as in generated MEFs herein, importin-a3 promoter activity was highest upon low-dose TNF-a treatment, while high-dose TNF-a treatment resulted in a reduction of importin-a3 gene expression ( Figures 2J and 2K ).", [["airway epithelial cells", "ANATOMY", 37, 60], ["MEFs", "ANATOMY", 85, 89], ["human", "ORGANISM", 31, 36], ["airway epithelial cells", "CELL", 37, 60], ["MEFs", "CELL", 85, 89], ["importin-a3", "GENE_OR_GENE_PRODUCT", 98, 109], ["TNF", "GENE_OR_GENE_PRODUCT", 154, 157], ["TNF", "GENE_OR_GENE_PRODUCT", 187, 190], ["importin-a3", "GENE_OR_GENE_PRODUCT", 230, 241], ["primary human airway epithelial cells", "CELL_TYPE", 23, 60], ["importin", "PROTEIN", 98, 106], ["a3 promoter", "DNA", 107, 118], ["TNF", "PROTEIN", 154, 157], ["TNF", "PROTEIN", 187, 190], ["importin", "PROTEIN", 230, 238], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["primary human airway epithelial cells", "PROBLEM", 23, 60], ["low-dose TNF", "TREATMENT", 145, 157], ["a treatment", "TREATMENT", 158, 169], ["high-dose TNF", "TREATMENT", 177, 190], ["a treatment", "TREATMENT", 191, 202], ["a reduction of importin", "TREATMENT", 215, 238], ["airway epithelial cells", "OBSERVATION", 37, 60]]], ["However, multi-passage cancerous A549 cells presented high resistance to TNF-a treatment ( Figure 2I ), suggesting a delayed dose-response curve.Importin-a3 Is the Most Abundantly Expressed Importina Isoform in the Mammalian Respiratory TractTreating MEFs with other cytokines, such as interleukin (IL)-10 or transforming growth factor b (TGF-b) did not significantly alter importin-a3 promoter activity, unlike TNF-a treatment ( Figures S2A and S2B ), albeit IL-10 presented a slight induction (Figure S2A ).", [["cancerous A549 cells", "ANATOMY", 23, 43], ["MEFs", "ANATOMY", 251, 255], ["cancerous A549 cells", "CELL", 23, 43], ["TNF", "GENE_OR_GENE_PRODUCT", 73, 76], ["Importin-a3 Is", "GENE_OR_GENE_PRODUCT", 145, 159], ["Importina Isoform", "GENE_OR_GENE_PRODUCT", 190, 207], ["MEFs", "CELL", 251, 255], ["interleukin (IL)-10", "GENE_OR_GENE_PRODUCT", 286, 305], ["transforming growth factor b", "GENE_OR_GENE_PRODUCT", 309, 337], ["TGF-b", "GENE_OR_GENE_PRODUCT", 339, 344], ["importin-a3", "GENE_OR_GENE_PRODUCT", 374, 385], ["TNF-a", "GENE_OR_GENE_PRODUCT", 412, 417], ["S2B", "GENE_OR_GENE_PRODUCT", 446, 449], ["IL-10", "GENE_OR_GENE_PRODUCT", 460, 465], ["multi-passage cancerous A549 cells", "CELL_LINE", 9, 43], ["TNF", "PROTEIN", 73, 76], ["Importin", "PROTEIN", 145, 153], ["Most Abundantly Expressed Importina Isoform", "PROTEIN", 164, 207], ["Mammalian Respiratory TractTreating MEFs", "CELL_LINE", 215, 255], ["cytokines", "PROTEIN", 267, 276], ["interleukin (IL)-10", "PROTEIN", 286, 305], ["TGF", "PROTEIN", 339, 342], ["importin", "PROTEIN", 374, 382], ["TNF", "PROTEIN", 412, 415], ["S2B", "PROTEIN", 446, 449], ["IL", "PROTEIN", 460, 462], ["multi-passage cancerous A549 cells", "PROBLEM", 9, 43], ["TNF", "TEST", 73, 76], ["a treatment ( Figure 2I", "TREATMENT", 77, 100], ["other cytokines", "TREATMENT", 261, 276], ["interleukin (IL)", "TREATMENT", 286, 302], ["transforming growth factor", "PROBLEM", 309, 335], ["a treatment", "TREATMENT", 416, 427], ["a slight induction (Figure S2A", "TREATMENT", 476, 506], ["A549 cells", "OBSERVATION", 33, 43], ["high resistance", "OBSERVATION", 54, 69], ["Respiratory TractTreating MEFs", "OBSERVATION", 225, 255]]], ["Next, we wanted to assess whether TNF-a-activated NF-kB is directly involved in regulating importin-a3 gene transcription.", [["TNF", "GENE_OR_GENE_PRODUCT", 34, 37], ["NF-kB", "GENE_OR_GENE_PRODUCT", 50, 55], ["importin-a3", "GENE_OR_GENE_PRODUCT", 91, 102], ["TNF", "PROTEIN", 34, 37], ["NF-kB", "PROTEIN", 50, 55], ["importin", "PROTEIN", 91, 99]]], ["Therefore, we used cells deficient in the NF-kB essential modulator (NEMO), the regulatory subunit of the IKK (IkB kinase), which is required for NF-kB phosphorylation and thus its activation.", [["cells", "ANATOMY", 19, 24], ["cells", "CELL", 19, 24], ["NF-kB", "GENE_OR_GENE_PRODUCT", 42, 47], ["NEMO", "GENE_OR_GENE_PRODUCT", 69, 73], ["IKK", "GENE_OR_GENE_PRODUCT", 106, 109], ["IkB kinase", "GENE_OR_GENE_PRODUCT", 111, 121], ["NF-kB", "GENE_OR_GENE_PRODUCT", 146, 151], ["NF-kB essential modulator", "PROTEIN", 42, 67], ["NEMO", "PROTEIN", 69, 73], ["regulatory subunit", "PROTEIN", 80, 98], ["IKK", "PROTEIN", 106, 109], ["IkB kinase", "PROTEIN", 111, 121], ["NF-kB", "PROTEIN", 146, 151], ["cells deficient", "PROBLEM", 19, 34], ["the IKK (IkB kinase", "TEST", 102, 121], ["NF-kB phosphorylation", "TREATMENT", 146, 167]]], ["Importin-a3 mRNA levels were reduced in TNFa-treated NEMO \u00c0/\u00c0 cells compared to untreated controls (Figure 2L) .", [["NEMO \u00c0/\u00c0 cells", "ANATOMY", 53, 67], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 0, 11], ["TNFa", "GENE_OR_GENE_PRODUCT", 40, 44], ["NEMO", "GENE_OR_GENE_PRODUCT", 53, 57], ["TNFa-treated NEMO \u00c0/\u00c0 cells", "CELL_LINE", 40, 67], ["mRNA levels", "TEST", 12, 23], ["TNFa", "TEST", 40, 44], ["NEMO \u00c0/\u00c0 cells", "TREATMENT", 53, 67]]], ["As expected, reduced importin-a3 mRNA levels also resulted in reduced importin-a3 protein expression in NEMO \u00c0/\u00c0 cells treated with TNF-a as compared to untreated cells (Figure 2M) .", [["NEMO \u00c0/\u00c0 cells", "ANATOMY", 104, 118], ["cells", "ANATOMY", 163, 168], ["importin-a3", "GENE_OR_GENE_PRODUCT", 21, 32], ["importin-a3", "GENE_OR_GENE_PRODUCT", 70, 81], ["NEMO", "GENE_OR_GENE_PRODUCT", 104, 108], ["TNF-a", "GENE_OR_GENE_PRODUCT", 132, 137], ["cells", "CELL", 163, 168], ["importin", "PROTEIN", 21, 29], ["importin", "PROTEIN", 70, 78], ["NEMO \u00c0/\u00c0 cells", "CELL_LINE", 104, 118], ["TNF", "PROTEIN", 132, 135], ["untreated cells", "CELL_TYPE", 153, 168], ["mRNA levels", "TEST", 33, 44], ["reduced importin", "PROBLEM", 62, 78], ["TNF", "TEST", 132, 135]]], ["Reduced importin-a3 expression in NEMO \u00c0/\u00c0 cells could be restored upon transfection of a NEMO-expressing plasmid back into NEMO \u00c0/\u00c0 cells ( Figure 2M ).", [["NEMO \u00c0/\u00c0 cells", "ANATOMY", 34, 48], ["plasmid", "ANATOMY", 106, 113], ["NEMO \u00c0/\u00c0 cells", "ANATOMY", 124, 138], ["importin-a3", "GENE_OR_GENE_PRODUCT", 8, 19], ["NEMO", "GENE_OR_GENE_PRODUCT", 34, 38], ["NEMO", "GENE_OR_GENE_PRODUCT", 90, 94], ["NEMO", "GENE_OR_GENE_PRODUCT", 124, 128], ["Figure 2M", "GENE_OR_GENE_PRODUCT", 141, 150], ["importin", "PROTEIN", 8, 16], ["a3", "PROTEIN", 17, 19], ["NEMO \u00c0/\u00c0 cells", "CELL_LINE", 34, 48], ["NEMO", "PROTEIN", 90, 94], ["NEMO \u00c0/\u00c0 cells", "CELL_LINE", 124, 138], ["Figure 2M", "PROTEIN", 141, 150], ["NEMO \u00c0/\u00c0 cells", "TREATMENT", 34, 48], ["a NEMO", "TEST", 88, 94], ["a3 expression", "OBSERVATION_MODIFIER", 17, 30]]], ["Control treatment of NEMO \u00c0/\u00c0 cells with IL-6, IL-10, interferon (IFN)-g or TGF-b showed similarly reduced importin-a3 mRNA expression levels as upon TNF-a treatment ( Figure 2N ).", [["NEMO \u00c0/\u00c0 cells", "ANATOMY", 21, 35], ["NEMO", "GENE_OR_GENE_PRODUCT", 21, 25], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["IL-10", "GENE_OR_GENE_PRODUCT", 47, 52], ["interferon (IFN)-g", "GENE_OR_GENE_PRODUCT", 54, 72], ["TGF-b", "GENE_OR_GENE_PRODUCT", 76, 81], ["importin-a3", "GENE_OR_GENE_PRODUCT", 107, 118], ["TNF", "GENE_OR_GENE_PRODUCT", 150, 153], ["NEMO \u00c0/\u00c0 cells", "CELL_LINE", 21, 35], ["IL-6", "PROTEIN", 41, 45], ["interferon (IFN)-g", "PROTEIN", 54, 72], ["TGF-b", "PROTEIN", 76, 81], ["importin", "PROTEIN", 107, 115], ["TNF", "PROTEIN", 150, 153], ["NEMO \u00c0/\u00c0 cells", "TEST", 21, 35], ["IL", "TEST", 41, 43], ["IL", "TEST", 47, 49], ["interferon (IFN", "TREATMENT", 54, 69], ["TGF", "TEST", 76, 79], ["mRNA expression levels", "PROBLEM", 119, 141], ["TNF", "TEST", 150, 153], ["a treatment", "TREATMENT", 154, 165]]], ["It is important to note that IL-6 transcription is directly dependent on NF-kB, unlike IL-10, IFN-g or TGF-b.", [["IL-6", "GENE_OR_GENE_PRODUCT", 29, 33], ["NF-kB", "GENE_OR_GENE_PRODUCT", 73, 78], ["IL-10", "GENE_OR_GENE_PRODUCT", 87, 92], ["IFN-g", "GENE_OR_GENE_PRODUCT", 94, 99], ["TGF", "GENE_OR_GENE_PRODUCT", 103, 106], ["IL-6", "PROTEIN", 29, 33], ["NF-kB", "PROTEIN", 73, 78], ["IFN", "PROTEIN", 94, 97], ["TGF", "PROTEIN", 103, 106], ["IL-6 transcription", "TREATMENT", 29, 47], ["IL", "TEST", 87, 89], ["IFN", "TEST", 94, 97], ["TGF", "TEST", 103, 106]]], ["These findings support the concept that TNF-a-activated NF-kB is crucial for importin-a3 gene expression.", [["TNF", "GENE_OR_GENE_PRODUCT", 40, 43], ["NF-kB", "GENE_OR_GENE_PRODUCT", 56, 61], ["importin-a3", "GENE_OR_GENE_PRODUCT", 77, 88], ["TNF", "PROTEIN", 40, 43], ["NF-kB", "PROTEIN", 56, 61], ["importin", "PROTEIN", 77, 85]]], ["However, other cytokines might also reduce importin-a3 expression at high, but not low, cytokine concentrations (Figure S2C) .", [["importin-a3", "GENE_OR_GENE_PRODUCT", 43, 54], ["cytokines", "PROTEIN", 15, 24], ["importin", "PROTEIN", 43, 51], ["a3", "PROTEIN", 52, 54], ["cytokine", "PROTEIN", 88, 96], ["a3 expression", "OBSERVATION_MODIFIER", 52, 65]]], ["Our findings support the concept that importin-a3 gene expression is controlled by TNF-a-activated NF-kB in a cell-and dose-dependent manner.", [["cell", "ANATOMY", 110, 114], ["importin-a3", "GENE_OR_GENE_PRODUCT", 38, 49], ["TNF", "GENE_OR_GENE_PRODUCT", 83, 86], ["NF-kB", "GENE_OR_GENE_PRODUCT", 99, 104], ["cell", "CELL", 110, 114], ["importin", "PROTEIN", 38, 46], ["TNF", "PROTEIN", 83, 86], ["NF-kB", "PROTEIN", 99, 104]]], ["This is in line with general control mechanisms in cells, such as negative or positive feedback loops, where gene transcription is regulated (e.g., either by activating or blocking the promoter, respectively, depending on demand) ( Figure 2O ).", [["cells", "ANATOMY", 51, 56], ["cells", "CELL", 51, 56], ["promoter", "DNA", 185, 193], ["positive feedback loops", "PROBLEM", 78, 101], ["gene transcription", "TREATMENT", 109, 127], ["feedback loops", "OBSERVATION", 87, 101]]], ["However, other, not yet defined, NF-kBindependent pathways might also affect importin-a3 gene expression.", [["NF-kBindependent", "GENE_OR_GENE_PRODUCT", 33, 49], ["importin-a3", "GENE_OR_GENE_PRODUCT", 77, 88], ["NF", "PROTEIN", 33, 35], ["importin", "PROTEIN", 77, 85]]], ["Future studies are required to dissect the importin-a3 promotor for transcription factor binding sites other than NF-kB.High-Level TNF-a-Inducing Human-Type HPAIV Infections Reduce Importin-a3 Protein Expression Levels in Human Respiratory CellsSince the NF-kB transporting nuclear import factor importin-a3 was the only isoform in the lung that altered its expression levels upon TNF-a treatment, we wanted to know how importin-a3 is regulated under respiratory stress associated with cellular cytokine changes.", [["nuclear", "ANATOMY", 274, 281], ["lung", "ANATOMY", 336, 340], ["cellular", "ANATOMY", 486, 494], ["importin-a3", "GENE_OR_GENE_PRODUCT", 43, 54], ["NF-kB.", "GENE_OR_GENE_PRODUCT", 114, 120], ["TNF", "GENE_OR_GENE_PRODUCT", 131, 134], ["Human-Type HPAIV", "ORGANISM", 146, 162], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 181, 192], ["Human", "ORGANISM", 222, 227], ["NF-kB", "GENE_OR_GENE_PRODUCT", 255, 260], ["nuclear", "CELLULAR_COMPONENT", 274, 281], ["importin-a3", "GENE_OR_GENE_PRODUCT", 296, 307], ["lung", "ORGAN", 336, 340], ["TNF", "GENE_OR_GENE_PRODUCT", 381, 384], ["importin-a3", "GENE_OR_GENE_PRODUCT", 420, 431], ["cellular", "CELL", 486, 494], ["importin", "PROTEIN", 43, 51], ["a3 promotor", "DNA", 52, 63], ["transcription factor binding sites", "DNA", 68, 102], ["NF", "PROTEIN", 114, 116], ["TNF", "PROTEIN", 131, 134], ["Importin", "PROTEIN", 181, 189], ["NF-kB transporting nuclear import factor importin-a3", "PROTEIN", 255, 307], ["TNF", "PROTEIN", 381, 384], ["importin-a3", "PROTEIN", 420, 431], ["cytokine", "PROTEIN", 495, 503], ["Human", "SPECIES", 146, 151], ["Human", "SPECIES", 222, 227], ["Future studies", "TEST", 0, 14], ["transcription factor binding sites", "PROBLEM", 68, 102], ["NF", "TEST", 114, 116], ["kB.", "TEST", 117, 120], ["Type HPAIV Infections", "PROBLEM", 152, 173], ["Expression Levels", "TEST", 201, 218], ["a treatment", "TREATMENT", 385, 396], ["respiratory stress", "PROBLEM", 451, 469], ["cellular cytokine changes", "PROBLEM", 486, 511], ["Respiratory", "ANATOMY", 228, 239], ["lung", "ANATOMY", 336, 340], ["respiratory stress", "OBSERVATION", 451, 469], ["cellular cytokine", "OBSERVATION", 486, 503]]], ["Therefore, we used an influenza infection model.", [["influenza infection", "DISEASE", 22, 41], ["an influenza infection model", "PROBLEM", 19, 47], ["influenza infection", "OBSERVATION", 22, 41]]], ["We infected MEFs with highly pathogenic avian influenza A virus (HPAIV) mutants that were known to act as low-or high-level TNF-a inducers ( Figure 3A ).", [["MEFs", "ANATOMY", 12, 16], ["avian influenza A", "DISEASE", 40, 57], ["MEFs", "CELL", 12, 16], ["avian influenza A virus", "ORGANISM", 40, 63], ["HPAIV", "ORGANISM", 65, 70], ["TNF", "GENE_OR_GENE_PRODUCT", 124, 127], ["TNF", "PROTEIN", 124, 127], ["avian influenza A virus", "SPECIES", 40, 63], ["avian influenza A virus", "SPECIES", 40, 63], ["HPAIV", "SPECIES", 65, 70], ["infected MEFs", "PROBLEM", 3, 16], ["highly pathogenic avian influenza A virus (HPAIV) mutants", "PROBLEM", 22, 79], ["infected MEFs", "OBSERVATION", 3, 16]]], ["Then, we infected MEFs either with the low-level TNF-a-inducing HPAIV containing an aviantype polymerase signature (SC35-PB2 701D ), common in influenza A virus (IAV) having a low replicative fitness in mammals, or its high-level TNF-a-inducing HPAIV counterpart containing a human-type polymerase signature (SC35M-PB2 701N ), common in IAV possessing a high replicative fitness and virulence (D and E) Nuclear fraction (NF; control p84) and cytoplasmic fraction (CF; control GAPDH) localization of NF-kB p65 in a3 \u00c0/\u00c0 MEFs or WT controls thereof (a3 +/+ ) after TNF-a treatment using cell fractionation assay (D) or immunofluorescence (E) as well as quantifications thereof (n = 3-5).", [["MEFs", "ANATOMY", 18, 22], ["cytoplasmic", "ANATOMY", 442, 453], ["a3 \u00c0/\u00c0 MEFs", "ANATOMY", 512, 523], ["cell", "ANATOMY", 585, 589], ["influenza A", "DISEASE", 143, 154], ["MEFs", "CELL", 18, 22], ["TNF", "GENE_OR_GENE_PRODUCT", 49, 52], ["HPAIV", "ORGANISM", 64, 69], ["SC35-PB2 701D", "GENE_OR_GENE_PRODUCT", 116, 129], ["influenza A virus", "ORGANISM", 143, 160], ["IAV", "ORGANISM", 162, 165], ["TNF", "GENE_OR_GENE_PRODUCT", 230, 233], ["HPAIV", "ORGANISM", 245, 250], ["human", "ORGANISM", 276, 281], ["SC35M-PB2 701N", "ORGANISM", 309, 323], ["IAV", "ORGANISM", 337, 340], ["p84", "GENE_OR_GENE_PRODUCT", 433, 436], ["cytoplasmic", "ORGANISM_SUBSTANCE", 442, 453], ["GAPDH", "GENE_OR_GENE_PRODUCT", 476, 481], ["NF-kB p65", "GENE_OR_GENE_PRODUCT", 499, 508], ["a3 \u00c0", "GENE_OR_GENE_PRODUCT", 512, 516], ["MEFs", "CELL", 519, 523], ["a3", "GENE_OR_GENE_PRODUCT", 548, 550], ["TNF", "GENE_OR_GENE_PRODUCT", 563, 566], ["cell", "CELL", 585, 589], ["TNF", "PROTEIN", 49, 52], ["aviantype polymerase signature", "DNA", 84, 114], ["SC35", "PROTEIN", 116, 120], ["PB2 701D", "PROTEIN", 121, 129], ["TNF", "PROTEIN", 230, 233], ["human-type polymerase signature", "DNA", 276, 307], ["SC35M", "PROTEIN", 309, 314], ["PB2 701N", "PROTEIN", 315, 323], ["NF", "PROTEIN", 421, 423], ["p84", "PROTEIN", 433, 436], ["cytoplasmic fraction", "PROTEIN", 442, 462], ["GAPDH", "PROTEIN", 476, 481], ["NF-kB p65", "PROTEIN", 499, 508], ["a3 \u00c0/\u00c0 MEFs", "CELL_LINE", 512, 523], ["a3", "PROTEIN", 548, 550], ["TNF", "PROTEIN", 563, 566], ["influenza A virus", "SPECIES", 143, 160], ["human", "SPECIES", 276, 281], ["influenza A virus", "SPECIES", 143, 160], ["IAV", "SPECIES", 162, 165], ["human", "SPECIES", 276, 281], ["IAV", "SPECIES", 337, 340], ["infected MEFs", "PROBLEM", 9, 22], ["the low-level TNF", "TREATMENT", 35, 52], ["HPAIV", "PROBLEM", 64, 69], ["an aviantype polymerase signature", "PROBLEM", 81, 114], ["common in influenza A virus (IAV", "PROBLEM", 133, 165], ["a low replicative fitness in mammals", "PROBLEM", 174, 210], ["Nuclear fraction", "TEST", 403, 419], ["cytoplasmic fraction", "TEST", 442, 462], ["NF", "TEST", 499, 501], ["MEFs", "TEST", 519, 523], ["WT controls", "TEST", 527, 538], ["TNF", "TREATMENT", 563, 566], ["a treatment", "TREATMENT", 567, 578], ["cell fractionation assay", "TEST", 585, 609], ["infected MEFs", "OBSERVATION", 9, 22], ["influenza", "OBSERVATION", 143, 152]]], ["Scale bar, 20 mm.High-Level TNF-a-Inducing Human-Type HPAIV Infections Reduce Importin-a3 Protein Expression Levels in Human Respiratory Cells(F and G) After seeding, cells were serum starved for 24 h.", [["Cells", "ANATOMY", 137, 142], ["cells", "ANATOMY", 167, 172], ["serum", "ANATOMY", 178, 183], ["TNF", "GENE_OR_GENE_PRODUCT", 28, 31], ["Human", "ORGANISM", 43, 48], ["HPAIV", "ORGANISM", 54, 59], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 78, 89], ["Human", "ORGANISM", 119, 124], ["Respiratory Cells", "CELL", 125, 142], ["F", "CELL", 143, 144], ["cells", "CELL", 167, 172], ["serum", "ORGANISM_SUBSTANCE", 178, 183], ["TNF", "PROTEIN", 28, 31], ["Importin", "PROTEIN", 78, 86], ["Human Respiratory Cells", "CELL_TYPE", 119, 142], ["Human", "SPECIES", 43, 48], ["Human", "SPECIES", 119, 124], ["High-Level TNF", "PROBLEM", 17, 31], ["Type HPAIV Infections", "PROBLEM", 49, 70], ["Expression Levels", "TEST", 98, 115], ["Human Respiratory Cells(F and G)", "TREATMENT", 119, 151], ["20 mm", "OBSERVATION_MODIFIER", 11, 16], ["Respiratory Cells", "ANATOMY", 125, 142]]], ["Subsequently, cells were control treated (w/o) or treated with TNF-a.", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["TNF", "GENE_OR_GENE_PRODUCT", 63, 66], ["TNF", "PROTEIN", 63, 66], ["TNF", "TREATMENT", 63, 66]]], ["Endogenous importin-a3 and NF-kB p65 protein levels were detected and quantified for whole-cell lysates (WCLs), CFs and NFs of WT MEFs (n = 3) (F), and WCLs of HSAEpCs (n = 3) (G).", [["whole-cell lysates", "ANATOMY", 85, 103], ["WCLs", "ANATOMY", 105, 109], ["CFs", "ANATOMY", 112, 115], ["NFs", "ANATOMY", 120, 123], ["MEFs", "ANATOMY", 130, 134], ["WCLs", "ANATOMY", 152, 156], ["HSAEpCs", "ANATOMY", 160, 167], ["importin-a3", "GENE_OR_GENE_PRODUCT", 11, 22], ["NF-kB p65", "GENE_OR_GENE_PRODUCT", 27, 36], ["cell lysates", "ORGANISM_SUBSTANCE", 91, 103], ["WCLs", "CELL", 105, 109], ["CFs", "CELL", 112, 115], ["NFs", "CELLULAR_COMPONENT", 120, 123], ["MEFs", "CELL", 130, 134], ["F", "CELL", 144, 145], ["WCLs", "CELL", 152, 156], ["importin", "PROTEIN", 11, 19], ["NF-kB p65", "PROTEIN", 27, 36], ["WCLs", "CELL_TYPE", 105, 109], ["CFs", "CELL_TYPE", 112, 115], ["NFs", "CELL_TYPE", 120, 123], ["WT MEFs", "CELL_TYPE", 127, 134], ["Endogenous importin", "TREATMENT", 0, 19], ["NF-kB p65 protein levels", "TEST", 27, 51], ["whole-cell lysates", "TEST", 85, 103], ["WCLs", "TEST", 105, 109], ["CFs", "TEST", 112, 115], ["NFs", "TEST", 120, 123], ["WT MEFs", "TEST", 127, 134], ["HSAEpCs", "TEST", 160, 167]]], ["Controltreated samples of each fraction were set to 100%.High-Level TNF-a-Inducing Human-Type HPAIV Infections Reduce Importin-a3 Protein Expression Levels in Human Respiratory Cells(H) NF-kB binding sites in the promoter element of the human importin-a3 gene in A549 cells (Raskatov et al., 2012) .High-Level TNF-a-Inducing Human-Type HPAIV Infections Reduce Importin-a3 Protein Expression Levels in Human Respiratory Cells(I-K) Effect of TNF-a treatment on importin-a3 promoter activity in HSAEpC (n = 2) (I), MEFs (n = 3) (J), and A549 cells (n = 6) (K) upon control (Ctr) or importin-a3 promoter reporter construct (a3) transfection.", [["samples", "ANATOMY", 15, 22], ["A549 cells", "ANATOMY", 263, 273], ["Cells", "ANATOMY", 419, 424], ["HSAEpC", "ANATOMY", 492, 498], ["MEFs", "ANATOMY", 512, 516], ["A549 cells", "ANATOMY", 534, 544], ["TNF", "GENE_OR_GENE_PRODUCT", 68, 71], ["Human", "ORGANISM", 83, 88], ["HPAIV", "ORGANISM", 94, 99], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 118, 129], ["Human", "ORGANISM", 159, 164], ["NF-kB", "GENE_OR_GENE_PRODUCT", 186, 191], ["human", "ORGANISM", 237, 242], ["importin-a3", "GENE_OR_GENE_PRODUCT", 243, 254], ["A549 cells", "CELL", 263, 273], ["TNF", "GENE_OR_GENE_PRODUCT", 310, 313], ["Human", "ORGANISM", 325, 330], ["HPAIV", "ORGANISM", 336, 341], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 360, 371], ["Human", "ORGANISM", 401, 406], ["Respiratory Cells", "CELL", 407, 424], ["TNF-a", "GENE_OR_GENE_PRODUCT", 440, 445], ["importin-a3", "GENE_OR_GENE_PRODUCT", 459, 470], ["MEFs", "CELL", 512, 516], ["A549 cells", "CELL", 534, 544], ["importin-a3", "GENE_OR_GENE_PRODUCT", 579, 590], ["TNF", "PROTEIN", 68, 71], ["Importin", "PROTEIN", 118, 126], ["Human Respiratory Cells(H) NF-kB binding sites", "DNA", 159, 205], ["promoter element", "DNA", 213, 229], ["human importin-a3 gene", "DNA", 237, 259], ["A549 cells", "CELL_LINE", 263, 273], ["TNF", "PROTEIN", 310, 313], ["Importin", "PROTEIN", 360, 368], ["Human Respiratory Cells", "CELL_TYPE", 401, 424], ["TNF", "PROTEIN", 440, 443], ["importin", "PROTEIN", 459, 467], ["MEFs", "CELL_LINE", 512, 516], ["A549 cells", "CELL_LINE", 534, 544], ["importin", "PROTEIN", 579, 587], ["a3 promoter reporter construct", "DNA", 588, 618], ["Human", "SPECIES", 83, 88], ["Human", "SPECIES", 159, 164], ["human", "SPECIES", 237, 242], ["Human", "SPECIES", 325, 330], ["Human", "SPECIES", 401, 406], ["human", "SPECIES", 237, 242], ["each fraction", "TEST", 26, 39], ["High-Level TNF", "PROBLEM", 57, 71], ["Type HPAIV Infections", "PROBLEM", 89, 110], ["Expression Levels", "TEST", 138, 155], ["NF", "PROBLEM", 186, 188], ["kB binding sites", "PROBLEM", 189, 205], ["High-Level TNF", "PROBLEM", 299, 313], ["Type HPAIV Infections", "PROBLEM", 331, 352], ["Expression Levels", "TEST", 380, 397], ["Human Respiratory Cells", "TEST", 401, 424], ["TNF", "TEST", 440, 443], ["a treatment", "TREATMENT", 444, 455], ["importin-a3 promoter activity", "TREATMENT", 459, 488], ["HSAEpC", "TEST", 492, 498], ["MEFs (n = 3) (J), and A549 cells", "TREATMENT", 512, 544], ["Respiratory Cells", "ANATOMY", 165, 182], ["A549 cells", "OBSERVATION", 263, 273], ["Respiratory Cells", "ANATOMY", 407, 424]]], ["Relative importin-a3 promoter activity in control-treated samples was set to 100%.High-Level TNF-a-Inducing Human-Type HPAIV Infections Reduce Importin-a3 Protein Expression Levels in Human Respiratory Cells(L) Importin-a3 mRNA levels in mock or TNF-a-treated MEF NEMO \u00c0/\u00c0 cells (n = 6).", [["samples", "ANATOMY", 58, 65], ["Cells", "ANATOMY", 202, 207], ["MEF NEMO \u00c0/\u00c0 cells", "ANATOMY", 260, 278], ["importin-a3", "GENE_OR_GENE_PRODUCT", 9, 20], ["TNF", "GENE_OR_GENE_PRODUCT", 93, 96], ["Human-Type HPAIV", "ORGANISM", 108, 124], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 143, 154], ["Human", "ORGANISM", 184, 189], ["Respiratory Cells", "CELL", 190, 207], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 211, 222], ["TNF-a-", "GENE_OR_GENE_PRODUCT", 246, 252], ["MEF", "CELL", 260, 263], ["importin", "PROTEIN", 9, 17], ["a3 promoter", "DNA", 18, 29], ["TNF", "PROTEIN", 93, 96], ["Importin", "PROTEIN", 143, 151], ["TNF-a-treated MEF NEMO \u00c0/\u00c0 cells", "CELL_LINE", 246, 278], ["Human", "SPECIES", 108, 113], ["Human", "SPECIES", 184, 189], ["a3 promoter activity in control", "TREATMENT", 18, 49], ["High-Level TNF", "PROBLEM", 82, 96], ["Type HPAIV Infections", "PROBLEM", 114, 135], ["Expression Levels", "TEST", 163, 180], ["Human Respiratory Cells", "TEST", 184, 207], ["mRNA levels", "TEST", 223, 234], ["TNF", "TEST", 246, 249], ["a3 promoter", "OBSERVATION_MODIFIER", 18, 29], ["activity", "OBSERVATION_MODIFIER", 30, 38], ["Respiratory Cells", "ANATOMY", 190, 207]]], ["Relative expression values of importin-a3 in samples were normalized to GAPDH, and importin-a1 mRNA expression was set to 1.", [["samples", "ANATOMY", 45, 52], ["importin-a3", "GENE_OR_GENE_PRODUCT", 30, 41], ["samples", "CANCER", 45, 52], ["GAPDH", "GENE_OR_GENE_PRODUCT", 72, 77], ["importin-a1", "GENE_OR_GENE_PRODUCT", 83, 94], ["importin-a3", "PROTEIN", 30, 41], ["GAPDH", "TEST", 72, 77]]], ["Each data point represents an individual sample.High-Level TNF-a-Inducing Human-Type HPAIV Infections Reduce Importin-a3 Protein Expression Levels in Human Respiratory Cells(M) MEF NEMO \u00c0/\u00c0 cells were transfected with empty plasmid (Mock) or NEMO and untreated or treated with 50 ng TNF-a.", [["Cells", "ANATOMY", 168, 173], ["MEF NEMO \u00c0/\u00c0 cells", "ANATOMY", 177, 195], ["plasmid", "ANATOMY", 224, 231], ["TNF", "GENE_OR_GENE_PRODUCT", 59, 62], ["Human-Type HPAIV", "ORGANISM", 74, 90], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 109, 120], ["Human", "ORGANISM", 150, 155], ["Respiratory Cells", "CELL", 156, 173], ["NEMO", "GENE_OR_GENE_PRODUCT", 242, 246], ["TNF", "GENE_OR_GENE_PRODUCT", 283, 286], ["TNF", "PROTEIN", 59, 62], ["Importin", "PROTEIN", 109, 117], ["Human Respiratory Cells(M) MEF NEMO \u00c0/\u00c0 cells", "CELL_LINE", 150, 195], ["empty plasmid", "DNA", 218, 231], ["NEMO", "PROTEIN", 242, 246], ["TNF", "PROTEIN", 283, 286], ["Human", "SPECIES", 74, 79], ["Human", "SPECIES", 150, 155], ["an individual sample", "TEST", 27, 47], ["High-Level TNF", "PROBLEM", 48, 62], ["Type HPAIV Infections", "PROBLEM", 80, 101], ["Expression Levels", "TEST", 129, 146], ["Human Respiratory Cells(M) MEF NEMO \u00c0/\u00c0 cells", "TREATMENT", 150, 195], ["empty plasmid (Mock)", "TREATMENT", 218, 238], ["Respiratory Cells", "ANATOMY", 156, 173]]], ["Importin-a3 and NEMO protein expression levels were detected (n = 3).", [["Importin-a3", "GENE_OR_GENE_PRODUCT", 0, 11], ["NEMO", "GENE_OR_GENE_PRODUCT", 16, 20], ["NEMO", "PROTEIN", 16, 20], ["NEMO protein expression levels", "TEST", 16, 46]]], ["GAPDH protein detection served as loading control.High-Level TNF-a-Inducing Human-Type HPAIV Infections Reduce Importin-a3 Protein Expression Levels in Human Respiratory Cells(N) MEF NEMO \u00c0/\u00c0 cells were treated with 10 ng TNF-a, IL-6, IL-10, IFN-g and TGF-b and importin-a3 mRNA levels were measured as described above (n = 3) (O) Importin-a3 gene expression is controlled by TNF-a-activated NF-kB in a dose-dependent manner.", [["Cells", "ANATOMY", 170, 175], ["MEF NEMO \u00c0/\u00c0 cells", "ANATOMY", 179, 197], ["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF", "GENE_OR_GENE_PRODUCT", 61, 64], ["Human-Type HPAIV", "ORGANISM", 76, 92], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 111, 122], ["Human", "ORGANISM", 152, 157], ["Respiratory Cells", "CELL", 158, 175], ["N) MEF", "CELL", 176, 182], ["TNF-a", "GENE_OR_GENE_PRODUCT", 222, 227], ["IL-6", "GENE_OR_GENE_PRODUCT", 229, 233], ["IL-10", "GENE_OR_GENE_PRODUCT", 235, 240], ["IFN-g", "GENE_OR_GENE_PRODUCT", 242, 247], ["TGF-b", "GENE_OR_GENE_PRODUCT", 252, 257], ["importin-a3", "GENE_OR_GENE_PRODUCT", 262, 273], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 331, 342], ["TNF", "GENE_OR_GENE_PRODUCT", 376, 379], ["NF-kB", "GENE_OR_GENE_PRODUCT", 392, 397], ["GAPDH protein", "PROTEIN", 0, 13], ["TNF", "PROTEIN", 61, 64], ["Importin", "PROTEIN", 111, 119], ["Human Respiratory Cells(N) MEF NEMO \u00c0/\u00c0 cells", "CELL_LINE", 152, 197], ["TNF", "PROTEIN", 222, 225], ["IFN", "PROTEIN", 242, 245], ["TNF", "PROTEIN", 376, 379], ["NF-kB", "PROTEIN", 392, 397], ["Human", "SPECIES", 76, 81], ["Human", "SPECIES", 152, 157], ["GAPDH protein detection", "TEST", 0, 23], ["loading control", "TREATMENT", 34, 49], ["High-Level TNF", "PROBLEM", 50, 64], ["Type HPAIV Infections", "PROBLEM", 82, 103], ["Importin", "TEST", 111, 119], ["Expression Levels", "TEST", 131, 148], ["Human Respiratory Cells", "TEST", 152, 175], ["MEF NEMO \u00c0/\u00c0 cells", "TEST", 179, 197], ["TNF", "TEST", 222, 225], ["IL", "TEST", 229, 231], ["IL", "TEST", 235, 237], ["IFN", "TEST", 242, 245], ["TGF", "TEST", 252, 255], ["mRNA levels", "TEST", 274, 285], ["Respiratory Cells", "ANATOMY", 158, 175]]], ["Low amounts of TNF-a induce activation of NF-kB and high expression of importin-a3 (upper panel).", [["TNF", "GENE_OR_GENE_PRODUCT", 15, 18], ["NF-kB", "GENE_OR_GENE_PRODUCT", 42, 47], ["importin-a3", "GENE_OR_GENE_PRODUCT", 71, 82], ["TNF", "PROTEIN", 15, 18], ["NF-kB", "PROTEIN", 42, 47], ["importin-a3", "PROTEIN", 71, 82], ["upper panel", "PROTEIN", 84, 95], ["Low amounts of TNF", "PROBLEM", 0, 18], ["a induce activation of NF", "TREATMENT", 19, 44]]], ["In contrast, high amounts of TNF-a induce high activation of NF-kB and low expression of importin-a3 (lower panel).", [["TNF", "GENE_OR_GENE_PRODUCT", 29, 32], ["NF-kB", "GENE_OR_GENE_PRODUCT", 61, 66], ["importin-a3", "GENE_OR_GENE_PRODUCT", 89, 100], ["TNF", "PROTEIN", 29, 32], ["NF-kB", "PROTEIN", 61, 66], ["importin-a3", "PROTEIN", 89, 100], ["TNF", "TEST", 29, 32], ["high amounts", "OBSERVATION_MODIFIER", 13, 25], ["low expression", "OBSERVATION_MODIFIER", 71, 85]]], ["Data shown represent means \u00b1 SD of at least three independent biological experiments. p < 0.001. in mammalian species.", [["mammalian species", "PROBLEM", 100, 117], ["biological experiments", "OBSERVATION", 62, 84], ["mammalian species", "OBSERVATION", 100, 117]]], ["Importin-a3 protein levels were strongly reduced in human-type HPAIV compared to avian-type HPAIVinfected MEFs ( Figures 3B-3E ).", [["MEFs", "ANATOMY", 106, 110], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 0, 11], ["human-type HPAIV", "ORGANISM", 52, 68], ["MEFs", "CELL", 106, 110], ["Figures 3B-3E", "CELL", 113, 126], ["Importin", "PROTEIN", 0, 8], ["avian-type HPAIVinfected MEFs", "CELL_LINE", 81, 110], ["human", "SPECIES", 52, 57], ["human-type HPAIV", "SPECIES", 52, 68], ["a3 protein levels", "TEST", 9, 26], ["type HPAIV", "PROBLEM", 58, 68]]], ["In contrast, protein expression levels of other importin-a isoforms (a1, a4, a5, and a7) were not affected ( Figures 3F and 3G ).", [["importin-a", "GENE_OR_GENE_PRODUCT", 48, 58], ["a1", "GENE_OR_GENE_PRODUCT", 69, 71], ["a4", "GENE_OR_GENE_PRODUCT", 73, 75], ["a5", "GENE_OR_GENE_PRODUCT", 77, 79], ["a7", "GENE_OR_GENE_PRODUCT", 85, 87], ["importin", "PROTEIN", 48, 56], ["a1", "PROTEIN", 69, 71], ["a4", "PROTEIN", 73, 75], ["a5", "PROTEIN", 77, 79], ["a7", "PROTEIN", 85, 87], ["protein expression levels", "TEST", 13, 38]]], ["Next, we wanted to assess whether replication of avian-and human-type HPAIV is affected in cells deficient in importin-a3.", [["cells", "ANATOMY", 91, 96], ["avian", "ORGANISM", 49, 54], ["human-type HPAIV", "ORGANISM", 59, 75], ["cells", "CELL", 91, 96], ["importin-a3", "GENE_OR_GENE_PRODUCT", 110, 121], ["importin-a3", "PROTEIN", 110, 121], ["human", "SPECIES", 59, 64], ["human-type HPAIV", "SPECIES", 59, 75], ["type HPAIV", "PROBLEM", 65, 75]]], ["Cells deficient in importin-a3 were obtained from fibroblasts of mice generated for this study with a deleted importin-a3 gene (a3 \u00c0/\u00c0 ; a3 \u00c0/\u00c0 MEFs; Figures S2D and S2E ).", [["Cells", "ANATOMY", 0, 5], ["fibroblasts", "ANATOMY", 50, 61], ["MEFs", "ANATOMY", 144, 148], ["Cells", "CELL", 0, 5], ["importin-a3", "GENE_OR_GENE_PRODUCT", 19, 30], ["fibroblasts", "CELL", 50, 61], ["mice", "ORGANISM", 65, 69], ["importin-a3", "GENE_OR_GENE_PRODUCT", 110, 121], ["a3 \u00c0", "GENE_OR_GENE_PRODUCT", 128, 132], ["importin-a3", "PROTEIN", 19, 30], ["fibroblasts", "CELL_TYPE", 50, 61], ["importin-a3 gene", "DNA", 110, 126], ["a3", "DNA", 128, 130], ["a3", "DNA", 137, 139], ["\u00c0 MEFs", "DNA", 142, 148], ["S2E", "DNA", 166, 169], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 65, 69], ["this study", "TEST", 84, 94], ["MEFs", "TEST", 144, 148], ["Figures", "TEST", 150, 157]]], ["MEFs with a deficient importin-a7 gene were obtained from mice with a deleted importin-a7 gene (a7 \u00c0/\u00c0 ), described previously (Gabriel et al., 2011) .", [["MEFs", "ANATOMY", 0, 4], ["MEFs", "CELL", 0, 4], ["importin-a7", "GENE_OR_GENE_PRODUCT", 22, 33], ["mice", "ORGANISM", 58, 62], ["importin-a7", "GENE_OR_GENE_PRODUCT", 78, 89], ["deficient importin-a7 gene", "DNA", 12, 38], ["deleted importin-a7 gene", "DNA", 70, 94], ["a7", "DNA", 96, 98], ["\u00c0", "DNA", 101, 102], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["a deficient importin", "TREATMENT", 10, 30]]], ["Replication kinetics in MEFs revealed that avian-type but not human-type HPAIV replication is impaired in cells with a deleted importin-a3 gene (a3 \u00c0/\u00c0 ), unlike in control cells, with a deleted importin-a7 gene (a7 \u00c0/\u00c0 ) that acts as a positive factor of human-type HPAIV replication in mammalian cells (Hudjetz and Gabriel, 2012) (Figures 3H and 3I) .", [["MEFs", "ANATOMY", 24, 28], ["cells", "ANATOMY", 106, 111], ["cells", "ANATOMY", 173, 178], ["mammalian cells", "ANATOMY", 288, 303], ["MEFs", "CELL", 24, 28], ["human-type HPAIV", "ORGANISM", 62, 78], ["cells", "CELL", 106, 111], ["importin-a3", "GENE_OR_GENE_PRODUCT", 127, 138], ["a3 \u00c0/\u00c0", "GENE_OR_GENE_PRODUCT", 145, 151], ["cells", "CELL", 173, 178], ["importin-a7", "GENE_OR_GENE_PRODUCT", 195, 206], ["a7 \u00c0/\u00c0", "GENE_OR_GENE_PRODUCT", 213, 219], ["human-type HPAIV", "ORGANISM", 256, 272], ["mammalian cells", "CELL", 288, 303], ["importin-a3 gene", "DNA", 127, 143], ["a3 \u00c0", "DNA", 145, 149], ["\u00c0", "DNA", 150, 151], ["importin-a7 gene", "DNA", 195, 211], ["a7 \u00c0", "DNA", 213, 217], ["\u00c0", "DNA", 218, 219], ["mammalian cells", "CELL_TYPE", 288, 303], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 256, 261], ["human-type HPAIV", "SPECIES", 62, 78], ["human", "SPECIES", 256, 261], ["HPAIV", "SPECIES", 267, 272], ["Replication kinetics in MEFs", "TEST", 0, 28], ["type HPAIV replication", "PROBLEM", 68, 90], ["human-type HPAIV replication", "TREATMENT", 256, 284]]], ["Interestingly, avian-type HPAIV replication in a3 \u00c0/\u00c0 MEFs is increased by >1,000 times compared to WT control cells.", [["a3 \u00c0/\u00c0 MEFs", "ANATOMY", 47, 58], ["cells", "ANATOMY", 111, 116], ["avian-type HPAIV", "ORGANISM", 15, 31], ["a3 \u00c0", "GENE_OR_GENE_PRODUCT", 47, 51], ["MEFs", "CELL", 54, 58], ["cells", "CELL", 111, 116], ["a3 \u00c0/\u00c0 MEFs", "CELL_LINE", 47, 58], ["WT control cells", "CELL_TYPE", 100, 116], ["HPAIV", "SPECIES", 26, 31], ["MEFs", "PROBLEM", 54, 58], ["HPAIV replication", "OBSERVATION", 26, 43], ["increased", "OBSERVATION_MODIFIER", 62, 71]]], ["Human-type HPAIV replication was comparable between WT and a3 \u00c0/\u00c0 cells ( Figures 3J and 3K ).", [["a3 \u00c0/\u00c0 cells", "ANATOMY", 59, 71], ["Human", "ORGANISM", 0, 5], ["HPAIV", "ORGANISM", 11, 16], ["a3 \u00c0/\u00c0 cells", "CELL_LINE", 59, 71], ["Human", "SPECIES", 0, 5], ["Human-type HPAIV", "SPECIES", 0, 16], ["Human-type HPAIV replication", "TREATMENT", 0, 28], ["WT", "TEST", 52, 54], ["Figures 3J", "TEST", 74, 84]]], ["In line, human-type SC35M-PB2 701N HPAIV replication was not affected in human H1299 a3 +/+ cells upon TNF-a treatment, likely due to the strong inhibition of importin-a3 protein expression ( Figure 3L ).", [["H1299 a3 +/+ cells", "ANATOMY", 79, 97], ["human-type SC35M-PB2 701N HPAIV", "ORGANISM", 9, 40], ["human", "ORGANISM", 73, 78], ["H1299 a3", "CELL", 79, 87], ["TNF-a", "GENE_OR_GENE_PRODUCT", 103, 108], ["importin-a3", "GENE_OR_GENE_PRODUCT", 159, 170], ["human H1299 a3 +/+ cells", "CELL_LINE", 73, 97], ["TNF", "PROTEIN", 103, 106], ["importin", "PROTEIN", 159, 167], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 73, 78], ["human-type SC35M-PB2 701N HPAIV", "SPECIES", 9, 40], ["human", "SPECIES", 73, 78], ["human-type SC35M", "TREATMENT", 9, 25], ["PB2", "TREATMENT", 26, 29], ["HPAIV replication", "TREATMENT", 35, 52], ["TNF", "TEST", 103, 106], ["a treatment", "TREATMENT", 107, 118]]], ["In human H1299 a3 \u00c0/\u00c0 cells, SC35M-PB2 701N HPAIV replication slightly increased, suggesting some residual inhibitory activity of importin-a3 in human cells ( Figure 3L ).", [["H1299 a3 \u00c0/\u00c0 cells", "ANATOMY", 9, 27], ["cells", "ANATOMY", 151, 156], ["human", "ORGANISM", 3, 8], ["H1299 a3 \u00c0/\u00c0 cells", "CELL", 9, 27], ["SC35M-PB2 701N HPAIV", "ORGANISM", 29, 49], ["importin-a3", "GENE_OR_GENE_PRODUCT", 130, 141], ["human", "ORGANISM", 145, 150], ["cells", "CELL", 151, 156], ["Figure 3L", "CELL", 159, 168], ["human H1299 a3 \u00c0/\u00c0 cells", "CELL_LINE", 3, 27], ["importin-a3", "PROTEIN", 130, 141], ["human cells", "CELL_TYPE", 145, 156], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 145, 150], ["human", "SPECIES", 3, 8], ["PB2 701N HPAIV", "SPECIES", 35, 49], ["human", "SPECIES", 145, 150], ["cells", "TEST", 22, 27], ["SC35M", "TEST", 29, 34], ["PB2", "TREATMENT", 35, 38], ["HPAIV replication", "PROBLEM", 44, 61], ["slightly", "OBSERVATION_MODIFIER", 62, 70], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["residual inhibitory activity", "OBSERVATION", 98, 126]]], ["These findings show that low-level TNF-a-inducing HPAIVs with avian-type polymerase signatures are highly sensitive to importin-a3-mediated virus restriction.", [["TNF", "GENE_OR_GENE_PRODUCT", 35, 38], ["HPAIVs", "GENE_OR_GENE_PRODUCT", 50, 56], ["importin-a3", "GENE_OR_GENE_PRODUCT", 119, 130], ["TNF", "PROTEIN", 35, 38], ["a-inducing HPAIVs", "PROTEIN", 39, 56], ["importin", "PROTEIN", 119, 127], ["a3", "PROTEIN", 128, 130], ["low-level TNF", "PROBLEM", 25, 38], ["a-inducing HPAIVs", "PROBLEM", 39, 56], ["avian-type polymerase signatures", "PROBLEM", 62, 94], ["importin-a3-mediated virus restriction", "TREATMENT", 119, 157], ["low", "OBSERVATION_MODIFIER", 25, 28]]], ["In contrast, high-level TNF-a-inducing HPAIVs with human-type polymerase genes are resistant to importin-a3mediated virus restriction.Importin-a3 Belongs to the Most Conserved Nuclear Transport Factors between Avian and Mammalian SpeciesDifferential regulation of importin-a3 expression levels upon avian-and human-type HPAIV infections prompted us to analyze the sequence identity of importin-a isoforms in various avian and mammalian species.", [["infections", "DISEASE", 326, 336], ["TNF", "GENE_OR_GENE_PRODUCT", 24, 27], ["HPAIVs", "GENE_OR_GENE_PRODUCT", 39, 45], ["human", "ORGANISM", 51, 56], ["importin", "GENE_OR_GENE_PRODUCT", 96, 104], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 134, 145], ["importin-a3", "GENE_OR_GENE_PRODUCT", 264, 275], ["avian", "ORGANISM", 299, 304], ["human-type HPAIV", "ORGANISM", 309, 325], ["importin-a", "GENE_OR_GENE_PRODUCT", 385, 395], ["TNF", "PROTEIN", 24, 27], ["a-inducing HPAIVs", "PROTEIN", 28, 45], ["human-type polymerase genes", "DNA", 51, 78], ["importin", "PROTEIN", 96, 104], ["Importin-a3", "PROTEIN", 134, 145], ["Conserved Nuclear Transport Factors", "PROTEIN", 166, 201], ["importin", "PROTEIN", 264, 272], ["a3", "PROTEIN", 273, 275], ["importin", "PROTEIN", 385, 393], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 309, 314], ["human", "SPECIES", 51, 56], ["human-type HPAIV", "SPECIES", 309, 325], ["a-inducing HPAIVs", "PROBLEM", 28, 45], ["human-type polymerase genes", "TREATMENT", 51, 78], ["importin-a3mediated virus restriction", "TREATMENT", 96, 133], ["expression levels", "TEST", 276, 293], ["type HPAIV infections", "PROBLEM", 315, 336], ["mammalian species", "OBSERVATION", 426, 443]]], ["Among all importin-a isoforms analyzed, importin-a1 was the most diverse nuclear import factor, with amino acid homology of 83.52% between chicken and humans ( Figure 4A ; Table S1 ).", [["nuclear", "ANATOMY", 73, 80], ["amino acid", "CHEMICAL", 101, 111], ["amino acid", "CHEMICAL", 101, 111], ["importin", "GENE_OR_GENE_PRODUCT", 10, 18], ["importin-a1", "GENE_OR_GENE_PRODUCT", 40, 51], ["amino acid", "AMINO_ACID", 101, 111], ["chicken", "ORGANISM", 139, 146], ["humans", "ORGANISM", 151, 157], ["importin", "PROTEIN", 10, 18], ["importin", "PROTEIN", 40, 48], ["a1", "PROTEIN", 49, 51], ["nuclear import factor", "PROTEIN", 73, 94], ["chicken", "SPECIES", 139, 146], ["humans", "SPECIES", 151, 157], ["chicken", "SPECIES", 139, 146], ["humans", "SPECIES", 151, 157], ["amino acid homology", "TEST", 101, 120]]], ["The isoforms importin-a3 and importin-a4 displayed the highest amino acid homologies between chicken and humans of 99.04% and 98.08%, respec-tively (Figures 4B and 4C; Table S1 ).", [["amino acid", "CHEMICAL", 63, 73], ["amino acid", "CHEMICAL", 63, 73], ["importin-a3", "GENE_OR_GENE_PRODUCT", 13, 24], ["importin-a4", "GENE_OR_GENE_PRODUCT", 29, 40], ["amino acid", "AMINO_ACID", 63, 73], ["chicken", "ORGANISM", 93, 100], ["humans", "ORGANISM", 105, 111], ["importin", "PROTEIN", 13, 21], ["a3", "PROTEIN", 22, 24], ["importin", "PROTEIN", 29, 37], ["a4", "PROTEIN", 38, 40], ["chicken", "SPECIES", 93, 100], ["humans", "SPECIES", 105, 111], ["chicken", "SPECIES", 93, 100], ["humans", "SPECIES", 105, 111], ["the highest amino acid homologies", "TREATMENT", 51, 84], ["respec", "TEST", 134, 140], ["Figures", "TEST", 149, 156]]], ["Importin-a5, -a6, and -a7 presented amino acid homologies between chicken and humans of 95.91%, 94.22%, and 94.4%, respectively (Figures 4D-4F; Table S1 ).", [["amino acid", "CHEMICAL", 36, 46], ["amino acid", "CHEMICAL", 36, 46], ["Importin-a5", "GENE_OR_GENE_PRODUCT", 0, 11], ["a6", "GENE_OR_GENE_PRODUCT", 14, 16], ["amino acid", "AMINO_ACID", 36, 46], ["chicken", "ORGANISM", 66, 73], ["humans", "ORGANISM", 78, 84], ["Importin", "PROTEIN", 0, 8], ["a5", "PROTEIN", 9, 11], ["a6", "DNA", 14, 16], ["a7", "DNA", 23, 25], ["chicken", "SPECIES", 66, 73], ["humans", "SPECIES", 78, 84], ["chicken", "SPECIES", 66, 73], ["humans", "SPECIES", 78, 84], ["amino acid homologies", "TEST", 36, 57], ["Figures", "TEST", 129, 136]]], ["These findings suggest that particularly importin-a3 and importin-a4, both known nuclear transporters of NF-kB (Fagerlund et al., 2005) , are highly conserved across species kingdoms.", [["nuclear", "ANATOMY", 81, 88], ["importin-a3", "GENE_OR_GENE_PRODUCT", 41, 52], ["importin-a4", "GENE_OR_GENE_PRODUCT", 57, 68], ["NF-kB", "GENE_OR_GENE_PRODUCT", 105, 110], ["importin", "PROTEIN", 41, 49], ["a3", "PROTEIN", 50, 52], ["importin", "PROTEIN", 57, 65], ["a4", "PROTEIN", 66, 68], ["nuclear transporters", "PROTEIN", 81, 101], ["NF-kB", "PROTEIN", 105, 110], ["species kingdoms", "OBSERVATION", 166, 182]]], ["However, importin-a3 is expressed up t\u00f5 5-times-higher levels than importin-a4 in the murine and human lung ( Figures 1C and 1D) , highlighting particularly the importance of importin-a3 in respiratory immune responses.", [["lung", "ANATOMY", 103, 107], ["respiratory", "ANATOMY", 190, 201], ["importin-a3", "GENE_OR_GENE_PRODUCT", 9, 20], ["importin-a4", "GENE_OR_GENE_PRODUCT", 67, 78], ["murine", "ORGANISM", 86, 92], ["human", "ORGANISM", 97, 102], ["lung", "ORGAN", 103, 107], ["importin-a3", "GENE_OR_GENE_PRODUCT", 175, 186], ["importin", "PROTEIN", 9, 17], ["a3", "PROTEIN", 18, 20], ["importin-a4", "PROTEIN", 67, 78], ["importin-a3", "PROTEIN", 175, 186], ["murine", "SPECIES", 86, 92], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["lung", "ANATOMY", 103, 107]]], ["Thus, acquiring the ability to downregulate importin-a3 in the lung might serve as an important basis in avianmammalian virus transmission.", [["lung", "ANATOMY", 63, 67], ["importin-a3", "GENE_OR_GENE_PRODUCT", 44, 55], ["lung", "ORGAN", 63, 67], ["avianmammalian virus", "ORGANISM", 105, 125], ["importin-a3", "PROTEIN", 44, 55], ["avianmammalian virus", "SPECIES", 105, 125], ["lung", "ANATOMY", 63, 67]]], ["In order to see whether differential importin-a3 regulation is also present in human isolates, we analyzed human-type HPAIV strains that caused poultry outbreaks with human infections in the Netherlands (H7N7) or Thailand (H5N1).", [["poultry outbreaks", "DISEASE", 144, 161], ["human infections", "DISEASE", 167, 183], ["importin-a3", "GENE_OR_GENE_PRODUCT", 37, 48], ["human", "ORGANISM", 79, 84], ["human-type HPAIV", "ORGANISM", 107, 123], ["human", "ORGANISM", 167, 172], ["importin", "PROTEIN", 37, 45], ["a3", "PROTEIN", 46, 48], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 79, 84], ["human-type HPAIV strains", "SPECIES", 107, 131], ["human", "SPECIES", 167, 172], ["human-type HPAIV strains", "TREATMENT", 107, 131], ["human infections", "PROBLEM", 167, 183]]], ["Infection of primary lung cultures with cytokine storm, including TNF-a-inducing H5N1 and H7N7 HPAIV isolates with human-type polymerase signatures (PB2 627K ; PB2 701N ), showed significantly reduced importin-a3 expression levels compared to their counterparts with aviantype polymerase signatures (PB2 627E ; PB2 701D ) ( Figures 4G and 4H ).", [["lung cultures", "ANATOMY", 21, 34], ["lung", "ORGAN", 21, 25], ["TNF", "GENE_OR_GENE_PRODUCT", 66, 69], ["-a-inducing H5N1", "ORGANISM", 69, 85], ["H7N7 HPAIV isolates", "ORGANISM", 90, 109], ["human", "ORGANISM", 115, 120], ["importin-a3", "GENE_OR_GENE_PRODUCT", 201, 212], ["cytokine", "PROTEIN", 40, 48], ["TNF", "PROTEIN", 66, 69], ["human-type polymerase signatures", "DNA", 115, 147], ["PB2 701N", "PROTEIN", 160, 168], ["importin", "PROTEIN", 201, 209], ["a3", "PROTEIN", 210, 212], ["aviantype polymerase signatures", "DNA", 267, 298], ["PB2 701D", "PROTEIN", 311, 319], ["H7N7 HPAIV", "SPECIES", 90, 100], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["primary lung cultures", "TEST", 13, 34], ["cytokine storm", "PROBLEM", 40, 54], ["TNF", "TEST", 66, 69], ["H5N1", "PROBLEM", 81, 85], ["H7N7 HPAIV isolates", "TEST", 90, 109], ["human-type polymerase signatures", "TEST", 115, 147], ["PB2", "TEST", 149, 152], ["K", "TEST", 156, 157], ["PB2", "TEST", 160, 163], ["significantly reduced importin-a3 expression levels", "PROBLEM", 179, 230], ["aviantype polymerase signatures", "TEST", 267, 298], ["PB2", "TEST", 300, 303], ["PB2", "TEST", 311, 314], ["Figures", "TEST", 324, 331], ["lung", "ANATOMY", 21, 25], ["cytokine storm", "OBSERVATION", 40, 54]]], ["These findings highlight the crucial role of importin-a3 as a respiratory factor conserved across animal kingdoms in HPAIV interspecies transmission.Human-Type Polymerase Signatures in HPAIV MediateReduced Importin-a3 mRNA Expression Levels in the Murine BE Next, we wanted to assess whether differential regulation of importin-a3 can also be detected in a murine infection model.", [["infection", "DISEASE", 364, 373], ["importin-a3", "GENE_OR_GENE_PRODUCT", 45, 56], ["HPAIV", "ORGANISM", 117, 122], ["Human", "ORGANISM", 149, 154], ["HPAIV", "ORGANISM", 185, 190], ["Importin-a3", "GENE_OR_GENE_PRODUCT", 206, 217], ["importin-a3", "GENE_OR_GENE_PRODUCT", 319, 330], ["murine", "ORGANISM", 357, 363], ["importin", "PROTEIN", 45, 53], ["a3", "PROTEIN", 54, 56], ["respiratory factor", "PROTEIN", 62, 80], ["importin", "PROTEIN", 319, 327], ["a3", "PROTEIN", 328, 330], ["Human", "SPECIES", 149, 154], ["murine", "SPECIES", 357, 363], ["HPAIV", "SPECIES", 117, 122], ["a respiratory factor", "PROBLEM", 60, 80], ["Expression Levels", "TEST", 223, 240], ["a murine infection model", "PROBLEM", 355, 379], ["HPAIV interspecies", "OBSERVATION", 117, 135], ["infection", "OBSERVATION", 364, 373]]], ["Therefore, we assessed importin-a3 expression levels in lung samples of HPAIV-infected WT mice.", [["lung samples", "ANATOMY", 56, 68], ["HPAIV-infected", "DISEASE", 72, 86], ["importin-a3", "GENE_OR_GENE_PRODUCT", 23, 34], ["lung samples", "CANCER", 56, 68], ["HPAIV", "ORGANISM", 72, 77], ["WT mice", "ORGANISM", 87, 94], ["importin", "PROTEIN", 23, 31], ["a3", "PROTEIN", 32, 34], ["mice", "SPECIES", 90, 94], ["HPAIV", "SPECIES", 72, 77], ["mice", "SPECIES", 90, 94], ["lung samples", "TEST", 56, 68], ["HPAIV", "PROBLEM", 72, 77], ["lung", "ANATOMY", 56, 60], ["HPAIV", "OBSERVATION", 72, 77]]], ["Infection with avian-type SC35-PB2 701D led to increased importin-a3 mRNA levels in the lung compared to uninfected controls on day 3 post infection (p.i.)", [["lung", "ANATOMY", 88, 92], ["infection", "DISEASE", 139, 148], ["avian-type SC35-PB2 701D", "ORGANISM", 15, 39], ["importin-a3", "GENE_OR_GENE_PRODUCT", 57, 68], ["lung", "ORGAN", 88, 92], ["SC35", "PROTEIN", 26, 30], ["PB2 701D", "PROTEIN", 31, 39], ["importin", "PROTEIN", 57, 65], ["Infection", "PROBLEM", 0, 9], ["infection", "PROBLEM", 139, 148], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["a3 mRNA", "OBSERVATION_MODIFIER", 66, 73], ["lung", "ANATOMY", 88, 92], ["infection", "OBSERVATION", 139, 148]]], ["In contrast, infection with humantype SC35M-PB2 701N resulted in significantly reduced importin-a3 mRNA levels ( Figure 5C ).", [["infection", "DISEASE", 13, 22], ["humantype SC35M-PB2 701N", "CHEMICAL", 28, 52], ["importin-a3", "GENE_OR_GENE_PRODUCT", 87, 98], ["PB2 701N", "PROTEIN", 44, 52], ["importin", "PROTEIN", 87, 95], ["humantype SC35M-PB2 701N", "SPECIES", 28, 52], ["infection", "PROBLEM", 13, 22], ["humantype SC35M", "TREATMENT", 28, 43], ["PB2", "TREATMENT", 44, 47], ["mRNA levels", "TEST", 99, 110], ["infection", "OBSERVATION", 13, 22]]], ["Since the human-type SC35M HPAIV contains mainly two host adaptive signatures (PB2 701N and NP 319K), we analyzed recombinant viruses with these single mutations to dissect their individual impact on the dysregulation of importin-a mRNA transcription.", [["human-type SC35M HPAIV", "ORGANISM", 10, 32], ["PB2 701N", "GENE_OR_GENE_PRODUCT", 79, 87], ["NP 319K", "GENE_OR_GENE_PRODUCT", 92, 99], ["importin", "GENE_OR_GENE_PRODUCT", 221, 229], ["PB2 701N", "DNA", 79, 87], ["NP 319K", "DNA", 92, 99], ["importin", "PROTEIN", 221, 229], ["human", "SPECIES", 10, 15], ["human-type SC35M HPAIV", "SPECIES", 10, 32], ["PB2", "TEST", 79, 82], ["NP", "TEST", 92, 94], ["recombinant viruses", "PROBLEM", 114, 133], ["these single mutations", "TREATMENT", 139, 161], ["a mRNA transcription", "TREATMENT", 230, 250]]], ["Herein, the PB2 D701N host adaptive mutation was predominantly responsible for reduced importin-a3 transcription, while its effect was further enhanced when combined with the NP N319K host (F and G) Additionally, importin-a1, -a4, -a5, and -a7 and viral NP protein were detected and quantified with GAPDH adjustment to confirm that observed effects were specific for importin-a3.", [["PB2 D701N", "GENE_OR_GENE_PRODUCT", 12, 21], ["importin-a3", "GENE_OR_GENE_PRODUCT", 87, 98], ["F and G)", "GENE_OR_GENE_PRODUCT", 190, 198], ["importin-a1", "GENE_OR_GENE_PRODUCT", 213, 224], ["-a4", "GENE_OR_GENE_PRODUCT", 226, 229], ["-a5", "GENE_OR_GENE_PRODUCT", 231, 234], ["-a7", "GENE_OR_GENE_PRODUCT", 240, 243], ["viral NP protein", "GENE_OR_GENE_PRODUCT", 248, 264], ["GAPDH", "GENE_OR_GENE_PRODUCT", 299, 304], ["importin-a3", "GENE_OR_GENE_PRODUCT", 367, 378], ["importin", "PROTEIN", 87, 95], ["a3", "PROTEIN", 96, 98], ["importin", "PROTEIN", 213, 221], ["a1", "PROTEIN", 222, 224], ["a4", "PROTEIN", 227, 229], ["a5", "PROTEIN", 232, 234], ["a7", "PROTEIN", 241, 243], ["viral NP protein", "PROTEIN", 248, 264], ["importin", "PROTEIN", 367, 375], ["a3", "PROTEIN", 376, 378], ["the PB2 D701N host adaptive mutation", "TREATMENT", 8, 44], ["importin", "TEST", 213, 221], ["viral NP protein", "TEST", 248, 264], ["GAPDH adjustment", "TREATMENT", 299, 315], ["a5", "ANATOMY", 232, 234]]], ["Control-treated, uninfected samples or SC35-PB2 701D -infected samples were set to 100%.", [["samples", "ANATOMY", 28, 35], ["samples", "ANATOMY", 63, 70], ["SC35-PB2 701D", "ORGANISM", 39, 52], ["samples", "CANCER", 63, 70], ["SC35", "PROTEIN", 39, 43], ["SC35", "TEST", 39, 43], ["PB2", "TEST", 44, 47], ["infected samples", "PROBLEM", 54, 70]]], ["Cross-reactivity of importin-a antibodies with NP resulted in a band (#) in (B) and (F).Human-Type Polymerase Signatures in HPAIV Mediate(H-K) Growth kinetics of avian-type SC35-PB2 701D (H and I) and human-type SC35M-PB2 701N (J and K) H7N7 HPAIV in importin-a \u00c0/\u00c0 MEFs (n = 3).", [["MEFs", "ANATOMY", 266, 270], ["importin", "GENE_OR_GENE_PRODUCT", 20, 28], ["Human", "ORGANISM", 88, 93], ["HPAIV", "ORGANISM", 124, 129], ["avian-type", "ORGANISM", 162, 172], ["SC35-PB2 701D", "ORGANISM", 173, 186], ["human", "ORGANISM", 201, 206], ["SC35M-PB2 701N", "ORGANISM", 212, 226], ["K) H7N7 HPAIV", "ORGANISM", 234, 247], ["importin", "GENE_OR_GENE_PRODUCT", 251, 259], ["importin", "PROTEIN", 20, 28], ["antibodies", "PROTEIN", 31, 41], ["NP", "PROTEIN", 47, 49], ["SC35", "PROTEIN", 173, 177], ["PB2 701D", "PROTEIN", 178, 186], ["importin", "PROTEIN", 251, 259], ["Human", "SPECIES", 88, 93], ["human", "SPECIES", 201, 206], ["HPAIV", "SPECIES", 124, 129], ["human-type SC35M-PB2 701N", "SPECIES", 201, 226], ["a band (#)", "PROBLEM", 62, 72], ["Human-Type Polymerase Signatures", "TEST", 88, 120], ["Growth kinetics", "TEST", 143, 158], ["avian", "TEST", 162, 167], ["PB2", "TEST", 178, 181], ["human", "TEST", 201, 206], ["PB2", "TEST", 218, 221]]], ["WT (black), importin-a3 \u00c0/\u00c0 (a3 \u00c0/\u00c0 , red), and importin-a7 \u00c0/\u00c0 (a7 \u00c0/\u00c0 , green) MEFs were infected with low (H and J) or high (I and K) multiplicities of infection (MOI).", [["MEFs", "ANATOMY", 81, 85], ["infection", "DISEASE", 155, 164], ["importin-a3", "GENE_OR_GENE_PRODUCT", 12, 23], ["\u00c0", "GENE_OR_GENE_PRODUCT", 26, 27], ["a3 \u00c0", "GENE_OR_GENE_PRODUCT", 29, 33], ["\u00c0", "GENE_OR_GENE_PRODUCT", 34, 35], ["importin-a7", "GENE_OR_GENE_PRODUCT", 48, 59], ["\u00c0", "GENE_OR_GENE_PRODUCT", 62, 63], ["MEFs", "CELL", 81, 85], ["importin", "PROTEIN", 12, 20], ["a3 \u00c0", "PROTEIN", 21, 25], ["\u00c0", "PROTEIN", 26, 27], ["a3 \u00c0", "PROTEIN", 29, 33], ["\u00c0", "PROTEIN", 34, 35], ["red", "PROTEIN", 38, 41], ["importin", "PROTEIN", 48, 56], ["a7 \u00c0/\u00c0 (a7 \u00c0/\u00c0 , green) MEFs", "CELL_LINE", 57, 85], ["WT", "TEST", 0, 2], ["importin", "TEST", 12, 20], ["importin", "TEST", 48, 56], ["MEFs", "TEST", 81, 85], ["high (I and K) multiplicities of infection", "PROBLEM", 122, 164], ["infection", "OBSERVATION", 155, 164]]], ["Virus titers given in plaque-forming units (p.f.u.) were determined by plaque assay on MDCKII cells (0, 24, 48, 72, and 96 h p.i.).", [["plaque", "ANATOMY", 22, 28], ["plaque", "ANATOMY", 71, 77], ["MDCKII cells", "ANATOMY", 87, 99], ["Virus", "ORGANISM", 0, 5], ["MDCKII cells", "CELL", 87, 99], ["MDCKII cells", "CELL_LINE", 87, 99], ["Virus titers", "TEST", 0, 12], ["MDCKII cells", "TEST", 87, 99], ["plaque", "OBSERVATION", 71, 77]]], ["(L) H1299 a3 +/+ (black) and a3 \u00c0/\u00c0 (red) cells were infected with human-type SC35M-PB2 701N HPAIV (MOI = 0.001) and replication kinetics measured in the presence or absence of TNF-a (n = 3).", [["a3 \u00c0/\u00c0 (red) cells", "ANATOMY", 29, 47], ["human", "ORGANISM", 67, 72], ["SC35M-PB2 701N HPAIV", "ORGANISM", 78, 98], ["TNF", "GENE_OR_GENE_PRODUCT", 177, 180], ["a3 \u00c0/\u00c0 (red) cells", "CELL_LINE", 29, 47], ["TNF", "PROTEIN", 177, 180], ["human", "SPECIES", 67, 72], ["human-type SC35M-PB2 701N HPAIV", "SPECIES", 67, 98], ["H1299 a3", "TEST", 4, 12], ["black", "TEST", 18, 23], ["a3 \u00c0/\u00c0", "TEST", 29, 35], ["red) cells", "TEST", 37, 47], ["human", "TEST", 67, 72], ["MOI", "TEST", 100, 103], ["replication kinetics", "PROBLEM", 117, 137], ["TNF", "TEST", 177, 180]]], ["Virus titers were determined by plaque assay on MDCKII cells (0, 24, 48 h p.i.).", [["plaque", "ANATOMY", 32, 38], ["MDCKII cells", "ANATOMY", 48, 60], ["Virus", "ORGANISM", 0, 5], ["MDCKII cells", "CELL", 48, 60], ["MDCKII cells", "CELL_LINE", 48, 60], ["Virus titers", "TEST", 0, 12]]], ["Data shown represent means of relative importin-a amounts or logarithmic virus titers \u00b1 SD of at least three independent biological experiments (p < 0.001).", [["importin", "GENE_OR_GENE_PRODUCT", 39, 47], ["importin", "PROTEIN", 39, 47], ["logarithmic virus titers", "PROBLEM", 61, 85], ["at least", "OBSERVATION_MODIFIER", 94, 102]]], ["(E and F) Relative mRNA-expression levels of antiviral genes under an NF-kB promoter determined by qRT-PCR 3 days p.i. in control (E) and infected lungs (F) of a3 +/+ and a3 \u00c0/\u00c0 mice.", [["lungs", "ANATOMY", 147, 152], ["NF-kB", "GENE_OR_GENE_PRODUCT", 70, 75], ["lungs", "ORGAN", 147, 152], ["a3", "GENE_OR_GENE_PRODUCT", 160, 162], ["a3", "GENE_OR_GENE_PRODUCT", 171, 173], ["antiviral genes", "DNA", 45, 60], ["NF-kB promoter", "DNA", 70, 84], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 178, 182], ["antiviral genes", "TREATMENT", 45, 60], ["an NF-kB promoter", "TREATMENT", 67, 84], ["PCR", "TEST", 103, 106], ["lungs", "ANATOMY", 147, 152]]], ["Relative expression values of a3 +/+ for each gene normalized to HPRT were set to 1.", [["a3", "GENE_OR_GENE_PRODUCT", 30, 32], ["HPRT", "GENE_OR_GENE_PRODUCT", 65, 69], ["a3", "PROTEIN", 30, 32], ["HPRT", "DNA", 65, 69], ["Relative expression values", "TEST", 0, 26], ["a3", "TEST", 30, 32], ["HPRT", "TEST", 65, 69]]], ["Data shown represent mean \u00b1 SD (n = 5; 10 4 p.f.u.", [["mean", "TEST", 21, 25]]], ["(100-fold MLD 50 of SC35M-PB2 701N in BALB/c mice 9 ) of SC35-PB2 701D , SC35M-PB2 701N , the single-point mutants SC35-PB2 701N or SC35-NP 319K or the double mutant SC35-PB2 701N -NP 319K .", [["BALB/c mice", "ORGANISM", 38, 49], ["SC35-PB2 701D", "ORGANISM", 57, 70], ["SC35M-PB2 701N", "ORGANISM", 73, 87], ["SC35M", "PROTEIN", 20, 25], ["PB2 701N", "PROTEIN", 26, 34], ["SC35", "PROTEIN", 57, 61], ["PB2 701N", "PROTEIN", 79, 87], ["SC35", "PROTEIN", 115, 119], ["PB2 701N", "PROTEIN", 120, 128], ["SC35", "PROTEIN", 132, 136], ["SC35", "PROTEIN", 166, 170], ["PB2 701N", "PROTEIN", 171, 179], ["mice", "SPECIES", 45, 49], ["MLD", "TEST", 10, 13], ["SC35M", "TEST", 20, 25], ["PB2", "TEST", 26, 29], ["SC35", "TEST", 57, 61], ["PB2", "TEST", 62, 65], ["SC35M", "TEST", 73, 78], ["SC35", "TEST", 115, 119], ["PB2", "TEST", 120, 123], ["SC35", "TEST", 132, 136], ["NP", "TEST", 137, 139], ["K", "TEST", 143, 144], ["PB2", "TEST", 171, 174]]], ["Control groups received PBS.", [["PBS", "TREATMENT", 24, 27]]], ["On day 3 p.i., five animals per time point were anaesthetized with an overdose of ketamine-xylazine (140 mg/kg and 14 mg/kg, respectively) and sacrificed after intracardial perfusion with DEPC-treated 1x PBS.", [["intracardial", "ANATOMY", 160, 172], ["overdose", "DISEASE", 70, 78], ["ketamine", "CHEMICAL", 82, 90], ["xylazine", "CHEMICAL", 91, 99], ["DEPC", "CHEMICAL", 188, 192], ["ketamine", "CHEMICAL", 82, 90], ["xylazine", "CHEMICAL", 91, 99], ["DEPC", "CHEMICAL", 188, 192], ["ketamine-xylazine", "SIMPLE_CHEMICAL", 82, 99], ["DEPC", "SIMPLE_CHEMICAL", 188, 192], ["ketamine", "TREATMENT", 82, 90], ["xylazine", "TREATMENT", 91, 99], ["intracardial perfusion", "TEST", 160, 182], ["DEPC", "TREATMENT", 188, 192]]], ["Perfused organs (lung, trachea, liver, spleen, brain) were removed and dissected into pieces (< 5 mm) and submerged in RNAlater RNA Stabilization Reagent (QIAGEN).", [["organs", "ANATOMY", 9, 15], ["lung", "ANATOMY", 17, 21], ["trachea", "ANATOMY", 23, 30], ["liver", "ANATOMY", 32, 37], ["spleen", "ANATOMY", 39, 45], ["brain", "ANATOMY", 47, 52], ["organs", "ORGAN", 9, 15], ["lung", "ORGAN", 17, 21], ["trachea", "MULTI-TISSUE_STRUCTURE", 23, 30], ["liver", "ORGAN", 32, 37], ["spleen", "ORGAN", 39, 45], ["brain", "ORGAN", 47, 52], ["organs", "ANATOMY", 9, 15], ["lung", "ANATOMY", 17, 21], ["trachea", "ANATOMY", 23, 30], ["liver", "ANATOMY", 32, 37], ["spleen", "ANATOMY", 39, 45], ["brain", "ANATOMY", 47, 52], ["pieces", "OBSERVATION_MODIFIER", 86, 92]]], ["Murine URT samples were obtained by decapitation of the head above the atlas.", [["URT samples", "ANATOMY", 7, 18], ["head", "ANATOMY", 56, 60], ["Murine", "ORGANISM", 0, 6], ["URT samples", "CANCER", 7, 18], ["head", "ORGANISM_SUBDIVISION", 56, 60], ["Murine", "SPECIES", 0, 6], ["Murine", "SPECIES", 0, 6], ["Murine URT samples", "TEST", 0, 18], ["head", "ANATOMY", 56, 60]]], ["After skinning and sagittal division of the head, the tissue of the nasal concha was excised and submerged in RNAlater.Animal ExperimentsFor relative mRNA-Expression levels determination of antiviral genes under an NF-kB promoter by RT-qPCR, WT (n = 5) and importin-a3 \u00c0/\u00c0 (n = 5) mice were infected with 10 6 p.f.u. of SC35M.", [["head", "ANATOMY", 44, 48], ["tissue", "ANATOMY", 54, 60], ["nasal concha", "ANATOMY", 68, 80], ["head", "ORGANISM_SUBDIVISION", 44, 48], ["tissue", "TISSUE", 54, 60], ["nasal concha", "ORGAN", 68, 80], ["NF-kB", "GENE_OR_GENE_PRODUCT", 215, 220], ["WT (n = 5", "ORGANISM", 242, 251], ["importin-a3", "GENE_OR_GENE_PRODUCT", 257, 268], ["mice", "ORGANISM", 281, 285], ["antiviral genes", "DNA", 190, 205], ["NF-kB promoter", "DNA", 215, 229], ["importin", "PROTEIN", 257, 265], ["mice", "SPECIES", 281, 285], ["mice", "SPECIES", 281, 285], ["relative mRNA", "PROBLEM", 141, 154], ["Expression levels", "TEST", 155, 172], ["antiviral genes", "TREATMENT", 190, 205], ["an NF-kB promoter", "TREATMENT", 212, 229], ["RT", "TEST", 233, 235], ["qPCR", "TEST", 236, 240], ["WT", "TEST", 242, 244], ["importin", "TEST", 257, 265], ["head", "ANATOMY", 44, 48], ["tissue", "ANATOMY", 54, 60], ["nasal concha", "ANATOMY", 68, 80]]], ["Control groups received PBS.", [["PBS", "TREATMENT", 24, 27]]], ["On day 3 p.i., five animals were anaesthetized with an overdose of ketamine-xylazine and sacrifice.", [["overdose", "DISEASE", 55, 63], ["ketamine", "CHEMICAL", 67, 75], ["xylazine", "CHEMICAL", 76, 84], ["ketamine", "CHEMICAL", 67, 75], ["xylazine", "CHEMICAL", 76, 84], ["ketamine", "SIMPLE_CHEMICAL", 67, 75], ["xylazine", "SIMPLE_CHEMICAL", 76, 84], ["ketamine", "TREATMENT", 67, 75], ["xylazine", "TREATMENT", 76, 84], ["sacrifice", "TREATMENT", 89, 98]]], ["Whole lungs were removed and dissected into pieces and submerged in RNAlater.", [["lungs", "ANATOMY", 6, 11], ["lungs", "ORGAN", 6, 11], ["lungs", "ANATOMY", 6, 11], ["removed", "OBSERVATION", 17, 24], ["submerged", "OBSERVATION_MODIFIER", 55, 64]]], ["Organs (lung, spleen, brain) of uninfected WT mice (n = 3) for western blot lysate preparation were obtained after short inhalative isoflurane narcosis followed by cervical dislocation.", [["Organs", "ANATOMY", 0, 6], ["lung", "ANATOMY", 8, 12], ["spleen", "ANATOMY", 14, 20], ["brain", "ANATOMY", 22, 27], ["lysate", "ANATOMY", 76, 82], ["cervical", "ANATOMY", 164, 172], ["isoflurane", "CHEMICAL", 132, 142], ["cervical dislocation", "DISEASE", 164, 184], ["isoflurane", "CHEMICAL", 132, 142], ["Organs", "ORGAN", 0, 6], ["lung", "ORGAN", 8, 12], ["spleen", "ORGAN", 14, 20], ["brain", "ORGAN", 22, 27], ["WT mice", "ORGANISM", 43, 50], ["cervical", "ORGAN", 164, 172], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 46, 50], ["western blot lysate preparation", "TREATMENT", 63, 94], ["short inhalative isoflurane narcosis", "TREATMENT", 115, 151], ["cervical dislocation", "PROBLEM", 164, 184], ["lung", "ANATOMY", 8, 12], ["spleen", "ANATOMY", 14, 20], ["brain", "ANATOMY", 22, 27], ["cervical", "ANATOMY", 164, 172], ["dislocation", "OBSERVATION", 173, 184]]], ["After dissection into small pieces, the organs were immediately frozen on dry ice.Animal ExperimentsFor virus titer determination of organs, WT (n = 3) and importin-a3 \u00c0/\u00c0 (n = 3) mice were infected with 610 4 p.f.u.;Animal Experiments30x MLD 50 of SC35M-PB2 701N , respectively).", [["organs", "ANATOMY", 40, 46], ["organs", "ANATOMY", 133, 139], ["organs", "ORGAN", 40, 46], ["organs", "ORGAN", 133, 139], ["importin-a3", "GENE_OR_GENE_PRODUCT", 156, 167], ["mice", "ORGANISM", 180, 184], ["importin", "PROTEIN", 156, 164], ["mice", "SPECIES", 180, 184], ["mice", "SPECIES", 180, 184], ["dissection into small pieces", "TREATMENT", 6, 34], ["Animal Experiments", "TEST", 82, 100], ["virus titer determination", "TEST", 104, 129], ["WT", "TEST", 141, 143], ["importin", "TEST", 156, 164], ["SC35M", "TEST", 249, 254], ["dissection", "OBSERVATION", 6, 16], ["small", "OBSERVATION_MODIFIER", 22, 27], ["pieces", "OBSERVATION_MODIFIER", 28, 34], ["organs", "ANATOMY", 40, 46]]], ["On days 3 and 6 p.i., three animals per time point were sacrificed, organs (lung, trachea, brain) removed, virus titers determined by plaque assay 64 , and the URT and LRT stained immunohistochemically against influenza virus and importin-a antigen.", [["organs", "ANATOMY", 68, 74], ["lung", "ANATOMY", 76, 80], ["trachea", "ANATOMY", 82, 89], ["brain", "ANATOMY", 91, 96], ["plaque", "ANATOMY", 134, 140], ["organs", "ORGAN", 68, 74], ["lung", "ORGAN", 76, 80], ["trachea", "MULTI-TISSUE_STRUCTURE", 82, 89], ["brain", "ORGAN", 91, 96], ["influenza virus", "ORGANISM", 210, 225], ["importin-a antigen", "GENE_OR_GENE_PRODUCT", 230, 248], ["LRT", "PROTEIN", 168, 171], ["importin", "PROTEIN", 230, 238], ["influenza virus", "SPECIES", 210, 225], ["influenza virus", "SPECIES", 210, 225], ["organs (lung, trachea, brain)", "PROBLEM", 68, 97], ["virus titers", "TEST", 107, 119], ["plaque assay", "TEST", 134, 146], ["the URT", "TEST", 156, 163], ["LRT", "TEST", 168, 171], ["influenza virus", "PROBLEM", 210, 225], ["organs", "ANATOMY", 68, 74], ["lung", "ANATOMY", 76, 80], ["trachea", "ANATOMY", 82, 89], ["brain", "ANATOMY", 91, 96], ["URT", "ANATOMY", 160, 163]]], ["For this, murine formalin-fixed, paraffin-embedded (FFPE) lungs or skinned, decalcified FFPE heads were thin sectioned (3 mm).", [["FFPE", "ANATOMY", 52, 56], ["lungs", "ANATOMY", 58, 63], ["FFPE heads", "ANATOMY", 88, 98], ["formalin", "CHEMICAL", 17, 25], ["formalin", "CHEMICAL", 17, 25], ["murine", "ORGANISM", 10, 16], ["lungs", "ORGAN", 58, 63], ["murine", "SPECIES", 10, 16], ["murine formalin", "TEST", 10, 25], ["skinned, decalcified FFPE heads", "TREATMENT", 67, 98], ["lungs", "ANATOMY", 58, 63]]], ["Heads were decalcified in 10% EDTA (pH 7,4) for 8 days, followed by sagittal division and incubation in same solution for 3 more days.", [["EDTA", "CHEMICAL", 30, 34], ["EDTA", "CHEMICAL", 30, 34], ["EDTA", "SIMPLE_CHEMICAL", 30, 34], ["pH", "TEST", 36, 38], ["incubation in same solution", "TREATMENT", 90, 117], ["decalcified", "OBSERVATION", 11, 22]]], ["Mouse lethal dose 50 (MLD 50 ) was assessed by infecting WT (n = 4-9) and importin-a3 \u00c0/\u00c0 (n = 4-9) mice with serial virus dilutions of SC35-PB2 701D (10 5 , 5 p < 0.05, ** p < 0.01, *** p < 0.001).DATA AND CODE AVAILABILITYTranscriptome sequence data reported in this publication is submitted to the European Nucleotide Archive (ENA) and is available under following link: https://www.ebi.ac.uk/ena/data/view/PRJEB8023.", [["Mouse", "ORGANISM", 0, 5], ["importin-a3", "GENE_OR_GENE_PRODUCT", 74, 85], ["mice", "ORGANISM", 100, 104], ["importin", "PROTEIN", 74, 82], ["SC35", "PROTEIN", 136, 140], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 100, 104], ["Mouse", "SPECIES", 0, 5], ["mice", "SPECIES", 100, 104], ["Mouse lethal dose", "TREATMENT", 0, 17], ["WT", "TEST", 57, 59], ["importin", "TEST", 74, 82], ["serial virus dilutions", "TEST", 110, 132], ["SC35", "TEST", 136, 140], ["PB2", "TEST", 141, 144], ["p", "TEST", 173, 174], ["p", "TEST", 187, 188], ["CODE AVAILABILITYTranscriptome sequence data", "TEST", 207, 251]]]], "ac214d6bd3b4db8cc28b85f435816dc374b61d88": [["A Basic Overview of Vaccine FunctionVaccines are one of the greatest public health innovations in human history.", [["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["Vaccine FunctionVaccines", "TREATMENT", 20, 44]]], ["Vaccination provides an extremely effective mechanism to deal with infectious diseases by preventing the development of morbidity and mortality.", [["infectious diseases", "DISEASE", 67, 86], ["Vaccination", "TREATMENT", 0, 11], ["infectious diseases", "PROBLEM", 67, 86], ["morbidity", "PROBLEM", 120, 129], ["morbidity", "OBSERVATION", 120, 129]]], ["The World Health Organization estimates that vaccines prevent 2-3 million human deaths annually, and these numbers would rise by at least 6 million if all children received the recommended vaccination schedule [1] .", [["deaths", "DISEASE", 80, 86], ["human", "ORGANISM", 74, 79], ["children", "ORGANISM", 155, 163], ["human", "SPECIES", 74, 79], ["children", "SPECIES", 155, 163], ["human", "SPECIES", 74, 79], ["vaccines", "TREATMENT", 45, 53], ["the recommended vaccination schedule", "TREATMENT", 173, 209]]], ["Only two infectious diseases have been eliminated in human history, both the result of a successful vaccination campaign.", [["infectious diseases", "DISEASE", 9, 28], ["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["two infectious diseases", "PROBLEM", 5, 28], ["a successful vaccination campaign", "TREATMENT", 87, 120], ["two", "OBSERVATION_MODIFIER", 5, 8], ["infectious", "OBSERVATION", 9, 19]]], ["The first, the human disease small-pox, was officially declared eliminated from the human population in 1979 [2] .", [["human", "ORGANISM", 15, 20], ["human", "ORGANISM", 84, 89], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 84, 89], ["human disease small-pox", "SPECIES", 15, 38], ["human", "SPECIES", 84, 89], ["the human disease small-pox", "PROBLEM", 11, 38], ["small", "OBSERVATION_MODIFIER", 29, 34]]], ["The second, the livestock disease rinderpest was declared eliminated in 2011 [3] .", [["livestock disease rinderpest", "DISEASE", 16, 44], ["the livestock disease rinderpest", "PROBLEM", 12, 44], ["livestock", "OBSERVATION_MODIFIER", 16, 25], ["disease", "OBSERVATION", 26, 33]]], ["While other diseases such as measles and polio are also close to elimination there is still much to be done [2] .A Basic Overview of Vaccine FunctionInfectious disease vaccines work by serving as a prophylactic controlled exposure to an infectious agent.", [["measles", "DISEASE", 29, 36], ["polio", "DISEASE", 41, 46], ["FunctionInfectious disease", "DISEASE", 141, 167], ["other diseases", "PROBLEM", 6, 20], ["measles", "PROBLEM", 29, 36], ["polio", "PROBLEM", 41, 46], ["Vaccine FunctionInfectious disease vaccines", "TREATMENT", 133, 176], ["a prophylactic controlled exposure", "TREATMENT", 196, 230], ["an infectious agent", "TREATMENT", 234, 253], ["infectious", "OBSERVATION", 237, 247]]], ["A vertebrate's immune system is composed of two different branches, the innate and adaptive immune system.", [["immune system", "ANATOMY", 15, 28], ["immune system", "ANATOMY", 92, 105], ["immune system", "ANATOMICAL_SYSTEM", 15, 28], ["immune system", "ANATOMICAL_SYSTEM", 92, 105], ["A vertebrate's immune system", "TREATMENT", 0, 28], ["immune system", "OBSERVATION", 15, 28], ["two", "OBSERVATION_MODIFIER", 44, 47], ["different", "OBSERVATION_MODIFIER", 48, 57], ["branches", "OBSERVATION_MODIFIER", 58, 66]]], ["Following exposure to an infectious agent or administration of a vaccine, activation of the innate immune system precedes generation of adaptive immunity.", [["an infectious agent", "TREATMENT", 22, 41], ["a vaccine", "TREATMENT", 63, 72], ["the innate immune system", "TREATMENT", 88, 112], ["adaptive immunity", "TREATMENT", 136, 153], ["infectious", "OBSERVATION", 25, 35]]], ["The innate immune system is composed of a diverse array of cell types such as neutrophils, dendritic cells, monocytes, macrophage, and eosinophils all which function to interact with foreign molecules in a nonspecific manner.", [["immune system", "ANATOMY", 11, 24], ["cell", "ANATOMY", 59, 63], ["neutrophils", "ANATOMY", 78, 89], ["dendritic cells", "ANATOMY", 91, 106], ["monocytes", "ANATOMY", 108, 117], ["macrophage", "ANATOMY", 119, 129], ["eosinophils", "ANATOMY", 135, 146], ["cell", "CELL", 59, 63], ["neutrophils", "CELL", 78, 89], ["dendritic cells", "CELL", 91, 106], ["monocytes", "CELL", 108, 117], ["macrophage", "CELL", 119, 129], ["eosinophils", "CELL", 135, 146], ["neutrophils", "CELL_TYPE", 78, 89], ["dendritic cells", "CELL_TYPE", 91, 106], ["monocytes", "CELL_TYPE", 108, 117], ["macrophage", "CELL_TYPE", 119, 129], ["eosinophils", "CELL_TYPE", 135, 146], ["foreign molecules", "PROTEIN", 183, 200], ["cell types", "PROBLEM", 59, 69], ["neutrophils", "TEST", 78, 89], ["dendritic cells", "PROBLEM", 91, 106], ["monocytes", "TEST", 108, 117], ["macrophage", "TEST", 119, 129], ["eosinophils", "TEST", 135, 146], ["foreign molecules", "PROBLEM", 183, 200], ["innate immune system", "OBSERVATION", 4, 24], ["diverse", "OBSERVATION_MODIFIER", 42, 49], ["cell types", "OBSERVATION", 59, 69], ["dendritic cells", "OBSERVATION", 91, 106], ["monocytes", "ANATOMY", 108, 117], ["macrophage", "OBSERVATION_MODIFIER", 119, 129], ["foreign molecules", "OBSERVATION", 183, 200]]], ["Innate immune cells phagocytose infectious agents, secrete inflammatory cytokines, and/or attract and activate other immune cells through the secretion of chemical messengers such as chemokines.", [["immune cells", "ANATOMY", 7, 19], ["immune cells", "ANATOMY", 117, 129], ["Innate immune cells", "CELL", 0, 19], ["immune cells", "CELL", 117, 129], ["Innate immune cells", "CELL_TYPE", 0, 19], ["inflammatory cytokines", "PROTEIN", 59, 81], ["immune cells", "CELL_TYPE", 117, 129], ["chemical messengers", "PROTEIN", 155, 174], ["chemokines", "PROTEIN", 183, 193], ["Innate immune cells phagocytose infectious agents", "TREATMENT", 0, 49], ["secrete inflammatory cytokines", "PROBLEM", 51, 81], ["immune cells", "OBSERVATION", 7, 19], ["phagocytose infectious", "OBSERVATION", 20, 42], ["inflammatory", "OBSERVATION_MODIFIER", 59, 71]]], ["These processes lead to initiation of an effective immune response [4] .A Basic Overview of Vaccine FunctionVaccines are ultimately dependent on the development of an effective adaptive immune response.", [["an effective immune response", "TREATMENT", 38, 66], ["Vaccine FunctionVaccines", "TREATMENT", 92, 116]]], ["Broadly, adaptive immune responses are divided into two different categories, humoral and cellular.", [["cellular", "ANATOMY", 90, 98], ["cellular", "CELL", 90, 98], ["adaptive immune responses", "TREATMENT", 9, 34], ["humoral", "ANATOMY", 78, 85], ["cellular", "OBSERVATION_MODIFIER", 90, 98]]], ["Cells of the adaptive immune system respond to specific regions of infectious agents known as epitopes.", [["Cells", "ANATOMY", 0, 5], ["immune system", "ANATOMY", 22, 35], ["Cells", "CELL", 0, 5], ["immune system", "ANATOMICAL_SYSTEM", 22, 35], ["epitopes", "PROTEIN", 94, 102], ["the adaptive immune system", "TREATMENT", 9, 35], ["infectious agents", "TREATMENT", 67, 84], ["infectious", "OBSERVATION", 67, 77]]], ["One or more epitopes are contained on a larger molecule known as an antigen.", [["epitopes", "PROTEIN", 12, 20], ["more", "OBSERVATION_MODIFIER", 7, 11], ["epitopes", "OBSERVATION", 12, 20]]], ["Humoral immune responses are dependent on the activity of antibodies, secreted glycoproteins from B cells that bind to specific epitopes.", [["B cells", "ANATOMY", 98, 105], ["B cells", "CELL", 98, 105], ["antibodies", "PROTEIN", 58, 68], ["secreted glycoproteins", "PROTEIN", 70, 92], ["B cells", "CELL_TYPE", 98, 105], ["epitopes", "PROTEIN", 128, 136], ["secreted glycoproteins", "PROBLEM", 70, 92], ["B cells", "TREATMENT", 98, 105], ["dependent", "OBSERVATION_MODIFIER", 29, 38]]], ["A na\u00efve B cell contains B cell receptors on its surface, which vary in their specificities.", [["B cell", "ANATOMY", 8, 14], ["B cell", "ANATOMY", 24, 30], ["surface", "ANATOMY", 48, 55], ["B cell", "CELL", 8, 14], ["B cell receptors", "CELL", 24, 40], ["surface", "CELLULAR_COMPONENT", 48, 55], ["na\u00efve B cell", "CELL_TYPE", 2, 14], ["B cell receptors", "PROTEIN", 24, 40], ["A na\u00efve B cell", "TREATMENT", 0, 14], ["B cell receptors", "TREATMENT", 24, 40], ["B cell", "OBSERVATION", 8, 14], ["B cell receptors", "OBSERVATION", 24, 40], ["surface", "OBSERVATION_MODIFIER", 48, 55]]], ["Upon binding of the B cell receptor to a matching epitope, B cells can mature into plasma cells and begin to secrete epitope specific antibodies that will ideally lead to protection against infection [5] .A Basic Overview of Vaccine FunctionCellular immune responses are based on the action of T cells.", [["B cell", "ANATOMY", 20, 26], ["B cells", "ANATOMY", 59, 66], ["plasma cells", "ANATOMY", 83, 95], ["T cells", "ANATOMY", 294, 301], ["infection", "DISEASE", 190, 199], ["B cell receptor", "GENE_OR_GENE_PRODUCT", 20, 35], ["B cells", "CELL", 59, 66], ["plasma cells", "CELL", 83, 95], ["T cells", "CELL", 294, 301], ["B cell receptor", "PROTEIN", 20, 35], ["B cells", "CELL_TYPE", 59, 66], ["plasma cells", "CELL_TYPE", 83, 95], ["epitope specific antibodies", "PROTEIN", 117, 144], ["T cells", "CELL_TYPE", 294, 301], ["the B cell receptor", "TREATMENT", 16, 35], ["B cells", "PROBLEM", 59, 66], ["secrete epitope specific antibodies", "PROBLEM", 109, 144], ["infection", "PROBLEM", 190, 199], ["Vaccine", "TREATMENT", 225, 232]]], ["All nucleated cells have on their surface Major Histocompatibility Complex Class I (MHC-I) molecules.", [["nucleated cells", "ANATOMY", 4, 19], ["surface", "ANATOMY", 34, 41], ["cells", "CELL", 14, 19], ["nucleated cells", "CELL_TYPE", 4, 19], ["surface Major Histocompatibility Complex Class I (MHC-I) molecules", "PROTEIN", 34, 100], ["All nucleated cells", "PROBLEM", 0, 19], ["nucleated cells", "OBSERVATION", 4, 19]]], ["When infected with an intracellular infectious agent, cells are able to present on their surface linear epitopes from those infectious agents complexed with MHC-I to alert the immune system of the infection.", [["intracellular", "ANATOMY", 22, 35], ["cells", "ANATOMY", 54, 59], ["surface", "ANATOMY", 89, 96], ["immune system", "ANATOMY", 176, 189], ["infection", "DISEASE", 197, 206], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["cells", "CELL", 54, 59], ["MHC-I", "GENE_OR_GENE_PRODUCT", 157, 162], ["immune system", "ANATOMICAL_SYSTEM", 176, 189], ["MHC-I", "PROTEIN", 157, 162], ["an intracellular infectious agent", "TREATMENT", 19, 52], ["those infectious agents", "TREATMENT", 118, 141], ["the infection", "PROBLEM", 193, 206], ["infectious", "OBSERVATION", 36, 46], ["infection", "OBSERVATION", 197, 206]]], ["Cytotoxic T cells (T C ) that contain the matching T cell receptor are able to bind to the MHC-I presenting specific epitopes leading to the death of the infected cell [4] .A Basic Overview of Vaccine FunctionComplex Class II (MHC-II) on their surface.", [["Cytotoxic T cells", "ANATOMY", 0, 17], ["T C", "ANATOMY", 19, 22], ["T cell", "ANATOMY", 51, 57], ["cell", "ANATOMY", 163, 167], ["surface", "ANATOMY", 244, 251], ["death", "DISEASE", 141, 146], ["MHC-II", "CHEMICAL", 227, 233], ["Cytotoxic T cells", "CELL", 0, 17], ["T C", "CELL", 19, 22], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 51, 66], ["MHC-I", "GENE_OR_GENE_PRODUCT", 91, 96], ["cell", "CELL", 163, 167], ["MHC-II", "GENE_OR_GENE_PRODUCT", 227, 233], ["surface", "CELLULAR_COMPONENT", 244, 251], ["Cytotoxic T cells", "CELL_TYPE", 0, 17], ["T C", "CELL_TYPE", 19, 22], ["T cell receptor", "PROTEIN", 51, 66], ["MHC-I", "PROTEIN", 91, 96], ["epitopes", "PROTEIN", 117, 125], ["Vaccine FunctionComplex Class II", "PROTEIN", 193, 225], ["MHC-II", "PROTEIN", 227, 233], ["Cytotoxic T cells (T C )", "PROBLEM", 0, 24], ["the matching T cell receptor", "TREATMENT", 38, 66], ["the death", "PROBLEM", 137, 146], ["the infected cell", "PROBLEM", 150, 167], ["infected cell", "OBSERVATION", 154, 167]]], ["These epitopes stimulate CD4 + T cells leading to their maturation into T H cells.", [["CD4 + T cells", "ANATOMY", 25, 38], ["T H cells", "ANATOMY", 72, 81], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["T H cells", "CELL", 72, 81], ["epitopes", "PROTEIN", 6, 14], ["CD4", "PROTEIN", 25, 28], ["T cells", "CELL_TYPE", 31, 38], ["T H cells", "CELL_TYPE", 72, 81], ["T cells", "PROBLEM", 31, 38]]], ["Active T H cells are able to stimulate cells of both the innate and adaptive immune system through the secretion of cytokines.", [["T H cells", "ANATOMY", 7, 16], ["cells", "ANATOMY", 39, 44], ["immune system", "ANATOMY", 77, 90], ["T H cells", "CELL", 7, 16], ["cells", "CELL", 39, 44], ["immune system", "ANATOMICAL_SYSTEM", 77, 90], ["T H cells", "CELL_TYPE", 7, 16], ["cytokines", "PROTEIN", 116, 125], ["Active T H cells", "TREATMENT", 0, 16]]], ["These cytokines are able to modulate the immune response leading to a stronger and more effective immune response.", [["cytokines", "PROTEIN", 6, 15]]], ["Based on the profile of the secreted cytokine responses they are either classed as T helper 1 response (T H 1) or T helper 2 response (T H 2).", [["T helper 1", "GENE_OR_GENE_PRODUCT", 83, 93], ["T H 1", "GENE_OR_GENE_PRODUCT", 104, 109], ["T helper 2", "GENE_OR_GENE_PRODUCT", 114, 124], ["T H 2", "GENE_OR_GENE_PRODUCT", 135, 140], ["cytokine", "PROTEIN", 37, 45]]], ["T H 1 responses favor the development of a cellular based immune response, while T H 2 responses favor the development of a humoral immune response.", [["cellular", "ANATOMY", 43, 51], ["T H 1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 43, 51], ["T H 2", "CELL", 81, 86], ["a cellular based immune response", "PROBLEM", 41, 73], ["a humoral immune response", "PROBLEM", 122, 147], ["humoral immune response", "OBSERVATION", 124, 147]]], ["Traditionally, vaccine development has focused on the development of strong T H 2 responses, but currently a vaccine candidate that has a balanced T H 1/T H 2 response is considered optimal [5] .A Basic Overview of Vaccine FunctionAfter activation, B cells, T H , and T C undergo proliferation to effectively deal with infection.", [["B cells", "ANATOMY", 249, 256], ["T C", "ANATOMY", 268, 271], ["infection", "DISEASE", 319, 328], ["T H 2", "CELL", 76, 81], ["T H 2", "GENE_OR_GENE_PRODUCT", 153, 158], ["B cells", "CELL", 249, 256], ["T H", "CELL", 258, 261], ["T C", "CELL", 268, 271], ["B cells", "CELL_TYPE", 249, 256], ["T H , and T C", "CELL_TYPE", 258, 271], ["T H", "SPECIES", 258, 261], ["vaccine", "TREATMENT", 15, 22], ["a balanced T H", "TEST", 136, 150], ["T H", "TEST", 258, 261], ["proliferation", "PROBLEM", 280, 293], ["infection", "PROBLEM", 319, 328], ["infection", "OBSERVATION", 319, 328]]], ["In an ideal situation some of these cells persist after clearance resulting in the development of immunological memory.", [["cells", "ANATOMY", 36, 41], ["cells", "CELL", 36, 41], ["immunological memory", "PROBLEM", 98, 118], ["immunological memory", "OBSERVATION", 98, 118]]], ["When a previously exposed host is exposed to an infectious agent again, antigen-specific immune memory cells are activated and proliferate faster and to a greater magnitude, leading to rapid clearance of the infectious agent and mitigation of disease.", [["immune memory cells", "ANATOMY", 89, 108], ["antigen", "GENE_OR_GENE_PRODUCT", 72, 79], ["immune memory cells", "CELL", 89, 108], ["immune memory cells", "CELL_TYPE", 89, 108], ["an infectious agent", "TREATMENT", 45, 64], ["antigen", "TEST", 72, 79], ["the infectious agent", "TREATMENT", 204, 224], ["disease", "PROBLEM", 243, 250], ["infectious", "OBSERVATION", 48, 58], ["greater magnitude", "OBSERVATION_MODIFIER", 155, 172], ["infectious", "OBSERVATION", 208, 218]]], ["Strong and effective memory responses protect hosts against subsequent infections leading to lifelong immunity, the hallmark of an effective vaccine [5] .A Basic Overview of Vaccine FunctionVaccines not only work on the organismal level, but also on the population level.", [["infections", "DISEASE", 71, 81], ["subsequent infections", "PROBLEM", 60, 81], ["an effective vaccine", "TREATMENT", 128, 148], ["Vaccine FunctionVaccines", "TREATMENT", 174, 198]]], ["In the concept known as herd immunity if a certain fraction of the population is immune to an infectious agent the disease will have a very low likelihood of finding another na\u00efve host and spreading.", [["herd", "ORGANISM_SUBDIVISION", 24, 28], ["an infectious agent the disease", "PROBLEM", 91, 122], ["infectious", "OBSERVATION", 94, 104]]], ["The number of people who need to be vaccinated for herd immunity varies from disease to disease, normally between 60-90%.", [["people", "ORGANISM", 14, 20], ["herd", "ORGANISM_SUBDIVISION", 51, 55], ["people", "SPECIES", 14, 20], ["disease to disease", "PROBLEM", 77, 95]]], ["It is extremely important because in any given population some vaccinated individuals will not develop protection based upon genetics, there will be individuals who cannot be vaccinated because of age or disease state, and there will be some unvaccinated individuals [6, 7] .", [["individuals", "ORGANISM", 74, 85], ["disease state", "PROBLEM", 204, 217]]], ["Herd immunity is the altruistic side of vaccination that will ultimately lead to the elimination of pathogens from either the human or animal population. typical small-pox lesion.", [["human", "ORGANISM", 126, 131], ["small-pox lesion", "PATHOLOGICAL_FORMATION", 162, 178], ["human", "SPECIES", 126, 131], ["human", "SPECIES", 126, 131], ["vaccination", "TREATMENT", 40, 51], ["pathogens", "PROBLEM", 100, 109], ["typical small-pox lesion", "PROBLEM", 154, 178], ["small", "OBSERVATION_MODIFIER", 162, 167], ["-pox", "OBSERVATION_MODIFIER", 167, 171], ["lesion", "OBSERVATION", 172, 178]]], ["He reasoned that by inoculating people with the material contained in cow-pox pustules he would protect them against subsequent infection with small-pox.", [["pustules", "ANATOMY", 78, 86], ["pustules", "DISEASE", 78, 86], ["infection", "DISEASE", 128, 137], ["people", "ORGANISM", 32, 38], ["cow", "ORGANISM", 70, 73], ["pox", "ORGANISM", 74, 77], ["pustules", "ORGANISM_SUBSTANCE", 78, 86], ["people", "SPECIES", 32, 38], ["cow", "SPECIES", 70, 73], ["cow-pox", "SPECIES", 70, 77], ["cow-pox pustules", "PROBLEM", 70, 86], ["subsequent infection", "PROBLEM", 117, 137], ["infection", "OBSERVATION", 128, 137], ["small", "OBSERVATION_MODIFIER", 143, 148]]], ["He performed the first known vaccine trial in 1796 by taking cow-pox pustules from a milkmaid, and inoculating an 8-year-old boy.", [["pustules", "ANATOMY", 69, 77], ["pustules", "DISEASE", 69, 77], ["cow", "ORGANISM", 61, 64], ["pox", "ORGANISM", 65, 68], ["pustules", "ORGANISM_SUBDIVISION", 69, 77], ["boy", "ORGANISM", 125, 128], ["cow", "SPECIES", 61, 64], ["boy", "SPECIES", 125, 128], ["cow-pox", "SPECIES", 61, 68], ["the first known vaccine trial", "TREATMENT", 13, 42]]], ["He noted that boy felt general malaise for a day, but recovered quickly.", [["boy", "ORGANISM", 14, 17], ["boy", "SPECIES", 14, 17], ["general malaise", "PROBLEM", 23, 38], ["malaise", "OBSERVATION", 31, 38]]], ["He later variolated the child with small-pox, however, the child did not show signs of becoming infected with the disease [9] .A Basic Overview of Vaccine FunctionWhile somewhat controversial in his time Jenner spent the rest of his life publicizing his technique.", [["child", "ORGANISM", 24, 29], ["child", "ORGANISM", 59, 64], ["child", "SPECIES", 24, 29], ["small-pox", "PROBLEM", 35, 44], ["the disease", "PROBLEM", 110, 121], ["Vaccine", "TREATMENT", 147, 154], ["small", "OBSERVATION_MODIFIER", 35, 40], ["infected", "OBSERVATION", 96, 104]]], ["At this point the germ theory of disease had not been established, and people did not understand that both small-pox and cow-pox were caused by closely related viruses.", [["germ", "ANATOMY", 18, 22], ["people", "ORGANISM", 71, 77], ["pox", "ORGANISM", 113, 116], ["cow-pox", "ORGANISM", 121, 128], ["people", "SPECIES", 71, 77], ["cow", "SPECIES", 121, 124], ["cow-pox", "SPECIES", 121, 128], ["disease", "PROBLEM", 33, 40], ["small-pox and cow-pox", "PROBLEM", 107, 128], ["disease", "OBSERVATION", 33, 40], ["small", "OBSERVATION_MODIFIER", 107, 112], ["viruses", "OBSERVATION", 160, 167]]], ["Many people had concerns that vaccination with a different disease would not actually lead to protection.", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11], ["vaccination", "TREATMENT", 30, 41], ["a different disease", "PROBLEM", 47, 66]]], ["It was not until 1837 when England began keeping Cause of Death Records, that William Farr was able to determine that communities that had have high vaccination rates had low rates of death from small-pox.", [["death", "DISEASE", 184, 189], ["high vaccination rates", "PROBLEM", 144, 166], ["death", "PROBLEM", 184, 189], ["small", "OBSERVATION_MODIFIER", 195, 200]]], ["Ultimately, in 1840 variolation was banned in England and vaccination became the standard prophylactic treatment for small-pox [8, 10] .", [["vaccination", "TREATMENT", 58, 69], ["the standard prophylactic treatment", "TREATMENT", 77, 112], ["small-pox", "PROBLEM", 117, 126]]], ["Jenner had succeeded in the development and implementation of the world's first vaccine ( Figure 1 , Table 1 ).A Basic Overview of Vaccine FunctionFrench Microbiologist and Chemist Louis Pasteur made the next major advance in the development of vaccines.", [["the world's first vaccine", "TREATMENT", 62, 87], ["vaccines", "TREATMENT", 245, 253]]], ["In 1879 while studying chicken cholera, Pasteurella multocida, he had chickens inoculated with a month old culture after a vacation.", [["chicken cholera", "DISEASE", 23, 38], ["Pasteurella multocida", "DISEASE", 40, 61], ["chicken", "ORGANISM", 23, 30], ["cholera", "ORGANISM_SUBDIVISION", 31, 38], ["Pasteurella multocida", "ORGANISM", 40, 61], ["chickens", "ORGANISM", 70, 78], ["chicken", "SPECIES", 23, 30], ["Pasteurella multocida", "SPECIES", 40, 61], ["chickens", "SPECIES", 70, 78], ["chicken", "SPECIES", 23, 30], ["Pasteurella multocida", "SPECIES", 40, 61], ["chickens", "SPECIES", 70, 78], ["Pasteurella multocida", "PROBLEM", 40, 61], ["a vacation", "TREATMENT", 121, 131]]], ["The inoculated chickens developed minor symptoms of the disease, but recovered.", [["chickens", "ORGANISM", 15, 23], ["chickens", "SPECIES", 15, 23], ["chickens", "SPECIES", 15, 23], ["minor symptoms", "PROBLEM", 34, 48], ["the disease", "PROBLEM", 52, 63], ["disease", "OBSERVATION", 56, 63]]], ["He later inoculated the same chickens with a fresh culture of bacteria and saw that chickens previously inoculated with the old culture were protected from infection, while na\u00efve birds still developed symptoms [10] .", [["infection", "DISEASE", 156, 165], ["chickens", "ORGANISM", 29, 37], ["chickens", "ORGANISM", 84, 92], ["birds", "ORGANISM", 179, 184], ["chickens", "SPECIES", 29, 37], ["chickens", "SPECIES", 84, 92], ["chickens", "SPECIES", 29, 37], ["chickens", "SPECIES", 84, 92], ["a fresh culture", "TEST", 43, 58], ["bacteria", "PROBLEM", 62, 70], ["the old culture", "TEST", 120, 135], ["infection", "PROBLEM", 156, 165], ["symptoms", "PROBLEM", 201, 209], ["infection", "OBSERVATION", 156, 165]]], ["Pasteur had stumbled onto the concept of attenuation.", [["attenuation", "OBSERVATION", 41, 52]]], ["If microorganisms are grown in suboptimal conditions, or are treated with certain chemicals they are not as virulent as microorganisms grown under ideal conditions.", [["microorganisms", "PROBLEM", 3, 17], ["virulent", "PROBLEM", 108, 116]]], ["By exposing the chickens to the attenuated bacteria Pasteur was able to induce protection against subsequent lethal challenge with the virulent P. multocida.", [["chickens", "ORGANISM", 16, 24], ["P. multocida", "ORGANISM", 144, 156], ["chickens", "SPECIES", 16, 24], ["P. multocida", "SPECIES", 144, 156], ["chickens", "SPECIES", 16, 24], ["P. multocida", "SPECIES", 144, 156], ["the attenuated bacteria", "PROBLEM", 28, 51], ["subsequent lethal challenge", "TREATMENT", 98, 125], ["the virulent P. multocida", "PROBLEM", 131, 156]]], ["In 1881 Pasteur was able to repeat similar findings by attenuating Bacillus anthracis and vaccinating farm animals with the attenuated B. anthracis [11] .A Basic Overview of Vaccine FunctionIn 1879 Pierre Galtier had discovered that something in the saliva of rabid dogs caused rabies in other mammals.", [["rabies", "DISEASE", 278, 284], ["Bacillus anthracis", "ORGANISM", 67, 85], ["B. anthracis", "ORGANISM", 135, 147], ["saliva", "ORGANISM_SUBSTANCE", 250, 256], ["dogs", "ORGANISM", 266, 270], ["Bacillus anthracis", "SPECIES", 67, 85], ["B. anthracis", "SPECIES", 135, 147], ["dogs", "SPECIES", 266, 270], ["Bacillus anthracis", "SPECIES", 67, 85], ["B. anthracis", "SPECIES", 135, 147], ["rabies", "SPECIES", 278, 284], ["attenuating Bacillus anthracis", "PROBLEM", 55, 85], ["the attenuated B. anthracis", "PROBLEM", 120, 147]]], ["By 1884 Pasteur had developed a way to propagate the infectious agent, decreasing the incubation time to days instead of months.", [["infectious", "OBSERVATION", 53, 63]]], ["He demonstrated that by inoculating dogs and other mammals with his attenuated strain of the rabies virus the animals were protected when challenged with the normal rabies virus.", [["dogs", "ORGANISM", 36, 40], ["rabies virus", "ORGANISM", 93, 105], ["animals", "ORGANISM", 110, 117], ["rabies virus", "ORGANISM", 165, 177], ["dogs", "SPECIES", 36, 40], ["rabies virus", "SPECIES", 93, 105], ["rabies virus", "SPECIES", 93, 105], ["rabies virus", "SPECIES", 165, 177], ["his attenuated strain of the rabies virus", "PROBLEM", 64, 105], ["rabies virus", "OBSERVATION", 165, 177]]], ["When 9 year old Joseph Meister was bitten by a rabid dog in 1885 Pasteur was able to vaccinate him with the attenuated virus preventing the boy from developing rabies [11] (Table 1) .", [["rabies", "DISEASE", 160, 166], ["dog", "ORGANISM", 53, 56], ["boy", "ORGANISM", 140, 143], ["dog", "SPECIES", 53, 56], ["boy", "SPECIES", 140, 143], ["the attenuated virus", "PROBLEM", 104, 124]]], ["Pasteur was able to demonstrate that an attenuated infectious agent could still result in protection of vaccinated humans against subsequent exposure to the virulent infectious agent.", [["humans", "ORGANISM", 115, 121], ["humans", "SPECIES", 115, 121], ["humans", "SPECIES", 115, 121], ["an attenuated infectious agent", "PROBLEM", 37, 67], ["vaccinated humans", "PROBLEM", 104, 121], ["the virulent infectious agent", "TREATMENT", 153, 182], ["attenuated", "OBSERVATION_MODIFIER", 40, 50], ["infectious", "OBSERVATION", 51, 61], ["virulent", "OBSERVATION_MODIFIER", 157, 165], ["infectious", "OBSERVATION", 166, 176]]], ["His work lead to the development of attenuated vaccines for the typhoid fever, cholera, and plague in the late 19 th and the early 20 th century [10] (Figure 1 ). also noted that animals that were given sub-lethal doses of purified toxin developed an antidote in their serum.", [["serum", "ANATOMY", 269, 274], ["typhoid fever", "DISEASE", 64, 77], ["cholera", "DISEASE", 79, 86], ["serum", "ORGANISM_SUBSTANCE", 269, 274], ["purified toxin", "PROTEIN", 223, 237], ["attenuated vaccines", "TREATMENT", 36, 55], ["the typhoid fever", "PROBLEM", 60, 77], ["cholera", "PROBLEM", 79, 86], ["purified toxin", "PROBLEM", 223, 237]]], ["These antidotes quickly became to be understood as antibodies that bind to the toxin, antigen, in a specific conformation leading to neutralization [10, 12] .", [["antibodies", "PROTEIN", 51, 61], ["toxin", "PROTEIN", 79, 84], ["the toxin", "TEST", 75, 84]]], ["Using a similar concept as Pasteur, scientists developed a vaccine candidate known as a toxoid vaccine that consisted of diphtheria toxin treated with formalin.", [["diphtheria toxin", "CHEMICAL", 121, 137], ["formalin", "CHEMICAL", 151, 159], ["formalin", "CHEMICAL", 151, 159], ["diphtheria toxin", "SIMPLE_CHEMICAL", 121, 137], ["formalin", "SIMPLE_CHEMICAL", 151, 159], ["diphtheria toxin", "PROTEIN", 121, 137], ["a vaccine", "TREATMENT", 57, 66], ["a toxoid vaccine", "TREATMENT", 86, 102], ["diphtheria toxin", "PROBLEM", 121, 137], ["formalin", "TREATMENT", 151, 159]]], ["While no longer toxic to the animal it is still immunogenic leading to the development of antibodies and ultimately protection against diphtheria [10, 13, 14] (Figure 1 , Table 1 ).The Golden Age of VaccinologyVaccine development was initially slow, partially because of the lack of techniques to culture infectious agents.", [["diphtheria", "DISEASE", 135, 145], ["antibodies", "PROTEIN", 90, 100], ["immunogenic", "PROBLEM", 48, 59], ["antibodies", "PROBLEM", 90, 100], ["diphtheria", "PROBLEM", 135, 145], ["Vaccine", "TREATMENT", 210, 217], ["culture infectious agents", "TREATMENT", 297, 322], ["no longer", "UNCERTAINTY", 6, 15]]], ["Viruses are intracellular parasites and need host tissue to reproduce and grow, so viral culture was dependent on the development of an effective tissue culture system.", [["intracellular", "ANATOMY", 12, 25], ["tissue", "ANATOMY", 50, 56], ["tissue culture", "ANATOMY", 146, 160], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 12, 25], ["tissue", "TISSUE", 50, 56], ["tissue", "TISSUE", 146, 152], ["Viruses", "PROBLEM", 0, 7], ["intracellular parasites", "PROBLEM", 12, 35], ["host tissue", "PROBLEM", 45, 56], ["viral culture", "TEST", 83, 96], ["an effective tissue culture system", "PROBLEM", 133, 167], ["intracellular parasites", "OBSERVATION", 12, 35], ["host tissue", "OBSERVATION_MODIFIER", 45, 56]]], ["The first attempts at growing animal tissues in vitro occurred in 1885, when Wilhelm Roux was able to sustain part of a chicken embryo in a saline solution for a few days.", [["tissues", "ANATOMY", 37, 44], ["embryo", "ANATOMY", 128, 134], ["tissues", "TISSUE", 37, 44], ["chicken", "ORGANISM", 120, 127], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 128, 134], ["chicken", "SPECIES", 120, 127], ["chicken", "SPECIES", 120, 127], ["Wilhelm Roux", "TREATMENT", 77, 89], ["a chicken embryo", "TREATMENT", 118, 134], ["a saline solution", "TREATMENT", 138, 155]]], ["Over the next 50 years the techniques and ability of scientists to maintain animal cultures began to improve [15] [16] [17] .", [["[15] [16] [17]", "SIMPLE_CHEMICAL", 109, 123], ["animal cultures", "TEST", 76, 91]]], ["By the mid-twentieth century tissue culture techniques had matured to the level were scientists were able to propagate viruses in culture, including in human tissues [18, 19] .The Golden Age of VaccinologyOne of the first diseases targeted for vaccine development was poliomyelitis, polio.", [["tissue", "ANATOMY", 29, 35], ["tissues", "ANATOMY", 158, 165], ["poliomyelitis", "DISEASE", 268, 281], ["polio", "DISEASE", 283, 288], ["tissue", "TISSUE", 29, 35], ["human", "ORGANISM", 152, 157], ["tissues", "TISSUE", 158, 165], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["tissue culture techniques", "TEST", 29, 54], ["culture", "TEST", 130, 137], ["the first diseases", "PROBLEM", 212, 230], ["vaccine development", "TREATMENT", 244, 263], ["poliomyelitis", "PROBLEM", 268, 281], ["polio", "PROBLEM", 283, 288], ["human tissues", "ANATOMY", 152, 165], ["Golden", "OBSERVATION_MODIFIER", 180, 186], ["poliomyelitis", "OBSERVATION", 268, 281]]], ["Polio is caused by one of three strains of the Enterovirus, Poliovirus.", [["Enterovirus", "DISEASE", 47, 58], ["Enterovirus", "ORGANISM", 47, 58], ["Poliovirus", "ORGANISM", 60, 70], ["Polio", "PROBLEM", 0, 5], ["the Enterovirus", "PROBLEM", 43, 58], ["Poliovirus", "PROBLEM", 60, 70], ["Enterovirus", "OBSERVATION", 47, 58]]], ["While polio was present in human populations since recorded history, epidemics only began to occur in the late nineteenth/early twentieth centuries.", [["polio", "DISEASE", 6, 11], ["human", "ORGANISM", 27, 32], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["epidemics", "PROBLEM", 69, 78]]], ["The worst recorded epidemic occurred in the United States in 1952 which resulted in 57,628 cases, 3,145 deaths, and 21,269 cases of paralysis [20] .", [["deaths", "DISEASE", 104, 110], ["paralysis", "DISEASE", 132, 141], ["paralysis", "PROBLEM", 132, 141]]], ["By this point the virus had been already cultured by John Enders, and vaccine development was underway [19] .", [["the virus", "PROBLEM", 14, 23], ["virus", "OBSERVATION", 18, 23]]], ["Salk had previously worked on a inactivated influenza vaccine, and believed the most effective candidate would be an inactivated poliovirus [21] .", [["influenza", "DISEASE", 44, 53], ["a inactivated influenza vaccine", "TREATMENT", 30, 61], ["an inactivated poliovirus", "PROBLEM", 114, 139]]], ["By this point scientists knew that protection against polio was mediated by Immunoglobulin G (IgG), and that viremia proceeded any paralytic effects in patients.", [["polio", "DISEASE", 54, 59], ["viremia", "DISEASE", 109, 116], ["paralytic", "DISEASE", 131, 140], ["Immunoglobulin G", "GENE_OR_GENE_PRODUCT", 76, 92], ["IgG", "GENE_OR_GENE_PRODUCT", 94, 97], ["patients", "ORGANISM", 152, 160], ["Immunoglobulin G", "PROTEIN", 76, 92], ["IgG", "PROTEIN", 94, 97], ["patients", "SPECIES", 152, 160], ["polio", "PROBLEM", 54, 59], ["Immunoglobulin G (IgG", "TREATMENT", 76, 97], ["viremia", "PROBLEM", 109, 116], ["viremia", "OBSERVATION", 109, 116]]], ["Salk hypothesized that by injecting patients with inactivated poliovirus they would develop the IgG response necessary for preventing clinical symptoms of the disease from developing.", [["patients", "ORGANISM", 36, 44], ["poliovirus", "ORGANISM", 62, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 96, 99], ["IgG", "PROTEIN", 96, 99], ["patients", "SPECIES", 36, 44], ["poliovirus", "SPECIES", 62, 72], ["inactivated poliovirus", "PROBLEM", 50, 72], ["the IgG response", "PROBLEM", 92, 108], ["clinical symptoms", "PROBLEM", 134, 151], ["the disease", "PROBLEM", 155, 166], ["disease", "OBSERVATION", 159, 166]]], ["Salk's inactivated trivalent polio vaccine (IPV) consisted of one of each of the three different strains of the Poliovirus that had been formalin inactivated.", [["formalin", "CHEMICAL", 137, 145], ["formalin", "CHEMICAL", 137, 145], ["trivalent polio vaccine", "ORGANISM", 19, 42], ["Poliovirus", "ORGANISM", 112, 122], ["formalin", "SIMPLE_CHEMICAL", 137, 145], ["Poliovirus", "SPECIES", 112, 122], ["Salk's inactivated trivalent polio vaccine", "TREATMENT", 0, 42], ["the Poliovirus", "PROBLEM", 108, 122]]], ["He developed the vaccine in 1952, and by 1953 had performed initial animal and human studies [22] .", [["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["human studies", "TEST", 79, 92]]], ["Over the next two years clinical studies increased in size until the IPV was determined to be safe and between 80-90% effective depending on the strain of poliovirus contracted [23] .", [["poliovirus", "ORGANISM", 155, 165], ["poliovirus", "SPECIES", 155, 165], ["clinical studies", "TEST", 24, 40], ["the strain of poliovirus contracted", "PROBLEM", 141, 176], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["size", "OBSERVATION_MODIFIER", 54, 58]]], ["The vaccine was approved in the United States in 1955.", [["The vaccine", "TREATMENT", 0, 11]]], ["Between 1954 and 1961 the incidence of paralytic polio in the US decreased from 13.9/100,000 to 0.8/100,000 due to the Salk Vaccine [24] .The Golden Age of VaccinologyThe second approach was the use of an attenuated oral polio vaccine (OPV).", [["oral", "ANATOMY", 216, 220], ["paralytic polio", "DISEASE", 39, 54], ["oral", "ORGANISM_SUBDIVISION", 216, 220], ["OPV", "SPECIES", 236, 239], ["paralytic polio", "TREATMENT", 39, 54], ["the US", "TEST", 58, 64], ["the Salk Vaccine", "TREATMENT", 115, 131], ["an attenuated oral polio vaccine", "TREATMENT", 202, 234]]], ["Some scientists believed that an IPV would not induce long term protection; the most famous of this group was Albert Sabin.", [["Albert Sabin", "ORGANISM", 110, 122], ["long term protection", "TREATMENT", 54, 74]]], ["He proposed using an attenuated virus delivered through an oral route, the natural infection route of the virus.", [["oral", "ANATOMY", 59, 63], ["infection", "DISEASE", 83, 92], ["oral", "ORGANISM_SUBDIVISION", 59, 63], ["an attenuated virus", "PROBLEM", 18, 37], ["an oral route", "TREATMENT", 56, 69], ["the natural infection route", "TREATMENT", 71, 98], ["the virus", "PROBLEM", 102, 111], ["virus", "OBSERVATION", 32, 37], ["infection", "OBSERVATION", 83, 92], ["virus", "OBSERVATION", 106, 111]]], ["By 1954 Sabin had generated four different OPV candidates, and by 1956 he had determined the three attenuated viral strains that would ultimately wind up in his final vaccine candidate [25, 26] .", [["the three attenuated viral strains", "PROBLEM", 89, 123]]], ["His OPV candidate underwent clinical studies between 1957-1960 in the United States, USSR, and around the world [26] .", [["clinical studies", "TEST", 28, 44]]], ["The OPV was approved in 1961 in the United States, and by 1965 had become the most widely accepted polio vaccine [27, 28] .", [["OPV", "CHEMICAL", 4, 7], ["polio vaccine", "TREATMENT", 99, 112]]], ["One of the major advantages of the OPV vaccines is because patients actually become infected with the vaccine they are able to spread the OPV viruses to their surrounding communities as they would if they were infected with a virulent strain of the virus [29] .", [["communities", "ANATOMY", 171, 182], ["OPV", "ORGANISM", 35, 38], ["patients", "ORGANISM", 59, 67], ["OPV viruses", "ORGANISM", 138, 149], ["patients", "SPECIES", 59, 67], ["the OPV vaccines", "TREATMENT", 31, 47], ["the vaccine", "TREATMENT", 98, 109], ["a virulent strain of the virus", "PROBLEM", 224, 254], ["infected", "OBSERVATION", 84, 92]]], ["The major disadvantage is that in a small number of patients spontaneous reversions will occur in the attenuated vaccine strains that lead to a virulent virus that can lead to vaccine derived paralytic poliomyelitis (VDPP) in the patient and their surrounding community [30] .The Golden Age of VaccinologyThe work of Salk and Sabin both moved the field of vaccinology further.", [["paralytic poliomyelitis", "DISEASE", 192, 215], ["VDPP", "DISEASE", 217, 221], ["patients", "ORGANISM", 52, 60], ["patient", "ORGANISM", 230, 237], ["Sabin", "ORGANISM", 326, 331], ["patients", "SPECIES", 52, 60], ["patient", "SPECIES", 230, 237], ["patients spontaneous reversions", "PROBLEM", 52, 83], ["the attenuated vaccine strains", "TREATMENT", 98, 128], ["a virulent virus", "PROBLEM", 142, 158], ["vaccine derived paralytic poliomyelitis", "PROBLEM", 176, 215], ["Sabin", "TREATMENT", 326, 331], ["major", "OBSERVATION_MODIFIER", 4, 9], ["disadvantage", "OBSERVATION_MODIFIER", 10, 22], ["small", "OBSERVATION_MODIFIER", 36, 41]]], ["They demonstrated that with two different approaches, it was possible to develop vaccine candidates that were able to prevent polio epidemics, and that each method has its own strengths and weaknesses.", [["vaccine candidates", "TREATMENT", 81, 99], ["polio epidemics", "PROBLEM", 126, 141]]], ["After 1965 most of the world moved to using the OPV in place of the IPV [27] .", [["the OPV", "TREATMENT", 44, 51]]], ["Because of the risk of the development of VDPP from the OPV, countries that have eliminated the disease have tended to move away from the trivalent OPV to IPV again [31] .", [["VDPP", "DISEASE", 42, 46], ["VDPP", "CANCER", 42, 46], ["VDPP", "PROBLEM", 42, 46], ["the disease", "PROBLEM", 92, 103]]], ["Currently, the United States uses only the IPV vaccine.", [["the IPV vaccine", "TREATMENT", 39, 54]]], ["This history also highlights the frequently changing needs of vaccine development in light of the biology and epidemiology of the infectious agent.The Golden Age of VaccinologyThe \"golden age\" of vaccinology also saw the generation of three other extremely important attenuated-virus vaccine candidates for childhood diseases.", [["vaccine development", "TREATMENT", 62, 81], ["the infectious agent", "TREATMENT", 126, 146], ["attenuated-virus vaccine", "TREATMENT", 267, 291], ["childhood diseases", "PROBLEM", 307, 325], ["infectious", "OBSERVATION", 130, 140], ["Golden", "OBSERVATION_MODIFIER", 151, 157]]], ["The first was for measles, a highly contagious disease that greater than 90% of the people eventually developed [32] .", [["measles", "DISEASE", 18, 25], ["people", "ORGANISM", 84, 90], ["people", "SPECIES", 84, 90], ["measles", "PROBLEM", 18, 25], ["a highly contagious disease", "PROBLEM", 27, 54], ["highly", "OBSERVATION_MODIFIER", 29, 35], ["contagious", "OBSERVATION_MODIFIER", 36, 46]]], ["The second disease was mumps.", [["mumps", "DISEASE", 23, 28], ["The second disease", "PROBLEM", 0, 18], ["mumps", "PROBLEM", 23, 28], ["second", "OBSERVATION_MODIFIER", 4, 10], ["disease", "OBSERVATION", 11, 18], ["mumps", "OBSERVATION", 23, 28]]], ["The final vaccine candidate was for rubella.", [["rubella", "DISEASE", 36, 43], ["The final vaccine", "TREATMENT", 0, 17], ["rubella", "PROBLEM", 36, 43]]], ["By the mid-1970s these three vaccines would be combined into a single multivalent attenuatedvirus vaccine candidate, the measles, mumps, and rubella vaccine (MMR) [33] .", [["measles, mumps", "DISEASE", 121, 135], ["rubella", "DISEASE", 141, 148], ["these three vaccines", "TREATMENT", 17, 37], ["a single multivalent attenuatedvirus vaccine", "TREATMENT", 61, 105], ["the measles", "PROBLEM", 117, 128], ["mumps", "PROBLEM", 130, 135], ["rubella vaccine", "TREATMENT", 141, 156]]], ["While different corporations produce different formulations of the same product the MMR vaccine has been determined to be safe and effective at reducing global morbidity and mortality from measles, mumps, and rubella [34] .The Third Phase of Vaccine Development: Subunit VaccinesDuring the 1950s and 1960s scientists' understanding of molecular microbial genetics increased.", [["measles", "DISEASE", 189, 196], ["mumps", "DISEASE", 198, 203], ["rubella", "DISEASE", 209, 216], ["different formulations", "TREATMENT", 37, 59], ["the MMR vaccine", "TREATMENT", 80, 95], ["measles", "PROBLEM", 189, 196], ["mumps", "PROBLEM", 198, 203], ["rubella", "PROBLEM", 209, 216]]], ["New knowledge as to the role of DNA in the cell, the nature of genes, the function of phage, and the discovery of restriction enzymes lead to the proposal that DNA molecules could be modified to include foreign DNA in the early 1970s [35] .", [["cell", "ANATOMY", 43, 47], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["cell", "CELL", 43, 47], ["DNA", "CELLULAR_COMPONENT", 160, 163], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["restriction enzymes", "PROTEIN", 114, 133], ["DNA molecules", "PROTEIN", 160, 173], ["restriction enzymes", "PROBLEM", 114, 133], ["DNA molecules", "PROBLEM", 160, 173], ["foreign DNA", "PROBLEM", 203, 214]]], ["Within fifteen years techniques were developed to generate recombinant DNA, transform or transduce it into a host cell such as Escherichia coli, Saccharomyces cerevisiae, or a baculovirus-insect cell expression system to produce recombinant proteins.", [["cell", "ANATOMY", 114, 118], ["cell", "ANATOMY", 195, 199], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["cell", "CELL", 114, 118], ["Escherichia coli", "ORGANISM", 127, 143], ["Saccharomyces cerevisiae", "ORGANISM", 145, 169], ["baculovirus", "ORGANISM", 176, 187], ["insect cell", "CELL", 188, 199], ["recombinant DNA", "DNA", 59, 74], ["recombinant proteins", "PROTEIN", 229, 249], ["Escherichia coli", "SPECIES", 127, 143], ["Saccharomyces cerevisiae", "SPECIES", 145, 169], ["Escherichia coli", "SPECIES", 127, 143], ["Saccharomyces cerevisiae", "SPECIES", 145, 169], ["baculovirus", "SPECIES", 176, 187], ["recombinant DNA", "TREATMENT", 59, 74], ["a host cell", "PROBLEM", 107, 118], ["Escherichia coli", "PROBLEM", 127, 143], ["Saccharomyces cerevisiae", "PROBLEM", 145, 169], ["a baculovirus", "TREATMENT", 174, 187], ["recombinant proteins", "PROBLEM", 229, 249], ["host cell", "OBSERVATION", 109, 118], ["Escherichia coli", "OBSERVATION", 127, 143]]], ["Over the subsequent 40 years more and more expression systems have been developed only increasing the ability to produce recombinant proteins.", [["recombinant proteins", "PROTEIN", 121, 141]]], ["This revolution in biology allowed vaccinologists to approach the concept of vaccines in a new light, working under the hypothesis that using specific antigens from various infectious agents, safe, cheap, and effective vaccine candidates could be produced.", [["vaccines", "TREATMENT", 77, 85], ["various infectious agents", "TREATMENT", 165, 190], ["cheap", "TREATMENT", 198, 203], ["effective vaccine candidates", "TREATMENT", 209, 237]]], ["All of the previous inactivated vaccines, attenuated vaccines, and toxoid vaccines required a culture of a given infectious agent before a vaccine candidate could be developed.", [["the previous inactivated vaccines", "TREATMENT", 7, 40], ["attenuated vaccines", "TREATMENT", 42, 61], ["toxoid vaccines", "TREATMENT", 67, 82], ["a culture", "TEST", 92, 101], ["infectious agent", "TREATMENT", 113, 129], ["a vaccine", "TREATMENT", 137, 146]]], ["By using recombinant DNA technology, protein antigens from organisms that are either unculturable, highly pathogenic, or extremely expensive to culture could be generated.", [["DNA", "CELLULAR_COMPONENT", 21, 24], ["protein antigens", "GENE_OR_GENE_PRODUCT", 37, 53], ["protein antigens", "PROTEIN", 37, 53], ["recombinant DNA technology", "TEST", 9, 35], ["protein antigens", "TEST", 37, 53], ["organisms", "PROBLEM", 59, 68], ["culture", "TEST", 144, 151]]], ["Subunit vaccines reduce the risk of side effects such as spontaneous reversions of attenuated vaccines and denaturing of antigenic peptides with inactivated vaccines [36] .The Third Phase of Vaccine Development: Subunit VaccinesThere are subunit vaccine candidates for almost every known human or animal vaccine in existence.", [["human", "ORGANISM", 288, 293], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 288, 293], ["Subunit vaccines", "TREATMENT", 0, 16], ["side effects", "PROBLEM", 36, 48], ["spontaneous reversions", "TREATMENT", 57, 79], ["attenuated vaccines", "TREATMENT", 83, 102], ["denaturing of antigenic peptides", "TREATMENT", 107, 139], ["inactivated vaccines", "TREATMENT", 145, 165], ["The Third Phase of Vaccine", "TREATMENT", 172, 198], ["Subunit Vaccines", "TREATMENT", 212, 228], ["subunit vaccine candidates", "TREATMENT", 238, 264], ["animal vaccine", "TREATMENT", 297, 311]]], ["However, there is a major problem with these subunit vaccines.", [["these subunit vaccines", "TREATMENT", 39, 61]]], ["Exposure to whole organism vaccines, whether inactivated, attenuated, or from a closely related species, does not just expose a subject to just one copy of an antigen in a vacuum.", [["whole organism vaccines", "TREATMENT", 12, 35], ["a closely related species", "PROBLEM", 78, 103], ["a vacuum", "TREATMENT", 170, 178], ["vacuum", "OBSERVATION", 172, 178]]], ["Whole organism vaccines contain multiple copies of each antigen, as well as other immunostimulatory molecules.", [["immunostimulatory molecules", "PROTEIN", 82, 109], ["Whole organism vaccines", "TREATMENT", 0, 23], ["multiple copies of each antigen", "PROBLEM", 32, 63], ["multiple", "OBSERVATION_MODIFIER", 32, 40], ["immunostimulatory molecules", "OBSERVATION", 82, 109]]], ["The resulting problem is that subunit vaccines in general are not as immunostimulatory [37] .", [["subunit vaccines", "TREATMENT", 30, 46]]], ["This effect is most likely caused by reduced ability to cross link B cell receptors as well as a reduced ability to stimulate APCs [4] .", [["B cell", "ANATOMY", 67, 73], ["APCs", "ANATOMY", 126, 130], ["B cell receptors", "GENE_OR_GENE_PRODUCT", 67, 83], ["APCs", "CELL", 126, 130], ["B cell receptors", "PROTEIN", 67, 83], ["APCs", "CELL_TYPE", 126, 130], ["reduced ability", "PROBLEM", 37, 52], ["B cell receptors", "TREATMENT", 67, 83], ["a reduced ability", "PROBLEM", 95, 112], ["most likely", "UNCERTAINTY", 15, 26]]], ["Many approaches have been taken to develop a subunit vaccine that is not only safe, easy to produce, but also as effective as a whole organism vaccine.Increasing the Immune Response to Subunit Vaccines: AdjuvantsOne way that vaccines can be modified to increase their efficacy is the addition of an adjuvant.", [["a subunit vaccine", "TREATMENT", 43, 60], ["a whole organism vaccine", "TREATMENT", 126, 150], ["Subunit Vaccines", "TREATMENT", 185, 201], ["Adjuvants", "TREATMENT", 203, 212], ["vaccines", "TREATMENT", 225, 233], ["an adjuvant", "TREATMENT", 296, 307], ["Immune Response", "OBSERVATION", 166, 181]]], ["The word adjuvant comes from the Latin word adiuvare, which means to help.", [["The word adjuvant", "TREATMENT", 0, 17]]], ["In the simplest terms an adjuvant is something that helps a vaccine function.", [["a vaccine function", "TREATMENT", 58, 76]]], ["That could mean the adjuvant allows the vaccine to be more immunogenic, induce a stronger humoral or a cellular immune response, increase antigen processing by APC, decrease the total amount of vaccine that needs to be injected in a processes known as dose sparing, or aid in the development of a long term memory response [38] .", [["cellular", "ANATOMY", 103, 111], ["cellular", "CELL", 103, 111], ["APC", "GENE_OR_GENE_PRODUCT", 160, 163], ["APC", "CELL_TYPE", 160, 163], ["the vaccine", "TREATMENT", 36, 47], ["a cellular immune response", "PROBLEM", 101, 127], ["the total amount of vaccine", "TREATMENT", 174, 201]]], ["Broadly, there are two main classes of adjuvants, immunopotentiators and delivery systems.", [["adjuvants", "TREATMENT", 39, 48], ["immunopotentiators and delivery systems", "TREATMENT", 50, 89], ["main", "OBSERVATION_MODIFIER", 23, 27], ["adjuvants", "OBSERVATION", 39, 48]]], ["Immunopotentiators stimulate the immune system, while delivery systems function to carry and present the vaccine to the hosts immune system [39] .", [["immune system", "ANATOMY", 33, 46]]], ["While adjuvants have been used with most vaccine formulations almost since the dawn of the vaccine age, they are essential for use with any subunit vaccine.", [["adjuvants", "TREATMENT", 6, 15], ["most vaccine formulations", "TREATMENT", 36, 61], ["any subunit vaccine", "TREATMENT", 136, 155]]], ["Despite being used for almost a century adjuvants are not well understood, and any new vaccine/immunopotentiator/delivery system formulation needs to be tested for efficacy and toxicity [40] .Increasing the Immune Response to Subunit Vaccines: AdjuvantsThe first known and most widely used adjuvant are aluminum salts, also known as Alum.", [["toxicity", "DISEASE", 177, 185], ["aluminum salts", "CHEMICAL", 303, 317], ["Alum", "CHEMICAL", 333, 337], ["aluminum salts", "CHEMICAL", 303, 317], ["Alum", "CHEMICAL", 333, 337], ["aluminum salts", "SIMPLE_CHEMICAL", 303, 317], ["Alum", "SIMPLE_CHEMICAL", 333, 337], ["a century adjuvants", "TREATMENT", 30, 49], ["new vaccine/immunopotentiator/delivery system formulation", "TREATMENT", 83, 140], ["toxicity", "PROBLEM", 177, 185], ["Subunit Vaccines", "TREATMENT", 226, 242], ["Adjuvants", "TREATMENT", 244, 253], ["adjuvant are aluminum salts", "TREATMENT", 290, 317], ["Immune Response", "OBSERVATION", 207, 222], ["Alum", "OBSERVATION", 333, 337]]], ["Aluminum containing salts are currently the only universally approved adjuvant for human use in the United States.", [["Aluminum", "CHEMICAL", 0, 8], ["Aluminum", "CHEMICAL", 0, 8], ["Aluminum containing salts", "SIMPLE_CHEMICAL", 0, 25], ["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["Aluminum containing salts", "TREATMENT", 0, 25]]], ["Aluminum potassium sulfate was first identified in 1926 to induce higher titers of antibodies in Guinea pigs when injected in formulation with a diphtheria toxoid, in comparison to the toxoid vaccine injected alone [41] .", [["Aluminum", "CHEMICAL", 0, 8], ["potassium sulfate", "CHEMICAL", 9, 26], ["diphtheria toxoid", "CHEMICAL", 145, 162], ["Aluminum potassium sulfate", "CHEMICAL", 0, 26], ["Aluminum potassium sulfate", "SIMPLE_CHEMICAL", 0, 26], ["Guinea pigs", "ORGANISM", 97, 108], ["diphtheria toxoid", "ORGANISM", 145, 162], ["antibodies", "PROTEIN", 83, 93], ["Guinea pigs", "SPECIES", 97, 108], ["Guinea pigs", "SPECIES", 97, 108], ["Aluminum potassium sulfate", "TREATMENT", 0, 26], ["higher titers of antibodies", "PROBLEM", 66, 93], ["Guinea pigs", "TREATMENT", 97, 108], ["a diphtheria toxoid", "TREATMENT", 143, 162], ["the toxoid vaccine", "TREATMENT", 181, 199]]], ["Subsequently, it has been demonstrated that aluminum-containing salts result in stronger humoral responses to vaccines, but do not affect cellular responses.", [["cellular", "ANATOMY", 138, 146], ["aluminum", "CHEMICAL", 44, 52], ["aluminum", "CHEMICAL", 44, 52], ["aluminum-containing salts", "SIMPLE_CHEMICAL", 44, 69], ["cellular", "CELL", 138, 146], ["aluminum-containing salts", "TREATMENT", 44, 69], ["vaccines", "TREATMENT", 110, 118]]], ["The exact mechanism of action is not completely understood and still widely debated, and most likely depends on the vaccine, route of injection, and organism the vaccine is being injected into.", [["the vaccine", "TREATMENT", 112, 123], ["injection", "TREATMENT", 134, 143], ["organism the vaccine", "TREATMENT", 149, 169]]], ["Generally, it is known that Alum attracts innate immune cells, particularly immature dendritic cells to the site of vaccination.", [["immune cells", "ANATOMY", 49, 61], ["dendritic cells", "ANATOMY", 85, 100], ["Alum", "CHEMICAL", 28, 32], ["Alum", "CHEMICAL", 28, 32], ["Alum", "SIMPLE_CHEMICAL", 28, 32], ["immune cells", "CELL", 49, 61], ["dendritic cells", "CELL", 85, 100], ["innate immune cells", "CELL_TYPE", 42, 61], ["immature dendritic cells", "CELL_TYPE", 76, 100], ["Alum attracts innate immune cells", "TREATMENT", 28, 61], ["immature dendritic cells", "PROBLEM", 76, 100], ["dendritic cells", "OBSERVATION", 85, 100]]], ["The cells are able to mature and present the vaccine to T H cells in lymph nodes.", [["cells", "ANATOMY", 4, 9], ["T H cells", "ANATOMY", 56, 65], ["lymph nodes", "ANATOMY", 69, 80], ["cells", "CELL", 4, 9], ["T H cells", "CELL", 56, 65], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 69, 80], ["T H cells", "CELL_TYPE", 56, 65], ["lymph nodes", "OBSERVATION", 69, 80]]], ["Which are subsequently able to stimulate B cells that have encountered the vaccine to generate high titers of antibodies.", [["B cells", "ANATOMY", 41, 48], ["B cells", "CELL", 41, 48], ["B cells", "CELL_TYPE", 41, 48], ["antibodies", "PROTEIN", 110, 120], ["the vaccine", "TREATMENT", 71, 82], ["high titers of antibodies", "PROBLEM", 95, 120]]], ["Alum also binds to proteins and has the potential, depending on vaccine route, to function as both as a immunopotentiator and as a delivery system [42, 43] .Increasing the Immune Response to Subunit Vaccines: AdjuvantsAnother major class of adjuvants are the emulsions.", [["Alum", "CHEMICAL", 0, 4], ["Alum", "CHEMICAL", 0, 4], ["Alum", "SIMPLE_CHEMICAL", 0, 4], ["vaccine route", "TREATMENT", 64, 77], ["Subunit Vaccines", "TREATMENT", 191, 207], ["Adjuvants", "TREATMENT", 209, 218], ["Immune Response", "OBSERVATION", 172, 187]]], ["The first emulsion adjuvant was generated by Jules Freund in 1944 and contained mineral oil, an emulsifying agent, and dried ground Mycobacterium tuberculosis creating a water-in-oil emulsion [44, 45] .", [["oil", "ANATOMY", 88, 91], ["Mycobacterium tuberculosis", "DISEASE", 132, 158], ["Mycobacterium tuberculosis", "SPECIES", 132, 158], ["Mycobacterium tuberculosis", "SPECIES", 132, 158], ["The first emulsion adjuvant", "TREATMENT", 0, 27], ["mineral oil", "TREATMENT", 80, 91], ["an emulsifying agent", "TREATMENT", 93, 113], ["dried ground Mycobacterium tuberculosis", "TREATMENT", 119, 158], ["Mycobacterium tuberculosis", "OBSERVATION", 132, 158]]], ["This formulation known as Freund's Complete Adjuvant (FCA) was shown to stimulate both the humoral and the cellular immune pathways.", [["cellular", "ANATOMY", 107, 115], ["Freund's Complete Adjuvant", "SIMPLE_CHEMICAL", 26, 52], ["FCA", "SIMPLE_CHEMICAL", 54, 57], ["cellular", "CELL", 107, 115], ["This formulation", "TREATMENT", 0, 16], ["Freund's Complete Adjuvant (FCA)", "TREATMENT", 26, 58], ["humoral", "ANATOMY", 91, 98], ["cellular immune", "OBSERVATION", 107, 122]]], ["Ultimately, because of the presence of M. tuberculosis it was determined to be too dangerous to use in humans.", [["tuberculosis", "DISEASE", 42, 54], ["M. tuberculosis", "ORGANISM", 39, 54], ["humans", "ORGANISM", 103, 109], ["M. tuberculosis", "SPECIES", 39, 54], ["humans", "SPECIES", 103, 109], ["M. tuberculosis", "SPECIES", 39, 54], ["humans", "SPECIES", 103, 109], ["M. tuberculosis", "PROBLEM", 39, 54], ["tuberculosis", "OBSERVATION", 42, 54]]], ["This resulted in the generation of Freund's Incomplete Adjuvant (IFA), which contained everything in FCA except the M. tuberculosis.", [["tuberculosis", "DISEASE", 119, 131], ["Freund's Incomplete Adjuvant", "SIMPLE_CHEMICAL", 35, 63], ["FCA", "SIMPLE_CHEMICAL", 101, 104], ["M. tuberculosis", "ORGANISM", 116, 131], ["M. tuberculosis", "SPECIES", 116, 131], ["M. tuberculosis", "SPECIES", 116, 131], ["Freund's Incomplete Adjuvant (IFA)", "TREATMENT", 35, 69], ["the M. tuberculosis", "PROBLEM", 112, 131], ["M.", "OBSERVATION_MODIFIER", 116, 118], ["tuberculosis", "OBSERVATION", 119, 131]]], ["IFA leads to primarily a humoral response to vaccines.Increasing the Immune Response to Subunit Vaccines: AdjuvantsEventually, IFA was used in formulation with IPV, however, its use was discontinued in humans due to it being too reactive [46] .Increasing the Immune Response to Subunit Vaccines: AdjuvantsThe initial successes with the immunogenicity of emulsions lead to the desire to create safer alternatives to FCA or IFA that would be as immunogenic, without the side effects.", [["IFA", "SIMPLE_CHEMICAL", 0, 3], ["IFA", "SIMPLE_CHEMICAL", 127, 130], ["humans", "ORGANISM", 202, 208], ["FCA", "SIMPLE_CHEMICAL", 415, 418], ["IFA", "SIMPLE_CHEMICAL", 422, 425], ["humans", "SPECIES", 202, 208], ["humans", "SPECIES", 202, 208], ["vaccines", "TREATMENT", 45, 53], ["Subunit Vaccines", "TREATMENT", 88, 104], ["Adjuvants", "TREATMENT", 106, 115], ["IFA", "TEST", 127, 130], ["IPV", "TREATMENT", 160, 163], ["too reactive", "PROBLEM", 225, 237], ["Subunit Vaccines", "TREATMENT", 278, 294], ["Adjuvants", "TREATMENT", 296, 305], ["the immunogenicity of emulsions", "TREATMENT", 332, 363], ["IFA", "TREATMENT", 422, 425], ["the side effects", "PROBLEM", 464, 480], ["Immune Response", "OBSERVATION", 69, 84], ["Immune Response", "OBSERVATION", 259, 274]]], ["Focus moved to oil-in-water emulsions.", [["oil-in-water emulsions", "SIMPLE_CHEMICAL", 15, 37]]], ["In 1997 MF59 (Novartis) the first oil-in-water emulsion was approved in Europe.", [["MF59", "CHEMICAL", 8, 12], ["the first oil-in-water emulsion", "TREATMENT", 24, 55]]], ["It is a mixture of squalene, span 85 (a surfactant), and tween 80 in a citrate buffer combined with the antigen [47] .", [["squalene", "CHEMICAL", 19, 27], ["citrate", "CHEMICAL", 71, 78], ["squalene", "CHEMICAL", 19, 27], ["citrate", "CHEMICAL", 71, 78], ["squalene", "SIMPLE_CHEMICAL", 19, 27], ["surfactant", "SIMPLE_CHEMICAL", 40, 50], ["citrate", "SIMPLE_CHEMICAL", 71, 78], ["a citrate buffer", "TREATMENT", 69, 85]]], ["It is believed to function by recruiting innate and adaptive immune cells to the site of injection, but like alum the mechanism is not completely understood.", [["immune cells", "ANATOMY", 61, 73], ["site", "ANATOMY", 81, 85], ["alum", "CHEMICAL", 109, 113], ["immune cells", "CELL", 61, 73], ["alum", "GENE_OR_GENE_PRODUCT", 109, 113], ["immune cells", "CELL_TYPE", 61, 73], ["adaptive immune cells", "TREATMENT", 52, 73], ["injection", "TREATMENT", 89, 98], ["believed to", "UNCERTAINTY", 6, 17]]], ["It is known to induce higher titers of antibodies as well as T C responses [47, 48] .", [["T C", "GENE_OR_GENE_PRODUCT", 61, 64], ["antibodies", "PROTEIN", 39, 49], ["higher titers of antibodies", "PROBLEM", 22, 49]]], ["Each one is slightly different, but as of now only MF59 is approved and only for an inactivated influenza vaccine in Europe [45] .Increasing the Immune Response to Subunit Vaccines: AdjuvantsOne of the most exciting area in adjuvant development is the use of pathogen associated molecular patterns (PAMPs) as adjuvants either by themselves, or in combination with another type of adjuvant (Table 2) .", [["MF59", "CHEMICAL", 51, 55], ["influenza", "DISEASE", 96, 105], ["MF59", "SIMPLE_CHEMICAL", 51, 55], ["pathogen associated molecular patterns", "GENE_OR_GENE_PRODUCT", 259, 297], ["pathogen associated molecular patterns", "PROTEIN", 259, 297], ["an inactivated influenza vaccine", "TREATMENT", 81, 113], ["Subunit Vaccines", "TREATMENT", 164, 180], ["Adjuvants", "TREATMENT", 182, 191], ["adjuvant development", "TREATMENT", 224, 244], ["adjuvant (Table", "TREATMENT", 380, 395], ["slightly", "OBSERVATION_MODIFIER", 12, 20], ["different", "OBSERVATION_MODIFIER", 21, 30], ["Immune Response", "OBSERVATION", 145, 160]]], ["PAMPs are repetitive molecules that are present in or on invading microorganisms.", [["PAMPs", "GENE_OR_GENE_PRODUCT", 0, 5], ["PAMPs", "PROTEIN", 0, 5], ["repetitive molecules", "PROBLEM", 10, 30]]], ["Multicellular organisms have evolved pattern recognition receptors (PRR) that are germ-line encoded receptors that recognize PAMPs.", [["germ-line", "ANATOMY", 82, 91], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 37, 66], ["PRR", "GENE_OR_GENE_PRODUCT", 68, 71], ["germ-line", "CELL", 82, 91], ["PAMPs", "GENE_OR_GENE_PRODUCT", 125, 130], ["pattern recognition receptors", "PROTEIN", 37, 66], ["PRR", "PROTEIN", 68, 71], ["germ-line encoded receptors", "PROTEIN", 82, 109], ["PAMPs", "PROTEIN", 125, 130], ["Multicellular organisms", "PROBLEM", 0, 23], ["organisms", "OBSERVATION", 14, 23]]], ["Some PRR are present on the cell membrane such as Toll-Like Receptors (TLR), and C-Type Lectin Receptors (CLR).", [["cell membrane", "ANATOMY", 28, 41], ["PRR", "GENE_OR_GENE_PRODUCT", 5, 8], ["cell membrane", "CELLULAR_COMPONENT", 28, 41], ["Toll-Like Receptors", "GENE_OR_GENE_PRODUCT", 50, 69], ["TLR", "GENE_OR_GENE_PRODUCT", 71, 74], ["C-Type Lectin Receptors", "GENE_OR_GENE_PRODUCT", 81, 104], ["CLR", "GENE_OR_GENE_PRODUCT", 106, 109], ["PRR", "PROTEIN", 5, 8], ["Toll-Like Receptors", "PROTEIN", 50, 69], ["TLR", "PROTEIN", 71, 74], ["C-Type Lectin Receptors", "PROTEIN", 81, 104], ["CLR", "PROTEIN", 106, 109], ["Some PRR", "PROBLEM", 0, 8], ["the cell membrane", "TREATMENT", 24, 41], ["C-Type Lectin Receptors", "TREATMENT", 81, 104], ["cell membrane", "OBSERVATION", 28, 41]]], ["While others are internal receptors such as NOD-Like Receptors (NLR) and RIG-I-Like Receptors (RLR).", [["NOD-Like Receptors", "GENE_OR_GENE_PRODUCT", 44, 62], ["NLR", "GENE_OR_GENE_PRODUCT", 64, 67], ["RIG-I-Like Receptors", "GENE_OR_GENE_PRODUCT", 73, 93], ["RLR", "GENE_OR_GENE_PRODUCT", 95, 98], ["NOD-Like Receptors", "PROTEIN", 44, 62], ["NLR", "PROTEIN", 64, 67], ["RIG-I-Like Receptors", "PROTEIN", 73, 93], ["RLR", "PROTEIN", 95, 98], ["internal receptors", "TREATMENT", 17, 35], ["NOD", "TEST", 44, 47], ["NLR", "TEST", 64, 67], ["RIG", "TEST", 73, 76]]], ["Each class of PRR is further subdivided into different receptors and each has a specific target and a specific signaling pathway.", [["PRR", "GENE_OR_GENE_PRODUCT", 14, 17], ["PRR", "PROTEIN", 14, 17]]], ["Many are well understood, which is a major advantage in adjuvant development.", [["adjuvant development", "TREATMENT", 56, 76]]], ["By using PAMPs that are well understood, vaccine formulations can be developed that lead to safer and more effective immune stimulation by reducing the side effects of other adjuvants. chain, the middle domain is known as the core domain, the final domain known as lipid A [49] .", [["PAMPs", "PROTEIN", 9, 14], ["middle domain", "PROTEIN", 196, 209], ["core domain", "PROTEIN", 226, 237], ["vaccine formulations", "TREATMENT", 41, 61], ["immune stimulation", "TREATMENT", 117, 135], ["other adjuvants", "TREATMENT", 168, 183], ["middle", "ANATOMY_MODIFIER", 196, 202]]], ["Lipid A is responsible for signaling through TLR4.", [["Lipid A", "SIMPLE_CHEMICAL", 0, 7], ["TLR4", "GENE_OR_GENE_PRODUCT", 45, 49], ["TLR4", "PROTEIN", 45, 49], ["signaling through TLR4", "PROBLEM", 27, 49]]], ["Upon initial stimulation of TLR4 signaling through TIRAP-MyD88 adapter protein leads to transcription via AP-1 and NF-\u03baB transcription factors of proinflammatory cytokines.", [["TLR4", "GENE_OR_GENE_PRODUCT", 28, 32], ["TIRAP-MyD88", "GENE_OR_GENE_PRODUCT", 51, 62], ["AP-1", "GENE_OR_GENE_PRODUCT", 106, 110], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 115, 120], ["TLR4", "PROTEIN", 28, 32], ["TIRAP", "PROTEIN", 51, 56], ["MyD88 adapter protein", "PROTEIN", 57, 78], ["AP", "PROTEIN", 106, 108], ["NF-\u03baB", "PROTEIN", 115, 120], ["transcription factors", "PROTEIN", 121, 142], ["proinflammatory cytokines", "PROTEIN", 146, 171], ["TLR4 signaling through TIRAP", "TREATMENT", 28, 56], ["AP", "TEST", 106, 108], ["NF", "TEST", 115, 117], ["proinflammatory cytokines", "PROBLEM", 146, 171], ["proinflammatory cytokines", "OBSERVATION", 146, 171]]], ["As signaling continues TLR4 is endocytosed which leads to signaling through TRAM-TRIF and transcription of interleukin-I genes, leading to antimicrobial activity [50, 51] .", [["TLR4", "GENE_OR_GENE_PRODUCT", 23, 27], ["TRAM-TRIF", "GENE_OR_GENE_PRODUCT", 76, 85], ["interleukin-I", "GENE_OR_GENE_PRODUCT", 107, 120], ["TLR4", "PROTEIN", 23, 27], ["TRAM", "PROTEIN", 76, 80], ["TRIF", "PROTEIN", 81, 85], ["interleukin-I genes", "DNA", 107, 126], ["signaling through TRAM", "TREATMENT", 58, 80], ["TRIF", "TREATMENT", 81, 85], ["antimicrobial activity", "TEST", 139, 161]]], ["Wildtype LPS is not a good adjuvant, even though it is highly immunogenic.", [["LPS", "CHEMICAL", 9, 12], ["LPS", "SIMPLE_CHEMICAL", 9, 12], ["Wildtype", "SPECIES", 0, 8], ["Wildtype LPS", "PROBLEM", 0, 12], ["highly", "OBSERVATION_MODIFIER", 55, 61], ["immunogenic", "OBSERVATION", 62, 73]]], ["Too much LPS leads to septic shock, and too little leads to endotoxin tolerance [53, 54] .", [["LPS", "CHEMICAL", 9, 12], ["septic shock", "DISEASE", 22, 34], ["endotoxin", "CHEMICAL", 60, 69], ["LPS", "SIMPLE_CHEMICAL", 9, 12], ["endotoxin", "SIMPLE_CHEMICAL", 60, 69], ["septic shock", "PROBLEM", 22, 34], ["endotoxin tolerance", "TEST", 60, 79], ["septic shock", "OBSERVATION", 22, 34]]], ["By chemically modifying Lipid A from Salmonella minnesota 595 to remove a phosphate group and generating slight alterations to the fatty acid chains a potential new adjuvant was generated known as monophosporyl lipid A (MPLA) [49] .", [["Salmonella minnesota 595", "CHEMICAL", 37, 61], ["phosphate", "CHEMICAL", 74, 83], ["fatty acid", "CHEMICAL", 131, 141], ["monophosporyl lipid A", "CHEMICAL", 197, 218], ["phosphate", "CHEMICAL", 74, 83], ["fatty acid", "CHEMICAL", 131, 141], ["monophosporyl", "CHEMICAL", 197, 210], ["Lipid A", "SIMPLE_CHEMICAL", 24, 31], ["Salmonella minnesota 595", "ORGANISM", 37, 61], ["monophosporyl lipid A", "SIMPLE_CHEMICAL", 197, 218], ["MPLA", "SIMPLE_CHEMICAL", 220, 224], ["Salmonella minnesota", "SPECIES", 37, 57], ["Salmonella minnesota", "SPECIES", 37, 57], ["a phosphate group", "TREATMENT", 72, 89], ["slight alterations", "PROBLEM", 105, 123], ["the fatty acid chains", "TREATMENT", 127, 148], ["new adjuvant", "TREATMENT", 161, 173]]], ["MPLA only signals through the TRAM-TRIF signaling pathway preventing the generation of proinflamatory cytokines [55] .", [["MPLA", "SIMPLE_CHEMICAL", 0, 4], ["TRAM", "GENE_OR_GENE_PRODUCT", 30, 34], ["TRIF", "GENE_OR_GENE_PRODUCT", 35, 39], ["TRAM", "PROTEIN", 30, 34], ["TRIF", "PROTEIN", 35, 39], ["proinflamatory cytokines", "PROTEIN", 87, 111], ["the TRAM", "TREATMENT", 26, 34], ["proinflamatory cytokines", "PROBLEM", 87, 111]]], ["This adjuvant has been shown to be able to increase serum antibody titers as well as inducing strong cellular immune responses [54, 56, 57] .", [["serum", "ANATOMY", 52, 57], ["cellular", "ANATOMY", 101, 109], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["cellular", "CELL", 101, 109], ["serum antibody", "PROTEIN", 52, 66], ["This adjuvant", "TREATMENT", 0, 13], ["serum antibody titers", "TEST", 52, 73]]], ["In humans 10,000 times the dose of MPLA is better tolerated than wildtype lipid A [58] .", [["MPLA", "CHEMICAL", 35, 39], ["MPLA", "CHEMICAL", 35, 39], ["humans", "ORGANISM", 3, 9], ["MPLA", "SIMPLE_CHEMICAL", 35, 39], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["MPLA", "TREATMENT", 35, 39]]], ["This adjuvant has been approved in combination with Alum for use in the Cervarix human papilloma virus (HPV) vaccine in the United States.Increasing the Immune Response to Subunit Vaccines: AdjuvantsAnother PAMP that is a potential adjuvant candidate is flagellin, a component of the bacterial flagellum (Table 2) .", [["flagellum", "ANATOMY", 294, 303], ["Alum", "CHEMICAL", 52, 56], ["human papilloma virus (HPV) vaccine", "DISEASE", 81, 116], ["Alum", "SIMPLE_CHEMICAL", 52, 56], ["Cervarix", "ORGANISM", 72, 80], ["human papilloma virus", "ORGANISM", 81, 102], ["HPV", "ORGANISM", 104, 107], ["PAMP", "GENE_OR_GENE_PRODUCT", 207, 211], ["flagellin", "GENE_OR_GENE_PRODUCT", 254, 263], ["PAMP", "PROTEIN", 207, 211], ["flagellin", "PROTEIN", 254, 263], ["human", "SPECIES", 81, 86], ["papilloma virus", "SPECIES", 87, 102], ["Cervarix human papilloma virus", "SPECIES", 72, 102], ["HPV", "SPECIES", 104, 107], ["This adjuvant", "TREATMENT", 0, 13], ["Alum", "TREATMENT", 52, 56], ["the Cervarix human papilloma virus (HPV) vaccine", "TREATMENT", 68, 116], ["Subunit Vaccines", "TREATMENT", 172, 188], ["Adjuvants", "TREATMENT", 190, 199], ["a potential adjuvant candidate", "TREATMENT", 220, 250], ["flagellin", "TREATMENT", 254, 263], ["the bacterial flagellum", "PROBLEM", 280, 303], ["Immune Response", "OBSERVATION", 153, 168], ["bacterial flagellum", "OBSERVATION", 284, 303]]], ["Each flagellin monomer is subdivided in four different domains D0, D1, D2, and D3 [59] .", [["flagellin", "GENE_OR_GENE_PRODUCT", 5, 14], ["flagellin monomer", "PROTEIN", 5, 22], ["D0", "PROTEIN", 63, 65], ["D1", "PROTEIN", 67, 69], ["D2", "PROTEIN", 71, 73], ["Each flagellin monomer", "TREATMENT", 0, 22]]], ["D0 and D1 are highly conserved regions, while D2 and D3 are considered variable regions.", [["D1", "GENE_OR_GENE_PRODUCT", 7, 9], ["D3", "SIMPLE_CHEMICAL", 53, 55], ["D0", "DNA", 0, 2], ["D1", "DNA", 7, 9], ["D2", "DNA", 46, 48], ["D3", "DNA", 53, 55], ["D3", "TREATMENT", 53, 55], ["variable", "OBSERVATION_MODIFIER", 71, 79]]], ["Flagellin stimulates cells through TLR5 via the conserved D1 domain [60] [61] [62] .", [["cells", "ANATOMY", 21, 26], ["Flagellin", "CHEMICAL", 0, 9], ["Flagellin", "GENE_OR_GENE_PRODUCT", 0, 9], ["cells", "CELL", 21, 26], ["TLR5", "GENE_OR_GENE_PRODUCT", 35, 39], ["Flagellin", "PROTEIN", 0, 9], ["TLR5", "PROTEIN", 35, 39], ["D1 domain", "PROTEIN", 58, 67], ["Flagellin stimulates cells", "TREATMENT", 0, 26]]], ["Upon stimulation TLR5 signals through a MyD88 pathway leading to the activation of the transcription factors AP-1 and NF-\u03baB and the transcription of proinflammatory cytokines [63] .", [["TLR5", "GENE_OR_GENE_PRODUCT", 17, 21], ["MyD88", "GENE_OR_GENE_PRODUCT", 40, 45], ["AP-1", "GENE_OR_GENE_PRODUCT", 109, 113], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 118, 123], ["TLR5", "PROTEIN", 17, 21], ["MyD88", "PROTEIN", 40, 45], ["transcription factors", "PROTEIN", 87, 108], ["AP-1", "PROTEIN", 109, 113], ["NF-\u03baB", "PROTEIN", 118, 123], ["proinflammatory cytokines", "PROTEIN", 149, 174], ["a MyD88 pathway", "TREATMENT", 38, 53], ["AP", "TEST", 109, 111], ["NF", "TEST", 118, 120], ["proinflammatory cytokines", "TEST", 149, 174]]], ["All studies indicate that flagellin functions to increase antibody titers [64, 65] .", [["flagellin", "GENE_OR_GENE_PRODUCT", 26, 35], ["flagellin", "PROTEIN", 26, 35], ["All studies", "TEST", 0, 11], ["flagellin functions", "PROBLEM", 26, 45], ["increase antibody titers", "TEST", 49, 73]]], ["This increase is attributed to the flagellin activating DC as well as other APCs and the recruitment of B and T cells to the lymph nodes [66] [67] [68] [69] [70] [71] .", [["DC", "ANATOMY", 56, 58], ["APCs", "ANATOMY", 76, 80], ["T cells", "ANATOMY", 110, 117], ["lymph nodes", "ANATOMY", 125, 136], ["flagellin", "GENE_OR_GENE_PRODUCT", 35, 44], ["DC", "CELL", 56, 58], ["APCs", "CELL", 76, 80], ["B", "CELL", 104, 105], ["T cells", "CELL", 110, 117], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 125, 136], ["flagellin", "PROTEIN", 35, 44], ["DC", "CELL_TYPE", 56, 58], ["APCs", "CELL_TYPE", 76, 80], ["B and T cells", "CELL_TYPE", 104, 117], ["the flagellin activating DC", "TREATMENT", 31, 58], ["other APCs", "TEST", 70, 80], ["lymph nodes", "OBSERVATION", 125, 136]]], ["This leads to interactions between B cells and T H cells leading to increased antibody production [64] .", [["B cells", "ANATOMY", 35, 42], ["T H cells", "ANATOMY", 47, 56], ["B cells", "CELL", 35, 42], ["T H cells", "CELL", 47, 56], ["B cells", "CELL_TYPE", 35, 42], ["T H cells", "CELL_TYPE", 47, 56], ["T H cells", "PROBLEM", 47, 56], ["increased antibody production", "PROBLEM", 68, 97], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["antibody production", "OBSERVATION", 78, 97]]], ["Initial studies seemed to indicate that flagellin is not a strong adjuvant for T C responses, however, it has repeatedly been demonstrated that it does function in this regard as well [72] [73] [74] [75] [76] .", [["flagellin", "GENE_OR_GENE_PRODUCT", 40, 49], ["T C", "GENE_OR_GENE_PRODUCT", 79, 82], ["flagellin", "PROTEIN", 40, 49], ["Initial studies", "TEST", 0, 15], ["flagellin", "PROBLEM", 40, 49]]], ["Flagellin is also able to activate the inflammasome via amino acids 441-476 which are present on the C terminus in the D0 domain.", [["Flagellin", "CHEMICAL", 0, 9], ["amino acids 441-476", "CHEMICAL", 56, 75], ["Flagellin", "CHEMICAL", 0, 9], ["amino acids", "CHEMICAL", 56, 67], ["C", "CHEMICAL", 101, 102], ["Flagellin", "GENE_OR_GENE_PRODUCT", 0, 9], ["amino acids", "AMINO_ACID", 56, 67], ["441-476", "AMINO_ACID", 68, 75], ["Flagellin", "PROTEIN", 0, 9], ["C terminus", "PROTEIN", 101, 111], ["D0 domain", "PROTEIN", 119, 128], ["Flagellin", "TREATMENT", 0, 9], ["amino acids", "TEST", 56, 67]]], ["These amino acids are able to interact with the PRR Naip5 [77, 78] .", [["amino acids", "CHEMICAL", 6, 17], ["amino acids", "CHEMICAL", 6, 17], ["amino acids", "AMINO_ACID", 6, 17], ["PRR", "PROTEIN", 48, 51], ["Naip5", "PROTEIN", 52, 57], ["These amino acids", "TREATMENT", 0, 17]]], ["The role of the inflamosome in regards to adjuvant function is not completely clear.Increasing the Immune Response to Subunit Vaccines: AdjuvantsUnmethylated CpG motifs are also currently being investigated as potential adjuvants ( Table 2) .", [["inflamosome", "ANATOMY", 16, 27], ["CpG", "CHEMICAL", 158, 161], ["inflamosome", "GENE_OR_GENE_PRODUCT", 16, 27], ["adjuvant function", "TREATMENT", 42, 59], ["Subunit Vaccines", "TREATMENT", 118, 134], ["AdjuvantsUnmethylated CpG motifs", "TREATMENT", 136, 168], ["clear", "OBSERVATION", 78, 83], ["Immune Response", "OBSERVATION", 99, 114]]], ["Bacteria do not frequently methylate CpG motifs, however, vertebrates do allowing for the differentiation of foreign DNA [79] .", [["CpG", "CHEMICAL", 37, 40], ["DNA", "CELLULAR_COMPONENT", 117, 120], ["CpG motifs", "DNA", 37, 47], ["Bacteria", "PROBLEM", 0, 8], ["methylate CpG motifs", "TREATMENT", 27, 47], ["foreign DNA", "PROBLEM", 109, 120]]], ["During a natural infection process CpG motifs are recognized by TLR9, which is present in endoplasmic reticulum (ER), late endosomal compartment, and the lysosomal compartment.", [["endoplasmic reticulum", "ANATOMY", 90, 111], ["ER", "ANATOMY", 113, 115], ["endosomal compartment", "ANATOMY", 123, 144], ["lysosomal compartment", "ANATOMY", 154, 175], ["infection", "DISEASE", 17, 26], ["CpG", "CHEMICAL", 35, 38], ["TLR9", "GENE_OR_GENE_PRODUCT", 64, 68], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 90, 111], ["ER", "GENE_OR_GENE_PRODUCT", 113, 115], ["late endosomal compartment", "CELLULAR_COMPONENT", 118, 144], ["lysosomal compartment", "CELLULAR_COMPONENT", 154, 175], ["CpG motifs", "DNA", 35, 45], ["TLR9", "PROTEIN", 64, 68], ["a natural infection process CpG motifs", "PROBLEM", 7, 45], ["infection", "OBSERVATION", 17, 26], ["endoplasmic reticulum", "OBSERVATION", 90, 111], ["late", "OBSERVATION_MODIFIER", 118, 122], ["endosomal compartment", "OBSERVATION", 123, 144], ["lysosomal compartment", "OBSERVATION", 154, 175]]], ["Different organisms localize TLR9 to different cell types, but it is most frequently localized to plasmacytoid DC and B cells in humans [80] .", [["cell", "ANATOMY", 47, 51], ["plasmacytoid DC", "ANATOMY", 98, 113], ["B cells", "ANATOMY", 118, 125], ["TLR9", "GENE_OR_GENE_PRODUCT", 29, 33], ["cell", "CELL", 47, 51], ["plasmacytoid DC", "CELL", 98, 113], ["B cells", "CELL", 118, 125], ["humans", "ORGANISM", 129, 135], ["TLR9", "PROTEIN", 29, 33], ["plasmacytoid DC", "CELL_TYPE", 98, 113], ["B cells", "CELL_TYPE", 118, 125], ["humans", "SPECIES", 129, 135], ["humans", "SPECIES", 129, 135], ["Different organisms", "PROBLEM", 0, 19], ["TLR9 to different cell types", "OBSERVATION", 29, 57]]], ["Upon stimulation TLR9 exits the ER and interacts with MyD88, which leads to the activation of signaling pathways leading to the activation of NF-\u03baB and AP-1, the production of T H 1 proinflamatory cytokines and increased innate and adaptive immune response [81] .", [["ER", "ANATOMY", 32, 34], ["TLR9", "GENE_OR_GENE_PRODUCT", 17, 21], ["ER", "GENE_OR_GENE_PRODUCT", 32, 34], ["MyD88", "GENE_OR_GENE_PRODUCT", 54, 59], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 142, 147], ["AP-1", "GENE_OR_GENE_PRODUCT", 152, 156], ["T H 1", "GENE_OR_GENE_PRODUCT", 176, 181], ["TLR9", "PROTEIN", 17, 21], ["ER", "PROTEIN", 32, 34], ["MyD88", "PROTEIN", 54, 59], ["NF-\u03baB", "PROTEIN", 142, 147], ["AP-1", "PROTEIN", 152, 156], ["T H 1 proinflamatory cytokines", "PROTEIN", 176, 206], ["MyD88", "TREATMENT", 54, 59], ["signaling pathways", "PROBLEM", 94, 112], ["NF", "TEST", 142, 144], ["T H 1 proinflamatory cytokines", "PROBLEM", 176, 206], ["increased innate", "PROBLEM", 211, 227]]], ["For adjuvant use synthetic CpG oligodeoxynucelotides (CpG ODN) are generated that contain unmethylated CpGs.", [["CpG oligodeoxynucelotides", "CHEMICAL", 27, 52], ["CpG ODN", "CHEMICAL", 54, 61], ["CpG oligodeoxynucelotides", "CHEMICAL", 27, 52], ["CpG", "CHEMICAL", 54, 57], ["CpGs", "CHEMICAL", 103, 107], ["CpG oligodeoxynucelotides", "SIMPLE_CHEMICAL", 27, 52], ["CpG ODN", "SIMPLE_CHEMICAL", 54, 61], ["CpGs", "CELLULAR_COMPONENT", 103, 107], ["unmethylated CpGs", "DNA", 90, 107], ["adjuvant use synthetic CpG oligodeoxynucelotides (CpG ODN)", "TREATMENT", 4, 62], ["unmethylated CpGs", "TREATMENT", 90, 107], ["unmethylated CpGs", "OBSERVATION", 90, 107]]], ["Generally, CpG ODNs contain a Karch [81] .", [["CpG", "CHEMICAL", 11, 14], ["CpG ODNs", "TREATMENT", 11, 19]]], ["Clinical trials using CpG as an adjuvant have been performed in a wide range of infectious diseases.", [["CpG", "CHEMICAL", 22, 25], ["infectious diseases", "DISEASE", 80, 99], ["CpG", "CHEMICAL", 22, 25], ["Clinical trials", "TREATMENT", 0, 15], ["CpG", "TREATMENT", 22, 25], ["an adjuvant", "TREATMENT", 29, 40], ["infectious diseases", "PROBLEM", 80, 99], ["infectious", "OBSERVATION", 80, 90]]], ["All resulted in an increase in the immunogenicity of the vaccine tested, with effects ranging from increased antibody production, faster memory response, or a change in the cytokine profile of the vaccine leading to a stronger immune response [80, 82] .Increasing the Immune Response to Subunit Vaccines: AdjuvantsRNA binding TLRs are also being examined as potential targets for adjuvant development ( Table 2 ).", [["AdjuvantsRNA binding TLRs", "GENE_OR_GENE_PRODUCT", 305, 330], ["cytokine", "PROTEIN", 173, 181], ["AdjuvantsRNA binding TLRs", "PROTEIN", 305, 330], ["an increase", "PROBLEM", 16, 27], ["the vaccine", "TREATMENT", 53, 64], ["increased antibody production", "PROBLEM", 99, 128], ["a change in the cytokine profile", "PROBLEM", 157, 189], ["the vaccine", "TREATMENT", 193, 204], ["Subunit Vaccines", "TREATMENT", 287, 303], ["AdjuvantsRNA binding TLRs", "TREATMENT", 305, 330], ["adjuvant development", "TREATMENT", 380, 400], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["antibody production", "OBSERVATION", 109, 128], ["Immune Response", "OBSERVATION", 268, 283]]], ["TLR7 and TLR8 are both localized to endosomes, with TLR7 primarily present in plasmacytoid DC and B cells and TLR8 primarily present in monocytes/macrophage and myeloid DC.", [["endosomes", "ANATOMY", 36, 45], ["plasmacytoid DC", "ANATOMY", 78, 93], ["B cells", "ANATOMY", 98, 105], ["monocytes", "ANATOMY", 136, 145], ["macrophage", "ANATOMY", 146, 156], ["myeloid DC", "ANATOMY", 161, 171], ["TLR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR8", "GENE_OR_GENE_PRODUCT", 9, 13], ["endosomes", "CELLULAR_COMPONENT", 36, 45], ["TLR7", "GENE_OR_GENE_PRODUCT", 52, 56], ["plasmacytoid DC", "CELL", 78, 93], ["B cells", "CELL", 98, 105], ["TLR8", "GENE_OR_GENE_PRODUCT", 110, 114], ["monocytes", "CELL", 136, 145], ["macrophage", "CELL", 146, 156], ["myeloid DC", "CELL", 161, 171], ["TLR7", "PROTEIN", 0, 4], ["TLR8", "PROTEIN", 9, 13], ["TLR7", "PROTEIN", 52, 56], ["plasmacytoid DC", "CELL_TYPE", 78, 93], ["B cells", "CELL_TYPE", 98, 105], ["TLR8", "PROTEIN", 110, 114], ["monocytes", "CELL_TYPE", 136, 145], ["macrophage", "CELL_TYPE", 146, 156], ["myeloid DC", "CELL_TYPE", 161, 171], ["TLR7 and TLR8", "TREATMENT", 0, 13], ["TLR7", "TREATMENT", 52, 56], ["B cells", "TEST", 98, 105], ["TLR8", "TEST", 110, 114], ["monocytes", "TEST", 136, 145], ["macrophage", "PROBLEM", 146, 156], ["myeloid DC", "PROBLEM", 161, 171], ["plasmacytoid DC", "OBSERVATION", 78, 93], ["TLR8", "ANATOMY", 110, 114], ["monocytes", "ANATOMY", 136, 145], ["macrophage", "ANATOMY", 146, 156], ["myeloid DC", "OBSERVATION", 161, 171]]], ["Both receptors bind single stranded RNA sequences from infecting microorganisms and TLR7 the synthetic agonist Imiquimod (R837) with both binding the synthetic agonist Resiquimond (R848).", [["Imiquimod", "CHEMICAL", 111, 120], ["R837", "CHEMICAL", 122, 126], ["Resiquimond", "CHEMICAL", 168, 179], ["Imiquimod", "CHEMICAL", 111, 120], ["Resiquimond", "CHEMICAL", 168, 179], ["TLR7", "GENE_OR_GENE_PRODUCT", 84, 88], ["Imiquimod", "SIMPLE_CHEMICAL", 111, 120], ["R837", "SIMPLE_CHEMICAL", 122, 126], ["Resiquimond", "SIMPLE_CHEMICAL", 168, 179], ["TLR7", "PROTEIN", 84, 88], ["single stranded RNA sequences", "TEST", 20, 49], ["infecting microorganisms", "PROBLEM", 55, 79], ["TLR7 the synthetic agonist Imiquimod", "TREATMENT", 84, 120]]], ["Stimulation of both leads to signaling through MyD88 and activation of NF-\u03baB and AP-1, and ultimately proinflammatory cytokines [83, 84] .", [["MyD88", "GENE_OR_GENE_PRODUCT", 47, 52], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 71, 76], ["AP-1", "GENE_OR_GENE_PRODUCT", 81, 85], ["MyD88", "PROTEIN", 47, 52], ["NF-\u03baB", "PROTEIN", 71, 76], ["AP-1", "PROTEIN", 81, 85], ["proinflammatory cytokines", "PROTEIN", 102, 127], ["Stimulation", "TREATMENT", 0, 11], ["NF", "TEST", 71, 73], ["AP", "TEST", 81, 83], ["proinflammatory cytokines", "TEST", 102, 127]]], ["The short half-life of RNA necessitates that in the development of successful long lasting vaccine formulation one of the synthetic agonists are used.", [["RNA", "TREATMENT", 23, 26], ["successful long lasting vaccine formulation", "TREATMENT", 67, 110], ["the synthetic agonists", "TREATMENT", 118, 140], ["short", "OBSERVATION_MODIFIER", 4, 9]]], ["Initial studies indicated both of these agonists are immunostimulatory when given as a topical ointment, however, when given admixed as an injection extremely high doses were necessary.", [["Initial studies", "TEST", 0, 15], ["these agonists", "TREATMENT", 34, 48], ["immunostimulatory", "TREATMENT", 53, 70], ["a topical ointment", "TREATMENT", 85, 103], ["an injection extremely high doses", "TREATMENT", 136, 169]]], ["Subsequent studies have determined that fusion of these agonists to a given antigen, admixture with other PAMPs, and newer agonist designs show promise as successful adjuvant candidates [85, 86] .Antigen DisplaysWhile the addition of a chemical or biological adjuvant to a vaccine is one mechanism to induce stronger immune responses, there are other ways too.", [["PAMPs", "PROTEIN", 106, 111], ["Subsequent studies", "TEST", 0, 18], ["fusion of these agonists", "TREATMENT", 40, 64], ["other PAMPs", "TREATMENT", 100, 111], ["a chemical or biological adjuvant", "TREATMENT", 234, 267], ["a vaccine", "TREATMENT", 271, 280]]], ["One aspect of a whole organism vaccine that makes it so successful is the fact that it expresses multiple antigens in a repetitive array.", [["antigens", "PROTEIN", 106, 114], ["a whole organism vaccine", "TREATMENT", 14, 38]]], ["In most cases there is not just one copy of a B cell antigen on the cell or viral surface.", [["B cell", "ANATOMY", 46, 52], ["cell", "ANATOMY", 68, 72], ["surface", "ANATOMY", 82, 89], ["B cell antigen", "GENE_OR_GENE_PRODUCT", 46, 60], ["cell", "CELL", 68, 72], ["viral surface", "CELLULAR_COMPONENT", 76, 89], ["B cell antigen", "PROTEIN", 46, 60], ["a B cell antigen", "PROBLEM", 44, 60], ["viral surface", "OBSERVATION", 76, 89]]], ["By vaccinating with a recombinant protein this effect does not occur, because the antigens become diluted in the patient's body fluids.", [["body", "ANATOMY", 123, 127], ["patient", "ORGANISM", 113, 120], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["fluids", "ORGANISM_SUBSTANCE", 128, 134], ["recombinant protein", "PROTEIN", 22, 41], ["antigens", "PROTEIN", 82, 90], ["patient", "SPECIES", 113, 120], ["a recombinant protein", "TREATMENT", 20, 41], ["the antigens", "PROBLEM", 78, 90], ["the patient's body fluids", "TREATMENT", 109, 134]]], ["Work beginning in the 1960s would lead to the development of another mechanism to generate more effective vaccine candidate that would more closely mimic a whole organism vaccine.Antigen DisplaysPatients infected with hepatitis B virus (HBV) produce a noninfectious particle in their blood [87, 88] .", [["blood", "ANATOMY", 284, 289], ["hepatitis B", "DISEASE", 218, 229], ["hepatitis B virus", "ORGANISM", 218, 235], ["HBV", "ORGANISM", 237, 240], ["blood", "ORGANISM_SUBSTANCE", 284, 289], ["hepatitis B virus", "SPECIES", 218, 235], ["hepatitis B virus", "SPECIES", 218, 235], ["HBV", "SPECIES", 237, 240], ["a whole organism vaccine", "TREATMENT", 154, 178], ["hepatitis B virus", "PROBLEM", 218, 235], ["a noninfectious particle", "PROBLEM", 250, 274], ["hepatitis", "OBSERVATION", 218, 227], ["noninfectious", "OBSERVATION_MODIFIER", 252, 265]]], ["This particle is actually composed of a protein antigen (S or HBsAg) that is present in the envelope of the HBV.", [["HBsAg", "CHEMICAL", 62, 67], ["HBsAg", "GENE_OR_GENE_PRODUCT", 62, 67], ["HBV", "ORGANISM", 108, 111], ["protein antigen", "PROTEIN", 40, 55], ["S", "PROTEIN", 57, 58], ["HBsAg", "PROTEIN", 62, 67], ["HBV", "SPECIES", 108, 111], ["a protein antigen", "PROBLEM", 38, 55], ["HBsAg", "PROBLEM", 62, 67], ["the HBV", "PROBLEM", 104, 111], ["HBV", "OBSERVATION", 108, 111]]], ["HBsAg is produced in large quantities during infection and is able to self-assemble into a 22 nm virus-like particle (VLP) [89] .", [["HBsAg", "CHEMICAL", 0, 5], ["infection", "DISEASE", 45, 54], ["HBsAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["HBsAg", "PROTEIN", 0, 5], ["HBsAg", "TEST", 0, 5], ["large quantities during infection", "PROBLEM", 21, 54], ["a 22 nm virus", "PROBLEM", 89, 102], ["large", "OBSERVATION_MODIFIER", 21, 26], ["quantities", "OBSERVATION_MODIFIER", 27, 37], ["infection", "OBSERVATION", 45, 54]]], ["VLPs are particles that resemble the size and shape of viruses but do not contain any viral genetic material, meaning they are not infectious [90] (see Figure 2B ).", [["VLPs", "ORGANISM", 0, 4], ["VLPs", "TREATMENT", 0, 4], ["viruses", "PROBLEM", 55, 62], ["any viral genetic material", "PROBLEM", 82, 108], ["infectious", "PROBLEM", 131, 141], ["particles", "OBSERVATION", 9, 18], ["size", "OBSERVATION_MODIFIER", 37, 41], ["shape", "OBSERVATION_MODIFIER", 46, 51], ["viruses", "OBSERVATION", 55, 62]]], ["Quickly it was identified that the VLP was about 1,000 times more immunogenic than non-assembled HBsAg [91] and these particles were identified as potential vaccine candidates [87] .Antigen DisplaysAt the time there was no culturable method for HBV, and only humans and certain nonhuman primates (NHP) could be infected.", [["HBsAg", "CHEMICAL", 97, 102], ["VLP", "ORGANISM", 35, 38], ["HBsAg", "GENE_OR_GENE_PRODUCT", 97, 102], ["HBV", "ORGANISM", 245, 248], ["humans", "ORGANISM", 259, 265], ["nonhuman primates", "ORGANISM", 278, 295], ["NHP", "ORGANISM", 297, 300], ["humans", "SPECIES", 259, 265], ["HBV", "SPECIES", 245, 248], ["humans", "SPECIES", 259, 265], ["the VLP", "TEST", 31, 38], ["HBsAg", "TEST", 97, 102], ["these particles", "PROBLEM", 112, 127], ["culturable method", "TEST", 223, 240], ["HBV", "PROBLEM", 245, 248], ["no", "UNCERTAINTY", 220, 222], ["infected", "OBSERVATION", 311, 319]]], ["It was proposed and eventually carried out that the best mechanism for developing a HBV vaccine was to harvest plasma from asymptomatic volunteers, chemically treat the plasma to inactivate it like it was an infectious particle, and use it as a vaccine candidate [92] [93] [94] [95] [96] .", [["plasma", "ANATOMY", 111, 117], ["plasma", "ANATOMY", 169, 175], ["HBV", "ORGANISM", 84, 87], ["plasma", "ORGANISM_SUBSTANCE", 111, 117], ["volunteers", "ORGANISM", 136, 146], ["plasma", "ORGANISM_SUBSTANCE", 169, 175], ["[92] [93] [94] [95", "SIMPLE_CHEMICAL", 263, 281], ["HBV", "SPECIES", 84, 87], ["a HBV vaccine", "TREATMENT", 82, 95], ["asymptomatic volunteers", "PROBLEM", 123, 146], ["the plasma", "TREATMENT", 165, 175], ["infectious", "OBSERVATION", 208, 218]]], ["While these initial studies were successful in high risk populations, they were occurring in the late 1970s and early 1980s which coincided with the beginning of the Acquired Human Immunodeficiency (AIDS) epidemic.", [["Human Immunodeficiency (AIDS) epidemic", "DISEASE", 175, 213], ["Human", "ORGANISM", 175, 180], ["Human", "SPECIES", 175, 180], ["these initial studies", "TEST", 6, 27], ["the Acquired Human Immunodeficiency (AIDS)", "PROBLEM", 162, 204], ["epidemic", "PROBLEM", 205, 213]]], ["The vaccine was approved for human use in 1981, but fears about the use of a human blood product, lack of volunteers, and cost led to abandonment of this vaccine and its eventual withdrawal from the United States by 1986 [97] .Antigen DisplaysA recombinant HBsAg based HBV vaccine became a top priority at the dawn of recombinant vaccines.", [["blood", "ANATOMY", 83, 88], ["HBsAg", "CHEMICAL", 257, 262], ["human", "ORGANISM", 29, 34], ["human", "ORGANISM", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["volunteers", "ORGANISM", 106, 116], ["HBsAg", "GENE_OR_GENE_PRODUCT", 257, 262], ["HBV", "ORGANISM", 269, 272], ["HBsAg", "PROTEIN", 257, 262], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 77, 82], ["HBV", "SPECIES", 269, 272], ["The vaccine", "TREATMENT", 0, 11], ["a human blood product", "TREATMENT", 75, 96], ["this vaccine", "TREATMENT", 149, 161], ["Antigen DisplaysA recombinant HBsAg", "TREATMENT", 227, 262], ["HBV vaccine", "TREATMENT", 269, 280], ["recombinant vaccines", "TREATMENT", 318, 338]]], ["HBsAg produced in E. coli was not immunogenic which led to a search for a different expression host [98] [99] [100] .", [["HBsAg", "CHEMICAL", 0, 5], ["HBsAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["E. coli", "ORGANISM", 18, 25], ["HBsAg", "PROTEIN", 0, 5], ["E. coli", "SPECIES", 18, 25], ["E. coli", "SPECIES", 18, 25], ["HBsAg", "TEST", 0, 5], ["E. coli", "PROBLEM", 18, 25], ["immunogenic", "PROBLEM", 34, 45], ["E. coli", "OBSERVATION_MODIFIER", 18, 25]]], ["In 1982, HBsAg was produced in its naturally glycosylated immunogenic form from S. cerevisiae [101] .", [["HBsAg", "CHEMICAL", 9, 14], ["HBsAg", "GENE_OR_GENE_PRODUCT", 9, 14], ["S. cerevisiae", "ORGANISM", 80, 93], ["HBsAg", "PROTEIN", 9, 14], ["S. cerevisiae", "SPECIES", 80, 93], ["S. cerevisiae", "SPECIES", 80, 93], ["HBsAg", "TEST", 9, 14]]], ["The vaccine was shown to be immunogenic and safe [102] [103] [104] .", [["The vaccine", "TREATMENT", 0, 11]]], ["The vaccine was approved in 1986 and still remains the standard HBV vaccine ( Figure 1 , Table 1 ).", [["HBV", "SPECIES", 64, 67], ["The vaccine", "TREATMENT", 0, 11], ["the standard HBV vaccine", "TREATMENT", 51, 75]]], ["The recombinant HBsAg has the distinction of not only becoming the first approved subunit vaccine, but also the first approved VLP.", [["HBsAg", "CHEMICAL", 16, 21], ["HBsAg", "GENE_OR_GENE_PRODUCT", 16, 21], ["VLP", "ORGANISM", 127, 130], ["recombinant HBsAg", "PROTEIN", 4, 21], ["The recombinant HBsAg", "TEST", 0, 21], ["HBsAg", "OBSERVATION", 16, 21]]], ["The knowledge used during the development of the recombinant HBsAg vaccine was eventually applied to other diseases such as HPV, leading to the development of clinically approved HPV vaccines [105] .", [["HBsAg", "CHEMICAL", 61, 66], ["HBsAg", "ORGANISM", 61, 66], ["HPV", "ORGANISM", 124, 127], ["HPV", "ORGANISM", 179, 182], ["HPV", "SPECIES", 124, 127], ["HPV", "SPECIES", 179, 182], ["the recombinant HBsAg vaccine", "TREATMENT", 45, 74], ["other diseases", "PROBLEM", 101, 115], ["HPV", "PROBLEM", 124, 127], ["HPV vaccines", "TREATMENT", 179, 191]]], ["It also became the foundation for other vaccines such as the most advanced malaria vaccine candidate RTS,S [106] .Antigen DisplaysVLPs also offer the advantage of being repetitive antigen displays.", [["malaria", "DISEASE", 75, 82], ["other vaccines", "TREATMENT", 34, 48], ["Antigen DisplaysVLPs", "TREATMENT", 114, 134]]], ["It has been consistently demonstrated that when antigens are displayed repetitively there is an increase of antibody titers [90, 107] .", [["antigens", "PROTEIN", 48, 56], ["an increase of antibody titers", "PROBLEM", 93, 123], ["increase", "OBSERVATION_MODIFIER", 96, 104]]], ["This occurs because of increased crosslinking of the B cell receptors leading to B cell activation [5, 108, 109] .", [["B cell", "ANATOMY", 53, 59], ["B cell", "ANATOMY", 81, 87], ["B cell receptors", "GENE_OR_GENE_PRODUCT", 53, 69], ["B cell", "CELL", 81, 87], ["B cell receptors", "PROTEIN", 53, 69], ["increased crosslinking of the B cell receptors", "PROBLEM", 23, 69], ["B cell activation", "TEST", 81, 98], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["crosslinking", "OBSERVATION", 33, 45], ["B cell receptors", "OBSERVATION", 53, 69], ["cell activation", "OBSERVATION", 83, 98]]], ["VLPs, because they are made of viral proteins, are processed by APC cells as a virus.", [["APC cells", "ANATOMY", 64, 73], ["VLPs", "ORGANISM", 0, 4], ["APC cells", "CELL", 64, 73], ["viral proteins", "PROTEIN", 31, 45], ["APC cells", "CELL_TYPE", 64, 73], ["VLPs", "TREATMENT", 0, 4], ["viral proteins", "PROBLEM", 31, 45], ["a virus", "PROBLEM", 77, 84], ["APC cells", "OBSERVATION", 64, 73]]], ["Increased and efficient processing leads to activation of T cells and also increased immune responses [90] .", [["T cells", "ANATOMY", 58, 65], ["T cells", "CELL", 58, 65], ["T cells", "CELL_TYPE", 58, 65], ["activation of T cells", "PROBLEM", 44, 65], ["increased immune responses", "PROBLEM", 75, 101]]], ["One problem with VLPs is that not every virus that a vaccine is needed for has a capsid protein that can self-assemble into an immunogenic VLP.", [["VLP", "ORGANISM", 139, 142], ["capsid protein", "PROTEIN", 81, 95], ["VLPs", "PROBLEM", 17, 21], ["a vaccine", "TREATMENT", 51, 60], ["a capsid protein", "PROBLEM", 79, 95], ["an immunogenic VLP", "TREATMENT", 124, 142], ["VLPs", "OBSERVATION", 17, 21], ["VLP", "OBSERVATION", 139, 142]]], ["The second problem is not every infectious disease is a virus.", [["every infectious disease", "PROBLEM", 26, 50], ["a virus", "PROBLEM", 54, 61], ["infectious", "OBSERVATION", 32, 42]]], ["For some diseases, successful fusion constructs have been generated such as RTS,S for malaria that uses the HBsAg as a carrier [106] .", [["malaria", "DISEASE", 86, 93], ["HBsAg", "CHEMICAL", 108, 113], ["HBsAg", "GENE_OR_GENE_PRODUCT", 108, 113], ["HBsAg", "PROTEIN", 108, 113], ["some diseases", "PROBLEM", 4, 17], ["successful fusion constructs", "TREATMENT", 19, 47], ["malaria", "PROBLEM", 86, 93], ["the HBsAg", "PROBLEM", 104, 113], ["diseases", "OBSERVATION", 9, 17]]], ["Generation of fusion constructs is not always successful, however [90] .", [["fusion constructs", "DNA", 14, 31], ["fusion constructs", "TREATMENT", 14, 31], ["fusion", "OBSERVATION", 14, 20], ["not always", "UNCERTAINTY", 35, 45]]], ["These problems have led for the development of new technologies that would incorporate the strengths of VLPs while minimizing their weakness.Nanotechnology and NanovaccinesAn exciting area in the development of vaccines is the use of nanotechnology.", [["VLPs", "ORGANISM", 104, 108], ["their weakness", "PROBLEM", 126, 140], ["Nanotechnology", "TREATMENT", 141, 155], ["Nanovaccines", "TREATMENT", 160, 172], ["vaccines", "TREATMENT", 211, 219], ["new", "OBSERVATION_MODIFIER", 47, 50], ["weakness", "OBSERVATION", 132, 140]]], ["He predicted in the future scientists would be able to manipulate matter on the atomic level leading to the development of tiny manufacturing machines [110] .", [["tiny", "OBSERVATION_MODIFIER", 123, 127]]], ["In 1981 K. Eric Dexler using the concepts of Feynman, and the advances in genetic engineering proposed that proteins could be designed to carry out atomic level fabrications [111] .", [["genetic engineering", "TREATMENT", 74, 93]]], ["Dexler's work is considered the true beginning of the field of nanotechnology, a field that has undergone exponential growth over the subsequent three decades.Nanotechnology and NanovaccinesToday nanotechnology is defined by the United States National Nanotechnology Initiative as the field that deals with nanoscale objects that are 1-100 nm in size.", [["exponential growth", "PROBLEM", 106, 124], ["exponential", "OBSERVATION_MODIFIER", 106, 117], ["growth", "OBSERVATION_MODIFIER", 118, 124], ["size", "OBSERVATION_MODIFIER", 346, 350]]], ["A nanoparticle is defined as an individual nanoscale object that is able to function as an independent unit [113] .", [["nanoparticle", "OBSERVATION", 2, 14], ["nanoscale object", "OBSERVATION", 43, 59]]], ["These nanoscale objects are composed of a wide range of materials including organic polymers, inorganic polymers, and biological macromolecules.", [["organic polymers", "SIMPLE_CHEMICAL", 76, 92], ["inorganic polymers", "SIMPLE_CHEMICAL", 94, 112], ["a wide range of materials", "PROBLEM", 40, 65], ["organic polymers", "TREATMENT", 76, 92], ["inorganic polymers", "TREATMENT", 94, 112], ["nanoscale objects", "OBSERVATION", 6, 23], ["wide range", "OBSERVATION_MODIFIER", 42, 52], ["organic polymers", "OBSERVATION", 76, 92], ["inorganic polymers", "OBSERVATION", 94, 112]]], ["Nanoscale assemblies have a diverse array of biomedical implications including use as biological sensors, cell targeting systems, drug delivery systems, and as subunit vaccine carriers [114] .Nanotechnology and NanovaccinesOne of the major benefits in the use of nanotechnology for the development of vaccines is the resulting nanovaccines can be designed to be effective antigen delivery systems.Nanotechnology and NanovaccinesAttempts have been made with many different types of nanomaterials to develop effective vaccine candidates.", [["cell", "ANATOMY", 106, 110], ["cell", "CELL", 106, 110], ["nanovaccines", "SIMPLE_CHEMICAL", 327, 339], ["biomedical implications", "TREATMENT", 45, 68], ["cell targeting systems", "TREATMENT", 106, 128], ["drug delivery systems", "TREATMENT", 130, 151], ["Nanotechnology", "TREATMENT", 192, 206], ["Nanovaccines", "TREATMENT", 211, 223], ["nanotechnology", "TREATMENT", 263, 277], ["vaccines", "TREATMENT", 301, 309], ["antigen delivery systems", "TREATMENT", 372, 396], ["Nanovaccines", "TREATMENT", 416, 428], ["nanomaterials", "TREATMENT", 481, 494], ["effective vaccine candidates", "TREATMENT", 506, 534]]], ["Nanotechnology is not a uniform field, but rather a mixture of many different nanoscale materials that vary in their chemical composition and behaviors.", [["many different nanoscale materials", "PROBLEM", 63, 97], ["nanoscale materials", "OBSERVATION", 78, 97], ["chemical composition", "OBSERVATION", 117, 137]]], ["The diversity in the field has led to the development of different approaches for nanovaccines.", [["nanovaccines", "TREATMENT", 82, 94], ["diversity", "OBSERVATION_MODIFIER", 4, 13]]], ["Each group has its own advantages and its own disadvantages making it unlikely that one approach will work for the development of each necessary vaccine.Nanotechnology and NanovaccinesOne approach is the use of different polymers and copolymers.", [["each necessary vaccine", "TREATMENT", 130, 152], ["Nanotechnology", "TREATMENT", 153, 167], ["Nanovaccines", "TREATMENT", 172, 184], ["different polymers and copolymers", "TREATMENT", 211, 244]]], ["A polymer is a molecule made up of one repeating subunit, while a copolymer is a molecule made up multiple repeating subunits.", [["multiple repeating subunits", "TREATMENT", 98, 125]]], ["Polymeric vaccines are made up of a broad range of compounds including (D, L-lactide-co-glycolide) (PLGA), poly(lactic acid) (PLA), poly(g-glutamic acid) (g-PGA), poly(ethylene glycol) (PEG), and polystyrene [115] .", [["D, L-lactide-co-glycolide", "CHEMICAL", 72, 97], ["PLGA", "CHEMICAL", 100, 104], ["poly(lactic acid", "CHEMICAL", 107, 123], ["PLA", "CHEMICAL", 126, 129], ["poly(g-glutamic acid", "CHEMICAL", 132, 152], ["g-PGA", "CHEMICAL", 155, 160], ["poly(ethylene glycol)", "CHEMICAL", 163, 184], ["PEG", "CHEMICAL", 186, 189], ["polystyrene", "CHEMICAL", 196, 207], ["(D, L-lactide-co-glycolide)", "CHEMICAL", 71, 98], ["PLGA", "CHEMICAL", 100, 104], ["poly(lactic acid)", "CHEMICAL", 107, 124], ["PLA", "CHEMICAL", 126, 129], ["poly(g-glutamic acid)", "CHEMICAL", 132, 153], ["g-PGA", "CHEMICAL", 155, 160], ["poly(ethylene glycol)", "CHEMICAL", 163, 184], ["PEG", "CHEMICAL", 186, 189], ["polystyrene", "CHEMICAL", 196, 207], ["(D, L-lactide-co-glycolide)", "SIMPLE_CHEMICAL", 71, 98], ["PLGA", "SIMPLE_CHEMICAL", 100, 104], ["poly(lactic acid)", "SIMPLE_CHEMICAL", 107, 124], ["PLA", "SIMPLE_CHEMICAL", 126, 129], ["poly(g-glutamic acid", "SIMPLE_CHEMICAL", 132, 152], ["g-PGA", "SIMPLE_CHEMICAL", 155, 160], ["poly(ethylene glycol)", "SIMPLE_CHEMICAL", 163, 184], ["PEG", "SIMPLE_CHEMICAL", 186, 189], ["polystyrene [115]", "SIMPLE_CHEMICAL", 196, 213], ["Polymeric vaccines", "TREATMENT", 0, 18], ["L-lactide", "TEST", 75, 84], ["poly(lactic acid", "TEST", 107, 123], ["PLA", "TEST", 126, 129], ["poly", "TEST", 132, 136], ["glutamic acid", "TEST", 139, 152], ["g", "TEST", 155, 156], ["poly(ethylene glycol) (PEG", "TREATMENT", 163, 189]]], ["Polymers can either function to encapsulate antigens, have antigens conjugated to their surface via a linker, have antigens adsorbed to their surface, or be admixed with the antigen.", [["surface", "ANATOMY", 88, 95], ["surface", "ANATOMY", 142, 149], ["surface", "CELLULAR_COMPONENT", 88, 95], ["surface", "CELLULAR_COMPONENT", 142, 149], ["antigens", "PROTEIN", 44, 52], ["antigens", "PROTEIN", 59, 67], ["antigens", "PROTEIN", 115, 123], ["Polymers", "TREATMENT", 0, 8]]], ["The chemistry of the polymer, and its interactions with the antigen determines the most effective mechanism for vaccine delivery.Nanotechnology and NanovaccinesThe PLGA nanoparticle vaccines are the prototypical encapsulated vaccine.", [["PLGA nanoparticle", "CHEMICAL", 164, 181], ["PLGA", "CHEMICAL", 164, 168], ["Nanovaccines", "SIMPLE_CHEMICAL", 148, 160], ["PLGA nanoparticle", "SIMPLE_CHEMICAL", 164, 181], ["the antigen", "TEST", 56, 67], ["vaccine delivery", "TREATMENT", 112, 128], ["Nanotechnology", "TREATMENT", 129, 143], ["Nanovaccines", "TREATMENT", 148, 160], ["The PLGA nanoparticle vaccines", "TREATMENT", 160, 190], ["the prototypical encapsulated vaccine", "TREATMENT", 195, 232]]], ["PLGA has been widely studied for about 60 years for a variety of biomedical applications including drug delivery and diagnostics [116] .", [["PLGA", "CHEMICAL", 0, 4], ["PLGA", "CHEMICAL", 0, 4], ["PLGA", "SIMPLE_CHEMICAL", 0, 4], ["biomedical applications", "TREATMENT", 65, 88], ["drug delivery", "TREATMENT", 99, 112]]], ["A nanoparticle consisting of PLGA has a core made up of its desired cargo, which is encapsulated by the polymer.", [["PLGA", "CHEMICAL", 29, 33], ["PLGA", "CHEMICAL", 29, 33], ["PLGA", "SIMPLE_CHEMICAL", 29, 33], ["A nanoparticle consisting of PLGA", "TREATMENT", 0, 33]]], ["Since 1969 PGLA has been approved by the Food and Drug Administration (FDA) for use as a drug delivery system.", [["PGLA", "CHEMICAL", 11, 15], ["a drug delivery system", "TREATMENT", 87, 109]]], ["The benefits of PLGA nanoparticles for any biomedical applications is they slowly degrade when exposed to water, meaning they can protect hydrophobic, hydrophilic, small molecule, or biological macromolecule cargo and release it over an extended period of time [117] .", [["PLGA nanoparticles", "CHEMICAL", 16, 34], ["PLGA", "CHEMICAL", 16, 20], ["PLGA nanoparticles", "SIMPLE_CHEMICAL", 16, 34], ["PLGA nanoparticles", "TREATMENT", 16, 34], ["any biomedical applications", "TREATMENT", 39, 66], ["hydrophobic, hydrophilic, small molecule", "PROBLEM", 138, 178], ["small molecule", "OBSERVATION", 164, 178]]], ["In preclinical studies this has been demonstrated to be an effective carrier in mouse models for vaccines composed of HBsAg, tetanus toxoid, Helicobacter pylori lysate, Listeria monocytogenes antigens, malaria antigens, and Bacillus anthracis spores [116, [118] [119] [120] [121] [122] [123] [124] [125] .Nanotechnology and NanovaccinesThese vaccines are able to generate long lasting humoral and cellular immune response.", [["lysate", "ANATOMY", 161, 167], ["cellular", "ANATOMY", 397, 405], ["HBsAg", "CHEMICAL", 118, 123], ["malaria", "DISEASE", 202, 209], ["mouse", "ORGANISM", 80, 85], ["HBsAg", "GENE_OR_GENE_PRODUCT", 118, 123], ["tetanus toxoid", "ORGANISM", 125, 139], ["Helicobacter pylori", "ORGANISM", 141, 160], ["lysate", "ORGANISM", 161, 167], ["Listeria monocytogenes antigens", "ORGANISM", 169, 200], ["malaria", "ORGANISM", 202, 209], ["Bacillus anthracis", "ORGANISM", 224, 242], ["[118] [119] [120] [121] [122] [123] [124] [125]", "SIMPLE_CHEMICAL", 256, 303], ["cellular", "CELL", 397, 405], ["HBsAg", "PROTEIN", 118, 123], ["Listeria monocytogenes antigens", "PROTEIN", 169, 200], ["malaria antigens", "PROTEIN", 202, 218], ["mouse", "SPECIES", 80, 85], ["tetanus toxoid", "SPECIES", 125, 139], ["Helicobacter pylori", "SPECIES", 141, 160], ["Listeria monocytogenes", "SPECIES", 169, 191], ["Bacillus anthracis", "SPECIES", 224, 242], ["mouse", "SPECIES", 80, 85], ["Helicobacter pylori", "SPECIES", 141, 160], ["Listeria monocytogenes", "SPECIES", 169, 191], ["Bacillus anthracis", "SPECIES", 224, 242], ["preclinical studies", "TEST", 3, 22], ["an effective carrier in mouse models", "TREATMENT", 56, 92], ["vaccines", "TREATMENT", 97, 105], ["HBsAg", "TEST", 118, 123], ["tetanus toxoid", "TREATMENT", 125, 139], ["Helicobacter pylori lysate", "TEST", 141, 167], ["Listeria monocytogenes antigens", "TEST", 169, 200], ["malaria antigens", "TEST", 202, 218], ["Bacillus anthracis spores", "TEST", 224, 249], ["Nanotechnology", "TREATMENT", 305, 319], ["Nanovaccines", "TREATMENT", 324, 336], ["These vaccines", "TREATMENT", 336, 350], ["Helicobacter pylori", "ANATOMY", 141, 160], ["cellular immune response", "OBSERVATION", 397, 421]]], ["They can also be given in an oral, aerosolized, subcutaneous, intraperitoneal, or intermuscular manner because of the nature of PLGA.Nanotechnology and NanovaccinesFurther strategies can be taken with polymer based nanoparticles to make them more effective vaccine candidates such as the synthetic vaccine particles (SVP).", [["oral", "ANATOMY", 29, 33], ["subcutaneous", "ANATOMY", 48, 60], ["intraperitoneal", "ANATOMY", 62, 77], ["intermuscular", "ANATOMY", 82, 95], ["PLGA", "CHEMICAL", 128, 132], ["PLGA", "CHEMICAL", 128, 132], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 77], ["PLGA", "SIMPLE_CHEMICAL", 128, 132], ["an oral, aerosolized, subcutaneous, intraperitoneal, or intermuscular manner", "TREATMENT", 26, 102], ["PLGA", "PROBLEM", 128, 132], ["Nanotechnology", "TREATMENT", 133, 147], ["Nanovaccines", "TREATMENT", 152, 164], ["polymer based nanoparticles", "TREATMENT", 201, 228], ["vaccine candidates", "TREATMENT", 257, 275], ["the synthetic vaccine particles", "TREATMENT", 284, 315], ["aerosolized", "OBSERVATION", 35, 46], ["subcutaneous", "ANATOMY", 48, 60], ["intraperitoneal", "ANATOMY", 62, 77], ["intermuscular", "ANATOMY", 82, 95]]], ["These particles can be used to carry not only antigens in their cores but also PAMPs as adjuvants.", [["PAMPs", "GENE_OR_GENE_PRODUCT", 79, 84], ["antigens", "PROTEIN", 46, 54], ["PAMPs", "PROTEIN", 79, 84]]], ["They can be encoated with phospholipids and decorated with B cell antigens leading to a potentially more efficient vaccine candidates that are function as repetitive antigen displays, delivery systems, and as immunopotentiators [126, 127] .Nanotechnology and NanovaccinesPolymers can also serve as inert cores for antigen conjugation or adsorption.", [["B cell", "ANATOMY", 59, 65], ["phospholipids", "SIMPLE_CHEMICAL", 26, 39], ["B cell antigens", "GENE_OR_GENE_PRODUCT", 59, 74], ["NanovaccinesPolymers", "SIMPLE_CHEMICAL", 259, 279], ["B cell antigens", "PROTEIN", 59, 74], ["phospholipids", "TREATMENT", 26, 39], ["B cell antigens", "TREATMENT", 59, 74], ["delivery systems", "TEST", 184, 200], ["Nanotechnology and NanovaccinesPolymers", "TREATMENT", 240, 279], ["antigen conjugation", "TREATMENT", 314, 333]]], ["One such example are polystyrene beads.", [["polystyrene", "CHEMICAL", 21, 32], ["polystyrene beads", "SIMPLE_CHEMICAL", 21, 38], ["polystyrene beads", "TREATMENT", 21, 38], ["polystyrene beads", "OBSERVATION", 21, 38]]], ["Nanoparticles with a solid inert core are also known as nanobeads.", [["Nanoparticles", "SIMPLE_CHEMICAL", 0, 13], ["Nanoparticles", "TREATMENT", 0, 13], ["a solid inert core", "TREATMENT", 19, 37]]], ["Proof of principle ovalbumine vaccines have been developed.", [["ovalbumine", "CHEMICAL", 19, 29], ["ovalbumine", "SIMPLE_CHEMICAL", 19, 29], ["principle ovalbumine vaccines", "TREATMENT", 9, 38]]], ["These vaccines function as repetitive antigen displays, but still need an external adjuvant added to generate strong immune responses.", [["repetitive antigen", "TEST", 27, 45], ["an external adjuvant", "TREATMENT", 71, 91]]], ["In comparison with other vaccination techniques they are not better at stimulating immune response [129] .", [["other vaccination techniques", "TEST", 19, 47]]], ["Polymers such as polystyrene are thought to be biocompatible, however, they are not biodegradable.", [["polystyrene", "CHEMICAL", 17, 28], ["polystyrene", "CHEMICAL", 17, 28], ["polystyrene", "SIMPLE_CHEMICAL", 17, 28], ["Polymers", "TREATMENT", 0, 8], ["polystyrene", "TREATMENT", 17, 28], ["thought to be", "UNCERTAINTY", 33, 46], ["biocompatible", "OBSERVATION_MODIFIER", 47, 60]]], ["Toxicology studies in cell culture models and small animals indicate that they do not generate free radicals and do not appear to cause adverse effects [128, 129, 131] .", [["cell culture", "ANATOMY", 22, 34], ["cell", "CELL", 22, 26], ["Toxicology studies", "TEST", 0, 18], ["cell culture models", "TEST", 22, 41], ["small animals", "PROBLEM", 46, 59], ["adverse effects", "PROBLEM", 136, 151]]], ["Long-term health effects are not known, however.", [["Long-term health effects", "PROBLEM", 0, 24], ["-term", "OBSERVATION_MODIFIER", 4, 9]]], ["While nanobeads with inert polymer cores function as repetitive antigen displays they still need to be adjuvanted and their long-term health effects are unknown making them not ideal candidates for vaccine development.Nanotechnology and NanovaccinesInorganic molecules can also be used as delivery systems for nanovaccines.", [["nanobeads", "SIMPLE_CHEMICAL", 6, 15], ["NanovaccinesInorganic molecules", "SIMPLE_CHEMICAL", 237, 268], ["nanovaccines", "SIMPLE_CHEMICAL", 310, 322], ["vaccine development", "TREATMENT", 198, 217], ["Nanotechnology and NanovaccinesInorganic molecules", "TREATMENT", 218, 268], ["delivery systems", "TREATMENT", 289, 305], ["nanovaccines", "TREATMENT", 310, 322]]], ["One of the best studied are gold nanoparticles (AuNP).", [["gold nanoparticles", "CHEMICAL", 28, 46], ["AuNP", "CHEMICAL", 48, 52], ["gold nanoparticles", "SIMPLE_CHEMICAL", 28, 46], ["AuNP", "SIMPLE_CHEMICAL", 48, 52]]], ["Gold is easily modified into nanoparticles of different sizes and shapes.", [["different", "OBSERVATION_MODIFIER", 46, 55], ["sizes", "OBSERVATION_MODIFIER", 56, 61], ["shapes", "OBSERVATION_MODIFIER", 66, 72]]], ["Gold also takes on unique optic properties based upon nanoparticle size and shape that has attracted attention for use in cellular imaging, drug delivery, and photothermal therapy [132, 133] .", [["optic", "ANATOMY", 26, 31], ["cellular", "ANATOMY", 122, 130], ["cellular", "CELL", 122, 130], ["unique optic properties", "TREATMENT", 19, 42], ["cellular imaging", "TEST", 122, 138], ["drug delivery", "TREATMENT", 140, 153], ["photothermal therapy", "TREATMENT", 159, 179], ["nanoparticle size", "OBSERVATION_MODIFIER", 54, 71], ["shape", "OBSERVATION_MODIFIER", 76, 81]]], ["Studies have determined that AuNP appear to be inert and biocompatible [134] .", [["AuNP", "CHEMICAL", 29, 33], ["AuNP", "SIMPLE_CHEMICAL", 29, 33], ["Studies", "TEST", 0, 7]]], ["AuNP can be used in a variety of ways in the development of vaccines with antigens adsorbed or conjugated to their surface [115] .", [["surface", "ANATOMY", 115, 122], ["AuNP", "CHEMICAL", 0, 4], ["AuNP", "SIMPLE_CHEMICAL", 0, 4], ["antigens", "PROTEIN", 74, 82], ["vaccines", "TREATMENT", 60, 68]]], ["Size and shape of AuNP has been linked to their function as vaccine candidates.", [["AuNP", "CHEMICAL", 18, 22], ["AuNP", "SIMPLE_CHEMICAL", 18, 22], ["shape", "OBSERVATION_MODIFIER", 9, 14], ["AuNP", "OBSERVATION", 18, 22]]], ["Different geometric shapes can lead to differential APC phagocytosis and antigen presentation.", [["APC", "GENE_OR_GENE_PRODUCT", 52, 55], ["APC", "CELL_TYPE", 52, 55], ["Different geometric shapes", "PROBLEM", 0, 26], ["differential APC phagocytosis", "PROBLEM", 39, 68], ["antigen presentation", "PROBLEM", 73, 93], ["geometric shapes", "OBSERVATION", 10, 26], ["differential", "OBSERVATION_MODIFIER", 39, 51], ["APC phagocytosis", "OBSERVATION", 52, 68]]], ["These findings also indicate that AuNP can function as effective delivery systems for vaccines [135] .", [["AuNP", "CHEMICAL", 34, 38], ["AuNP", "SIMPLE_CHEMICAL", 34, 38], ["effective delivery systems", "TREATMENT", 55, 81], ["vaccines", "TREATMENT", 86, 94]]], ["Successful, preclinical vaccine candidates have been developed for diseases such as influenza, West Nile Virus, and plague [135] [136] [137] .", [["influenza", "DISEASE", 84, 93], ["West Nile Virus", "DISEASE", 95, 110], ["West Nile Virus", "ORGANISM", 95, 110], ["Nile Virus", "SPECIES", 100, 110], ["West Nile Virus", "SPECIES", 95, 110], ["preclinical vaccine candidates", "TREATMENT", 12, 42], ["diseases", "PROBLEM", 67, 75], ["influenza", "PROBLEM", 84, 93]]], ["There has also been interest and initial studies on the development of both prophylactic and therapeutic cancer vaccines based off of AuNP [138, 139] .", [["cancer", "ANATOMY", 105, 111], ["cancer", "DISEASE", 105, 111], ["AuNP", "CHEMICAL", 134, 138], ["cancer", "CANCER", 105, 111], ["AuNP", "SIMPLE_CHEMICAL", 134, 138], ["initial studies", "TEST", 33, 48], ["prophylactic and therapeutic cancer vaccines", "TREATMENT", 76, 120], ["AuNP", "TEST", 134, 138], ["therapeutic", "OBSERVATION_MODIFIER", 93, 104], ["cancer", "OBSERVATION", 105, 111]]], ["Despite the fact that AuNP can be easily modified into the most immunogenic shape and size in all published studies an external adjuvant needed to be added to generate a protective or effective vaccine candidate.Nanotechnology and NanovaccinesCarbon nanotubes (CNTs) are another class of inorganic nanoparticles of interest in vaccine development.", [["AuNP", "CHEMICAL", 22, 26], ["NanovaccinesCarbon nanotubes", "CHEMICAL", 231, 259], ["CNTs", "CHEMICAL", 261, 265], ["NanovaccinesCarbon", "CHEMICAL", 231, 249], ["AuNP", "SIMPLE_CHEMICAL", 22, 26], ["NanovaccinesCarbon nanotubes", "SIMPLE_CHEMICAL", 231, 259], ["inorganic nanoparticles", "SIMPLE_CHEMICAL", 288, 311], ["an external adjuvant", "TREATMENT", 116, 136], ["Nanotechnology and NanovaccinesCarbon nanotubes (CNTs", "TREATMENT", 212, 265], ["inorganic nanoparticles", "TREATMENT", 288, 311], ["size", "OBSERVATION_MODIFIER", 86, 90]]], ["These are sheets of graphene that are folded into a tube shape, that can occur in a single layer, single-walled carbon nanotubes (SWNT), or in multiple layers, multiwalled carbon nanotubes (MWNT).", [["tube", "ANATOMY", 52, 56], ["carbon nanotubes", "CHEMICAL", 112, 128], ["SWNT", "CHEMICAL", 130, 134], ["multiwalled carbon nanotubes", "CHEMICAL", 160, 188], ["MWNT", "CHEMICAL", 190, 194], ["graphene", "CHEMICAL", 20, 28], ["carbon", "CHEMICAL", 112, 118], ["carbon", "CHEMICAL", 172, 178], ["MWNT", "CHEMICAL", 190, 194], ["graphene", "SIMPLE_CHEMICAL", 20, 28], ["tube", "TISSUE", 52, 56], ["single-walled carbon nanotubes", "SIMPLE_CHEMICAL", 98, 128], ["SWNT", "SIMPLE_CHEMICAL", 130, 134], ["multiwalled carbon nanotubes", "SIMPLE_CHEMICAL", 160, 188], ["MWNT", "SIMPLE_CHEMICAL", 190, 194], ["sheets of graphene", "TREATMENT", 10, 28], ["single-walled carbon nanotubes (SWNT", "TREATMENT", 98, 134], ["multiwalled carbon nanotubes (MWNT", "TREATMENT", 160, 194], ["tube shape", "OBSERVATION", 52, 62], ["carbon nanotubes", "OBSERVATION", 112, 128], ["multiple", "OBSERVATION_MODIFIER", 143, 151], ["layers", "OBSERVATION_MODIFIER", 152, 158], ["multiwalled", "OBSERVATION", 160, 171], ["carbon nanotubes", "OBSERVATION", 172, 188]]], ["CNTs have many advantages that make them an ideal candidate for vaccine development.", [["CNTs", "SIMPLE_CHEMICAL", 0, 4], ["vaccine development", "TREATMENT", 64, 83]]], ["They have a large surface area that makes them excellent potential repetitive antigen displays.", [["surface area", "ANATOMY", 18, 30], ["a large surface area", "PROBLEM", 10, 30], ["large", "OBSERVATION_MODIFIER", 12, 17], ["surface", "OBSERVATION_MODIFIER", 18, 25], ["excellent", "OBSERVATION_MODIFIER", 47, 56]]], ["Adsorption and or conjugation of antigens to their surface is fairly easy [140] .", [["surface", "ANATOMY", 51, 58], ["surface", "CELLULAR_COMPONENT", 51, 58], ["antigens", "PROTEIN", 33, 41], ["Adsorption", "TREATMENT", 0, 10], ["conjugation of antigens", "TREATMENT", 18, 41]]], ["Studies have indicated that they are highly immunogenic in and off themselves, which could potentially indicate that besides functioning as antigen delivery Karch systems they also could function as immunopotentiators [140] [141] [142] [143] .", [["antigen delivery Karch systems", "TREATMENT", 140, 170], ["immunopotentiators", "TEST", 199, 217]]], ["One of the major problems with the application of CNT to vaccinology is that their toxicology is not established and studies are highly conflicting.Nanotechnology and NanovaccinesOther inorganic nanoscale assemblies based on silica, aluminum, and calcium phosphate, have been used in an attempt to develop effective vaccine candidates [144] .", [["silica", "CHEMICAL", 225, 231], ["aluminum", "CHEMICAL", 233, 241], ["calcium phosphate", "CHEMICAL", 247, 264], ["silica", "CHEMICAL", 225, 231], ["aluminum", "CHEMICAL", 233, 241], ["calcium phosphate", "CHEMICAL", 247, 264], ["silica", "SIMPLE_CHEMICAL", 225, 231], ["aluminum", "SIMPLE_CHEMICAL", 233, 241], ["calcium phosphate", "SIMPLE_CHEMICAL", 247, 264], ["Nanotechnology", "TREATMENT", 148, 162], ["Nanovaccines", "TREATMENT", 167, 179], ["Other inorganic nanoscale assemblies", "TREATMENT", 179, 215], ["silica, aluminum", "TREATMENT", 225, 241], ["calcium phosphate", "TREATMENT", 247, 264], ["major", "OBSERVATION_MODIFIER", 11, 16], ["problems", "OBSERVATION", 17, 25]]], ["The primary issue is that the long-term health effects are not known.", [["the long-term health effects", "PROBLEM", 26, 54]]], ["Initial studies have focused on in vitro models and small animal models.", [["Initial studies", "TEST", 0, 15], ["small animal models", "PROBLEM", 52, 71], ["small", "OBSERVATION_MODIFIER", 52, 57]]], ["For every class of inorganic nanoparticle, studies have indicated that there is some form of toxicology [145] .", [["inorganic nanoparticle", "SIMPLE_CHEMICAL", 19, 41], ["inorganic nanoparticle", "TREATMENT", 19, 41]]], ["While there are benefits to each class, the lack of understanding of their long-term health effects makes developing a clinical product difficult at this current time.Biologically Derived NanovaccinesAs first proposed by Dexler, the use of biological molecules has many advantages for development of nanotechnology, particularly nanovaccines.", [["nanovaccines", "SIMPLE_CHEMICAL", 329, 341], ["a clinical product", "PROBLEM", 117, 135], ["nanovaccines", "TREATMENT", 329, 341]]], ["The first approved subunit vaccine, HBV vaccine, is technically a nanoparticle that is composed completely of protein.Biologically Derived NanovaccinesThe VLPs made by the HBsAg self-assemble into 22 nm particles, which falls well into the 1-100 nm designation of nanoscale assemblies.", [["HBsAg", "CHEMICAL", 172, 177], ["HBV", "ORGANISM", 36, 39], ["VLPs", "ORGANISM", 155, 159], ["HBsAg", "GENE_OR_GENE_PRODUCT", 172, 177], ["HBsAg", "PROTEIN", 172, 177], ["HBV", "SPECIES", 36, 39], ["The first approved subunit vaccine", "TREATMENT", 0, 34], ["HBV vaccine", "TREATMENT", 36, 47], ["The VLPs", "TREATMENT", 151, 159], ["the HBsAg", "TEST", 168, 177]]], ["Other biologically based technologies have also been developed to repetitively display antigens, with potentially lower levels of toxicity in comparison to inorganic and synthetic polymer nanoparticles.", [["toxicity", "DISEASE", 130, 138], ["inorganic", "CHEMICAL", 156, 165], ["inorganic", "SIMPLE_CHEMICAL", 156, 165], ["polymer nanoparticles", "SIMPLE_CHEMICAL", 180, 201], ["antigens", "PROTEIN", 87, 95], ["lower levels of toxicity", "PROBLEM", 114, 138], ["inorganic and synthetic polymer nanoparticles", "TREATMENT", 156, 201]]], ["By capitalizing on biological macromolecules scientists are able to develop vaccine candidates that more closely resemble microorganisms, meaning they should function more efficiently inside the host.Biologically Derived NanovaccinesOne example of biologically derived nanoparticles are liposomes, which are phospholipid bilayers surrounding an aqueous chamber.", [["liposomes", "SIMPLE_CHEMICAL", 287, 296], ["phospholipid bilayers", "SIMPLE_CHEMICAL", 308, 329], ["vaccine candidates", "TREATMENT", 76, 94], ["nanoparticles", "OBSERVATION", 269, 282], ["liposomes", "OBSERVATION", 287, 296], ["phospholipid bilayers", "OBSERVATION", 308, 329], ["aqueous chamber", "OBSERVATION", 345, 360]]], ["In 1965 it was noted that phospholipids could assemble into these structures [146] .", [["phospholipids", "SIMPLE_CHEMICAL", 26, 39], ["phospholipids", "TREATMENT", 26, 39]]], ["By 1974 the first study came out that indicated that liposomes could function as an adjuvant to increase the immune response to diphtheria toxoid vaccine contained in their aqueous chamber [147] .", [["diphtheria toxoid", "CHEMICAL", 128, 145], ["liposomes", "SIMPLE_CHEMICAL", 53, 62], ["diphtheria toxoid", "ORGANISM", 128, 145], ["the first study", "TEST", 8, 23], ["an adjuvant", "TREATMENT", 81, 92], ["the immune response", "TREATMENT", 105, 124], ["diphtheria toxoid vaccine", "TREATMENT", 128, 153]]], ["In the subsequent years, studies have established liposomes as safe and effective antigen delivery system as well as adjuvant.", [["liposomes", "SIMPLE_CHEMICAL", 50, 59], ["studies", "TEST", 25, 32], ["liposomes", "TREATMENT", 50, 59], ["effective antigen delivery system", "TREATMENT", 72, 105], ["adjuvant", "TREATMENT", 117, 125]]], ["Liposomes are extremely plastic, meaning size, shape, charge, phospholipid composition, and supporting molecular composition can be altered to elicit the desired effect.", [["Liposomes", "SIMPLE_CHEMICAL", 0, 9], ["phospholipid", "SIMPLE_CHEMICAL", 62, 74], ["phospholipid composition", "TREATMENT", 62, 86], ["extremely", "OBSERVATION_MODIFIER", 14, 23], ["plastic", "OBSERVATION", 24, 31], ["size", "OBSERVATION_MODIFIER", 41, 45], ["shape", "OBSERVATION_MODIFIER", 47, 52], ["phospholipid composition", "OBSERVATION_MODIFIER", 62, 86]]], ["They can function as repetitive antigen displays when antigens are either incorporated into the phospholipid bilayer, or adsorbed onto the membrane.", [["phospholipid bilayer", "ANATOMY", 96, 116], ["membrane", "ANATOMY", 139, 147], ["phospholipid bilayer", "SIMPLE_CHEMICAL", 96, 116], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["antigens", "PROTEIN", 54, 62]]], ["Liposomes can also carry T cell epitopes as cargo in their aqueous chamber [148] .Biologically Derived NanovaccinesStudies indicate that liposomes are functional for two main reasons.", [["T cell", "ANATOMY", 25, 31], ["Liposomes", "SIMPLE_CHEMICAL", 0, 9], ["T cell", "CELL", 25, 31], ["liposomes", "SIMPLE_CHEMICAL", 137, 146], ["T cell epitopes", "PROTEIN", 25, 40], ["Liposomes", "TREATMENT", 0, 9], ["T cell epitopes", "PROBLEM", 25, 40]]], ["The fact that they are composed of phospholipids increases the ability of APC cells to phagocytose the particles leading to increased antigen processing and presentation [149] .", [["APC cells", "ANATOMY", 74, 83], ["phospholipids", "SIMPLE_CHEMICAL", 35, 48], ["APC cells", "CELL", 74, 83], ["APC cells", "CELL_TYPE", 74, 83], ["phospholipids", "TREATMENT", 35, 48], ["APC cells", "TREATMENT", 74, 83], ["phagocytose the particles", "PROBLEM", 87, 112], ["increased antigen processing", "PROBLEM", 124, 152], ["increased", "OBSERVATION_MODIFIER", 124, 133]]], ["Studies have indicated that cationic liposomes are the most effective adjuvants because they remain longer associated with cell membranes because of electrostatic interactions [150, 151] .", [["cell membranes", "ANATOMY", 123, 137], ["cationic liposomes", "SIMPLE_CHEMICAL", 28, 46], ["cell membranes", "CELLULAR_COMPONENT", 123, 137], ["Studies", "TEST", 0, 7], ["cationic liposomes", "TREATMENT", 28, 46], ["cell membranes", "PROBLEM", 123, 137], ["cationic liposomes", "OBSERVATION", 28, 46], ["most effective", "OBSERVATION_MODIFIER", 55, 69], ["cell membranes", "OBSERVATION", 123, 137]]], ["The longer a liposome is associated with the membrane the higher the probably that APC will phagocytose and present the antigens.", [["membrane", "ANATOMY", 45, 53], ["APC", "CHEMICAL", 83, 86], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["APC", "GENE_OR_GENE_PRODUCT", 83, 86], ["APC", "CELL_TYPE", 83, 86], ["antigens", "PROTEIN", 120, 128], ["liposome", "OBSERVATION", 13, 21]]], ["Liposomes can also carry external adjuvants in their chambers, or have Karch adjuvants like PAMPS incorporated into their membranes leading to stronger immune responses [148, 152, 153] .Biologically Derived NanovaccinesVirosomes could be considered a cross between VLPs and liposomes.", [["membranes", "ANATOMY", 122, 131], ["PAMPS", "CHEMICAL", 92, 97], ["Liposomes", "SIMPLE_CHEMICAL", 0, 9], ["PAMPS", "SIMPLE_CHEMICAL", 92, 97], ["membranes", "CELLULAR_COMPONENT", 122, 131], ["Virosomes", "GENE_OR_GENE_PRODUCT", 219, 228], ["VLPs", "ORGANISM", 265, 269], ["liposomes", "SIMPLE_CHEMICAL", 274, 283], ["PAMPS", "PROTEIN", 92, 97], ["Liposomes", "TREATMENT", 0, 9], ["external adjuvants", "TREATMENT", 25, 43], ["Karch adjuvants", "TREATMENT", 71, 86], ["Virosomes", "TREATMENT", 219, 228], ["a cross between VLPs and liposomes", "PROBLEM", 249, 283], ["liposomes", "ANATOMY", 274, 283]]], ["Traditionally, each virosome is composed of the phospholipids contained in the envelope of influenza virus along with the viral envelope proteins hemagglutinin and neuraminidase.", [["influenza virus", "ORGANISM", 91, 106], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 146, 159], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 164, 177], ["viral envelope proteins", "PROTEIN", 122, 145], ["hemagglutinin", "PROTEIN", 146, 159], ["neuraminidase", "PROTEIN", 164, 177], ["influenza virus", "SPECIES", 91, 106], ["influenza virus", "SPECIES", 91, 106], ["the phospholipids", "TREATMENT", 44, 61], ["influenza virus", "PROBLEM", 91, 106], ["the viral envelope proteins hemagglutinin", "TREATMENT", 118, 159], ["neuraminidase", "TREATMENT", 164, 177], ["influenza virus", "OBSERVATION", 91, 106]]], ["With this design the particles function as immunogenic influenza viruses, but because they do not contain a genome they are unable to replicate.", [["influenza viruses", "DISEASE", 55, 72], ["immunogenic influenza viruses", "PROBLEM", 43, 72]]], ["They demonstrate increased fusion with APC and subsequently, elevated antigen presentation [154] .", [["APC", "GENE_OR_GENE_PRODUCT", 39, 42], ["APC", "CELL_TYPE", 39, 42], ["increased fusion", "PROBLEM", 17, 33], ["APC", "PROBLEM", 39, 42], ["elevated antigen presentation", "PROBLEM", 61, 90], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["fusion", "OBSERVATION", 27, 33], ["elevated", "OBSERVATION_MODIFIER", 61, 69]]], ["The phospholipids and envelope proteins were originally isolated from influenza viral cultures grown in embryonated eggs, but now they are synthetically produced and assembled.", [["eggs", "ANATOMY", 116, 120], ["phospholipids", "SIMPLE_CHEMICAL", 4, 17], ["envelope proteins", "PROTEIN", 22, 39], ["influenza viral cultures", "CELL_LINE", 70, 94], ["The phospholipids", "TREATMENT", 0, 17], ["envelope proteins", "PROBLEM", 22, 39], ["influenza viral cultures", "PROBLEM", 70, 94], ["embryonated eggs", "PROBLEM", 104, 120]]], ["As with liposomes antigens can be added to the membrane, adsorbed onto the membrane, or carried as cargo in the virosome [155] .Biologically Derived NanovaccinesTwo different virosomes have been used successfully since in the 1990s in humans.", [["membrane", "ANATOMY", 47, 55], ["membrane", "ANATOMY", 75, 83], ["liposomes antigens", "GENE_OR_GENE_PRODUCT", 8, 26], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["membrane", "CELLULAR_COMPONENT", 75, 83], ["virosomes", "CANCER", 175, 184], ["humans", "ORGANISM", 235, 241], ["humans", "SPECIES", 235, 241], ["humans", "SPECIES", 235, 241], ["liposomes antigens", "TREATMENT", 8, 26], ["Two different virosomes", "TREATMENT", 161, 184]]], ["The first is Inflexal, which is an influenza vaccine [156] .", [["Inflexal", "TREATMENT", 13, 21], ["an influenza vaccine", "TREATMENT", 32, 52]]], ["The second is Epaxal, which is formalin inactivated hepatis A that is adsorbed to an influenza virosome [157] .", [["Epaxal", "CHEMICAL", 14, 20], ["formalin", "CHEMICAL", 31, 39], ["formalin", "CHEMICAL", 31, 39], ["Epaxal", "SIMPLE_CHEMICAL", 14, 20], ["formalin", "SIMPLE_CHEMICAL", 31, 39], ["hepatis A", "CANCER", 52, 61], ["Epaxal", "TREATMENT", 14, 20], ["an influenza virosome", "PROBLEM", 82, 103], ["Epaxal", "OBSERVATION", 14, 20], ["hepatis", "ANATOMY", 52, 59]]], ["Both vaccines have been shown to be effective with good safety profiles.", [["Both vaccines", "TREATMENT", 0, 13]]], ["They have also demonstrated that virosomes can function both as antigen delivery system as well as adjuvants.", [["virosomes", "SIMPLE_CHEMICAL", 33, 42], ["virosomes", "PROTEIN", 33, 42], ["virosomes", "TREATMENT", 33, 42], ["antigen delivery system", "TREATMENT", 64, 87], ["adjuvants", "TREATMENT", 99, 108]]], ["Currently, vaccines for malaria, hepatitis C, various cancers, HIV, and Candida albicans are in various stages of clinical development using influenza virosomes as a core [158] .Biologically Derived NanovaccinesNanoparticles composed of protein that can self-assemble into repetitive antigen displays are an area of intense interest in the development of nanovaccines.", [["cancers", "ANATOMY", 54, 61], ["malaria", "DISEASE", 24, 31], ["hepatitis C", "DISEASE", 33, 44], ["cancers", "DISEASE", 54, 61], ["HIV", "DISEASE", 63, 66], ["Candida albicans", "DISEASE", 72, 88], ["influenza virosomes", "DISEASE", 141, 160], ["hepatitis C", "ORGANISM", 33, 44], ["cancers", "CANCER", 54, 61], ["HIV", "ORGANISM", 63, 66], ["Candida albicans", "ORGANISM", 72, 88], ["nanovaccines", "CANCER", 355, 367], ["HIV", "SPECIES", 63, 66], ["Candida albicans", "SPECIES", 72, 88], ["hepatitis C", "SPECIES", 33, 44], ["HIV", "SPECIES", 63, 66], ["Candida albicans", "SPECIES", 72, 88], ["vaccines", "TREATMENT", 11, 19], ["malaria", "PROBLEM", 24, 31], ["hepatitis C", "PROBLEM", 33, 44], ["various cancers", "PROBLEM", 46, 61], ["HIV", "PROBLEM", 63, 66], ["Candida albicans", "PROBLEM", 72, 88], ["influenza virosomes", "TREATMENT", 141, 160], ["Biologically Derived NanovaccinesNanoparticles", "TREATMENT", 178, 224], ["nanovaccines", "TREATMENT", 355, 367], ["malaria", "OBSERVATION", 24, 31], ["hepatitis", "OBSERVATION", 33, 42], ["cancers", "OBSERVATION", 54, 61], ["Candida albicans", "OBSERVATION", 72, 88], ["intense", "OBSERVATION_MODIFIER", 316, 323]]], ["One class of these nanoscale assemblies are derived from the protein ferritin ( Figure 2C ).", [["ferritin", "GENE_OR_GENE_PRODUCT", 69, 77], ["protein ferritin", "PROTEIN", 61, 77], ["the protein ferritin", "TEST", 57, 77]]], ["Ferritin is an iron metabolism protein that is present in bacteria, animals, and plants.", [["Ferritin", "CHEMICAL", 0, 8], ["iron", "CHEMICAL", 15, 19], ["iron", "CHEMICAL", 15, 19], ["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["iron", "SIMPLE_CHEMICAL", 15, 19], ["Ferritin", "PROTEIN", 0, 8], ["iron metabolism protein", "PROTEIN", 15, 38], ["Ferritin", "TEST", 0, 8], ["an iron metabolism protein", "PROBLEM", 12, 38], ["bacteria", "PROBLEM", 58, 66], ["iron metabolism protein", "OBSERVATION", 15, 38], ["bacteria", "OBSERVATION_MODIFIER", 58, 66]]], ["Under normal conditions 24 monomers of ferritin will self-assemble into a spherical particle with octahedral symmetry containing an open central cavity.", [["ferritin", "GENE_OR_GENE_PRODUCT", 39, 47], ["ferritin", "PROTEIN", 39, 47], ["ferritin", "TEST", 39, 47], ["an open central cavity", "TREATMENT", 129, 151], ["octahedral symmetry", "OBSERVATION", 98, 117], ["open", "OBSERVATION_MODIFIER", 132, 136], ["central cavity", "OBSERVATION", 137, 151]]], ["This structure is known as a ferritin cage [159] .", [["ferritin", "GENE_OR_GENE_PRODUCT", 29, 37]]], ["Ferritin cages have an overall diameter of 12 nm, while the cores have a diameter of 8 nm.", [["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Ferritin cages", "TEST", 0, 14], ["overall", "OBSERVATION_MODIFIER", 23, 30], ["diameter", "OBSERVATION_MODIFIER", 31, 39], ["12 nm", "OBSERVATION_MODIFIER", 43, 48], ["diameter", "OBSERVATION_MODIFIER", 73, 81], ["8 nm", "OBSERVATION_MODIFIER", 85, 89]]], ["Under starvation, bacterial ferritin can assemble into a particle with tetrameric symmetry composed of 12 ferritin monomers [161] .", [["ferritin", "GENE_OR_GENE_PRODUCT", 28, 36], ["ferritin", "GENE_OR_GENE_PRODUCT", 106, 114], ["bacterial ferritin", "PROTEIN", 18, 36], ["bacterial ferritin", "TEST", 18, 36], ["bacterial ferritin", "OBSERVATION", 18, 36]]], ["Ferritin cages have been used for a wide variety of biomedical applications including medical imaging and drug delivery [159] .Biologically Derived NanovaccinesStudies have determined that ferritin cages can function as vaccine delivery systems.", [["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["ferritin", "GENE_OR_GENE_PRODUCT", 189, 197], ["Ferritin cages", "TREATMENT", 0, 14], ["medical imaging", "TEST", 86, 101], ["drug delivery", "TREATMENT", 106, 119], ["NanovaccinesStudies", "TEST", 148, 167], ["ferritin cages", "TREATMENT", 189, 203], ["vaccine delivery systems", "TREATMENT", 220, 244]]], ["Hemagglutinin from H1N1 subtype of influenza has been fused to ferritin from H. pylori leading to the generation of an influenza vaccine candidate.", [["Hemagglutinin", "CHEMICAL", 0, 13], ["influenza", "DISEASE", 35, 44], ["Hemagglutinin", "GENE_OR_GENE_PRODUCT", 0, 13], ["H1N1 subtype", "ORGANISM", 19, 31], ["influenza", "ORGANISM", 35, 44], ["ferritin", "GENE_OR_GENE_PRODUCT", 63, 71], ["H. pylori", "ORGANISM", 77, 86], ["ferritin", "PROTEIN", 63, 71], ["H. pylori", "SPECIES", 77, 86], ["H. pylori", "SPECIES", 77, 86], ["Hemagglutinin", "TREATMENT", 0, 13], ["H1N1", "PROBLEM", 19, 23], ["influenza", "PROBLEM", 35, 44], ["ferritin", "TEST", 63, 71], ["H. pylori", "PROBLEM", 77, 86], ["an influenza vaccine", "TREATMENT", 116, 136], ["H1N1", "OBSERVATION", 19, 23], ["influenza", "OBSERVATION", 35, 44]]], ["The resulting particle expresses eight trimeric hemagglutinin molecules in their native conformation on the vertices of the particle.", [["trimeric hemagglutinin molecules", "PROTEIN", 39, 71], ["eight trimeric hemagglutinin molecules", "PROBLEM", 33, 71], ["particle", "OBSERVATION_MODIFIER", 14, 22], ["hemagglutinin molecules", "OBSERVATION", 48, 71], ["particle", "OBSERVATION_MODIFIER", 124, 132]]], ["When vaccinated into ferrets the animals developed antibodies to both the head domain and the stalk domain of hemagglutinin.", [["head", "ANATOMY", 74, 78], ["ferrets", "ORGANISM", 21, 28], ["animals", "ORGANISM", 33, 40], ["head", "ORGANISM_SUBDIVISION", 74, 78], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 110, 123], ["antibodies", "PROTEIN", 51, 61], ["head domain", "PROTEIN", 74, 85], ["stalk domain", "PROTEIN", 94, 106], ["hemagglutinin", "PROTEIN", 110, 123], ["ferrets", "SPECIES", 21, 28], ["ferrets", "SPECIES", 21, 28], ["antibodies", "PROBLEM", 51, 61], ["hemagglutinin", "TREATMENT", 110, 123], ["head", "ANATOMY", 74, 78]]], ["The head domain of hemagglutinin from influenza is immunodominant, but it is subject to antigenic drift necessitating seasonal changes in vaccine formulations.", [["head", "ANATOMY", 4, 8], ["influenza", "DISEASE", 38, 47], ["head", "ORGANISM_SUBDIVISION", 4, 8], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 19, 32], ["head domain", "PROTEIN", 4, 15], ["hemagglutinin", "PROTEIN", 19, 32], ["hemagglutinin", "PROBLEM", 19, 32], ["influenza", "PROBLEM", 38, 47], ["immunodominant", "PROBLEM", 51, 65], ["antigenic drift", "PROBLEM", 88, 103], ["seasonal changes in vaccine formulations", "TREATMENT", 118, 158], ["head", "ANATOMY", 4, 8], ["hemagglutinin", "OBSERVATION", 19, 32], ["influenza", "OBSERVATION", 38, 47]]], ["In a desire to generate a vaccine candidate that focuses on the conserved stem domain, a recombinant ferritin molecule was generated that lacked the head domain.", [["stem domain", "ANATOMY", 74, 85], ["head", "ANATOMY", 149, 153], ["ferritin", "GENE_OR_GENE_PRODUCT", 101, 109], ["head", "ORGANISM_SUBDIVISION", 149, 153], ["conserved stem domain", "PROTEIN", 64, 85], ["recombinant ferritin molecule", "PROTEIN", 89, 118], ["head domain", "PROTEIN", 149, 160], ["a vaccine", "TREATMENT", 24, 33], ["a recombinant ferritin molecule", "TEST", 87, 118], ["head", "ANATOMY", 149, 153]]], ["This construct was able to raise stalk specific antibodies and completely protect mice against challenge, and partially protect ferrets [163] .", [["mice", "ORGANISM", 82, 86], ["ferrets", "ORGANISM", 128, 135], ["stalk specific antibodies", "PROTEIN", 33, 58], ["mice", "SPECIES", 82, 86], ["ferrets", "SPECIES", 128, 135], ["mice", "SPECIES", 82, 86], ["stalk specific antibodies", "PROBLEM", 33, 58]]], ["Karch While ferritin cages are exciting potential repetitive display antigen candidates, they do have weaknesses.", [["ferritin", "GENE_OR_GENE_PRODUCT", 12, 20], ["Karch", "SPECIES", 0, 5], ["weaknesses", "PROBLEM", 102, 112]]], ["Ferritin cages have a very rigid assembly.", [["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["Ferritin cages", "TEST", 0, 14], ["a very rigid", "PROBLEM", 20, 32], ["very rigid", "OBSERVATION_MODIFIER", 22, 32]]], ["If an antigen needs to be presented in a certain conformation to be immunogenic, ferritin cages may not be able to present it in the most immunogenic form.", [["ferritin", "GENE_OR_GENE_PRODUCT", 81, 89], ["an antigen", "PROBLEM", 3, 13], ["immunogenic, ferritin cages", "TREATMENT", 68, 95]]], ["Ferritin cages seem like excellent candidates for the development of some vaccines, but will not be able to be used for every antigen.Biologically Derived NanovaccinesAnother naturally occurring nanoscale assembly that has attracted attention are vault proteins (Figure 2A ).", [["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["vault proteins", "PROTEIN", 247, 261], ["Figure 2A", "PROTEIN", 263, 272], ["Ferritin cages", "TEST", 0, 14], ["some vaccines", "TREATMENT", 69, 82]]], ["These proteins are naturally occurring in most eukaryotes, and may play a role in nuclear transport, signal transduction, and innate immune responses, but no exact function has been established [164] .", [["nuclear", "ANATOMY", 82, 89], ["nuclear", "CELLULAR_COMPONENT", 82, 89]]], ["Each vault is a 70 nm organelle-like structure that is composed of three proteins: the major vault protein (MVP) makes up 70% of the complex, telomerase associated protein-1, poly ADP-ribose polymerase (PARP), and non-coding RNAs [165] .", [["poly ADP-ribose", "CHEMICAL", 175, 190], ["poly ADP-ribose", "CHEMICAL", 175, 190], ["MVP", "GENE_OR_GENE_PRODUCT", 108, 111], ["telomerase associated protein-1", "GENE_OR_GENE_PRODUCT", 142, 173], ["poly ADP-ribose polymerase", "GENE_OR_GENE_PRODUCT", 175, 201], ["PARP", "GENE_OR_GENE_PRODUCT", 203, 207], ["major vault protein", "PROTEIN", 87, 106], ["MVP", "PROTEIN", 108, 111], ["telomerase associated protein-1", "PROTEIN", 142, 173], ["poly ADP-ribose polymerase", "PROTEIN", 175, 201], ["PARP", "PROTEIN", 203, 207], ["non-coding RNAs", "RNA", 214, 229], ["a 70 nm organelle-like structure", "PROBLEM", 14, 46], ["MVP", "TEST", 108, 111], ["telomerase associated protein", "TEST", 142, 171], ["poly ADP-ribose polymerase", "TEST", 175, 201], ["PARP", "TEST", 203, 207], ["vault", "ANATOMY", 5, 10], ["70 nm", "OBSERVATION_MODIFIER", 16, 21]]], ["Vaults can be designed to express heterologous proteins inside their central cavity.", [["central cavity", "ANATOMY", 69, 83], ["central cavity", "MULTI-TISSUE_STRUCTURE", 69, 83], ["heterologous proteins", "PROTEIN", 34, 55], ["central cavity", "ANATOMY", 69, 83]]], ["This is easily done by adding a specific sequence to the protein that has been determined to associate the PARP protein with MVP [165] .", [["PARP", "GENE_OR_GENE_PRODUCT", 107, 111], ["MVP [165]", "GENE_OR_GENE_PRODUCT", 125, 134], ["PARP protein", "PROTEIN", 107, 119], ["MVP", "PROTEIN", 125, 128], ["MVP", "PROBLEM", 125, 128]]], ["Vaults are not immunogenic themselves and do not lead to the development of autoimmune responses making them a good vaccine delivery system [165, 166] .", [["autoimmune responses", "PROBLEM", 76, 96], ["not", "UNCERTAINTY", 11, 14], ["autoimmune", "OBSERVATION", 76, 86]]], ["Using the model protein ovalbumin, vaults were successful at inducing T C and T H responses in vaccinated animals.", [["T C", "CELL", 70, 73], ["T H", "GENE_OR_GENE_PRODUCT", 78, 81], ["the model protein ovalbumin", "TREATMENT", 6, 33]]], ["Vaults have been developed as vaccine candidates for Chlamydia muridarium infections.", [["Chlamydia muridarium infections", "DISEASE", 53, 84], ["Chlamydia muridarium", "ORGANISM", 53, 73], ["Chlamydia muridarium", "SPECIES", 53, 73], ["Chlamydia muridarium", "SPECIES", 53, 73], ["vaccine candidates", "TREATMENT", 30, 48], ["Chlamydia muridarium infections", "PROBLEM", 53, 84]]], ["Inoculation induced both T H and T C responses leading to protection against challenge [168] .", [["T H", "GENE_OR_GENE_PRODUCT", 25, 28], ["T C", "GENE_OR_GENE_PRODUCT", 33, 36]]], ["Despite the success with vaults their biggest weakness is that the antigen is contained within the vault cavity, which prevents it from stimulating B cells leading to strong humoral responses.", [["vault cavity", "ANATOMY", 99, 111], ["B cells", "ANATOMY", 148, 155], ["B cells", "CELL", 148, 155], ["B cells", "CELL_TYPE", 148, 155], ["vaults their biggest weakness", "PROBLEM", 25, 54], ["the antigen", "PROBLEM", 63, 74], ["stimulating B cells", "PROBLEM", 136, 155], ["biggest", "OBSERVATION_MODIFIER", 38, 45], ["weakness", "OBSERVATION", 46, 54], ["vault cavity", "ANATOMY", 99, 111]]], ["Currently, vaults could function as strong vaccine candidates for intracellular pathogens, or for diseases such as cancer, but further development is needed for their use against a wide range of pathogens.Rationally Designed Protein NanovaccinesWhile naturally occurring nanoscale assemblies can be good vaccine candidates for certain infectious diseases, they may not be applicable to a wide range of infectious organisms.", [["intracellular", "ANATOMY", 66, 79], ["cancer", "ANATOMY", 115, 121], ["cancer", "DISEASE", 115, 121], ["infectious diseases", "DISEASE", 335, 354], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 79], ["cancer", "CANCER", 115, 121], ["intracellular pathogens", "PROBLEM", 66, 89], ["diseases", "PROBLEM", 98, 106], ["cancer", "PROBLEM", 115, 121], ["pathogens", "PROBLEM", 195, 204], ["Designed Protein Nanovaccines", "TREATMENT", 216, 245], ["certain infectious diseases", "PROBLEM", 327, 354], ["infectious organisms", "PROBLEM", 402, 422], ["cancer", "OBSERVATION", 115, 121], ["infectious", "OBSERVATION", 402, 412]]], ["Another approach in development of nanovaccines is the use of rationally designed proteins.", [["nanovaccines", "TREATMENT", 35, 47]]], ["By combining knowledge of structural biology, biophysics, protein engineering, infectious disease biology, and molecular biology new proteins can be developed to function as ideal vaccine candidates.", [["infectious disease", "DISEASE", 79, 97]]], ["This approach is considered a bottom-up approach, taking small parts and generating a more complex assembly [169] .", [["a bottom-up approach", "TREATMENT", 28, 48], ["bottom", "OBSERVATION_MODIFIER", 30, 36]]], ["VLPs and other approaches are a top-down approach and take a complex protein assembly and strip it down to its basic components, which in the terms of a vaccine would be the smallest part that induces protective immunity [170] .Rationally Designed Protein NanovaccinesThere are many benefits and challenges associated with vaccine development from bottomup rationally designed proteins.", [["bottomup rationally designed proteins", "PROTEIN", 348, 385], ["VLPs", "TREATMENT", 0, 4], ["a top-down approach", "TREATMENT", 30, 49], ["a complex protein assembly", "TREATMENT", 59, 85], ["a vaccine", "TREATMENT", 151, 160], ["Designed Protein Nanovaccines", "TREATMENT", 239, 268], ["vaccine development", "TREATMENT", 323, 342]]], ["The major benefit is that these designed proteins can function as repetitive antigen displays for a wide range of antigens.", [["antigens", "PROTEIN", 114, 122], ["repetitive antigen", "TEST", 66, 84]]], ["They are not limited like ferritin cages or vaults in what conformations of antigens they can present.", [["ferritin", "GENE_OR_GENE_PRODUCT", 26, 34], ["antigens", "PROTEIN", 76, 84], ["ferritin cages or vaults", "PROBLEM", 26, 50]]], ["They also can be optimized to induce both strong cellular and humoral immune responses by the addition of new antigenic domains.", [["cellular", "ANATOMY", 49, 57], ["cellular", "CELL", 49, 57], ["antigenic domains", "PROTEIN", 110, 127], ["new antigenic domains", "PROBLEM", 106, 127], ["humoral immune", "OBSERVATION", 62, 76]]], ["This self-assembly needs to occur without an added enzyme in a specific and reproducible manner [171] .", [["an added enzyme", "TEST", 42, 57]]], ["The major drawback of this approach is protein sequence, no matter how well designed, does not always perfectly correlate with structure and function [172] .", [["protein sequence", "TEST", 39, 55]]], ["This problem leads to the need for each design to be empirically tested and optimized to achieve the desired structure and ultimately the desired protective effect in vaccinated animals.Rationally Designed Protein NanovaccinesA technique that been applied to the development of rationally designed protein nanoparticles is the layer-by-layer (LbL) fabrication of polypeptide films on solid CaCO 3 cores.", [["CaCO 3", "CHEMICAL", 390, 396], ["Rationally Designed Protein NanovaccinesA technique", "TREATMENT", 186, 237], ["rationally designed protein nanoparticles", "TREATMENT", 278, 319], ["polypeptide films on solid CaCO 3 cores", "TREATMENT", 363, 402]]], ["In this method polypeptide layers of alternating opposite charges are deposited on a CaCO 3 nanoparticle core.", [["CaCO 3 nanoparticle", "CHEMICAL", 85, 104], ["CaCO 3", "CHEMICAL", 85, 91], ["a CaCO 3 nanoparticle core", "TREATMENT", 83, 109], ["layers", "OBSERVATION_MODIFIER", 27, 33], ["opposite charges", "OBSERVATION", 49, 65]]], ["The electrostatic interactions between the opposite charged polypeptide layers keep particle together.", [["The electrostatic interactions", "PROBLEM", 0, 30], ["electrostatic interactions", "OBSERVATION", 4, 30]]], ["Contained within the different layers different B and T cell antigens can be added allowing for the development of vaccine candidates for different disease states [173] .", [["T cell", "ANATOMY", 54, 60], ["B", "CELL", 48, 49], ["T cell antigens", "GENE_OR_GENE_PRODUCT", 54, 69], ["B and T cell antigens", "PROTEIN", 48, 69], ["B and T cell antigens", "TREATMENT", 48, 69], ["vaccine candidates", "TREATMENT", 115, 133], ["different disease states", "PROBLEM", 138, 162], ["different", "OBSERVATION_MODIFIER", 21, 30], ["layers", "OBSERVATION_MODIFIER", 31, 37], ["different", "OBSERVATION_MODIFIER", 38, 47]]], ["A malaria and a respiratory syncytial virus (RSV) vaccine candidate designed using this approach were immunogenic and capable of raising neutralizing antibodies for both either malaria or RSV respectively and the malaria candidate was able to generate cellular responses as well [174, 175] .Rationally Designed Protein NanovaccinesOne approach for the development of a rationally designed protein nanoparticle are nanofibers, nanoscale assemblies that are derived from the \u03b2-sheet secondary structure.", [["cellular", "ANATOMY", 252, 260], ["malaria", "DISEASE", 2, 9], ["respiratory syncytial virus", "DISEASE", 16, 43], ["malaria", "DISEASE", 177, 184], ["malaria", "DISEASE", 213, 220], ["respiratory syncytial virus", "ORGANISM", 16, 43], ["RSV", "ORGANISM", 45, 48], ["RSV", "ORGANISM", 188, 191], ["cellular", "CELL", 252, 260], ["neutralizing antibodies", "PROTEIN", 137, 160], ["\u03b2-sheet secondary structure", "PROTEIN", 473, 500], ["respiratory syncytial virus (RSV", "SPECIES", 16, 48], ["respiratory syncytial virus", "SPECIES", 16, 43], ["RSV", "SPECIES", 45, 48], ["RSV", "SPECIES", 188, 191], ["A malaria", "PROBLEM", 0, 9], ["a respiratory syncytial virus", "PROBLEM", 14, 43], ["RSV) vaccine", "TREATMENT", 45, 57], ["this approach", "TREATMENT", 83, 96], ["neutralizing antibodies", "TREATMENT", 137, 160], ["malaria", "PROBLEM", 177, 184], ["RSV", "PROBLEM", 188, 191], ["the malaria", "PROBLEM", 209, 220], ["Designed Protein Nanovaccines", "TREATMENT", 302, 331], ["a rationally designed protein nanoparticle are nanofibers", "TREATMENT", 367, 424], ["malaria", "OBSERVATION", 2, 9], ["respiratory", "ANATOMY", 16, 27], ["syncytial virus", "OBSERVATION", 28, 43], ["malaria", "OBSERVATION", 177, 184]]], ["The initial design of the nanofiber core consisted of 11 amino acids (Q11) that could selfassemble into unbranched antiparallel \u03b2-sheets [176, 177] .", [["amino acids", "CHEMICAL", 57, 68], ["Q11", "CHEMICAL", 70, 73], ["amino acids", "CHEMICAL", 57, 68], ["amino acids", "AMINO_ACID", 57, 68], ["the nanofiber core", "TREATMENT", 22, 40], ["11 amino acids", "TREATMENT", 54, 68]]], ["Initially designed for the purpose of regenerative medicine, nanofibers were determined to be nonimmunogenic and well tolerated in animals [177] .", [["regenerative medicine", "TREATMENT", 38, 59], ["nanofibers", "TREATMENT", 61, 71], ["nonimmunogenic", "PROBLEM", 94, 108]]], ["When a 17 amino acid fragment of ovalbumin with established B and T epitopes was added to the N terminus of the construct, nanofibers that self-assembled functioned as repetitive antigen displays.", [["amino acid", "CHEMICAL", 10, 20], ["amino acid", "CHEMICAL", 10, 20], ["N", "CHEMICAL", 94, 95], ["amino acid", "AMINO_ACID", 10, 20], ["B", "CELL", 60, 61], ["T epitopes", "GENE_OR_GENE_PRODUCT", 66, 76], ["antigen", "GENE_OR_GENE_PRODUCT", 179, 186], ["17 amino acid fragment", "PROTEIN", 7, 29], ["ovalbumin", "PROTEIN", 33, 42], ["B and T epitopes", "PROTEIN", 60, 76], ["N terminus", "PROTEIN", 94, 104], ["a 17 amino acid fragment of ovalbumin", "TREATMENT", 5, 42], ["B and T epitopes", "TREATMENT", 60, 76], ["nanofibers", "TREATMENT", 123, 133]]], ["Antibody titers from vaccinated animals were greater than animals vaccinated with the ovalbumin fragment with FCA [178] .", [["Antibody titers", "TEST", 0, 15], ["vaccinated animals", "TEST", 21, 39], ["the ovalbumin fragment", "PROBLEM", 82, 104], ["FCA", "TEST", 110, 113], ["ovalbumin fragment", "OBSERVATION", 86, 104]]], ["Another study also indicated that when animals are vaccinated with nanofibers that contain only T C epitopes from ovalbumin they develop strong T C responses [179] .", [["T C epitopes", "GENE_OR_GENE_PRODUCT", 96, 108], ["T C", "GENE_OR_GENE_PRODUCT", 144, 147], ["T C epitopes", "PROTEIN", 96, 108], ["Another study", "TEST", 0, 13], ["nanofibers", "TREATMENT", 67, 77], ["T C epitopes from ovalbumin", "TREATMENT", 96, 123]]], ["These initial prototypical studies determined that nanofibers could function as successful vaccine candidates.Rationally Designed Protein NanovaccinesNanofibers have been successfully used in infectious disease models as well.", [["These initial prototypical studies", "TEST", 0, 34], ["nanofibers", "TREATMENT", 51, 61], ["successful vaccine candidates", "TREATMENT", 80, 109], ["Rationally Designed Protein NanovaccinesNanofibers", "TREATMENT", 110, 160]]], ["A vaccine candidate against malaria was able to induce high titers of antibodies that functioned to prevent infection in an in vitro assay [180] .", [["malaria", "DISEASE", 28, 35], ["infection", "DISEASE", 108, 117], ["malaria", "ORGANISM", 28, 35], ["antibodies", "PROTEIN", 70, 80], ["A vaccine", "TREATMENT", 0, 9], ["malaria", "PROBLEM", 28, 35], ["high titers of antibodies", "PROBLEM", 55, 80], ["infection", "PROBLEM", 108, 117], ["an in vitro assay", "TEST", 121, 138], ["infection", "OBSERVATION", 108, 117]]], ["Attempts have been made to increase T H responses to nanofibers by adding the pan-allelic DR epitope (PADRE) a universal T H epitope.", [["T H", "GENE_OR_GENE_PRODUCT", 36, 39], ["DR epitope", "GENE_OR_GENE_PRODUCT", 90, 100], ["T H epitope", "GENE_OR_GENE_PRODUCT", 121, 132], ["pan-allelic DR epitope", "PROTEIN", 78, 100], ["PADRE", "PROTEIN", 102, 107], ["T H epitope", "PROTEIN", 121, 132], ["nanofibers", "TREATMENT", 53, 63], ["the pan-allelic DR epitope (PADRE", "TREATMENT", 74, 107], ["a universal T H epitope", "TREATMENT", 109, 132]]], ["A heterogeneous mixture of Q11, Q11-B-cell epitope, and Q11-PADRE was used to develop a Staphylococcus aureus vaccine candidate.", [["Staphylococcus aureus", "DISEASE", 88, 109], ["Q11", "SIMPLE_CHEMICAL", 27, 30], ["Q11-B-cell", "CELL", 32, 42], ["Q11-PADRE", "SIMPLE_CHEMICAL", 56, 65], ["Staphylococcus aureus", "ORGANISM", 88, 109], ["Q11", "PROTEIN", 27, 30], ["Q11", "PROTEIN", 32, 35], ["B", "PROTEIN", 36, 37], ["Q11", "PROTEIN", 56, 59], ["PADRE", "PROTEIN", 60, 65], ["Staphylococcus aureus", "SPECIES", 88, 109], ["Staphylococcus aureus", "SPECIES", 88, 109], ["a Staphylococcus aureus vaccine", "TREATMENT", 86, 117], ["heterogeneous", "OBSERVATION_MODIFIER", 2, 15], ["Staphylococcus aureus", "OBSERVATION", 88, 109]]], ["Addition of PADRE resulted in an antibody titer increase in a PADRE concentration related manner [181] .", [["PADRE", "CHEMICAL", 12, 17], ["PADRE", "CHEMICAL", 62, 67], ["PADRE", "SIMPLE_CHEMICAL", 12, 17], ["PADRE", "SIMPLE_CHEMICAL", 62, 67], ["PADRE", "PROTEIN", 12, 17], ["PADRE", "TREATMENT", 12, 17], ["an antibody titer", "TEST", 30, 47], ["antibody", "OBSERVATION", 33, 41]]], ["While there have been some successes with the nanofiber technology there have been instances were nanofibers did not elicit strong immune responses [182] .Rationally Designed Protein NanovaccinesWhile nanofibers are a successful application of rationally designed protein nanoparticles many problems exist with their use.", [["the nanofiber technology", "TREATMENT", 42, 66], ["Designed Protein Nanovaccines", "TREATMENT", 166, 195], ["nanofibers", "TREATMENT", 201, 211], ["a successful application of rationally designed protein nanoparticles", "TREATMENT", 216, 285]]], ["The core sequence is only 11 amino acids long.", [["amino acids", "CHEMICAL", 29, 40], ["amino acids", "CHEMICAL", 29, 40], ["amino acids", "AMINO_ACID", 29, 40], ["The core sequence", "TEST", 0, 17]]], ["This is extremely short preventing the addition of large antigens.", [["large antigens", "PROBLEM", 51, 65], ["short", "OBSERVATION_MODIFIER", 18, 23], ["large", "OBSERVATION_MODIFIER", 51, 56]]], ["Allowing for only the addition of short regions of antigens severely limits their immunogenicity.", [["antigens", "PROTEIN", 51, 59], ["short regions of antigens", "PROBLEM", 34, 59], ["short", "OBSERVATION_MODIFIER", 34, 39]]], ["These short peptides need to be chemically synthesized, cannot be epitope tagged, and expressed in a protein expression system [178] [179] [180] [181] [182] [183] .", [["These short peptides", "PROBLEM", 0, 20]]], ["Karch One of the most appealing protein structural motifs for rational design of nanovaccines are coiled-coil oligomerization domains.", [["nanovaccines", "SIMPLE_CHEMICAL", 81, 93], ["coiled-coil oligomerization domains", "PROTEIN", 98, 133], ["Karch", "SPECIES", 0, 5], ["rational design of nanovaccines", "TREATMENT", 62, 93], ["coiled-coil oligomerization domains", "TREATMENT", 98, 133], ["coil oligomerization", "OBSERVATION", 105, 125]]], ["These motifs consist of two or more \u03b1-helices wrapped around each other.", [["\u03b1-helices", "PROTEIN", 36, 45]]], ["Coiled-coils are one of the most common, best understood, and stable oligomerization domains [184] .", [["oligomerization domains", "PROTEIN", 69, 92], ["Coiled-coils", "TREATMENT", 0, 12], ["coils", "OBSERVATION", 7, 12], ["most common", "OBSERVATION_MODIFIER", 28, 39], ["stable", "OBSERVATION_MODIFIER", 62, 68]]], ["One application of the coiled-coil oligomerization domain to vaccine design are Synthetic Virus Like Particles (SVLP).", [["coiled-coil oligomerization domain", "PROTEIN", 23, 57], ["the coiled-coil oligomerization domain", "TREATMENT", 19, 57], ["vaccine design", "TREATMENT", 61, 75], ["Synthetic Virus Like Particles (SVLP)", "TREATMENT", 80, 117]]], ["These particles are based on chemically synthesized monomers that consist of a lipid attached to a coiled-coil trimeric domain that is chemically attached to an antigen.", [["coiled-coil trimeric domain", "PROTEIN", 99, 126], ["chemically synthesized monomers", "TREATMENT", 29, 60], ["a lipid", "TREATMENT", 77, 84], ["a coiled-coil trimeric domain", "TREATMENT", 97, 126]]], ["Based on basic biophysical properties 60-90 monomers can self-assemble into a 20-25 nm particle that contains a lipid core and a surface decorated by antigens.", [["surface", "ANATOMY", 129, 136], ["antigens", "PROTEIN", 150, 158], ["basic biophysical properties", "TEST", 9, 37], ["a lipid core", "TREATMENT", 110, 122]]], ["SVLP function as repetitive antigen displays and are capable of inducing humoral responses in vaccinated animals [185, 186] .Rationally Designed Protein NanovaccinesPerhaps, one of the most promising nanoscale assemblies for vaccine development are Self-Assembling Protein Nanoparticles (SAPNs; Figure 2D ).", [["SVLP", "GENE_OR_GENE_PRODUCT", 0, 4], ["Self-Assembling Protein Nanoparticles", "SIMPLE_CHEMICAL", 249, 286], ["SVLP", "PROTEIN", 0, 4], ["repetitive antigen displays", "TEST", 17, 44], ["Designed Protein Nanovaccines", "TREATMENT", 136, 165], ["vaccine development", "TREATMENT", 225, 244]]], ["SAPNs are rationally designed repetitive antigen displays that can function for a diverse array of antigens.", [["SAPNs", "SIMPLE_CHEMICAL", 0, 5], ["SAPNs", "PROTEIN", 0, 5], ["antigens", "PROTEIN", 99, 107]]], ["Disease antigens can be added to either the C or the N terminus of each SAPN monomer, and in the prototypical SAPN 60 monomers will self-assemble into a particle with regular symmetry [187] [188] [189] [190] .", [["N", "CHEMICAL", 53, 54], ["SAPN", "GENE_OR_GENE_PRODUCT", 72, 76], ["Disease antigens", "PROTEIN", 0, 16], ["N terminus", "PROTEIN", 53, 63], ["SAPN monomer", "PROTEIN", 72, 84], ["SAPN 60 monomers", "PROTEIN", 110, 126], ["Disease antigens", "PROBLEM", 0, 16]]], ["Each assembled SAPN is decorated on its surface with 60 copies of an antigen, making them excellent repetitive antigen displays ( Figure 2D ).", [["surface", "ANATOMY", 40, 47], ["SAPN", "GENE_OR_GENE_PRODUCT", 15, 19], ["SAPN", "DNA", 15, 19], ["an antigen", "TEST", 66, 76], ["decorated", "OBSERVATION_MODIFIER", 23, 32]]], ["Not only do SAPNs function as repetitive antigen displays, but the individual particles resemble small viruses in both shape as well as in size at about 25 nm.", [["SAPNs", "GENE_OR_GENE_PRODUCT", 12, 17], ["antigen", "GENE_OR_GENE_PRODUCT", 41, 48], ["SAPNs", "PROTEIN", 12, 17], ["repetitive antigen", "TEST", 30, 48], ["small viruses in both shape", "PROBLEM", 97, 124], ["small", "OBSERVATION_MODIFIER", 97, 102], ["viruses", "OBSERVATION", 103, 110], ["both shape", "OBSERVATION_MODIFIER", 114, 124], ["size", "OBSERVATION_MODIFIER", 139, 143], ["25 nm", "OBSERVATION_MODIFIER", 153, 158]]], ["Together these factors make them excellent immunostimulatory particles and prime vaccine candidates.Rationally Designed Protein NanovaccinesOne of the major benefits of the SAPN design is the wide variety of coiled-coil oligomerization domains.", [["SAPN", "CHEMICAL", 173, 177], ["coiled-coil oligomerization domains", "PROTEIN", 208, 243], ["prime vaccine candidates", "TREATMENT", 75, 99], ["Protein NanovaccinesOne", "TREATMENT", 120, 143], ["the SAPN design", "TREATMENT", 169, 184], ["coiled-coil oligomerization domains", "TREATMENT", 208, 243], ["wide", "OBSERVATION_MODIFIER", 192, 196], ["variety", "OBSERVATION_MODIFIER", 197, 204], ["coiled", "OBSERVATION", 208, 214], ["coil oligomerization", "OBSERVATION", 215, 235]]], ["In nature coiled-coils exist that consist of 2, 3, 4, 5, and 6 \u03b1helices while 7 membered coiled-coil domains have been synthesized in the laboratory [191] .", [["2, 3, 4, 5, and 6 \u03b1helices", "PROTEIN", 45, 71], ["coiled-coil domains", "PROTEIN", 89, 108], ["coiled-coils", "TREATMENT", 10, 22], ["7 membered coiled-coil domains", "TREATMENT", 78, 108], ["coils", "OBSERVATION", 17, 22]]], ["B-cell epitopes can be conformational, meaning the epitope is based on the structure of the antigen, not the linear sequence [192] .", [["B-cell", "ANATOMY", 0, 6], ["B-cell", "CELL", 0, 6], ["B-cell epitopes", "PROTEIN", 0, 15], ["B-cell epitopes", "PROBLEM", 0, 15], ["cell epitopes", "OBSERVATION", 2, 15]]], ["The toolbox of well-established wellunderstood coiled-coil oligomerization domains allows for the presentation of antigens, in particular for oligomeric antigens, in their native conformations.", [["wellunderstood coiled-coil oligomerization domains", "PROTEIN", 32, 82], ["antigens", "PROTEIN", 114, 122], ["oligomeric antigens", "PROTEIN", 142, 161], ["coiled-coil oligomerization domains", "TREATMENT", 47, 82], ["antigens", "PROBLEM", 114, 122], ["oligomeric antigens", "PROBLEM", 142, 161]]], ["Choosing different oligomerization domains will ultimately change the geometry of each SAPN particle, however, they will still self-assemble and function as effective repetitive antigen display.", [["oligomerization domains", "PROTEIN", 19, 42], ["Choosing different oligomerization domains", "PROBLEM", 0, 42], ["oligomerization", "OBSERVATION", 19, 34]]], ["Another enticing feature of the SAPN is the ability to add universal T H epitopes to the core [193] .Rationally Designed Protein NanovaccinesSAPNs have been used as effective vaccine candidates for a variety of diseases.", [["NanovaccinesSAPNs", "CHEMICAL", 129, 146], ["H", "CHEMICAL", 71, 72], ["T H epitopes", "GENE_OR_GENE_PRODUCT", 69, 81], ["SAPN", "DNA", 32, 36], ["T H epitopes", "PROTEIN", 69, 81], ["universal T H epitopes", "TREATMENT", 59, 81], ["Rationally Designed Protein NanovaccinesSAPNs", "TREATMENT", 101, 146], ["effective vaccine", "TREATMENT", 165, 182], ["diseases", "PROBLEM", 211, 219], ["diseases", "OBSERVATION", 211, 219]]], ["Successful candidates have been developed for the viral diseases Avian Influenza, SARS, and HIV [194] [195] [196] .", [["viral diseases", "DISEASE", 50, 64], ["Influenza", "DISEASE", 71, 80], ["SARS", "DISEASE", 82, 86], ["Avian Influenza", "SPECIES", 65, 80], ["HIV", "SPECIES", 92, 95], ["HIV", "SPECIES", 92, 95], ["the viral diseases", "PROBLEM", 46, 64], ["Influenza", "PROBLEM", 71, 80], ["SARS", "PROBLEM", 82, 86], ["HIV", "PROBLEM", 92, 95]]], ["In each viral disease that SAPN technology has been applied to high antibody titers have been observed, and in most cases these antibodies were demonstrated to be functional in in vitro assays.", [["viral disease", "DISEASE", 8, 21], ["antibodies", "PROTEIN", 128, 138], ["each viral disease", "PROBLEM", 3, 21], ["SAPN technology", "TREATMENT", 27, 42], ["high antibody titers", "PROBLEM", 63, 83], ["these antibodies", "TEST", 122, 138], ["vitro assays", "TEST", 180, 192], ["viral disease", "OBSERVATION", 8, 21]]], ["One of the most challenging classes of infectious agents to develop vaccines for are parasitic diseases.", [["parasitic diseases", "DISEASE", 85, 103], ["infectious agents", "TREATMENT", 39, 56], ["vaccines", "TREATMENT", 68, 76], ["parasitic diseases", "PROBLEM", 85, 103], ["most challenging", "OBSERVATION_MODIFIER", 11, 27], ["infectious", "OBSERVATION", 39, 49], ["parasitic", "OBSERVATION_MODIFIER", 85, 94]]], ["Parasites are complex organisms with multiple life stages, immune avoiding mechanisms, and generally infect multiple hosts [197] .", [["Parasites", "CELL", 0, 9], ["Parasites", "PROBLEM", 0, 9], ["complex organisms", "PROBLEM", 14, 31], ["multiple life stages", "PROBLEM", 37, 57], ["complex", "OBSERVATION_MODIFIER", 14, 21], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["life stages", "OBSERVATION_MODIFIER", 46, 57]]], ["SAPNs are effective in the development of parasitic vaccine candidates.", [["SAPNs", "SIMPLE_CHEMICAL", 0, 5], ["parasitic vaccine candidates", "TREATMENT", 42, 70], ["effective", "OBSERVATION_MODIFIER", 10, 19]]], ["SAPN candidates induce strong humoral and cellular immune responses against malaria in murine models leading to protection against challenge [193, 198, 199] .", [["cellular", "ANATOMY", 42, 50], ["malaria", "DISEASE", 76, 83], ["SAPN", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 42, 50], ["murine", "ORGANISM", 87, 93], ["murine", "SPECIES", 87, 93], ["SAPN candidates", "TREATMENT", 0, 15], ["malaria in murine models", "PROBLEM", 76, 100], ["cellular immune", "OBSERVATION", 42, 57]]], ["SAPNs have also been shown to be immunogenic and able to induce protection against challenge in a murine model of Toxoplasma gondii [200] .", [["Toxoplasma gondii", "DISEASE", 114, 131], ["SAPNs", "SIMPLE_CHEMICAL", 0, 5], ["murine", "ORGANISM", 98, 104], ["Toxoplasma gondii", "ORGANISM", 114, 131], ["SAPNs", "PROTEIN", 0, 5], ["murine", "SPECIES", 98, 104], ["Toxoplasma gondii", "SPECIES", 114, 131], ["Toxoplasma gondii", "SPECIES", 114, 131], ["immunogenic", "PROBLEM", 33, 44], ["Toxoplasma gondii", "PROBLEM", 114, 131]]], ["This success further demonstrates the strength of the SAPN as a vaccine technology.Future DirectionsSince Jenner developed the first vaccine candidate in 1796 great advances have been made in the field of infectious disease vaccinology.", [["SAPN", "CHEMICAL", 54, 58], ["infectious disease vaccinology", "DISEASE", 205, 235], ["SAPN", "SIMPLE_CHEMICAL", 54, 58], ["a vaccine technology", "TREATMENT", 62, 82], ["infectious disease vaccinology", "TREATMENT", 205, 235]]], ["The field has moved from the traditional method of vaccine development, where an organism had to be cultured, attenuated, or killed before it could become an effective vaccine candidate.", [["an organism", "PROBLEM", 78, 89]]], ["Today, through modern biological techniques extremely targeted safer vaccines can be developed much more quickly than ever before.", [["modern biological techniques", "TREATMENT", 15, 43], ["safer vaccines", "TREATMENT", 63, 77]]], ["The major problem with these candidates is that they tend to be less immunogenic and ultimately less protective than whole organism vaccines.", [["whole organism vaccines", "TREATMENT", 117, 140]]], ["Resolving these issues is the current main focus of vaccine development.Future DirectionsThere is a current need for the rapid and effective development of infectious disease vaccines.", [["infectious disease", "DISEASE", 156, 174], ["vaccine development", "TREATMENT", 52, 71], ["infectious disease vaccines", "TREATMENT", 156, 183], ["infectious", "OBSERVATION", 156, 166]]], ["Besides the big three diseases in need of vaccines, HIV, tuberculosis, and malaria, there are outbreaks of new and emerging diseases such as Ebola and Zika Virus that threaten global public health.", [["HIV, tuberculosis", "DISEASE", 52, 69], ["malaria", "DISEASE", 75, 82], ["Ebola and Zika Virus", "DISEASE", 141, 161], ["HIV", "ORGANISM", 52, 55], ["Ebola", "ORGANISM", 141, 146], ["Zika Virus", "ORGANISM", 151, 161], ["HIV", "SPECIES", 52, 55], ["HIV", "SPECIES", 52, 55], ["the big three diseases", "PROBLEM", 8, 30], ["vaccines", "TREATMENT", 42, 50], ["HIV", "PROBLEM", 52, 55], ["tuberculosis", "PROBLEM", 57, 69], ["malaria", "PROBLEM", 75, 82], ["new and emerging diseases", "PROBLEM", 107, 132], ["Ebola", "PROBLEM", 141, 146], ["Zika Virus", "PROBLEM", 151, 161], ["diseases", "OBSERVATION", 22, 30], ["tuberculosis", "OBSERVATION", 57, 69], ["malaria", "OBSERVATION", 75, 82], ["new", "OBSERVATION_MODIFIER", 107, 110]]], ["New technologies may provide a mechanism for quick development and rapid implementation of vaccines.", [["rapid implementation of vaccines", "TREATMENT", 67, 99]]], ["By further developing vaccine technologies to include more immunostimulatory molecules as well as more epitopes better vaccine candidates will be generated.Future DirectionsVaccinology as a discipline has traditionally been focused on the development of vaccines for the prevention of infectious diseases.", [["infectious diseases", "DISEASE", 285, 304], ["immunostimulatory molecules", "PROTEIN", 59, 86], ["epitopes", "PROTEIN", 103, 111], ["vaccine technologies", "TREATMENT", 22, 42], ["more immunostimulatory molecules", "TREATMENT", 54, 86], ["vaccines", "TREATMENT", 254, 262], ["infectious diseases", "PROBLEM", 285, 304], ["infectious", "OBSERVATION", 285, 295]]], ["This unique relationship has allowed vaccinology to develop hand in hand with immunology and infectious disease biology.", [["hand", "ANATOMY", 60, 64], ["hand", "ANATOMY", 68, 72], ["infectious disease", "DISEASE", 93, 111], ["hand", "ORGANISM_SUBDIVISION", 60, 64], ["hand", "ORGANISM_SUBDIVISION", 68, 72]]], ["As knowledge of these disciplines has increased it has allowed for the development of new vaccine technologies to be applied to other disease states such as cancer.", [["cancer", "ANATOMY", 157, 163], ["cancer", "DISEASE", 157, 163], ["cancer", "CANCER", 157, 163], ["new vaccine technologies", "TREATMENT", 86, 110], ["other disease states", "PROBLEM", 128, 148], ["cancer", "PROBLEM", 157, 163], ["cancer", "OBSERVATION", 157, 163]]], ["As development of vaccine technologies continues to be refined and improved more applications will become available to disease states such as cancer, addiction, and obesity.", [["cancer", "ANATOMY", 142, 148], ["cancer, addiction", "DISEASE", 142, 159], ["obesity", "DISEASE", 165, 172], ["cancer", "CANCER", 142, 148], ["vaccine technologies", "TREATMENT", 18, 38], ["cancer", "PROBLEM", 142, 148], ["obesity", "PROBLEM", 165, 172], ["cancer", "OBSERVATION", 142, 148], ["obesity", "OBSERVATION", 165, 172]]], ["Potentially, in the near future scientists will be able to apply these new technologies to the development of prophylactic treatments to a broad range of diseases leading to further decreases in global morbidity and mortality from everything from infectious diseases to cancer.", [["cancer", "ANATOMY", 270, 276], ["infectious diseases", "DISEASE", 247, 266], ["cancer", "DISEASE", 270, 276], ["cancer", "CANCER", 270, 276], ["prophylactic treatments", "TREATMENT", 110, 133], ["diseases", "PROBLEM", 154, 162], ["further decreases in global morbidity", "PROBLEM", 174, 211], ["infectious diseases to cancer", "PROBLEM", 247, 276], ["decreases", "OBSERVATION_MODIFIER", 182, 191], ["global", "OBSERVATION_MODIFIER", 195, 201], ["morbidity", "OBSERVATION", 202, 211]]], ["Vaccinology in its first 200 years of development has only scratched the surface of what is possible.", [["surface", "ANATOMY", 73, 80], ["Vaccinology", "TREATMENT", 0, 11], ["scratched", "OBSERVATION", 59, 68]]], ["A timeline showing when different classes of vaccines became clinically available and the overlap of availability.", [["vaccines", "TREATMENT", 45, 53]]], ["Some vaccines like Hepatitis B technically fall into multiple classes such as subunit as well as nanovaccines.", [["Hepatitis B", "DISEASE", 19, 30], ["Hepatitis B", "ORGANISM", 19, 30], ["Hepatitis B", "SPECIES", 19, 30], ["Some vaccines", "TREATMENT", 0, 13], ["Hepatitis B technically fall", "PROBLEM", 19, 47], ["nanovaccines", "TREATMENT", 97, 109], ["Hepatitis", "OBSERVATION", 19, 28]]], ["Karch shows the RNA bacteriophage Q beta forming a T=3 icosahedral particle (PDB-RCSB code 1QBE).", [["Q beta", "GENE_OR_GENE_PRODUCT", 34, 40], ["RNA bacteriophage Q beta", "PROTEIN", 16, 40], ["RCSB", "PROTEIN", 81, 85], ["Karch", "TEST", 0, 5], ["the RNA bacteriophage", "TREATMENT", 12, 33]]], ["The view is down the two-fold axis of the icosahedron.", [["icosahedron", "CHEMICAL", 42, 53], ["icosahedron", "SIMPLE_CHEMICAL", 42, 53], ["icosahedron", "PROTEIN", 42, 53], ["The view", "TEST", 0, 8], ["the icosahedron", "TREATMENT", 38, 53]]], ["C) Ferritin: Shown is the octahedral structure of ferritin from the marine pennate diatom Pseudo-nitzschia multiseries (PmFTN) (PDB-RCSB code 4ZKW).", [["Ferritin", "GENE_OR_GENE_PRODUCT", 3, 11], ["ferritin", "GENE_OR_GENE_PRODUCT", 50, 58], ["ferritin", "PROTEIN", 50, 58], ["Pseudo-nitzschia multiseries", "SPECIES", 90, 118], ["Ferritin", "TEST", 3, 11], ["ferritin", "TEST", 50, 58], ["the marine", "TEST", 64, 74], ["ferritin", "OBSERVATION", 50, 58]]], ["The view is down the four-fold axis of the octahedron.", [["The view", "TEST", 0, 8], ["the octahedron", "TREATMENT", 39, 53]]], ["D) SAPNs: The example shows a SAPN composed of a pentameric (blue) and trimeric (cyan) coiled-coil domain displaying the trimeric coiled-coil epitope HRC (red) from the SARS coronavirus.", [["SARS coronavirus", "DISEASE", 169, 185], ["SARS coronavirus", "ORGANISM", 169, 185], ["SAPN", "PROTEIN", 30, 34], ["pentameric (blue) and trimeric (cyan) coiled-coil domain", "PROTEIN", 49, 105], ["trimeric coiled-coil epitope", "PROTEIN", 121, 149], ["HRC", "PROTEIN", 150, 153], ["red", "PROTEIN", 155, 158], ["SARS coronavirus", "SPECIES", 169, 185], ["a pentameric (blue", "TREATMENT", 47, 65], ["trimeric (cyan) coiled-coil domain", "TREATMENT", 71, 105], ["the trimeric coiled-coil epitope HRC", "TREATMENT", 117, 153], ["the SARS coronavirus", "PROBLEM", 165, 185], ["SARS coronavirus", "OBSERVATION", 169, 185]]], ["The view is down the three-fold axis of the icosahedron.", [["icosahedron", "CHEMICAL", 44, 55], ["icosahedron", "SIMPLE_CHEMICAL", 44, 55], ["icosahedron", "PROTEIN", 44, 55], ["The view", "TEST", 0, 8], ["the icosahedron", "TREATMENT", 40, 55]]], ["KarchFuture DirectionsBiochem Pharmacol.", [["Biochem Pharmacol", "TREATMENT", 22, 39]]]]}